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 Abstract 
Delivery of siRNA therapeutics to their target site within the cell interior is a 
challenge that hinders their effective use in disease treatment.  PP-75, a pH-
responsive polymer, demonstrates potential to enhance intracellular siRNA-delivery 
by overcoming endosomal entrapment.  PP-75 also provides a promising platform for 
development of targeted delivery, following conjugation of DARPin targeting ligands. 
Novel PP-75 cross-linker derivatives, PP-75-aminofluorescein, PP-75-siRNA 
and PP-75-DARPin conjugates have been developed and characterised for in vitro 
application.  PP-75 delivery to SK-BR-3 (Her2+) and MDA-MB-231 (Her2-) breast 
cancer cells has been demonstrated for the first time.  The membrane-lytic activity of 
PP-75 was limited at physiological pH but effective within the pH range typical of early 
endosomes.  PP-75 did not demonstrate cytoxicity, with cells tolerating treatments up 
to 2.5 mg/mL over 72 h.  Cellular internalisation and endosomal escape of PP-75 
aminofluorescein (AFC) was confirmed via confocal microscopy, demonstrated by 
diffuse cytoplasmic delivery.  Flow cytometry confirmed cellular internalisation of PP-
75 AFC was via endocytosis. 
As reporter cells expressing firefly and Renilla luciferases, the breast cancer 
lines offered a robust assay read out capable of distinguishing between target specific 
and non-specific gene knockdown.  The functionality of novel siRNA payloads that 
targeted firefly luciferase was confirmed by mRNA and protein knockdown and 
provided the foundation for delivery of PP-75 siRNA conjugates.  Target specific 
DARPin affinity was confirmed for the SK-BR-3 (Her2+) cells and not MDA-MD-231 
(Her2-) cells, demonstrating selective binding to the extracellular Her2 protein.  The 
expression of a novel but structurally comparable negative control DARPin (5K D1) 
demonstrated no affinity for either cell line.  The introduction of a free cysteine residue 
to the DARPin sequences facilitated attachment onto PP-75. 
PP-75 therefore has the potential to demonstrate intracellular delivery of siRNA 
payloads, capable of delivery to specific cell populations via DARPin targeting. 
 Table of Contents 
List of Figures ...................................................................................................................... i 
List of Tables ....................................................................................................................... v 
Abbreviations ..................................................................................................................... vi 
Chapter 1 ........................................................................................................................... 10 
1 Introduction ......................................................................................................... 10 
1.1 Stimuli-Responsive Polymers for Drug Delivery .................................................... 10 
1.2 Challenges, Barriers and Opportunities for Intracellular Delivery ........................... 11 
1.3 pH-Responsive Endosomolytic Polymers .............................................................. 14 
1.4 Cationic Polymers ................................................................................................. 17 
1.4.1 Poly(L-lysine) (PLL) .............................................................................................. 18 
1.4.2 Poly(ethyleneimine) (PEI) ..................................................................................... 19 
1.5 Anionic Polymers .................................................................................................. 20 
1.5.1 Poly(vinyl)s ........................................................................................................... 21 
1.5.2 Poly(amino acid)s ................................................................................................. 23 
1.5.3 Pseudo-Peptidic Polymers .................................................................................... 23 
1.6 PP-75.................................................................................................................... 26 
1.7 Polymer-Drug Conjugates ..................................................................................... 28 
1.7.1 Controlled Release of Payloads ............................................................................ 32 
1.7.2 siRNA Payloads .................................................................................................... 33 
1.8 Targeted Delivery.................................................................................................. 36 
1.8.1 Cancer Targets and Cell Surface Receptors ......................................................... 37 
1.8.2 Designed Ankyrin Repeat Proteins (DARPins) ...................................................... 38 
1.9 Aims of the Study .................................................................................................. 41 
1.9.1 Novelty of Research .............................................................................................. 43 
1.9.2 Research Impact ................................................................................................... 44 
1.10 Thesis Outline ....................................................................................................... 45 
Chapter 2 ........................................................................................................................... 47 
2 Materials and Methods ....................................................................................... 47 
2.1 Materials ............................................................................................................... 47 
2.2 Organic Synthesis ................................................................................................. 50 
2.2.1 Poly(L-lysine isophthalamide) (PLP) ..................................................................... 50 
2.2.2 PP-75: PLP Grafted with L-Phenylalanine ............................................................. 52 
2.2.3 PP-75 plus Cross-linkers....................................................................................... 53 
2.2.4 PP-75 plus Payloads and Targeting Ligands ......................................................... 56 
2.3 Biophysical Polymer Characterisation ................................................................... 62 
 2.3.1 Fourier Transform Infrared (FT-IR) Spectroscopy ................................................. 62 
2.3.2 Nuclear Magnetic Resonance (NMR) Spectrometry .............................................. 62 
2.3.3 Gel Permeation Chromatography (GPC) ............................................................... 62 
2.3.4 Sodium Dodecyl Sulphate Polyacrylamide Gel Electrophoresis (SDS-PAGE) ....... 63 
2.3.5 Mass Spectrometry (MS) ...................................................................................... 63 
2.3.6 PP-75 AFC Thin Layer Chromatography (TLC) ..................................................... 64 
2.3.7 Pyridine-2-Thione Absorption Assay ..................................................................... 64 
2.3.8 Absorbance and Fluorescence Assays ................................................................. 64 
2.3.9 Agarose Gel Electrophoresis ................................................................................ 65 
2.3.10 DARPin Enzyme-Linked Immunosorbent Assay (ELISA) ...................................... 65 
2.3.11 Dynamic Light Scattering (DLS) ............................................................................ 66 
2.4 Cell Culture ........................................................................................................... 66 
2.4.1 Parental and Dual Luciferase Reporter Cell Lines ................................................. 66 
2.4.2 Maintaining Adherent Cell Lines ............................................................................ 67 
2.4.3 Determination of Cell Concentration ..................................................................... 67 
2.4.4 Cryopreservation of Cells for Long-Term Storage ................................................. 67 
2.4.5 Reviving Cells ....................................................................................................... 68 
2.4.6 Viable Growth Curves ........................................................................................... 68 
2.4.7 Calculating Cell Line Generation Time .................................................................. 68 
2.5 Biological Characterisation of PP-75 Delivery Systems ......................................... 69 
2.5.1 PP-75 Cytotoxicity Testing .................................................................................... 69 
2.5.2 Lactate Dehydrogenase (LDH) Assay ................................................................... 71 
2.5.3 Intracellular Localisation of PP-75 AFC ................................................................. 72 
2.5.4 PP-75 Mediated Intracellular siRNA Delivery ........................................................ 74 
2.5.5 DARPin Targeted PP-75 Delivery ......................................................................... 78 
Chapter 3 ........................................................................................................................... 88 
3 Polymer Synthesis, siRNA and DARPin Conjugation and Characterisation .. 88 
3.1 Introduction ........................................................................................................... 88 
3.2 Results and Discussion ......................................................................................... 91 
3.2.1 PLP and PP-75 ..................................................................................................... 91 
3.2.2 PP-75 plus Cross-linkers..................................................................................... 103 
3.2.3 PP-75 plus Payloads ........................................................................................... 106 
3.2.4 pH-Responsive Polymer Function ....................................................................... 122 
3.3 Conclusions ........................................................................................................ 130 
Chapter 4 ......................................................................................................................... 132 
4 Cell Line Characterisation and PP-75 Cytotoxicity ......................................... 132 
4.1 Introduction ......................................................................................................... 132 
 4.2 Results and Discussion ....................................................................................... 134 
4.2.1 Characterisation of Model Cell Lines ................................................................... 134 
4.2.2 PP-75 Cytotoxicity Testing .................................................................................. 145 
4.3 Conclusions ........................................................................................................ 157 
Chapter 5 ......................................................................................................................... 159 
5 PP-75 Mediated Intracellular Delivery and siRNA Knockdown ...................... 159 
5.1 Introduction ......................................................................................................... 159 
5.2 Results and Discussion ....................................................................................... 162 
5.2.1 siRNA Payload Design ........................................................................................ 162 
5.2.2 Lipofectamine® Mediated siRNA Delivery ........................................................... 163 
5.2.3 PP-75 Intracellular Delivery ................................................................................. 182 
5.3 Conclusions ........................................................................................................ 197 
Chapter 6 ......................................................................................................................... 200 
6 PP-75 Targeted Delivery ................................................................................... 200 
6.1 Introduction ......................................................................................................... 200 
6.2 Results and Discussion ....................................................................................... 202 
6.2.1 DARPin Expression ............................................................................................ 202 
6.2.2 DARPin Binding Affinity for fluc/Rluc Reporter Cell Lines .................................... 210 
6.3 Conclusions ........................................................................................................ 212 
Chapter 7 ......................................................................................................................... 214 
7 Conclusions ...................................................................................................... 214 
7.1 Future Scope of the Project ................................................................................ 216 
7.1.1 Characterisation of PP-75 and Derivatives .......................................................... 217 
7.1.2 PP-75 Payload Release ...................................................................................... 218 
7.1.3 Therapeutic Potential .......................................................................................... 219 
7.1.4 Subcellular Fate of Polymers and Biodegradability ............................................. 219 
7.2 Closing Remarks ................................................................................................ 219 
Bibliography .................................................................................................................... 221 
Appendix ......................................................................................................................... 233 
8 Appendix ........................................................................................................... 233 
8.1 P-2-T Calibration Curve (DMF) ........................................................................... 233 
8.2 Beer-Lambert Law .............................................................................................. 233 
8.3 AFC Absorption Calibration Curve (10% DMF: 90% PBS) .................................. 234 
8.4 AFC Fluorescence Calibration Curve (10% DMF: 90% PBS) .............................. 234 
8.5 Luciferase Gene Sequences with PCR Primers and Probes ............................... 235 
8.6 Negative Binding DARPin Sequences with PCR Primers .................................... 236 
 
i 
List of Figures 
Figure 1.1: Common Mechanisms of Endocytosis for Macromolecular Cell Entry. .............. 12 
Figure 1.2: pH-Responsive Polymers for Drug Delivery. ..................................................... 15 
Figure 1.3: pH-Dependent Ionisation of Polyelectrolytes. .................................................... 16 
Figure 1.4: Cationic Proton-Sponge Polymers..................................................................... 18 
Figure 1.5: Anionic Polymer Coil-to-Globule Transition. ...................................................... 21 
Figure 1.6: PP-Polymer Units. ............................................................................................. 24 
Figure 1.7: Mechanism of RNA Interference. ...................................................................... 34 
Figure 1.8: Illustration of a Model Polymer-Drug Conjugate. ............................................... 36 
Figure 1.9: DARPin Crystal Structure. ................................................................................. 40 
Figure 2.1: PLP Synthesis Schematic. ................................................................................ 50 
Figure 2.2: PP-75 Synthesis Schematic (PLP Grafted with L-Phenylalanine). ..................... 52 
Figure 2.3: PP-75 PDPH Synthesis Schematic. .................................................................. 54 
Figure 2.4: PP-75 EMCH Synthesis Schematic. .................................................................. 55 
Figure 2.5: PP-75 AFC Synthesis Schematic. ..................................................................... 56 
Figure 2.6: PP-75 AFC EMCH Synthesis Schematic. .......................................................... 57 
Figure 2.7: PP-75 PDPH siRNA Conjugation Schematic. .................................................... 58 
Figure 2.8: PP-75 AFC EMCH DARPin Conjugation Schematic. ......................................... 59 
Figure 2.9: PP-75 PDPH, EMCH-DARPin Conjugation Schematic. ..................................... 60 
Figure 2.10: PP-75 PDPH DARPin Conjugation Schematic. ............................................... 61 
Figure 3.1: Mechanism of DCC/DMAP Mediated Peptide Bond Formation. ........................ 90 
Figure 3.2: FT-IR Structural Characterisation of PLP Methyl Ester. ..................................... 92 
Figure 3.3: NMR Structural Characterisation of PLP Methyl Ester. ...................................... 93 
Figure 3.4: FT-IR Structural Characterisation of PLP. ......................................................... 95 
Figure 3.5: NMR Structural Characterisation of PLP. .......................................................... 96 
Figure 3.6: NMR Structural Characterisation of PP-75. ....................................................... 99 
Figure 3.7: Polymer Migration Characterised by SDS PAGE. ............................................ 102 
Figure 3.8: Extended AFC Fluorescence Calibration Curve (10% DMF:90% PBS). .......... 109 
Figure 3.9: PP-75 siRNA Conjugation Characterised by Agarose Gel Electrophoresis. ..... 112 
Figure 3.10: PP-75 AFC EMCH DARPin Conjugations Characterised by SDS PAGE. ...... 114 
Figure 3.11: ELISA to Determine DARPin Presence in PP-75 AFC EMCH DARPin 
Conjugates. ....................................................................................................................... 115 
Figure 3.12: Relative Fluorescence of PP-75 AFC DARPin Conjugates. ........................... 116 
Figure 3.13: MALDI-TOF/TOF MS EMCH DARPin Linkage. ............................................. 117 
ii 
Figure 3.14: PP-75 PDPH EMCH DARPin Conjugations Characterised by SDS PAGE. ... 118 
Figure 3.15: P-2-T Release Assay .................................................................................... 120 
Figure 3.16: PP-75 PDPH EMCH DARPin Conjugations Characterised by SDS PAGE. ... 121 
Figure 3.17: DLS Traces to Indicate PLP pH-Responsive Function. .................................. 122 
Figure 3.18: DLS Traces to Indicate PP-75 pH-Responsive Function. .............................. 123 
Figure 3.19: Cell Lysis as an Indicator of pH-Responsive PLP Membrane Activity. ........... 126 
Figure 3.20: Cell Lysis as an Indicator of pH-Responsive PP-75 Membrane Activity. ........ 127 
Figure 4.1: Growth of Parental and fluc/Rluc Reporter Cell Lines. ..................................... 136 
Figure 4.2: Luciferase Protein Expression Determined via DLR™ Assay. ......................... 140 
Figure 4.3: Luciferase Gene Expression Determined via RT-qPCR .................................. 144 
Figure 4.4: alamarBlue® Assay Optimisation for SK-BR-3 (Her2+) fluc/Rluc Cells. ........... 147 
Figure 4.5: alamarBlue® Assay Optimisation for MDA-MB-231 (Her2-) fluc/Rluc Cells. .... 148 
Figure 4.6: PP-75 Treatment of SK-BR-3 (Her2+) fluc/Rluc Cells (alamarBlue®). ............. 150 
Figure 4.7: PP-75 Treatment of MDA-MB-231 (Her2-) fluc/Rluc Cells (alamarBlue®). ...... 151 
Figure 4.8: PP-75 Treatment of SK-BR-3 (Her2+) fluc/Rluc Cells (CellTitre-Glo®). ........... 154 
Figure 4.9: PP-75 Treatment of MDA-MB-231 (Her2-) fluc/Rluc Cells (CellTitre-Glo®). .... 155 
Figure 5.1: Intracellular Localisation of Lipofectamine® Delivered siRNA Cy3 at 1, 6 and 24 
h Post Treatment to SK-BR-3 (Her2+) fluc/Rluc Cells. ...................................................... 164 
Figure 5.2: Intracellular Localisation of Lipofectamine® Delivered siRNA Cy3 at 1, 6 and 24 
h Post Treatment to MDA-MB-231 (Her2-) fluc/Rluc Cells. ................................................ 165 
Figure 5.3: Intracellular Localisation of Lipofectamine® Delivered siRNA Cy3 in SK-BR-3 
(Her2+) fluc/Rluc Cells. ..................................................................................................... 167 
Figure 5.4: Intracellular Localisation of Lipofectamine® Delivered siRNA Cy3 in MDA-MB-
231 fluc/Rluc Cells. ........................................................................................................... 168 
Figure 5.5: Relative fluc Protein Expression in SK-BR-3 (Her2+) fluc/Rluc Reporter Cells via 
Lipofectamine® Delivered fluc Targeting siRNA as Measured via DLR™ Assay. .............. 170 
Figure 5.6: Relative fluc Protein Expression in MDA-MB-231 (Her2-) fluc/Rluc Reporter Cells 
via Lipofectamine® Delivered fluc Targeting siRNA as Measured via DLR™ Assay. ........ 171 
Figure 5.7: Relative fluc Protein Expression in SK-BR-3 (Her2+) fluc/Rluc Reporter Cells via 
Lipofectamine® Delivered fluc Targeting siRNA as Measured via DLR™ Assay. .............. 174 
Figure 5.8: Relative fluc Protein Expression in MDA-MB-231 (Her2-) fluc/Rluc Reporter Cells 
via Lipofectamine® Delivered fluc Targeting siRNA as Measured via DLR™ Assay. ........ 175 
Figure 5.9: GeNorm™ Analysis; Average Expression Levels of Endogenous Genes. ....... 177 
Figure 5.10: Primer Efficiency Indicative of Quantitative Gene Expression. ....................... 179 
Figure 5.11: Relative Expression Indicative of Quantitative Gene Expression. .................. 179 
iii 
Figure 5.12: Relative fluc mRNA Knockdown in SK-BR-3 (Her2+) fluc/Rluc Reporter Cells 
via Lipofectamine® Delivered fluc Targeting siRNA as Measured via RT-qPCR. .............. 181 
Figure 5.13: Relative fluc mRNA Knockdown in MDA-MB-231 (Her2-) fluc/Rluc Reporter 
Cells via Lipofectamine® Delivered fluc Targeting siRNA as Measured via RT-qPCR. ..... 181 
Figure 5.14: PP-75 AFC Intracellular Uptake and Localisation following 1 h Treatment plus 1 
h incubation with MDA-MB-231 (Her2-) fluc/Rluc cells. ..................................................... 183 
Figure 5.15: PP-75 AFC Intracellular Uptake and Localisation following 1 h Treatment plus 
24 h incubation with MDA-MB-231(Her2-) fluc/Rluc cells. ................................................. 183 
Figure 5.16: PP-75 AFC Intracellular Uptake Measured via Flow Cytometry. .................... 184 
Figure 5.17: PP-75 AFC Intracellular Uptake and Localisation following 1, 6 and 24 h 
Treatments to SK-BR-3 (Her2+) fluc/Rluc Cells. ............................................................... 186 
Figure 5.18: PP-75 AFC Intracellular Uptake and Localisation following 1, 6 and 24 h 
Treatments to MDA-MB-231 (Her2-) fluc/Rluc Cells. ......................................................... 187 
Figure 5.19: PP-75 AFC Intracellular Uptake and Localisation following 1, 6 and 24 h 
Treatments to SK-BR-3 (Her2+) fluc/Rluc Cells. ............................................................... 189 
Figure 5.20: PP-75 AFC Intracellular Uptake and Localisation following 1, 6 and 24 h 
Treatments to MDA-MB-231 (Her2-) fluc/Rluc Cells. ......................................................... 190 
Figure 5.21: PP-75 AFC Intracellular Uptake and Localisation following 1, 6 and 24 h 
Treatments to SK-BR-3 (Her2+) fluc/Rluc Cells. ............................................................... 191 
Figure 5.22: Intracellular Localisation of PP-75 siRNA Cy3 Conjugates at 1, 6 and 24 h Post 
Treatment to SK-BR-3 fluc/Rluc and MDA-MB-231 fluc/Rluc Cells. ................................... 192 
Figure 5.23: Relative fluc Protein Knockdown in fluc/Rluc Reporter Cells via PP-75 plus fluc 
targeting siRNA (mixed components). ............................................................................... 193 
Figure 5.24: Relative fluc Protein Knockdown in SK-BR-3 (Her2+) fluc/Rluc and MDA-MB-
231 (Her2-) fluc/Rluc Reporter Cells via PP-75 Conjugated fluc Targeting siRNA. ............ 195 
Figure 5.25: Relative fluc Protein Knockdown in SK-BR-3 (Her2+) fluc/Rluc and MDA-MB-
231 (Her2-) fluc/Rluc Reporter Cells via PP-75 fluc Targeting siRNA Conjugates. ............ 196 
Figure 6.1: Phage ELISA Screen of Negative-Binding DARPin Sequences. ..................... 204 
Figure 6.2: Agarose Gel Analysis of PCR Amplified DARPin Clones. ................................ 206 
Figure 6.3: Agarose Gel Analysis of DARPin Clone Restriction Digest. ............................. 207 
Figure 6.4: Schematic of Vector plus DARPin Ligation. ..................................................... 207 
Figure 6.5: Primary DARPin ELISA Screen of Negative-Binding DARPin Sequences. ...... 209 
Figure 6.6: DARPin Cell ELISA Binding Affinity via Anti-His Antibody Detection. .............. 211 
Figure 6.7: ELISA Fold Change in Binding Affinity on fluc/Rluc Reporter Cells via Anti-His 
Antibody Detection (Relative to Secondary Only Control). ................................................ 211 
iv 
Figure 6.8: ELISA Fold Change in Binding Affinity on fluc/Rluc Reporter Cells with Anti-His 
Antibody Detection, Relative to Negative-Binding DARPin. ............................................... 212 
Figure 7.1: PP-75 PDPH siRNA and DARPin Conjugation Schematic. ............................. 217 
  
v 
List of Tables 
Table 2.1: PCR Amplification Protocol. ............................................................................... 77 
Table 3.1: Structural Composition of PLP Methyl Ester characterised by NMR. .................. 94 
Table 3.2: GPC Molecular Weight Characterisation of PLP. ................................................ 97 
Table 3.3: Grafting Efficiency and Molecular Weight Characterisation of PP-75. ............... 101 
Table 3.4: PP-75 PDPH Grafting Efficiency and Molecular Weight.................................... 104 
Table 3.5: PP-75 EMCH Grafting Efficiency and Molecular Weight. .................................. 105 
Table 3.6: Concentration Dependent Release of P-2-T. .................................................... 105 
Table 3.7: PP-75 AFC Grafting Efficiency (Absorption Calibration Curve). ........................ 107 
Table 3.8: PP-75 AFC Grafting Efficiency (Fluorescence Calibration Curve). .................... 107 
Table 3.9: PP-75 AFC Degree of Grafting and Molecular Weight. ..................................... 108 
Table 3.10: PP-75 PDPH siRNA Conjugation Efficiency Determined by P-2-T Assay. ...... 111 
Table 3.11: siRNA Stock Concentration ............................................................................ 112 
Table 4.1: Cell Line Characteristics of Parental and fluc/Rluc Reporter Cell Lines. ........... 135 
Table 4.2: Cell Line Generation Time ................................................................................ 136 
Table 4.3: Primer and Probe Design Guidelines ................................................................ 142 
Table 4.4: Primer and Probe Sequences........................................................................... 142 
Table 5.1: fluc siRNA Targeting Sequence. ....................................................................... 162 
Table 6.1: Negative-Binding Control DARPin Sequences from DARPin Library Screen. ... 203 
Table 6.2: PCR Forward and Reverse Primer Design. ...................................................... 205 
Table 6.3: Her2 Binding and 5K D1 Negative-Binding DARPin Sequences. ...................... 210 
  
vi 
Abbreviations 
18S 18S rRNA 
  
A adenine 
Å angstrom 
ACTB beta-actin 
AFC aminofluorescein 
AFM atomic force microscopy 
aq aqueous 
ATCC American Type Culture Collection 
ATP Adenosine 5’-triphosphate 
  
B2M beta-2-microglobulin 
Bcl-2 B-cell lymphoma/leukaemia-2 gene 
Bis-Tris bis(2-hydroxyethyl)amino-tris(hydroxymethyl)methane 
bp base pairs 
BOC butyloxycarbonyl protecting group 
BSA bovine serum albumin 
  
C (Cys) cysteine 
C cytosine 
cad cadaverine 
cDNA complementary DNA 
CEA6 carcinoembryonic antigen 6 
CHO Chinese hamster ovary derived cell line 
Conc concentration 
COS1 CV-1 in origin with SV40 genetic material cell line 
Cy cyanine 
CYC1 cytochrome c-1 
  
Da Dalton 
DARPin designed ankyrin repeat protein 
DCC N,N'-dicyclohexylcarbodiimide 
DCM dichloromethane 
DDS drug delivery system 
dH2O deionised water 
DLR dual luciferase reporter 
DLS dynamic light scattering 
DMAP 4-dimethylaminopyridine 
DMF N,N-dimethylformamide 
DMSO dimethyl sulfoxide 
DNA deoxyribonucleic acid 
dNTP deoxy-nucleotide triphosphate 
DPBS Dulbecco's phosphate-buffered saline 
ds double stranded 
DTT dithiothreitol 
  
vii 
EDTA ethylene-diamine-tetra-acetic acid 
ELISA enzyme-linked immunosorbent assay 
EMCH N-ε-maleimidocaproic acid hydrazide 
Et ethyl 
equiv molar equivalent 
ex/em excitation/emission wavelengths 
  
FAD flavin adenine dinucleotide 
FBS foetal bovine serum 
Fc fragment crystallisable 
fluc firefly luciferase 
FITC fluorescein isothiocyanate 
FP forward primer 
FT-IR fourier transform infrared 
FACS Fluorescence-activated cell sorting 
  
G (Gly) glycine 
G guanine 
x g relative centrifugal force (x gravity) 
GAPDH glyceraldehyde 3-phosphate dehydrogenase 
GPC gel permeation chromatography 
GSH glutathione 
  
h hour 
1H proton 
HeLa Henrietta Lacks cell line 
Her2 human epidermal growth factor receptor 2 
His histidine 
HPLC high pressure liquid chromatography 
HRP horseradish peroxidase 
  
IgG Immunoglobulin G 
  
LAMP-1 lysosomal-associated membrane protein 1 
LAR luciferase assay reagent 
LDH lactate dehydrogenase 
LU light unit 
luc luciferase 
LSCM laser scanning confocal microscopy 
  
M molar (mol/litre) 
mAb monoclonal antibody 
MALDI matrix-assisted laser desorption/ionization 
Me methyl 
MES 2-(N-morpholino)ethanesulfonic acid 
min minute 
Mn number average molecular weight 
mol mole 
mol % molar percentage 
viii 
mRNA messenger RNA 
MS mass spectrometry 
MTT 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide 
Mw weight average molecular weight 
  
NAD nicotinamide adenine dinucleotide 
NMR nuclear magnetic resonance 
  
OD optical density 
orf open reading frame 
  
P-2-T pyridine-2-thione 
PA PEG grafted PLP 
PAA poly(aspartic acid)  
PBAA poly(α-butylacyrlic acid) 
PCR polymerase chain reaction 
PDI Polydispersity index 
PDPH 3-(2-pyridyldithio)propionyl hydrazide 
PEAA poly(α-ethylacrylic acid) 
PEG poly(ethylene glycol) 
PEI poly(ethyleneimine) 
PEO poly(ethylene oxide) 
PFA paraformaldehyde 
PGA poly(glutamic acid) 
Phe phenylalanine 
pKa acid dissociation constant 
PL-75 75 % L-leucine grafted PLP 
PLL poly(L-lysine) 
PLP poly(L-lysine isophthalamide) 
PP-50 50 % L-phenylalanine grafted PLP 
PP-75 75 % L-phenylalanine grafted PLP 
PPAA poly(α-propylacrylic acid) 
  
Rab Rabaptin 
redox reduction and oxidation 
RES reticulo-endothelial system 
RISC RNA-induced silencing complex 
Rluc Renilla luciferase 
RNA ribonucleic acid 
RNAi RNA interference 
RP reverse primer 
rpm rotations per minute 
RPMI Roswell Park Memorial Institute 
rRNA ribosomal RNA 
RT reverse transcription 
RT-qPCR real time – quantitative PCR 
rxn reaction 
  
SANS small-angle neutron scattering 
ix 
scFv single chain fragment variable 
Scr scrambled (non-targeted siRNA) 
SDS-PAGE sodium dodecyl sulphate-polyacrylamide gel electrophoresis 
sec second 
SEM standard error of the mean 
siRNA small interfering RNA 
SPDP N-succinimidyl 3-[2-pyridyldithio]-propionate 
SDHA succinate dehydrogenase subunit A 
ss single stranded 
  
t time 
T thymine 
TAE Tris base, acetic acid and EDTA 
TCEP-HCl tris(2-carboxyethyl)phosphine hydrochloride 
TFA trifluoroacetic acid 
TEM transmission electron microscopy 
TLC thin layer chromatography 
Tm melting temperature 
TMB 3,3',5,5'-tetramethylbenzidine 
TOF Time of Flight 
TY bacto-tryptone, bacto-yeast extract 
TYAG TY plus ampicillin, plus glucose 
TYAK TY plus ampicillin, plus kanamycin 
  
UTC untreated control 
  
V volt 
v/v volume per volume 
  
wt % weight percentage 
w/v weight per volume 
  
  
10 
Chapter 1 
1 Introduction 
This chapter presents an introduction to the basic concepts, advances and 
current status of stimuli-responsive, in particular pH-responsive, polymers developed 
for use in controlled drug delivery.  Entrapment and degradation of drug payloads 
within the endo-lysosomal trafficking pathway remains a major challenge to effective 
drug delivery.  PP-75, a biomimetic membrane-disruptive pseudo-peptide, belonging 
to a novel class of anionic pH-responsive polymers, directly addresses this challenge.  
The application and advantage of delivering therapeutic siRNA payloads in 
combination with polymeric delivery systems is discussed, followed by the concept of 
targeted drug delivery; whereby attachment of high affinity target-specific ligands onto 
delivery systems facilitates drug release at the required site of action.  Designed 
ankyrin repeat proteins (DARPins) capable of efficient tumour penetration are explored 
for this use.  Therefore in combination, drug delivery systems can enhance therapeutic 
drug potency resulting in more efficient disease-specific treatments. 
The chapter concludes by outlining the research project objectives and thesis 
structure, to provide context and understanding of the research presented herein. 
1.1 Stimuli-Responsive Polymers for Drug Delivery 
Stimuli-responsive, ‘smart’ polymers are characterised by their ability to sense 
and respond to environmental stimuli in a controlled manner. 
Physical stimuli, such as temperature and light, must overcome energetic 
thresholds in order to promote polymer responsive activity.  Chemical stimuli, for 
example, pH, redox potential, ionic strength or chemical agents, induce polymer 
activity by altering inter- and intra-molecular polymer interactions (Gil & Hudson 2004).  
Responsive behaviour occurs due to varying electrostatic interactions within the 
polymer as well as the hydrophilic and hydrophobic associations between the polymer 
and its environment.  Conformational transitions can occur due to swelling and/or 
contraction of cross-linked chains (Khare & Peppas 1995), coil-to-globule chain 
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transformations (Schild 1992), or self-assembly of amphiphilic polymer chains (Topp 
et al. 1997).  These shifts in structure consequently alter polymer solubility, hence 
responding to changes in their environmental stimuli. 
The concept of polymer-based drug delivery platforms, utilising stimuli-
responsive polymers, was subsequently proposed (Ringsdorf 1975).  Polymeric 
carriers, required to be non-toxic and non-immunogenic, have been developed with a 
view to achieving enhanced payload delivery.  To do so these delivery systems must 
first evade, or overcome the common barriers faced by therapeutic drugs for the 
treatment of disease in vivo. 
1.2 Challenges, Barriers and Opportunities for Intracellular Delivery 
A series of systemic and subcellular barriers must be overcome to facilitate 
delivery of membrane-impermeable payloads such as macromolecules, small 
molecule drugs and biopharmaceuticals to their target sites within the cell interior. 
The intracellular delivery of free drugs is often inefficient, attributable to low their 
stability, resulting in loss of drug maintenance within the bloodstream (Pack et al. 
2005).  Rapid elimination by the reticulo-endothelial system (RES) in conjunction with 
renal clearance further hinders systemic circulation, preventing subsequent target cell 
accumulation (Dickson & Gagnon 2004, Dincer et al. 2005).  Intracellular polymeric 
drug delivery systems (DDS) therefore face these same systemic barriers.  Factors 
such as polymer concentration, size, molecular weight (Mw) and charge density all 
impact upon cellular internalisation (Thomas et al. 1994, Matthews et al. 1996).  
Improving the efficacy of intracellular polymeric delivery is later addressed (Section 
1.7 and 1.8); however, application of pH-responsive polymers, as the primary focus of 
this thesis herein, more directly addresses the intracellular challenges faced by drugs 
once they reach the cell, and as such are discussed first. 
For efficient intracellular delivery, payloads must pass through the cell 
membrane and into the cell interior.  Nanoparticle DDS are often too large (typically 
50 - 200 nm) to circumvent the extracellular membrane via diffusion (Luo & Saltzman 
2000) or pinocytosis (Pratten & Lloyd 1986) alone.  Direct penetration is reserved for 
small molecules, typically less than 1 kDa with a diameter of 1 - 2 nm, and therefore 
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do not compromise cell membrane integrity (Goda et al. 2010).  Two main and distinct 
mechanisms of cell entry can therefore be employed for uptake of larger 
macromolecules (Figure 1.1). 
 
Figure 1.1: Common Mechanisms of Endocytosis for Macromolecular Cell Entry. 
In mammalian cells several different mechanisms of cell uptake and internalisation are observed that 
occur constitutively or as a result of ligand binding which drives internalisation. 
1) Clathrin-independent endocytosis encompasses several methods of uptake including 
macropinocytosis, where the plasma cell membrane invaginates inwards into the cell and fuses 
with the endosomal pathway, and caveolin mediated uptake, involving cholesterol coated pits; 
although the most common route of clathrin-independent uptak it is not observed in all cells. 
2) Clathrin-mediated endocytosis is considered the most common method of uptake.  It is a dynamic 
process that occurs constitutively within the cell, mediated by the protein clathrin, which forms a 
clathrin-coated pit on the interior surface of the cellular plasma membrane.  The pit buds into the 
cell to form a coated vesicle in the cytoplasm of the cell, it is then trafficked into the endosomal 
pathway. 
Adapted from Marsh & Helenius 2006. 
Non-specific adsorption and receptor mediated uptake occurs via endocytosis 
(Sieczkarski & Whittaker 2002, Christie & Grainger 2003); whereby membrane-bound 
vesicles bud in from the cell surface, by a process of invagination, to form endosomes.  
Clathrin-dependent, receptor mediated endocytosis, is the most common route of 
entry for macromolecules (Mellman 1996).  Clathrin protein molecules are recruited to 
the surface of the intracellular membrane and form coated pits that mature into 
endosomes (Tuma & Hubbard 2003).  Uptake is rapid, with transition from the 
extracellular to the intracellular environment typically occurring within 2 - 3 minutes 
(Mukherjee et al. 1997, Mellman & Warren 2000). 
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Subsequent to endocytotic uptake, intracellular fate remains uncertain and 
internalised macromolecules are located within endosomal organelles.  Rapid 
acidification of early endosomes, ranging between pH 6.0 - 6.8, from physiological pH 
7.4, accompanies vesicle maturation and trafficking toward late-stage endosomes at 
pH 5.0 - 6.0 (Mulligan 1993, Stayton et al. 2005, Pack et al.2005).  Systematic 
acidification occurs following the active influx of protons delivered via endosomal 
membrane-bound ATP-dependent proton pumps (Mukherjee et al. 1997).  Further 
acidification promotes fusion to lysosomes.  The increasingly acidic concentration 
gradient stimulates the activation of lytic proteases, with lysosomal degradation 
facilitated at pH 4.5 - 5.5 (Authier et al. 1996).  Endo-lysosomal trafficking speeds vary 
and can extend from 30 - 60 minutes (Mellman 1996, Murthy et al. 2003a) to over 
several hours (Pack et al. 2005).  This represents a significant intracellular challenge; 
many drugs susceptible to enzymatic degradation are rendered ineffective as a result 
of inefficient trafficking to the intended intracellular target sites (Mukherjee et al. 1997, 
Stayton et al. 2005).  Internalised agents must therefore overcome the endo-lysosomal 
trafficking barrier and avoid compartmentalisation and accumulation within the 
adverse endosomal vesicles (Mellman 1996, Sheff 2004).  Endosomal escape, 
resulting in cytoplasmic release of payloads is therefore necessary to avoid such an 
outcome (El-Sayed et al. 2005a, Varkouhi et al. 2011). 
De Duve first reported the concept of hijacking cellular endocytosis for 
lysosomotrophic drug delivery (de Duve et al. 1974).  Key to realising this idea is the 
development of agents that can escape the endosomal maturation pathway.  Following 
passage through the cell membrane bilayer, pH-responsive polymeric DDS are able 
to respond to the decreasing pH gradient (Yessine & Leroux 2004), therefore inducing 
membrane disruption prior to lysosomal degradation of drug payloads.  Endocytosed 
payloads are subsequently released into the cytoplasm facilitating delivery to the cell 
interior (Murthy et al. 2003b).  Endocytotic uptake offers advantages enabling direct 
entry deep into the cell cytoplasm, utilising molecular motors to facilitate intracellular 
movement and bypassing intracellular challenges of cytosolic crowding (Marsh & Bron 
1997, Marsh & Helenius 2006).  Promotion of endocytosis is therefore desirable to 
enhance intracellular delivery. 
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Viral cell entry mechanisms provide valuable insight into the properties required 
for development of efficient polymeric delivery systems.  Amphiphilic peptides within 
the viral protein coat undergo protonation and facilitate membrane destabilisation as 
a result of endosomal acidification.  The viral genome is subsequently delivered to the 
cell interior, enabling viral reproduction and spread of infection following cell death.  
Despite high transfection efficiency (Wagner et al. 1992), the potential application of 
viral gene delivery is limited due to inherent viral cell tropisms and worries over large-
scale production.  Viral toxicity, ability to illicit an immune response and potential 
reversion to wild-type are also often considered as disadvantages to viral delivery 
methods in clinical use (McTaggart & Al-Rubeai 2002, Dincer et al. 2005, Knight et al. 
2013).  Nonetheless the use of recombinant virus, where viral DNA is replaced, and 
synthetic viral peptides, have been extensively investigated; further indicating the 
mechanisms of effective endosomal drug escape. 
1.3 pH-Responsive Endosomolytic Polymers 
pH-responsive polymers that sense and respond to pH changes in the 
extracellular and/or intracellular environment are ideally suited for drug delivery 
applications.  pH profiles vary within the body, for example the acidic pH within the 
stomach, at pH 2, contrasts with the more alkaline pH of the lower intestine around pH 
6.2 - 7.5.  The intracellular endo-lysosomal trafficking pathway, as discussed, also 
exhibits an increasingly acidic pH profile, with endosomal pH ranging from 5.0 - 6.8, 
and lysosomal pH from 4.5 - 5.5 (Mellman 1996, Mukherjee et al. 1997).  Unhealthy, 
inflamed or diseased tissues also often demonstrate altered pH profiles compared with 
healthy tissues (Ganta et al. 2008).  Low extracellular pH is the distinguishing 
characteristic of many solid tumours resulting from the higher conversion rate of 
glucose into glycolic acid by the tumour cells, so called the ‘Warburg Effect’ (Warburg 
et al. 1926).  Intracellular pH remains similar to healthy tissue.  Dependent on cancer 
type, acidic tumour microenvironments ranging across pH 6.5 - 7.2 (Vaupel et al. 1989, 
Robey et al. 2009, Pu et al. 2012), can result in the protonation of chemotherapeutic 
payloads such as doxorubicin and vincristine (Raghunand et al. 1999, Raghunand & 
Gillies 2000, Gerweck et al. 2006).  Subsequent drug uptake is therefore affected.  pH-
responsive polymers can exploit these differing pH microenvironments exhibited 
15 
across the body, facilitating protective and controlled delivery to specific cellular 
locations (Kataoka et al. 2000, Liechty et al. 2010). 
When applied as intracellular DDS, pH-responsive polymers are capable of 
circumventing the intracellular delivery barriers.  Successful cell entry and avoidance 
of lysosomal degradation occurs following endosomal membrane disruption and 
subsequent endosomal escape (Figure 1.2). 
 
Figure 1.2: pH-Responsive Polymers for Drug Delivery. 
pH-responsive polymers are able to overcome endo-lysosomal trafficking following exposure to acidic 
pH.  The polymers undergo conformational change to induce endosomal membrane destabilisation, 
facilitating the intracellular delivery of drugs to the cell cytoplasm.  Reproduced from Duncan 2003. 
pH-responsive endosomolytic DDS are required to be essentially non-lytic at 
pH 7.4 and efficiently facilitating cytoplasmic delivery at mildly acidic environments 
across a pH range 5.9 - 6.8 (Mellman 1996, Mukherjee et al. 1997). 
Triggered by exposure to low pH, synthetic polymers containing multiple 
ionisable functional groups, are capable of buffering against the changes in pH.  These 
groups may be basic amino or, acidic carboxylic or sulfonic acid groups (Na & Bae 
2005b) (Figure 1.3).  The presence of these ionisable groups facilitates polymer 
response as a result of changes in the cellular environment (Eccleston et al. 2005, 
Marsh & Helenius 2006).  A reversible shift from non-active conformations, typically at 
physiological pH, toward functionally activated polymer forms occurs on exposure to 
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increasingly acidic environments, and pH-dependent protonation.  pH reduction below 
polymer pKa profile results in either conformational swelling or coil-to-globule 
aggregation (Olea & Thomas 1989).  These phase changes result from the respective 
disassociation or association of hydrophobic polymer regions, influencing functional 
endosomolytic activity (Stayton et al. 2005, Dincer et al. 2005). 
 
Figure 1.3: pH-Dependent Ionisation of Polyelectrolytes. 
Cationic polymers e.g. poly(N.N’-diethylaminoethyl methacrylate) undergo responsive-swelling upon 
acidification.  Anionic Polymers e.g. poly(acrylic acid) form compact, hydrophobically stabilised, globular 
structures upon acidification.  Adapted from Na & Bae 2005b. 
pH-mediated membrane interactivity therefore relies on polymer characteristics 
regarding hydrophobicity, surface-charge and number of available functional groups 
(Liechty et al. 2010).  The balance of hydrophobic associations and electrostatic 
repulsions between substituent groups influences polymer conformation (Tonge & 
Tighe 2001, Chen et al. 2009b).  Endosomal escape may be achieved in several ways 
dependent on polymeric properties (Varkouhi et al. 2011).  Insertion of complexes into 
the membrane to destabilise bilayer structure, endosomal membrane pore formation, 
and endosomal pH buffering all result in osmolytic bursting (Boussif et al. 1995, Murthy 
et al. 2003a, Varkouhi et al. 2011). 
Successful pH-responsive polymeric DDS are not only required to facilitate 
endosomal escape.  Other desirable properties include high aqueous solubility, lack 
of immunogenicity and the absence of off-target toxicity.  DDS can also offer more 
than just a protective shell for their cargos, ideally improving drug efficacy, stability 
Cationic
Anionic
17 
and biocompatibility, whilst also ensuring target-specific payload release.  To avoid 
bioaccumulation post-delivery, DDS are also required to be biodegradable to allow 
excretion from the body. 
Generally classified as either cationic or anionic delivery agents, polymeric 
micelles (Wang et al. 2005), poly (amino acids) (Al-Muallem et al. 2002) and 
biomimetic pseudo-peptidic polymers (Eccleston et al. 2000) have been developed, 
demonstrating pH-responsive activity as a result of their structural conformation 
(Liechty et al. 2010). 
1.4 Cationic Polymers 
Positively-charged polycations were first developed for use as non-viral DDS; 
hypothesised to interact favourably with the negatively-charged endosomal 
membrane.  Cationic polymers exhibit rapid and enhanced cell uptake in comparison 
to other DDS (Matthews et al. 1996). 
Endosomolytic activity at acidic pH is facilitated by the high-charge density of 
cationic polymers, attributed to the presence of ionisable amine groups.  Proton-
sponge polymers (Figure 1.4) mediate endosomal escape due to the presence of 
multiple, secondary and tertiary amine groups, with pKa values ranging across 
physiological and lysosomal pH (Hoffman 2013).  The active influx of protons, via 
ATPase proton pumps, following endosomal acidification, facilitates cationic polymer 
protonation.  The polycation acts as a proton-sponge; exposed amine groups buffer 
against increasing endosomal acidification and neutralise excess protons (Behr 1997).  
An additional influx of protons is pumped into the endosome in comparison to the non-
buffered state; this increasing positive charge is paralleled by an influx of negatively-
charged counter ions.  Osmotic pressure within the endosome increases and 
endosomal swelling results in membrane rupture (Pack et al. 2005, Liechty et al. 
2010).  Endocytosed agents are therefore delivered to the cytoplasm (Kircheis et al. 
2001, Akhtar & Benter 2007). 
18 
 
Figure 1.4: Cationic Proton-Sponge Polymers. 
Cationic polymers buffer the pH change in endo-lysosomal vesicles and induce the further influx of 
protons and counter-ions into these vesicles to compensate.  The increasing osmotic pressure within 
the vesicle causes the endosome to swell and rupture.  Reproduced from Pack et al. 2005. 
Cationic polymers demonstrate pH-dependent swelling with progression from 
physiological to lysosomal pH.  Compact polycations become more hydrophilic, 
displaying open or swollen forms following acidification and protonation of amine 
groups (Lavignac et al. 2005).  In addition, electrostatic and hydrophobic interactions 
between positively-charged polymer groups and the negatively-charged endosomal 
membrane influence membrane destabilisation (Eccleston et al. 2000, Yessine et al. 
2003). 
Polycationic DDS are considered popular due to the increasing application of 
gene therapy and use of anionic nucleic acid therapeutics.  The electrostatic 
complexation of nucleic acids with cationic systems interacts with the negatively-
charged endosomal membrane and therefore facilitates the delivery of nucleic acids 
to intracellular target sites following endocytosis (Kircheis et al. 2001, Akhtar & Benter 
2007). 
1.4.1 Poly(L-lysine) (PLL) 
PLL was one of the first cationic polymers used to deliver nucleic acids 
intracellularly (Zauner et al. 1998).  Low cytotoxicity and the biodegradable nature of 
PLL make it an attractive in vivo agent; however, the presence of only primary amine 
groups results in a less membrane-disruptive polymer.  PLL is therefore fully 
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protonated prior to entering the endo-lysosomal pathway and cannot initiate 
endosomal membrane disruption (Alexander 2006).  Owing to limited intracellular 
delivery and poor transfection efficiency the use of PLL on its own is limited.  
Functional modification to alter polymer pKa and proton-sponge capabilities could 
further the use of PLL as a DDS (Pack et al. 2000, Putnam et al. 2003). 
1.4.2 Poly(ethyleneimine) (PEI) 
Another cationic pH-responsive polymer, PEI (Behr 1997, Kircheis et al. 2001) 
is capable of effective intracellular delivery following membrane destabilisation (Pack 
et al. 2005).  PEI has been widely used for in vitro and in vivo intracellular delivery for 
20 years (Boussif et al. 1995, Erbacher et al. 2004).  PEI demonstrates effective 
transfection efficiency, influenced by the presence of primary, secondary and tertiary 
amine groups that give rise to multiple physiologically relevant pKa values for the 
polymer.  Less than 20% of these amine groups are protonated at physiological pH 
(Suh et al. 1994, Behr 1997).  Protonation following endosomal acidification alters 
polymer conformation, facilitating membrane-lytic behaviour and delivery of 
therapeutic agents.  This has been demonstrated in vivo whereby non-covalent 
complexation of siRNA to PEI has resulted in the reduction of tumour growth following 
siRNA delivery to mouse tumour models (Urban-Klein et al. 2004, Twaites et al. 2005). 
The clinical use of cationic polymers is however limited.  Polycationic delivery 
systems often lack biocompatibility due to instability resulting from their positive 
charge.  Non-specific interaction and off-target adsorption of serum proteins, anionic 
molecules and cell components can occur (Plank et al. 1996) limiting systemic polymer 
circulation and inducing immunogenicity (Putnam et al. 2003).  The electrostatic 
interaction between cationic polymers and the negatively charged cell membrane, 
whilst proposed as a favourable interaction, often results in polymer induced 
cytotoxicity, owing to a lack of cell specific interaction, thus limiting the wider 
application of polycations.  Further to this, the non-degradable nature of such cationic 
polymers results in their cytotoxic accumulation within target cells, further enhancing 
their immunogenicity (Murthy et al. 1999, Kircheis et al. 2001). 
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Polymers able to mimic the buffering capacity of polycations, between 
physiological pH and endo-lysosomal pH 5.0 - 6.8 have therefore been explored as 
promising candidates for effective intracellular delivery. 
1.5 Anionic Polymers 
Anionic pH-responsive endosomolytic polymers have been designed to more 
closely mimic the structure and function of pH-responsive fusogenic viral peptides.  
These anionic polymers are classed as amphiphilic; composed of hydrophobic alkyl 
groups and ionisable carboxylate or sulfonate groups.  The interaction between 
hydrophobic polymer components and the hydrophobic cell membrane drives the 
association of anionic polymers with the cell or endosomal membrane (Yessine & 
Leroux 2004).  Biomimetic to viral proteins (Soliman et al. 2012) the pH within the 
endosome dictates polymer behaviour.  At physiological pH these amphiphilic 
polymers are hydrophilic.  On endosomal acidification, hydrophobicity increases 
inducing polymer associated membrane-destabilisation.  Anionic polymers undergo 
pH-responsive endosomal escape facilitating intracellular delivery, and demonstrating 
a similar delivery strategy to their viral counterparts (Chen et al. 2009b, Soliman et al. 
2012). 
Decreasing endosomal pH results in the protonation of the weakly charged 
ionisable groups that are present along the anionic backbone.  Electrostatic repulsion 
along the backbone decreases and polymer hydrophobicity increases, altering the 
hydrophilic-to-hydrophobic balance of polymer components.  Extended hydrophilic 
polymer coils condense to compact globular structures, stabilised by polymer 
hydrophobicity (Na & Bae 2005a, Chen et al. 2009b) (Figure 1.5).  The balance 
between electrostatic interactions of the charged carboxyl groups, and the 
hydrophobic interaction of the alkyl groups, is dependent on endosomal pH (Tonge & 
Tighe 2001).  The coil-to-globule transition facilitates amphipathic polymer association 
with the endosomal membrane; destabilisation occurs with increasing hydrophobic 
association (Murthy et al. 2003b, El-Sayed et al. 2005b, Lavignac et al. 2005).  Delivery 
into the cell interior is facilitated, following release of endocytosed payloads (Tonge & 
Tighe 2001, Yessine & Leroux 2004, Liechty et al. 2010).  Membrane-lytic activity is 
effective within the pH range of conformational transition (Chen et al. 2005) and 
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endosomal release occurs before the onset of polymer precipitation which would 
render DDS inactive (Chen et al. 2009b). 
 
Figure 1.5: Anionic Polymer Coil-to-Globule Transition. 
At neutral pH, anionic polymers remain in extended conformation; negative charge maintains 
electrostatic repulsion along the polymer backbone.  As pH decreases becoming more acidic, the 
presence of protons (H+) in the environment neutralise the negative polymer charge.  A conformational 
shift occurs as the polymer is no longer restricted to a linear conformation.  Once neutralised, 
hydrophobic polymer interactions dominate to maintain a stabilised globular structure capable of 
insertion into the hydrophobic membrane lipid bilayer. 
Polyanionic delivery systems have been widely developed, ranging from non-
biodegradable poly(vinyl)s (Pack et al. 2005) to biodegradable poly(amino acid)s (Al-
Muallem et al. 2002) and pseudo-peptides (Eccleston et al. 1999, Eccleston et al. 
2000). 
1.5.1 Poly(vinyl)s 
The membrane solubilisation effects of pH-responsive poly(carboxylic acids) 
demonstrating liposomal membrane disruption were first published by Tirrell et al. 
(Tirrell et al. 1985, Thomas et al. 1994, Thomas et al. 1995).  Similar vinyl-based 
polymers able to disrupt cell and endosomal membranes in acidic environments were 
also developed.  Poly(α-ethylacrylic acid) (PEAA) is non-endosomolytic at 
physiological pH but demonstrates a sharp transition to a functionally active, 
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membrane-lytic polymer on exposure to acidic endosomal pH (Murthy et al. 1999, 
Lackey et al. 2002).  Hoffman et al. also designed a set of pH-responsive poly(vinyl)s 
with similar hydrophobic moieties.  These included α-alkyl acrylic acids and alkyl 
acrylates that demonstrate pH-dependent membrane disruption with pKa profile 
ranges corresponding to endo-lysosomal pH (Yessine et al. 2003, Kusonwiriyawong 
et al. 2003, Yessine & Leroux 2004). 
Modification of PEAA to poly(α-propylacrylic acid) (PPAA) via addition of a 
methylene group, demonstrated 15-fold more efficient membrane haemolysis (Murthy 
et al. 1999, Stayton et al. 2000).  Increasing alkyl group length, and therefore 
hydrophobicity, enhances membrane-disruptive activity (Murthy et al. 1999, Stayton 
et al. 2005).  The pKa profile of PPAA corresponds to membrane destabilisation at 
endosomal pH 6.0 (Pack et al. 2005).  Haemolysis by poly(α-butylacyrlic acid) (PBAA) 
containing three methylene groups, shifts functional activity to physiological pH, and 
is not used as an effective DDS (Murthy et al. 2001).  The altered pKa profiles of these 
anionic polymers indicate pH-responsive activity is influenced by the increasingly 
hydrophobic nature of the extended alkyl groups (Murthy et al. 1999, Stayton et al. 
2005).  The ratio of carboxylic to hydrophobic groups is key to controlling pH-
dependent membrane disruption (Pack et al. 2005).  PPAA has demonstrated 
successful cytoplasmic delivery of an antibody complex and streptavidin (Lackey et al. 
2002, Stayton et al. 2005).  Despite promise as intracellular delivery systems, pH-
responsive vinyl-based polymers present major drawbacks for clinical use as their 
carbon-carbon backbones are not readily biodegradable (Matthews et al. 1996).  The 
use of poly(vinyl)s are therefore limited by their size; molecular weight must be less 
than the renal exclusion threshold of 40 kDa (Duncan 2006) to avoid bioaccumulation 
and allow systemic clearance (Seymour et al. 1987).  Consequently circulation time 
within the blood stream is limited by RES clearance (Garnett 2001, Duncan 2006).  To 
address this problem, hydrolytic or enzymatically degradable linkages, such as 
amides, anhydrides or esters can be integrated within polymer backbone design 
(Eccleston et al. 1999).  Amide bond-containing poly(amino acid)s and amphiphilic 
pseudo-peptidic polymers that demonstrate membrane-active, biodegradable and 
biocompatible characteristics have since been developed (Eccleston et al. 2000, Al-
Muallem et al. 2002). 
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1.5.2 Poly(amino acid)s 
Biodegradable anionic poly(amino acid)s are ideal for use as systemic drug 
delivery agents.  Consisting of repeated amino acid units forming the polymer chain, 
examples include poly(aspartic acid) (PAA), poly(glutamic acid) (PGA) and their 
derivatives.  Ionisable carboxylic acid side-chain groups enable anionic poly(amino 
acid)s to respond to pH change, resulting in membrane disruption (Chen 2013).  Drug 
solubility and stability may be increased following attachment and, with modification 
poly(amino acid)s are capable of self-assembly into micelles, nanofibers and solid 
nanoparticles, effectively encapsulating their payloads (Lalatsa et al. 2012).  The 
straightforward derivatisation of amino acids enables easy modification of poly(amino 
acid) backbones; altering DDS properties as desired.  As DDS they demonstrate low 
toxicity, are less likely to raise an adverse immune response and are easily 
metabolised in vivo due to their biodegradable nature (Sigma-Aldrich 2015). 
1.5.3 Pseudo-Peptidic Polymers 
Amphiphilic pseudo-peptides, similar in design to poly(amino acid)s have been 
synthesised to more closely mimic the function and conformational activity of viral 
fusogenic peptides (Chen et al. 2009c).  These polymers incorporate alternating 
hydrophobic aromatic, and charged carboxyl, groups into their linear backbone.  They 
offer enhanced biocompatibility and biodegradability over many other synthetic 
polymers, and as such demonstrate greater adaptability and potential clinical use. 
1.5.3.1 Poly(L-lysine isophthalamide) (PLP) Polymers 
PLP is an anionic pH-responsive amphiphilic poly-amide, developed by 
Eccleston et al. (Eccleston et al. 1999, Eccleston et al. 2000) (Figure 1.6 (a)).  Typical 
PLP molecular weight is reported at 35.7 kDa, number-average molecular weight (Mn) 
at 17.9 kDa, and with a polydispersity index (PDI) of 1.99 (Eccleston et al. 2000, Yue 
et al. 2005a).  PLP is synthesised via the polycondensation of aqueous L-lysine methyl 
ester dihydrochloride, with an equivalent quantity of isophthaloyl chloride in acetone.  
Subsequent hydrolysis in DMSO with ethanolic sodium hydroxide yields a water 
soluble polymer form (Eccleston et al. 1999, Eccleston et al. 2005).  PLP is 
metabolically derived, demonstrating limited cytotoxicity and advantage over other 
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anionic polymers, due to the presence of biodegradable amide bonds incorporated 
into the peptide-like polymer backbone.  PLP molecular weight is therefore not 
restricted by the renal-exclusion limit and degradation of the amide bonds facilitates 
polymer clearance post-delivery (Eccleston et al. 1999, Eccleston et al. 2000). 
 
Figure 1.6: PP-Polymer Units. 
(a) The poly(L-lysine isophthalamide) (PLP) polymeric unit. (b) The PLP polymeric unit with L-
phenylalanine grafted at the pendant carboxylic acid residue (in red). 
The hydrophobic PLP backbone with pendant carboxyl groups undergoes the 
coil-to-globule pH-dependent conformational transition typical of anionic polymers 
(Eccleston et al. 2004, Yue et al. 2005a, Dai et al. 2006).  Protonation of the exposed 
carboxylic acid groups collapses the extended hydrophilic polymer-chain to a compact 
hydrophobic globule.  Subsequent membrane disruption occurs over the narrow pH 
range of pH 4.6 - 5.0, associated with late stage endo-lysosomal trafficking (Chen et 
al. 2005, Chen et al. 2008). 
Despite potential application as a cytoplasmic DDS, PLP displays limited 
clinical use due to low membrane-lytic activity, approximately 15% haemolysis, and 
the low pH at which enhanced lysis occurs (Chen et al. 2005, Chen et al. 2008).  Endo-
lysosomal agents would ideally be activated within the endosomal pH range 5.0 - 6.8, 
ensuring avoidance of lysosomal degradation (Gruenberg & Maxfield 1995, Plank et 
al. 1996).  PLP lacks the pendant, hydrophobic alkyl groups present in viral peptides 
and vinyl polymers.  This is thought to contribute to the limited delivery efficacy 
displayed by PLP.  Membrane-disruptive polymer properties can be modulated 
(a) (b)
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following adjustment of polymer hydrophobicity; specifically, by conjugating 
hydrophobic moieties onto the polymer backbone (Murthy et al. 2001, Yessine & 
Leroux 2004).  Increasing the hydrophobicity of anionic polymers offers to improve 
cellular uptake as well as endosomal escape.  The close association of the 
hydrophobic polymer with hydrophobic membranes provides an additive effect (Lloyd 
et al. 1984).  Following acidification, protonation masks the charged backbone 
residues to overcome electrostatic repulsions; increased hydrophobicity enhances 
polymer activity (Lloyd & Williams 1984, Lloyd et al. 1984).  As a result, grafting of 
hydrophobic moieties onto PLP to synthesise the PLP derived, so-called ‘PV, PL and 
PP’ polymers was investigated.  L-valine, L-leucine and L-phenylalanine, the 
hydrophobic amino acids present in viral fusogenic peptides (Chen et al. 2009b), were 
grafted onto PLP pendant carboxyl groups, altering PLP polymer amphiphilicity and 
structure (Chen et al. 2009c).  These modifications enhanced membrane-disruptive 
activity and fine-tuned the active properties of PLP toward more desirable pH profiles.  
Functional activity of the amino-acid grafted-polymers is reportedly aligned more 
closely with early-to-late endosomal pH transitions (Chen et al. 2009c, Chen et al. 
2009b). 
A range of pH-responsive membrane-lytic profiles were established to define 
optimal polymer pH-transition range, indicating functional activity.  Systematic 
modification of the hydrophobic content, controlled by the degree of amino-acid 
grafting (between 30 – 100%), allowed for improved membrane-lytic efficiency.  pH-
responsive polymer behaviour, dependent on the degree of ligand grafting has also 
been reported elsewhere (Yue et al. 2005a, Yue et al. 2005b).  The more highly grafted 
polymers, demonstrating increased hydrophobicity, were the focus of further 
investigations. 
Physicochemical properties, specifically polymer conformation, the degree of 
hydrophobic grafting and pH induced aggregation were investigated.  Membrane-
disruptive activity, in vitro cytotoxicity, sub-cellular localisation and ability to facilitate 
the endosomal release of endocytosed materials into the cytoplasm were also 
explored (Chen et al. 2009b, Chen et al. 2009c). 
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The increased hydrophobicity of phenylalanine and leucine compared to valine, 
indicated that the more hydrophobic amino acids gave rise to more membrane lytic 
polymers, and increasing the pH of polymer precipitation.  The similarity in 
hydrophobicity of phenylalanine and leucine suggested that hydrophobicity was not 
the only factor to influence membrane lytic behaviour.  Phenylalanine grafted polymers 
have been described as displaying enhanced membrane-lytic activity due to the 
presence of π-π interactions between aromatic rings along the PLP backbone and the 
phenylalanine moieties (Chen et al. 2009a, Chen et al. 2009c).  This was investigated 
following synthesis of PY polymers; PLP grafted with the aromatic, non-hydrophobic 
amino acid tyrosine.  Despite the large difference in amino acid hydrophobicity 
between phenylalanine and tyrosine, little difference in the onset of pH-responsive 
activity was observed.  These findings indicated the influence of the aromatic ring 
presence on polymer pH-responsiveness and conformation change.  The pH of 
membrane disruption was not governed solely by hydrophobicity (Khormaee et al. 
2010). 
In general terms, increasing side chain hydrophobicity and the extent of side-
chain grafting resulted in an increased pH at which the onset of globular conformation 
transition occurred; therefore enhancing the limited lysis capacity of PLP.  Owing to 
their improved efficacy for membrane disruption, the PP (phenylalanine grafted) 
polymers became the focus of subsequent investigations for intracellular delivery. 
1.6 PP-75 
PLP grafted with phenylalanine at a 75% stoichiometric molar substitution, 
resulted in PP-75, shown to be the most promising for use as an intracellular DDS 
(Chen et al. 2009c) (Figure 1.6 (b)).  Despite the molar synthesis ratio (the number of 
phenylalanine grafts per 100 carboxylic acid groups along the PLP backbone) 
characterisation of PP-75 via 1H-NMR confirmed the actual degree of phenylalanine 
grafting to be in the region of 63%.  Therefore PP-75 molecular weight is reported as 
49.55 kDa, number average molecular weight as 24.94 kDa, and a 1.99 polydispersity 
index (Chen et al. 2009c). 
PP-75 demonstrates optimum membrane-disruptive activity between pH 6.0 - 
7.0.  In a model cell system, 0.5 µM PP-75 demonstrated 90% haemolysis at pH 6.5, 
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whilst being essentially non-lytic, and displaying no functional activity at physiological 
pH 7.4 (Chen et al. 2009c).  The efficiency in membrane destabilisation occurs as a 
result of significantly enhanced hydrophobic interactions between PP-75 and the cell 
membrane; owing to the hydrophobicity and aromatic presence within side-chain 
grafts (Zhang et al. 2011).  The conformational transition of PP-75, occurs with an 
increasingly acidic environment and is analogous to the change in pH observed during 
the maturation of the endo-lysosomal pathway, as described previously.  This activity 
is not yet fully understood, and it remains unclear as to whether the potential of PP-75 
as a DDS is as a result of pore formation within the endosomal membrane (Khormaee 
et al. 2012), entire disruption and destabilisation of the endosomal membrane (Chen 
et al. 2009c), or via direct membrane penetration (Lynch et al. 2011).  PP-75 
membrane-disruptive behaviour is reported as 35-fold greater than that of melittin, a 
highly lytic bee-sting peptide (Chen et al. 2009c).  This pH-dependent highly lytic 
functional profile demonstrates the potential of PP-75 as an effective intracellular DDS, 
facilitating cytoplasmic delivery and avoiding lysosomal payload degradation. 
The presence of carboxylic acid groups along the PLP and PP polymer 
backbones gives rise to their net-negative charge.  PP-75 membrane destabilisation 
demonstrates that anionic polymer negative charge does not prevent efficient cellular 
uptake.  Electrostatic repulsion between anionic PP-75 and the negatively charged 
cell membrane is either negligible or overcome by the hydrophobic association of the 
polymer and membrane (Khormaee et al. 2012).  In addition, anionic polymers are 
less likely to bind negatively-charged serum proteins in vivo, therefore preventing 
polymer inactivation.  Serum stability is a crucial factor for successful drug delivery.  
Many cationic DDS become inhibited following protein aggregation due to their 
electrostatic attraction and interaction with components present in serum (Richards-
Grayson et al. 2006, Whitehead et al. 2009, Khormaee et al. 2012). 
PP-75 has been used to deliver a range of small molecule model drugs and 
biotherapeutics both in vitro and in vivo (Liechty et al. 2009, Chen et al. 2009c, 
Khormaee et al. 2012).  Delivery of fluorescent calcein, and fluorescently-labelled 
apoptin, a small tumour specific apoptosis-inducing protein, into adherent cancer cell 
cultures has been achieved by simply mixing PP-75 with the payloads (Chen et al. 
2009c, Liechty et al. 2009).  The potential for efficient tumour cell penetration and 
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delivery is also demonstrated, with PP-75 retaining membrane-lytic activity in 3D HeLa 
cell spheroid cultures (Ho et al. 2010).  PP-75 delivery of fluorescein isothiocyanate 
(FITC) dye and nucleic acid payloads following conjugation with the polymer (Section 
1.7) (Chen et al. 2009c, Khormaee et al. 2012) has been observed.  The subcutaneous 
treatment of malignant glioma cells with PP-75 covalently loaded with small interfering 
RNA (siRNA) (Section 1.7.2) was reported to successfully inhibit tumour growth, 
therefore demonstrating effective intracellular delivery (Khormaee et al. 2012). 
PP-75 has therefore been proposed as a promising non-toxic and effective 
candidate for intracellular therapeutic drug delivery following pH-responsive 
endosomolysis (Khormaee et al. 2012). 
1.7 Polymer-Drug Conjugates 
Biologic based macro-drugs are promising therapeutic candidates with 
macromolecular and gene therapeutics currently under development and in clinical 
trials to treat a range of disease types including cancers (McNeish et al. 2004, Craik 
et al. 2013).  These highly specific biological agents often fall into the class of proteins 
such as antibodies, hormones, therapeutic enzymes or synthetic oligopeptides, or, 
nucleic acids, for example plasmid DNA, antisense oligonucleotides or siRNAs (Dincer 
et al. 2005) (Section 1.7.2).  There is increasing interest in bringing these drug classes 
to market owing to their high target specificity and efficiency in modulating intracellular 
interactions (Guillard et al. 2015). 
However, following systemic administration, these already unstable protein and 
nucleic acid payloads are subject to several challenges within the extracellular 
environment and can lead to a loss of functionality (Pack et al. 2005).  As a 
consequence these biotherapeutics require more frequent administration and at 
higher dosages, resulting in amplification of non-specific cytotoxicity and adverse side-
effects (Kimura et al. 1987).  Their potential clinical use is therefore limited. 
To understand the application and advantages of conjugated delivery, the 
extracellular challenges applicable to delivery systems are discussed.  The rapid and 
premature elimination of many drugs from systemic circulation is common place as a 
result of RES clearance and renal filtration.  These two functions prevent effective drug 
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delivery by decreasing drug availability and preventing cellular accumulation (Poste 
1983, Adams et al. 2003, Christie & Grainger 2003).  The ability to avoid these 
clearance mechanisms can therefore prolong drug circulation; the influencing factors 
to avoiding clearance are likely to be a combination of size, charge, hydrophobicity 
and molecular weight.  Drugs of larger size or higher molecular weight are cleared 
much more slowly from the bloodstream.  Coupling drugs to polymers can therefore 
significantly enhance their systemic circulation.  By prolonging plasma residence time, 
drug penetration may be improved.  The molecular weight of polymeric DDS can be 
specifically designed and adjusted to overcome RES clearance and renal filtration.  
Carriers with a diameter larger than 200 nm demonstrate relatively high RES 
clearance (Litzinger et al. 1994), whilst those with a molecular weight above, the renal 
threshold limit of 40 kDa, for non-biodegradable polymers, will avoid renal clearance.  
Ensuring that polymer-drug conjugate properties overcome these limitations will 
enhance drug circulation time (Harris & Chess 2003, Duncan 2006). 
Once the extracellular barriers have been circumvented, biomacromolecules 
must still gain entry into the cell by traversing the extracellular membrane.  Owing to 
their large size and charge they are less easily endocytosed than small molecule 
drugs.  The combination of biological payloads with DDS can enhance the transport 
of different sized therapeutic payloads across the cell membrane. 
In the case of treating solid tumour cancers, delivery to target cells may be 
aided by tumour growth physiology through a mechanism known as the enhanced 
permeation and retention (EPR) effect (Matsumura & Maeda 1986).  The EPR effect 
is typical of solid tumours, owing to their increased vascular density resulting from 
rapid tumour angiogenesis.  The endothelial linings of tumour blood vasculature are 
more porous and permeable than in normal tissue.  Coupled with impaired lymphatic 
system clearance, the accumulation of polymer-drug conjugates in tumour 
microenvironments is readily aided by enhanced passive uptake (Maeda et al. 2009, 
Maeda et al. 2013).  By optimising polymer molecular weight, the size of polymer-drug 
conjugates can be controlled to maximize the benefits of EPR for delivery to solid 
tumour sites (Vicent et al. 2009). 
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Further argument for polymer-drug conjugation results from in vitro studies 
where DDS and their payloads are mixed, rather than conjugated, and delivered in a 
tightly controlled environment.  This however may not be representative of the 
distribution of free polymers and their payloads in vivo.  For DDS to demonstrate their 
functional effect they must be in close proximity to the payload they are delivering, 
therefore coupling of drugs to DDS are often required to maximise efficiency. 
Polymeric DDS have therefore been designed to facilitate covalent drug 
conjugation, electrostatic drug complexation, or drug encapsulation within the 
hydrophobic polymer core (Christie & Grainger 2003).  The covalent attachment of 
therapeutic agents onto polymeric DDS was first proposed by Ringsdorf in 1975 
(Ringsdorf 1975).  Consequently, the development of polymer-drug conjugates has 
received increasing impetus.  Ringsdorf’s model comprised of a minimum of three 
elements; (i) a water-soluble polymer, capable of trafficking the active drug, (ii) a 
covalently bound biodegradable linker, facilitating controlled drug release and (iii) the 
active payload, amenable to conjugation.  Adaptable polymer chemistry allows for the 
incorporation of multiple functional groups within the polymer backbone, allowing 
effective polymer-to-linker-to-payload conjugation.  Targeting moieties, to enable cell-
specific delivery and enhance uptake were also incorporated within this model and will 
be discussed separately (Section 1.8). 
DDS can also offer a protective advantage by physically encapsulating drug 
payloads to enhance delivery to diseased tissues and aid drug passage across the 
cellular membrane into the cytoplasm (siRNA therapeutics) or toward the nucleus 
(DNA and protein therapeutics).  The coil-to-globule transition of anionic polymer-drug 
conjugates may act to protect drug payloads, shielding them within the globular core 
prior to target cell accumulation (Yoo et al. 2011).  Protected delivery also offers to 
reduce untimely drug release and prevent non-specific interactions with healthy cells; 
an attractive benefit when delivering highly cytotoxic chemotherapeutic agents. 
The conjugation of biotherapeutics to polymeric DDS therefore improves their 
plasma-half-life (Garnett 2001).  Systemic circulation is enhanced and stability is 
improved as a result of polymers protecting their payloads against degradation.  
Conjugation can also improve drug solubility, colloidal stability and absorption profiles, 
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aiding drug formulations and ease of patient administration (Li & Wallace 2008, David 
et al. 2010).  The addition of the unstructured and hydrophilic polyethylene glycol 
(PEG) polymer is commonly used to enhance the solubility of drugs (Harris & Chess 
2003).  PEGylation therefore enhances the bioavailability of molecules, increasing 
systemic retention and drug association.  The earliest application of polymer-protein 
conjugates revolutionised anti-cancer therapeutic delivery with the introduction of 
styrene maleic anhydrideneocarzinostatin (SMANCS) and PEGylated proteins into the 
clinic in the 1990s (Duncan 2006). 
First generation polymer-drug conjugates focused on improving the efficacy 
and specificity of several small molecule, low molecular weight anti-cancer agents.  
Poor performance of compounds such as doxorubicin, camptothecin and paclitaxel, 
agents in routine clinical use, is a consequence of their rapid loss from the bloodstream 
due to RES clearance and renal filtration, therefore reducing target tissue drug 
accumulation.  To combat this loss in concentration, increasing chemotherapeutic 
doses are administered, leading to off-target interactions, undesirable side effects and 
toxicity in non-target tissues (Duncan 2006).  Polymer-drug conjugates that enhance 
the therapeutic distribution of these drugs have therefore been developed and entered 
into clinical trials (Duncan 2006, Vicent et al. 2009).  The aim of these therapies is to 
achieve effective drug delivery and controlled release; reducing adverse side-effects 
commonly associated with anti-cancer chemotherapeutics (Liechty et al. 2010).  More 
recently the successful delivery of macromolecular protein and nucleic acid biologic 
agents, to the cell interior has been shown (Yoo et al. 2011). 
Aside from polymer-drug conjugates, other polymeric drug formulations have 
been developed for use as non-viral DDS (Pack et al. 2005).  Examples include 
polymeric micelles (Lukyanov & Torchilin 2004, Hrubý et al. 2005) and multi-
component polyplexes; complexes of polymers and nucleic acids or proteins (Kuo & 
Hua 2003, Vinod 2005). 
Conjugation of therapeutic payloads to polymeric DDS, whilst offering many 
advantages, may also demonstrate potential drawbacks for both payloads and 
polymers.  Alteration of the polymeric hydrophobic-to-hydrophilic balance is likely to 
alter membrane functionality due to the interaction of charged biomacromolecules.  
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Drug loading capacity must therefore be considered.  Conjugation may also alter 
pharmacokinetic and pharmacodynamic drug properties, influencing drug release 
kinetics and potentially rendering drugs inactive (Kopeček et al. 2000, Liang et al. 
2005).  Therefore the biophysical properties of polymer-drug conjugates require 
functional characterisation before clinical use. 
1.7.1 Controlled Release of Payloads 
Polymer-drug conjugates are often classed as pro-drugs whereby cleavage of 
the drug from the carrier, generally via enzymatic activity is required for drug activity 
(Wang et al. 2012).  DDS are required to be stable in circulation but sensitive to the 
intracellular environment with release of payloads from the DDS offering to maximise 
functional drug interaction at the target site.  The controlled-release of payloads offers 
to constrain drug delivery to the target site or, allow sustained release over a prolonged 
period of time to maintain effective dosage (Langer 1998, Kopeček et al. 2000, Allen 
& Cullis 2004). 
Incorporation of linkages containing cleavable ester, amide or glycoside bonds 
between the DDS and payload facilitates release via hydrolysis.  Cleavage of these 
bonds often requires specific enzyme classes such as esterase, protease or 
glycosidases to catalyse the reactions (Haag et al. 2006, Leriche et al. 2012).  
Inclusion of acid-labile bonds, degradable within the endosomes, provides an obvious 
mechanism for pH-responsive polymer-payload release (Murthy et al. 2003a, Murthy 
et al. 2003b, Christie & Grainger 2003); however, many acid-sensitive groups degrade 
too slowly for use as unloading mechanisms, and lysosomal degradation may ensue 
(Pack et al. 2005). 
Thiol-containing disulphide-linkages, capable of rapid drug release when 
cleaved, hold greater potential (El-Sayed et al. 2005a, Meng et al. 2009, Wang et al. 
2012).  Oxidation of paired sulfhydryl groups that form the disulphide bond, can be 
chemically cleaved by mild reducing agents such as dithiothreitol (DTT) or tris (2-
carboxyethyl) phosphine (TCEP) (Leriche et al. 2012).  The key advantage to 
disulphide-linkages is the difference in redox potential between the extracellular 
(oxidising) and intracellular (reducing) environments. 
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This difference arises due to the increased concentration of cytoplasmic 
glutathione (GSH), an abundant thiol reducing agent at 0.5 – 10 mM intracellulary, 
relative to the low levels found extracellularly, between 2 - 20 μM (Meister 1991, Meng 
et al. 2009, Leriche et al. 2012).  Disulphide linked polymer-drug conjugates are 
therefore relatively stable in the extracellular environment, aiding delivery to target 
cells (Bulmus et al. 2003, Wang et al. 2012).  Following internalisation and subsequent 
endosomal escape, payloads are released having reached the reducing environment 
of the cytoplasm (Saito et al. 2003).  Free cysteine, also present intracellulary can act 
as another naturally occurring reducing agent, and has been identified in the 
endosomal fractions of some cell types (Pisoni et al. 1990, Gainey et al.1996).  
Furthermore, tumour-cell environments are known to be highly reducing, with at least 
4-fold higher concentrations of GSH reported in comparison to healthy tissues.  DDS 
containing cleavable disulphide linkages are therefore ideally suited for tumour-
specific drug delivery (Kuppusamy et al. 1998, Kuppusamy et al. 2002). 
1.7.2 siRNA Payloads 
The discovery of RNA interference (RNAi) and the potential use of synthetic 
small interfering RNA (siRNA) in the treatment of cancers (Fire et al. 1998, Behlke 
2006) has accelerated the therapeutic application of gene silencing over the past 15 
years (Whitehead et al. 2009).  siRNA is able to silence the expression of specific 
genes at the transcriptional level (Fire et al. 1998, Convertine et al. 2010), down-
regulating the production of a wide range of proteins, following selective messenger 
RNA (mRNA) degradation (Elbashir et al. 2001, Convertine et al. 2010, de Fougerolles 
et al. 2007).  RNAi therefore offers sequence-specific, post-transcriptional silencing of 
target genes, achieved following the intracellular delivery of siRNA into the cytoplasm 
(Fire et al. 1998, Elbashir et al. 2001). 
Long double stranded RNA (dsRNA) molecules of over 100 nucleotides, are 
enzymatically processed by Dicer and RNase III, into siRNA fragments of 21 - 25 base-
pairs long (Hammond et al. 2001).  These cleaved siRNAs are then presented to the 
RNA-induced silencing complex (RISC), a ribonuclear protein within the cytoplasm.  
RISC is a multi-protein complex that contains nuclease, helicase and RNA-dependent 
polymerase enzymes that target and degrade specific mRNAs (Muratovska & Eccles 
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2004).  Upon double stranded siRNA complexing with RISC, the sense strand is 
cleaved (de Fougerolles et al. 2007) and the antisense strand guides RISC toward the 
complementary target mRNA.  Gene expression is silenced as RISC RNase activity 
cleaves the target mRNA, preventing translation, and therefore inhibiting protein 
synthesis (Meister et al. 2004, Song et al. 2004).  The activated RISC complex can be 
recycled, cleaving multiple mRNA’s before inactivation (Figure 1.7).  The site of siRNA 
activity is within the cytoplasm where the RISC protein is located. 
 
Figure 1.7: Mechanism of RNA Interference. 
dsRNA in the cytoplasm is cleaved into siRNA by the Dicer enzyme.  siRNA can alternatively be 
introduced directly into the cell.  siRNA is complexed to RISC resulting in sense strand cleavage.  The 
anti-sense strand recognising the complementary, target mRNA, binding and silencing gene 
expression.  The activated RISC complex can then be recycled.  Adapted from Whitehead et al. 2009. 
Synthetic siRNA mimics, analogous in length to Dicer cleaved siRNA, may be 
delivered directly into the cytoplasm, joining the interference pathway at the point of 
RISC recognition (de Fougerolles et al. 2007).  siRNA has shown high in vitro 
experimental efficacy and provides an ideal therapeutic candidate for intracellular 
delivery (Panyam et al. 2004).  Achieving successful cytoplasmic delivery will further 
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enhance the potential for delivery of DNA and protein therapeutics that require nuclear 
targeting. 
Despite their promise as a strategy for gene-therapy, several barriers prevent 
current effective use of siRNA therapeutics; specifically their instability and poor cell 
penetration.  Low siRNA molecular weight, approximately 13 - 15 kDa, prevents 
prolonged systemic circulation due to rapid elimination by renal filtration (Soutschek 
et al. 2004).  siRNAs are also subject to easy degradation by plasma nucleases.  
Cellular uptake and crossing of the cell membrane is limited by siRNA negative charge 
and size; unable to freely diffuse across the cell membrane lipid-bilayer, siRNA activity 
is often not preserved (Aagaard & Rossi 2007).  If cell entry is achieved following 
endocytosis, entrapment and accumulation of siRNA within the endosomes precedes 
their extracellular clearance and/or degradation by lytic enzymes of the lysosomes 
(Medina-Kauwe et al. 2005, Convertine et al. 2010).  Effective intracellular delivery of 
siRNA following cell uptake and intracellular endo-lysosomal trafficking is therefore 
still a major challenge (Convertine et al. 2010).  Delivery systems designed to enhance 
cellular uptake and facilitate release of siRNA from within the endosomes into the 
cytoplasm are therefore essential.  Delivery of siRNA has been demonstrated using 
pH-responsive liposomes and dendrimers, as well as cationic and anionic polymer 
systems (Whitehead et al. 2009, Endoh & Ohtsuki 2009, Khormaee et al. 2012). 
siRNA is therefore an ideal biotherapeutic payload candidate amenable to 
conjugation with pH-responsive polymers, to facilitate transport across the external 
cell membrane and into the cytoplasmic target site (Endoh & Ohtsuki 2009, Convertine 
et al. 2009, Khormaee et al. 2012). 
The wide application of siRNA therapeutics stems from their potential to 
specifically silence any gene and knockdown expression of any protein within a cell.  
Their high efficacy requires only a small number of siRNA molecules to reach their 
target site, resulting in large reductions in target expression (de Fougerolles et al. 
2007). 
siRNA targeting the expression of stathmin, a chemo-resistant protein essential 
to cell-cycle and growth was covalently linked to PP-75 via SPDP-cad, a cross-linking 
molecule that contains a cleavable disulphide-bond.  Treatment with this PP-75-siRNA 
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conjugate has shown siRNA knockdown in vivo, demonstrating the efficient cellular 
uptake, endosomal escape and subsequent siRNA unloading potential of PP-75-
siRNA complexes (Khormaee et al. 2012). 
1.8 Targeted Delivery 
Efficacious targeted delivery is a major hurdle in drug therapy; DDS are often 
inefficient at achieving target-cell specific uptake.  Passive diffusion tends to result in 
poor distribution of drugs and high off-target cytotoxicity.  The concept of selective 
drug delivery to the site of action was first described in 1906 by Paul Ehrlich (Ehrlich 
1906).  The ability to develop drug carriers that effectively guide drugs to their site of 
action and avoid cytotoxicity due to drug accumulation in non-target cells, is essential 
to the delivery of even the most efficacious drugs (Figure 1.8). 
 
Figure 1.8: Illustration of a Model Polymer-Drug Conjugate. 
Attachment of drugs to the polymeric backbone is achieved using cleavable linkers that remain stable 
during trafficking.  On delivery to the target site, the linkages become susceptible to bond cleavage; 
facilitating drug unloading (Duncan 2006).  Covalent attachment of targeting moieties, e.g. antibodies 
or peptides, encourages cell specific targeting through receptor-mediated endocytosis (Kopeček et al. 
2000, Duncan 2005, Duncan 2006).  Reproduced from Cassidy & Schatzlein 2004. 
As mentioned previously a variety of factors can influence the affinity of DDS 
for the cell membrane; these include polymer concentration, hydrophobicity, molecular 
weight and charge density (Thomas et al. 1994, Matthews et al. 1996).  Uptake and 
internalisation via endocytosis can be enhanced following increased exposure time to 
the target cells; affinity for the cell surface dominates the rate of cell uptake (Matthews 
et al. 1996).  The addition of targeting moieties that enhance DDS specificity can 
therefore enable the directed delivery of payloads to their disease specific cells (Pack 
et al. 2005).  As a concept targeted delivery could revolutionise the current status of 
many therapeutics, in particular those previously disregarded due to low target cell 
uptake (Pack et al. 2005, Haag & Kratz 2006). 
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Targeting moieties include sugar or protein ligands that demonstrate high 
affinity for specific receptors present on the target cell, and not on healthy cells 
(Bareford & Swaan 2007).  The ability of ligands to target and bind these membrane-
bound receptor proteins facilitates active targeting and intracellular uptake via 
receptor-mediated endocytosis (Funhoff et al. 2005, Pack et al. 2005, Bareford & 
Swaan 2007).  Interaction of the DDS with the cell membrane can be influenced by 
ligand affinity and density on the polymer surface.  Active targeting reduces passive 
diffusion, preventing delivery to non-target tissues and reduce toxicity, poor distribution 
and low dosage.  Specific targeting ligands include immunoglobulin antibodies or 
antibody fragments, for example antibody Fab’s (fragment antigen-binding), single-
chain variable fragment’s (scFv’s) or antibody mimetics such as designed ankyrin 
repeat proteins DARPins (Section 1.8.2) (Stayton et al. 2005, Stumpp et al. 2008, 
Zahnd et al. 2010). 
The adaptable properties of polymeric DDS readily facilitate the attachment of 
targeting ligands.  Covalently bound cross-linkers, in addition to those used for drug 
loading, present along the polymer backbone enable this further modification of the 
DDS.  Targeted delivery to specific cells, as well as to intracellular target sites is 
therefore achievable. 
1.8.1 Cancer Targets and Cell Surface Receptors 
Targeted therapy for the treatment of cancer has been made possible by the 
increasing research into cancer pathogenesis.  Mutations in specific genes that play 
roles in diverse cellular functions such as cell adhesion, signal transduction, 
differentiation, development or DNA-repair have been identified.  Cancer-associated 
mutant cell surface molecules are ideal candidates to target tumour cells owing to their 
lack of presence in healthy, non-tumour cells (Becker & Hofler 2004).  Targeted 
therapeutics can therefore impair tumour growth and cancer progression (Hanahan & 
Weinberg 2011). 
1.8.1.1 Her2 
Human epidermal growth factor receptor 2 (Her2) is a transmembrane, tyrosine 
kinase receptor, encoded by the Her2 proto-oncogene.  The Her2 glycoprotein 
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regulates cellular proliferation and differentiation (Scott et al. 1993).  As one of the 
most studied signal-transduction pathways in cancer (Hynes & Lane 2005), Her2 is 
reportedly over-expressed in multiple cancer types, notably in ovarian, and in at least 
20 - 35% of invasive breast carcinomas (Slamon et al. 1989, Hoff et al. 2002).  Her2 
expression correlates with aggressive tumour presentation, metastasis and poor 
prognosis (Slamon et al. 1989, Barros et al. 2010).  Her2 is considered the influencing 
factor regarding tumour development and progression (Harari & Yarden 2000, Menard 
et al. 2000) and is implicated in chemotherapeutic resistance (Smith et al. 2004, Nahta 
et al. 2005).  Her2 gene amplification therefore provides an important diagnostic 
marker and a determinant for therapeutic direction; whilst also enabling cancer-cell-
specific targeting (Sampath et al. 2007). 
Her2 over expressing breast tumours have been extensively studied.  Targeting 
Her2 therfore provides a strong reference platform to evaluate target-specific delivery 
of therapeutic molecules localised to tumours.  For both diagnostic and therapeutic 
applications the affinity of the targeting ligand to the Her2 receptor is crucial. 
1.8.2 Designed Ankyrin Repeat Proteins (DARPins) 
Antibodies are a major focus of the pharmaceutical industry with several 
therapeutic antibody drug formulations on the market and in clinical development.  
There are several Her2 antibody formulations currently approved for the treatment of 
Her2 expressing breast cancers.  Trastuzumab, more commonly known as Herceptin, 
was the first humanized monoclonal antibody approved for therapeutic use; displaying 
efficacious oncogene-targeted treatment resulting in enhanced survival of those with 
Her2 positive breast cancers (Baselga & Albanell 2001).  Another monoclonal antibody 
Pertuzumab (Perjeta®), binds a different, distinct region of the receptor and can be 
given in combination with Trastuzumab; together demonstrating a synergistic effect, 
further inhibiting tumour growth and improving patient clinical outcome (Wong & 
Hurvitz 2014).  Ado-trastuzumab emtansine (Kadcyla™) is an antibody drug conjugate 
that utilises the target specificity of the trastuzumab antibody in combination with the 
efficacy of the cytotoxic maytansinoid, a small molecule drug that targets cellular 
microtubules to inhibit cell proliferation during mitosis (Oroudjev et al. 2010). 
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The key to antibody success is their ability to bind targets with high affinity, 
resulting in more targeted functionality (Reichert 2001, Schrama et al. 2006).  
Therapeutic antibodies have been used to target solid tumours (Waldmann & Morris 
2006, Dalle et al. 2008, Boyiadzis & Foon 2008) and improve the lack of specificity of 
anti-cancer drugs.  Clinical efficacy of these antibodies is however often limited, 
despite demonstrating slow clearance and high tumour accumulation; many 
antibodies only exhibit low tissue contrast between target tissues and non-target 
tissues, and as such target-cell specificity is not fully achieved (Cobleigh et al. 1999, 
Nahta & Esteva 2006).  scFv’s are a promising class of antibody mimetics, their smaller 
size (~27 kDa relative to whole antibodies at ~150 kDa) allows enhanced tissue 
penetration, however faster clearance results in only moderate tumour accumulation. 
Ankyrin repeat proteins are another natural class of binding proteins that offer 
to improve upon the advantages of antibodies (Northrup & Erickson 1992).  
Consecutive amino acid residues assemble from a single structural motif into, on 
average, three repeat units comprising a β-turn followed by two antiparallel α-helices 
(Plank et al. 1994, Pack et al. 2005) (Figure 1.9).  These consensus repeat modules 
form into a protein domain stabilised by hydrophobic interactions.  The hydrophobic 
core is maintained within a hydrophilic shell as a result of the N- and C-cap regions, 
therefore enhancing protein solubility (Kobe & Kajava 2000).  Ankyrin repeat proteins 
offer high binding capabilities owing to the ability of the repeat units to stack and form 
rigid domains. The high sequence homology between protein repeats enables 
sequential mutation, therefore higher affinity sequences can be designed.  Designed 
ankyrin repeat proteins (DARPins) are therefore a novel class of specific binding 
ligands that can be selected for binding to targets with high specificity and affinity.  As 
single domain proteins their small size and low molecular weight (~15 kDa) offer 
exceptional stability and folding efficiency as a result of strong coupling between 
repeat units.  The smallest DARPin molecules containing two random repeat modules 
(termed N2C) demonstrate increased affinities relative to three repeat DARPins, and 
rapid tumour penetration owing to their smaller surface of interaction and ability to take 
greater advantage of the EPR effect.  Targeting capability is proportional to affinity, 
suggesting higher affinity DARPins might further increase tumour targeting.  DARPins 
have been evolved to bind a variety of targets within picomolar affinities. 
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Figure 1.9: DARPin Crystal Structure. 
(a) DARPin libraries are composed of two caps (N- and C-) and a varying number of repeat units (n), 
all shown as grey ribbon representation with a transparent space fill surface. Each library module 
corresponds to an ankyrin repeat of 33 amino acids, where seven positions are variable, displayed as 
red side chains (diversity > 107). Typically, two to four library modules (n = 2 – 4) are combined into one 
protein domain (diversity > 1014), giving rise to DARPins between 14 and 21 kDa, respectively, which 
is about one tenth the size of a conventional antibody.  From Stumpp et al. 2008. 
By design DARPins do not contain any cysteine residues, therefore the 
introduction of cysteine residues allows for site specific couplings.  In combination with 
various effecter functions DARPins can be engineered to provide completely new drug 
formats.  DARPins bound to PEG have demonstrated enhanced function owing to 
prolonged circulation within the bloodstream (Stumpp et al. 2008).  In higher molecular 
weight formulations DARPin affinity, and therefore targeting efficiency, need not be so 
pronounced.  However, without effective targeting, formulations that remain in 
circulation for longer may accumulate within non-tumour tissues.  High affinity and 
specificity is therefore still essential to efficacious delivery. 
Her2 receptor expression provides an ideal model system to explore DARPin 
affinity maturation.  DARPins demonstrating low nanomolar binding affinities against 
purified Her2 have been subjected to affinity maturation via error prone PCR, yielding 
optimised DARPin clones.  The highest affinity DARPin exhibiting binding at 90 pM KD 
was therefore highly sensitive at detecting Her2 (Zahnd et al. 2007).  Winkler et al 
(Winkler et al. 2009) demonstrate that the delivery of a bcl-2 targeting siRNA is 
receptor dependent when using an anti-epCAM DARPin to aid delivery.  DARPin 
affinity for the Her2 receptor is essential to target delivery to Her2 expressing cells. 
+ +
n
N-Cap C-CapRepeat Unit
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Conjugation of a high affinity Her2 DARPin onto PP-75 would provide a robust 
platform to demonstrate the cell-targeting capabilities of PP-75 as a DDS, capable of 
delivering siRNA to the cell interior as a result of endosomal escape. 
1.9 Aims of the Study 
The scope of this project is to develop the current understanding of intracellular 
drug delivery via the application and evaluation of PP-75, a pH-responsive, 
biomimetic, polymer-based DDS. 
The aim is to validate a reporter assay platform to quantify successful delivery 
of siRNA payloads into model tumour cell systems, facilitating functional, intracellular, 
target-specific, gene knockdown.  By optimising a dual luciferase-reporter (DLR) 
assay, the targeted knockdown of firefly luciferase by siRNA can be demonstrated.  
The dual reporter nature of the assay allows for an internal assay control, assaying 
target-specific knockdown whilst monitoring altered expression of Renilla luciferase.  
Measuring knockdown of luminescent reporter proteins provides an easily measurable 
readout.  This is essential to the study, providing a quantifiable target specific 
measurement; indicative of target knockdown and not as a result of whole-cell death 
which would also result in a total loss of gene expression.  Distinguishing between 
target and whole-cell knockdown is essential to develop disease specific therapeutics.  
In addition, to further optimise delivery capacity, a high affinity DARPin, capable of 
specifically binding extracellular markers of disease, can be conjugated onto PP-75; 
with the intention to facilitate targeted delivery to specific cell populations.  The PP-75 
platform can therefore be validated for use as an effective intracellular delivery agent, 
mediating the specific delivery of functionally active payloads.  Following successful 
proof of concept, PP-75 polymer technology can be applied in other cellular systems 
to assess delivery of alternative biotherapeutic siRNA payloads, addressing a variety 
of disease targets. 
As a pH-responsive polymeric delivery platform, capable of endosomal 
membrane escape, PP-75 can demonstrate efficient intracellular delivery with low 
associated cell toxicity, when compared against commercially available delivery 
systems. 
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Preliminary work regarding polymer synthesis and cell assay design raises key 
questions to be addressed in the project: 
PP-75 Synthesis and Derivatisation 
i. Can the PP-75 polymers be reproducibly synthesised for use as a drug delivery 
platform? 
ii. Does PP-75 demonstrate pH-responsive properties and facilitate membrane 
destabilisation? 
iii. Can PP-75 be successfully derivatised with cross-linkers to facilitate payload 
attachment? 
iv. Can PP-75 be fluorescently labelled to visually demonstrate intracellular 
polymer localisation? 
v. Can siRNA payloads be efficiently conjugated onto PP-75? 
vi. Can DARPin targeting ligands be efficiently conjugated onto PP-75? 
PP-75 Assay Development 
i. Is the growth of the fluc/Rluc reporter cell lines comparable to the parental wild-
type cells? 
ii. Do the reporter cell lines stably express fluc and Rluc proteins at a measurable 
level via the DLR™ assay? 
iii. Can fluc and Rluc mRNA levels be measured in the cells? 
iv. Does PP-75 demonstrate cytotoxicity? 
v. Are fluc siRNA payloads functional and do they demonstrate target-specific 
knockdown without associated cytotoxicity? 
vi. Can DARPins selectively target the reporter cell lines? 
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Further questions within the framework to the project: 
PP-75 Intracellular Delivery 
i. Can PP-75 successfully deliver payloads into cells? 
ii. Do PP-75 polymers demonstrate endosomal release? 
PP-75 Targeted Delivery 
i. Is the expression of DARPin constructs containing a free cysteine possible? 
ii. Do DARPins demonstrate specific binding to their targets? 
iii. Is PP-75 delivery enhanced following attachment of a high affinity DARPin onto 
PP-75? 
iv. Is delivery targeted and therefore selective for Her2 expressing cell 
populations? 
1.9.1 Novelty of Research 
The published work introduces PP-75 as a promising drug delivery system and 
provides a foundation on which to develop the novel research presented within this 
thesis. 
The research presented here looks to extend the capabilities of the PP-75 
delivery platform by demonstrating the potential for target-specific siRNA delivery, 
through use of a model reporter system, and, to demonstrate the potential for cell-
specific delivery following attachment of target-specific DARPin.  These will be 
achieved as outlined; 
Derivatisation of PP-75 with the commercially available thiol-cleavable cross-
linker, 3-(2-pyridyldithio)propionyl hydrazide (PDPH), provides a robust and 
characterisable reaction to facilitate payload attachment to, and unloading from, PP-
75, respectively.  Optimisation of the pyridine-2-thione detection assay is required to 
characterise PDPH grafting in organic solvents as well as in aqueous solutions.  
Derivatisation of PP-75 with another commercially available cross-linker, N-ε-
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maleimidocaproic acid hydrazide (EMCH) offers a non-cleavable alternative as 
DARPin release is non-essential.  Aminofluorescein can be employed as a dye to label 
PP-75 and demonstrate PP-75 intracellular localisation.  Quantification of the degree 
of fluorescent labelling can control batch-to-batch consistency and uptake via flow 
cytometry can provide an alternative readout, useful to discriminate between target 
specific and non-specific uptake using the PP-75 platform.  The novel siRNA payload, 
capable of demonstrating functional knockdown of the target firefly luciferase gene, 
can be validated and conjugated onto PP-75 via the PDPH linker.  The expression, 
modification and purification of novel DARPin sequences allows conjugation onto PP-
75, via EMCH and PDPH linkers.  Delivery of PP-75 and its derivatives into breast 
cancer cell lines SK-BR-3 (Her2+) and MDA-MB-231 (Her2-) develops the wider 
application of PP-75 delivery across cancer types.  All aspects of cellular assays 
should be optimised for future use regarding reporter cell growth and seeding densities 
for multiple assay formats.  Modification of the lactate dehydrogenase assay, to 
provide a whole cell model for membrane lysis, provides a measure of PP-75 pH-
responsive membrane function in addition to the haemolysis model published.  PP-75 
cytotoxicity can also be examined via alternative assay formats to enhance the breadth 
of PP-75 functional data known.  Characterisation of PP-75 plus payloads in more 
detail, utilising SDS-PAGE and agarose gel electrophoresis provides insight into PP-
75 modification.  Demonstration of DARPin binding affinity via ELISA indicates the 
potential for target-specific PP-75 DARPin conjugate delivery. 
1.9.2 Research Impact 
PP-75 is proposed as an effective and promising candidate for intracellular, 
therapeutic drug-delivery.  The work undertaken in this project will develop 
understanding of intracellular delivery mechanisms, characterising PP-75 activity for 
use as an intracellular delivery agent.  Results generated within the model system can 
be used to enhance the design and development of PP-75 to optimise the delivery 
technology.  As an adaptable platform, PP-75 may in future be used to deliver a range 
of therapeutic payloads, to a variety of intracellular target sites.  PP-75 may therefore 
provide the basis for a polymer-drug conjugate portfolio, valuable for treatment of 
multiple disease models.  In turn this work can contribute to the design of more efficient 
macromolecular drug carriers and allow fine tuning of polymeric DDS properties, 
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tailoring delivery to target specific applications.  The collaborative nature of this 
academia-industry research project, spanning scientific disciplines, therefore drives 
the progression and understanding of the development pipeline, from bench to clinic. 
This research is of interest to biopharmaceutical and healthcare sectors.  
Developing an efficient delivery-system will increase the number of target 
opportunities available to biological therapeutics.  Targeted drug-delivery and 
controlled drug-release will enhance current treatments; minimising undesirable side-
effects and off-target cytotoxicity.  Drug resistance, often associated with the 
administration of increasing therapeutic doses may also be prevented with more 
effective delivery systems. 
1.10 Thesis Outline 
This work presented within this thesis comprises of seven chapters, outlined as 
follows: 
Chapter 1 provides an introduction to the field of intracellular drug delivery, 
describing the concepts, advances and current status of pH-responsive polymeric drug 
delivery systems.  In particular PP-75 is discussed, which provides the focus of the 
research presented within this thesis.  The application of target-specific siRNA 
payloads and the concept of targeted drug delivery following DARPins conjugation is 
introduced. 
Chapter 2 describes, in detail the materials and methods used to complete the 
research communicated in subsequent chapters of this thesis.  Optimised methods 
and protocols cover synthesis and characterisation of PP-75 and its derivatives, 
describing linker modification, payload conjugation and DARPin attachment.  Cell line 
characterisation and cell assays determining PP-75 function, delivery capacity and 
cytotoxicity are also described. 
Chapter 3 describes the necessary modification of PP-75, in order to 
demonstrate its potential application as a targetable, intracellular delivery agent, 
capable of controlled payload release.  The synthesis and characterisation of PP-75 
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and its derivatives with siRNA payloads and DARPin constructs are discussed, with 
pH-responsive function also explored. 
Chapter 4 describes the characterisation of the model reporter cell lines used 
for the biological testing of PP-75 and the PP-75 siRNA and DARPin conjugates.  PP-
75 and siRNA cytotoxicity was investigated, with assay design and optimisation 
explored.  The results are discussed within the context of providing background 
information to the findings highlighted in subsequent chapters. 
Chapter 5 describes the intracellular uptake of PP-75, its location within the cell 
interior and the delivery capacity of PP-75 to mediate target-specific siRNA 
knockdown.  PP-75 mediated intracellular delivery is discussed with comparison to the 
Lipofectamine® 2000 transfection agent (Life Technologies). 
Chapter 6 describes the selection and validation of DARPin targeting moieties 
for addition onto the PP-75 polymer; with the aim to facilitate targeted delivery of PP-
75 conjugated siRNA payloads.  The work in this chapter provides preliminary data, 
describing the potential use of DARPins for PP-75 targeted delivery. 
Chapter 7 draws conclusions surrounding the research presented in the 
preceding results chapters.  References to and comparison within the wider research 
field is made, with recommendations for future research and development highlighted. 
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Chapter 2 
2 Materials and Methods 
This chapter describes in detail the materials and methods used in order to 
complete the research communicated in subsequent chapters of this thesis.  The 
materials listed include all chemicals, solvents, cell lines, culture media, reagents, 
assay kits and equipment.  Optimised methods and protocols cover synthesis and 
characterisation of PP-75 and its derivatives, describing linker modification, payload 
conjugation and DARPin attachment.  Cell line characterisation and cell assays 
determining PP-75 function, delivery capacity and cytotoxicity are also described. 
2.1 Materials 
Potassium carbonate, acetone, sodium hydroxide, hydrochloric acid, ethanol, 
methanol, triethylamine, 4-dimethylaminopyridine (DMAP), cryovials, sulphuric acid, 
universal sterilin tubes, Nunc™ cell culture flasks and Nunc™ 6-well tissue culture 
plates, disposable inoculating loops and BL21 Competent cells were purchased from 
Thermo Fisher Scientific (Leicestershire, UK). 
Iso-phthaloyl chloride, dimethyl sulfoxide (DMSO), N-boc-cadaverine, 
acetonitrile, ethyl acetate, trifluoroacetic acid (TFA), acetic acid, tert-butanol, sodium 
sulphate, 6-aminofluorescein, d6-DMSO, 2-mercaptopyridine (pyridine-2-thione), 
Millex® syringe filter units, Accutase® Cell Detachment Solution, 2-propanol 
(isopropanol), Triton™ X-100, sodium azide, formaldehyde solution, TWEEN® 20, L-
glutathione, L-cysteine, Tetracycline, Kanamycin, Ampicillin, PCR tubes plus cap 
strips, GenElute™ PCR Clean-Up Kit and anti-mouse IgG–peroxidase antibody were 
purchased from Sigma-Aldrich (Dorset, UK). 
L-lysine methyl ester dihydrochloride, L-phenylalanine methyl ester 
hydrochloride and N,N’-dicyclohexylcarbodiimide (DCC) were purchased from Alfa 
Aesar (Massachusetts, USA). 
3-(2-pyridyldithio)propionyl hydrazide (PDPH), N-ε-maleimidocaproic acid 
hydrazide (EMCH), tris(2-carboxyethyl)phosphine hydrochloride (TCEP-HCl), Slide-A-
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Lyzer® Dialysis Cassette Kits and Zeba™ Spin Desalting Columns were purchased 
from Thermo Scientific, Pierce Protein Biology Products (Illinois, USA). 
Dithiothreitol (DTT), Dulbecco's phosphate-buffered saline (PBS), NuPAGE® 
LDS sample loading buffer (4x), NuPAGE® Novex® 4-12% Bis-Tris Gel, NuPAGE® 
MES SDS Running Buffer (20x), Novex® Sharp Pre-stained Protein Standard, 
SeeBlue® Plus2 Pre-stained Protein Standard (1x), Modified McCoy’s 5A Medium 
(1x), RPMI 1640 (1x) + GlutaMAX™, foetal bovine serum (FBS), Trypan Blue Solution 
0.4%, Molecular Probes® Hoechst 33342, Molecular Probes® CellMask™ Deep Red 
Plasma Membrane Stain, Molecular Probes® LysoTracker® Red, anti-rabbit IgG 
Alexa Fluor® 610 conjugate, UltraPure™ Glycerol, ReddyMix™ PCR Master Mix, 
nuclease-free water, 1 kb Plus DNA Ladder and SYBR® Safe DNA gel stain were 
purchased from Life Technologies (Paisley, UK). 
N,N-dimethylformamide (DMF), diethyl ether, dichloromethane (DCM), Greiner 
96-well polypropylene plates, ALUGRAM® aluminium TLC sheets, disposable plastic 
eppendorfs, Greiner Bio-One 96-well plates, TG1 Competent cells and dried skimmed 
milk powder (Marvel) were purchased from VWR International Ltd (Lutterworth, UK).  
Distel High Level Laboratory Surface Disinfectant was purchased from Tristel 
Solutions Ltd (Cambridgeshire, UK).  70% ethanol was purchased from Severn 
Biotech Ltd® (Kidderminster, UK).  Rely+On™ Virkon® tablets were purchased from 
DuPont™ (Delaware, USA). 
Costar® 96-well assay plates, Corning® Costar® serological plastic pipettes, 
Corning® cell culture flasks and Corning® Erlenmeyer cell culture flasks were 
purchased from Corning Life Sciences (Amsterdam, Netherlands). 
SK-BR-3 (Her2+) and MDA-MB-231 (Her2-) human epithelial breast 
adenocarcinoma cell lines were purchased from American Type Culture Cell (ATCC®, 
Virginia, USA).  SK-BR-3 (Her2+) fluc/Rluc and MDA-MB-231 (Her2-) fluc/Rluc human 
epithelial breast adenocarcinoma cell lines were stably transfected at MedImmune 
(Cambridge, UK). 
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Cell Titre-Glo® Luminescent Cell Viability Assay, CytoTox-ONE™ 
Homogeneous Membrane Integrity Assay and Dual-Luciferase® Reporter Assay 
System was purchased from Promega (Southampton, UK). 
Rab 5 (C8B1) Rabbit mAb, Rab7 (D95F2) XP® Rabbit mAb, LAMP1 (D2D11) 
XP® Rabbit mAb, NdeI, BamHI-HF®, NEBuffer 4, T4 DNA Ligase and T4 DNA Ligase 
Reaction Buffer were purchased from New England BioLabs (Hitchin, UK). 
RNeasy Plus Mini Kit, RNase-Free DNase Set, QIAshredder columns, Plasmid 
Plus Midi Kit, QIAprep Spin Miniprep Kit and QIAquick® Gel Extraction Kit were 
purchased from Qiagen® (Manchester, UK). 
Precision nanoscript™ Reverse Transcription Kit, geNorm™ Reference Gene 
Selection Kit, 2x Precision™ Mastermix, 96-well BrightWhite Real-time PCR plates, 
Custom Designed Real-Time PCR Assay Kit and Copy Number Positive Controls were 
purchased from Primerdesign Ltd (Southampton, UK). 
siRNA duplexes were purchased from Integrated DNA Technologies (Leuven, 
Belgium).  Poly(ethylene oxide) (PEO) standards were purchased from Waters Ltd 
(Hertfordshire, UK).  Phosphate buffered saline (Dulbecco A) tablets were 
manufactured by Oxoid Ltd (Basingstoke, UK).  35 mm Glass-bottom dishes were 
manufactured by MatTek (Massachusetts, USA) InstantBlue™ was purchased from 
Expedeon (Cambridge, UK).  Polypropylene conical Falcon™ tubes were purchased 
from BD Biosciences (Oxford, UK).  AlamarBlue® and mouse anti-polyhistindine 
antibody AD1.1.10 was purchased from AbD serotec (Oxford, UK).  Amicon Ultra 
Centrifugal Filter Units and the pET16b vector (Novagen) were purchased from Merck 
Millipore (Watford, UK).  XL1-Blue Competent cells were purchased from Agilent 
Technologies (California, USA).  Agarose, Pulse-field Certified™ was manufactured 
by Bio-Rad (Hertfordshire, UK).  SureBlue Reserve™ TMB Microwell Peroxidase 
Substrate was purchased from KPL, Inc. (Maryland, USA).  Sterile disposable scalpel 
blades were purchased from Swann-Morton (Sheffield, UK).  HRP/Anti-M13 
Monoclonal Conjugate was purchased from GE Healthcare (Buckinghamshire, UK). 
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The DARPin library and Her2 DARPin was expressed according to Zahnd et al. 
(Zahnd et al. 2007a, Zahnd et al. 2007b) by MedImmune (Cambridge, UK).  The anti-
DARPin antibody was developed by MedImmune (Cambridge, UK). 
1x PBS/0.1% Tween, TAE buffer, PBS buffer, glycerol, 2x TY media, 2x TYAG 
bioassay plates, 2x TYAG petri dishes, loading dye and sulphuric acid stock solutions 
were made and provided by MedImmune (Cambridge, UK). 
2.2 Organic Synthesis 
The PP-75 polymer backbone was derived from the parent polymer poly(L-
lysine iso-phthalamide).  Modification of PP-75 was necessary to demonstrate the 
potential application of PP-75 as a targetable, intracellular delivery agent, capable of 
controlled payload release.  The design and synthesis of the novel functionalised PP-
75 derivatives are outlined in the following sections. 
2.2.1 Poly(L-lysine isophthalamide) (PLP) 
Poly(L-lysine isophthalamide) (PLP) was synthesised via single phase 
polymerisation, according to the method outlined by Eccleston (Eccleston et al. 1999, 
Eccleston et al. 2000) (Figure 2.1). 
 
Figure 2.1: PLP Synthesis Schematic. 
Single phase polymerisation between L-lysine and iso-phthaloyl chloride gave yield to PLP. 
Polycondensation 
Typically, a 1:4 molar ratio of L-lysine methyl ester dihydrochloride (35 g, 0.15 
mol, 1 equiv) to potassium carbonate (83 g, 0.60 mol, 4 equiv), was dissolved in dH2O 
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(750 mL) and stirred on ice.  Pre-cooled (-20 °C) anhydrous iso-phthaloyl chloride (30 
g, 0.15 mol, 1 equiv) in dried acetone (750 mL) was rapidly poured into the reaction 
mix and stirred at full speed.  Solvent-swollen poly(L-lysine methyl ester 
isophthalamide) precipitated out and was removed after 30 min.  Polymer was washed 
three times with dH2O to remove excess solvent, stretched and left to oven-dry at 55 
˚C.  The stiff polymer was then blended to a white powder. 
Ester hydrolysis 
Sodium hydroxide (20 g, 0.5 mol, 2.5 equiv per polymer repeat unit) was 
dissolved in anhydrous ethanol (400 mL) and added in several portions to poly(L-lysine 
methyl ester isophthalamide) (60 g, 0.21 mol; 1 equiv; with respect to repeat unit 
[COOCH3]; repeat unit Mw 290) in dry DMSO (400 mL) and stirred.  Hydrolysed poly(L-
lysine isophthalamide) (PLP) precipitated in 5 min and was collected by vacuum 
filtration.  PLP was re-dissolved in a minimum volume of dH2O. 
Purification 
Dialysis of the crude PLP solution against dH2O was carried out in Visking 
membrane tubing (Medicell, Mw cut-off 12 - 14 kDa) for one week, to remove residual 
solvent, inorganic salts and low molecular weight oligomers.  Dialysed PLP was 
adjusted to pH 7.4 with aqueous sodium hydroxide (0.2 M), concentrated and 
lyophilised to give a white powder (PLP sodium salt form).  Acidification to pH 3 with 
aqueous hydrochloric acid (0.2 M) yielded neutral PLP (designated PLP from here-on-
in).  The precipitate was collected via vacuum filtration and washed three times with 
dH2O before lyophilisation to a fine white powder. 
The PLP salt was used to prepare aqueous solutions for physiochemical and 
biological polymer studies, PLP was used for structural characterisation and further 
modification. 
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2.2.2 PP-75: PLP Grafted with L-Phenylalanine 
PP-75 was synthesised as described by Chen et al. (Chen et al. 2009c), grafting 
PLP with L-phenylalanine at a 75 mol% stoichiometric ratio (Figure 2.2).  The reaction 
proceeded via standard DCC promoted amide-coupling according to Haslam (Haslam 
1980). 
 
Figure 2.2: PP-75 Synthesis Schematic (PLP Grafted with L-Phenylalanine). 
PLP was grafted at 75 mol% L-phenylalanine via DCC promoted amide-coupling. 
DCC mediated L-phenylalanine grafting 
PLP (3.0 g, 11 mmol, 1 equiv; with respect to repeat unit [COOH]; repeat unit 
Mw 276), L-phenylalanine methyl ester hydrochloride (1.8 g, 8.2 mmol, 0.75 equiv), 
triethylamine (2.7 mL, 20 mmol, 1.8 equiv) and DMAP (0.6 g, 20 wt% of PLP) were 
dissolved in anhydrous DMSO: DMF (1:3 v/v, 60 mL) and stirred at room temperature.  
DCC (5.0 g, 24 mmol, 2.25 equiv) in anhydrous DMF (20 mL) was added drop-wise 
and the reaction was left to proceed for 60 h, stirring at room temperature.  PLP grafted 
with L-phenylalanine methyl ester (PP-75) was not purified prior to ester hydrolysis, 
but used directly. 
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Ester hydrolysis and purification 
Solid impurities and the dicyclohexylurea side product were removed by 
vacuum filtration.  Sodium hydroxide (1.1 g, 27 mmol, 2.5 equiv per polymer repeat 
unit) was dissolved in anhydrous ethanol (22 mL) and added to the polymer solution.  
Hydrolysed polymers with a low degree of grafting (< 25%) precipitated directly out in 
5 min; the highly grafted polymers remained in solution.  After 3 h highly grafted 
polymers were precipitated following rapid addition into five volumes of diethyl ether 
(540 mL).  The precipitant was collected and re-dissolved in a minimum volume of 
aqueous sodium hydroxide (0.2 M).  PP-75 sodium salt and neutral PP-75 (PP-75 from 
here-on-in) polymers were obtained following dialysis, pH adjustment and 
lyophilisation, as described for PLP (Section 2.2.1).  A fine white powder was obtained. 
The degree of grafting was controlled by the stoichiometric molar ratio of L-
phenylalanine [NH2] to PLP [COOH]. 
2.2.3 PP-75 plus Cross-linkers 
Novel PP-75 derivatives were synthesised, grafting PP-75 with cross-linkers at 
defined stoichiometric ratios (Figure 2.3 and Figure 2.4).  The reactions proceeded via 
standard DCC promoted amide-coupling as with PP-75 (Section 2.2.1). 
2.2.3.1 PP-75 3-[2-pyridyldithio]propionyl hydrazide (PDPH) 
PP-75 was grafted with PDPH (Figure 2.3), a commercially available 
pyridyldithiol-and-hydrazide cross-linker to facilitate cleavable payload conjugation. 
DCC mediated PDPH grafting 
PP-75 (100 mg, 0.27 mmol, 1 equiv; with respect to repeat unit [COOH]; repeat 
unit Mw 373), PDPH (3.1 mg, 14 μmol, 0.05 equiv) and DMAP (20 mg, 20 wt% of PP-
75) were dissolved in anhydrous DMF (400 μL) and stirred at room temperature.  DCC 
(8.3 mg, 41 μmol, 0.15 equiv) in anhydrous DMF (20 μL) was added drop-wise and 
the reaction was left to proceed for 24 h, stirring at room temperature. 
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Precipitation and purification 
PDPH linked PP-75 was precipitated following rapid addition into excess diethyl 
ether (5 mL).  The precipitant was collected and re-dissolved in a minimum volume of 
aqueous sodium hydroxide (0.2 M).  PP-75 PDPH was obtained following dialysis 
against 0.1x PBS (in dH2O) with Slide-A-Lyzer® Dialysis Cassettes (Mw cut-off 20 
kDa).  pH adjustment and lyophilisation were carried out as described previously 
(Section 2.2.1).  A fine white powder was obtained. 
The degree of grafting was controlled by the stoichiometric molar ratio of PDPH 
[NH2] to PP-75 [COOH]. 
 
Figure 2.3: PP-75 PDPH Synthesis Schematic. 
PP-75 was grafted at 5 mol% and 20 mol% PDPH via DCC promoted amide-coupling. 
 
2.2.3.2 PP-75 3,3’-N-[ε-maleimidocaproic acid] hydrazide (EMCH) 
PP-75 was grafted with EMCH (Figure 2.4) a commercially available maleimide-
and-hydrazide cross-linker to facilitate stable payload conjugation. 
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Figure 2.4: PP-75 EMCH Synthesis Schematic. 
PP-75 was grafted at 5 mol% EMCH via DCC promoted amide-coupling. 
DCC mediated EMCH grafting 
PP-75 (100 mg, 0.27 mmol, 1 equiv; with respect to repeat unit [COOH]; repeat 
unit Mw 373), EMCH (4.6 mg, 13 μmol, 0.05 equiv) and DMAP (20 mg, 20 wt% of PP-
75) were dissolved in anhydrous DMF (400 μL) and stirred at room temperature.  DCC 
(8.3 mg, 41 μmol, 0.15 equiv) in anhydrous DMF (20 μL) was added drop-wise and 
the reaction was left to proceed for 24 h, stirring at room temperature. 
Precipitation and purification 
EMCH linked PP-75 was precipitated following rapid addition into excess diethyl 
ether (5 mL).  The precipitant was collected and re-dissolved in a minimum of aqueous 
sodium hydroxide (0.2 M).  PP-75 EMCH was obtained following obtained following 
dialysis 0.1x PBS (in dH2O) with Slide-A-Lyzer® Dialysis Cassettes (Mw cut-off 20 
kDa).  pH adjustment and lyophilisation were carried out as described previously 
(Section 2.2.1).  A fine white powder was obtained. 
The degree of grafting was controlled by the stoichiometric molar ratio of EMCH 
[NH2] to PP-75 [COOH]. 
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2.2.4 PP-75 plus Payloads and Targeting Ligands 
Novel PP-75 conjugates were synthesised following attachment of payloads 
directly onto PP-75 or by conjugation to PP-75 plus cross-linkers at defined 
stoichiometric ratios.  PP-75 was fluorescently labelled (Figure 2.5, Figure 2.6), 
conjugated with siRNA payloads (Figure 2.7) or with DARPin cell targeting ligands 
(Figure 2.8, Figure 2.9, Figure 2.10). 
2.2.4.1 PP-75 6-aminofluorescein 
PP-75 aminofluorescein was synthesised, grafting PP-75 with 6-
aminofluorescein (fluoresceinamine isomer II), an amine reactive fluorescein dye 
derivative (Figure 2.5).  The reaction proceeded via standard DCC promoted amide-
coupling as with PP-75 (Section 2.2.2). 
 
Figure 2.5: PP-75 AFC Synthesis Schematic. 
PP-75 was grafted at 20 mol% AFC via DCC promoted amide-coupling. 
DCC mediated 6-aminofluorescein labelling 
PP-75 (100 mg, 0.27 mmol, 1 equiv; with respect to repeat unit [COOH]; repeat 
unit Mw 373), 6-aminofluorescein (19 mg, 54 μmol, 0.2 equiv) and DMAP (20 mg, 20 
wt% of PP-75) were dissolved in anhydrous DMF (800 μL) and stirred at room 
temperature.  DCC (33 mg, 0.16 mmol, 0.6 equiv) in anhydrous DMF (50 μL) was 
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added drop-wise and the reaction was left to proceed for 24 h, stirring at room 
temperature. 
Precipitation and purification 
Aminofluorescein linked PP-75 was precipitated following rapid addition into 
excess diethyl ether (5 mL).  The precipitant was collected and re-dissolved in a 
minimum of aqueous sodium hydroxide (0.2 M).  PP-75 aminofluorescein (PP-75 AFC 
from here-on-in) was obtained following dialysis against 0.1x PBS (in dH2O) with Slide-
A-Lyzer® Dialysis Cassettes (Mw cut-off 20 kDa), pH adjustment and lyophilisation 
were carried out as described previously (Section 2.2.1).  A pale yellow powder was 
obtained. 
The degree of grafting was controlled by the stoichiometric molar ratio of 
aminofluorescein [NH2] to PP-75 [COOH]. 
2.2.4.2 PP-75 AFC EMCH 
PP-75 AFC was grafted with EMCH (Figure 2.6) following the procedure 
outlined previously (Section 2.2.3.2).  A pale yellow powder was obtained. 
 
Figure 2.6: PP-75 AFC EMCH Synthesis Schematic. 
PP-75 AFC was grafted at 5 mol% EMCH via DCC promoted amide-coupling. 
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2.2.4.3 PP-75 PDPH linked siRNA 
Thiol modified siRNA duplexes (Section 5.2.1) were conjugated to PP-75 PDPH 
via disulphide bond formation (Figure 2.7).  Target-specific and scrambled (non-
specific) siRNA was conjugated at a 1:1 stoichiometric ratio of polymer to payload. 
 
Figure 2.7: PP-75 PDPH siRNA Conjugation Schematic. 
PP-75 PDPH was conjugated at a 1:1 ratio with thiol modified, fluc targeting siRNA, Cy3 labelled fluc 
targeting siRNA and Scr (non-targeting) siRNA duplexes (remaining R groups are hydroxyl OH). 
siRNA reduction 
DTT (500 mM, 2.4 μL) was added to a solution of siRNA in dH2O (1.0 mg/mL, 
244 μL, 17 nmol) and left to proceed for 90 min, stirring at room temperature.  The 
reaction was passed down a desalting column (Mw cut-off 7 kDa) to remove DTT from 
the siRNA flow-through. 
siRNA conjugation 
PP-75 PDPH (1.0 mg, 17 nmol, 1 equiv) was dissolved in anhydrous DMSO: 
DMF (1:3 v/v, 1 mL) and stirred at room temperature.  Reduced siRNA (17 nmol, 1 
equiv) was added drop-wise and the reaction was left to proceed overnight, stirring at 
room temperature. 
PP-75 PDPH siRNA conjugates (PP-75 siRNA conjugates here-on-in) were 
obtained following dialysis against 0.1x PBS (in dH2O) with Slide-A-Lyzer® Dialysis 
Cassettes (Mw cut-off 20 kDa) and lyophilised to obtain a fluffy white powder.  A pale 
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pink powder was produced on conjugation with Cyanine 3 (Cy 3) fluorescently labelled 
siRNA. 
2.2.4.4 PP-75 AFC EMCH linked DARPin 
 
Figure 2.8: PP-75 AFC EMCH DARPin Conjugation Schematic. 
PP-75 AFC EMCH was conjugated at a 1:1 ratio with cysteine modified, Her2 targeting, and non-
targeting (negative control) DARPin sequence. 
Cysteine modified DARPin sequences (Section 6.2.1) were conjugated to PP-
75 AFC EMCH (Figure 2.8) via formation of thioether bonds.  Her2 target-specific 
(positive) and non-specific (negative) DARPins were conjugated at a 1:1 stoichiometric 
ratio of DARPin per polymer. 
DARPin reduction 
TCEP-HCl (500 mM, 0.7 μL) was added in excess to DARPin stock solution 
(4.1 mg/mL, 67 μL, 17 nmol) and left to proceed for 90 min, stirring at room 
temperature.  The reaction was passed down a desalting column (Mw cut-off 7 kDa) to 
remove TCEP from the DARPin flow-through. 
DARPin conjugation 
PP-75 AFC EMCH sodium salt (1 mg, 17 nmol, 1 equiv) was dissolved in 1x 
PBS (250 μL) and stirred at room temperature.  The reduced DARPin solution (17 
nmol, 1 equiv) was added drop-wise and the reaction was left to proceed overnight, 
stirring at room temperature.  PP-75 AFC EMCH DARPin conjugates were obtained 
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following purification via desalting column (Mw cut-off 40 kDa), dialysis and 
lyophilisation to obtain a pale yellow powder. 
2.2.4.5 PP-75 PDPH, EMCH linked DARPin 
Cysteine modified DARPin sequences (Section 6.2.1) were conjugated 1:1 to 
EMCH, prior to grafting at 5 mol% to PP-75 PDPH (Figure 2.9). 
 
Figure 2.9: PP-75 PDPH, EMCH-DARPin Conjugation Schematic. 
PP-75 PDPH was conjugated at a 5 mol% EMCH linked Her2 targeting DARPin sequence. 
EMCH linked DARPin 
DARPin reduction was carried out as previously described (Section 2.2.4.4).  
DARPin (3.3 mg, 0.20 μmol, 1 equiv) was reacted with EMCH (0.7 mg, 2.0 μmol, 10 
equiv) in total volume 4 mL PBS, proceeding overnight, and stirring at room 
temperature.  EMCH DARPin conjugates were obtained following overnight dialysis 
against 0.1x PBS (in dH2O). 
PP-75 PDPH grafted with EMCH linked DARPin 
PP-75 PDPH (1 mg, 2.7 μmol (relative to PP-75 unit Mw) 1 equiv), DARPin 
EMCH (2.2 mg, 0.1 μmol, 0.05 equiv) and EDC.HCl aq. (1 μg/mL, 77 μL, 0.4 μmol, 
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0.15 equiv) were dissolved in dH2O (4 mL) and left to react at room temperature 
overnight. 
PP-75 PDPH EMCH-DARPin conjugates were obtained following dialysis 
against 0.1x PBS (in dH2O) containing TCEP (5 mM) with Slide-A-Lyzer® Dialysis 
Cassettes (Mw cut-off 20 kDa) and lyophilised to obtain a fluffy white powder. 
2.2.4.6 PP-75 PDPH linked DARPin 
PP-75 PDPH was conjugated with the Her2 targeting DARPin sequence (Figure 
2.10) following DARPin reduction (Section 2.2.4.4) and conjugation of PDPH onto PP-
75 (Section 2.2.3.1) with modification. 
PP-75 PDPH salt form (1 mg, 16 nmol, 1 equiv (17% graft)) was dissolved in 
PBS (1 mL) and stirred at room temperature.  PP-75 PDPH salt form (100 μL) was 
added to a 96-well, clear, round bottom, polypropylene assay plate (Greiner) and 
reduced DARPins (3 mg/mL, 84 µL 16 nmol, 1 equiv) were added.  The absorbance 
(340 nm) was measured immediately and monitored for a 90 min period using an 
EnVision® Multilabel Reader (PerkinElmer, Massachusetts, USA).  Conjugations at 
2:1 and 5:1 molar ratio DARPin: PP-75 PDPH were carried out simultaneously.  
Conjugations were also carried out in organic solvents using PP-75 PDPH (neutral 
form) for comparison.  The absorbance (340 nm) of a known quantity of 2-
mercaptopyridine (pyridine-2-thione) in the appropriate solvent (1 mg/mL stock) was 
used as a calibration curve (Section 3.2.2.1). 
 
Figure 2.10: PP-75 PDPH DARPin Conjugation Schematic. 
PP-75 PDPH was conjugated with cysteine modified Her2 targeting DARPin sequences at 1:1, 2:1and 
5:1 ratios (remaining R groups are hydroxyl OH). 
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2.3 Biophysical Polymer Characterisation 
The compositions, structures, molecular weights, and hydrodynamic diameters 
of PP-75 and the novel derivatives were characterised by Fourier Transform Infrared 
(FT-IR) spectroscopy, Nuclear Magnetic Resonance (NMR) spectrometry, Gel 
Permeation Chromatography (GPC), SDS-PAGE, Mass Spectrometry (MS), Thin 
Layer Chromatography (TLC), absorption and fluorescence assays, agarose gel 
electrophoresis, Enzyme-Linked Immunosorbant Assays (ELISA’s) and Dynamic Light 
Scattering (DLS) where possible, as follows. 
2.3.1 Fourier Transform Infrared (FT-IR) Spectroscopy 
Polymer samples (~10 mg) were dissolved in DMSO-d6 (1 mL) and placed 
between sodium chloride discs and measured against a DMSO-d6 blank.  FT-IR 
spectra were obtained using a Nicolet 6700 FT-IR Spectrometer (Thermo Scientific, 
Massachusetts, USA). 
2.3.2 Nuclear Magnetic Resonance (NMR) Spectrometry 
Samples (~10 mg) were dissolved in deuterated solvents DMSO-d6 or CDCl3 
(1 mL) as appropriate.  1H- and 13C-NMR spectra were obtained at room temperature 
using the Bruker Avance 500 MHz NMR spectrometer (Bruker Biospin, Ettlingen, 
Germany) and Bruker DPX 300 MHz NMR spectrometer (Bruker Biospin, Ettlingen, 
Germany), respectively.  MestRe-C 2.3a (Mestrelab Research SL, Santiago de 
Compostela, Spain) was used for NMR data analysis. 
2.3.3 Gel Permeation Chromatography (GPC) 
Sodium salt polymers (10 mg) were dissolved in 1x PBS (1 mL, pH 7.4) and 
passed through Millex® syringe filter units (0.45 μm) and allowed to equilibrate for 48 
h before use. 
GPC traces were obtained by Dr Xiaohua Sun with supervision from Dr Kamran 
Yunus (Department of Chemical Engineering and Biotechnology, University of 
Cambridge, Cambridge, UK) using an aqueous phase GPC system (Viscotek) 
consisting of 2×30 cm ViscoGEL GMPW columns equipped with a VE3580 refractive 
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index detector.  Polymer samples (1 mg/mL, 100 μL injection) were run in static (no 
gradient) GPC buffer (0.1 M sodium nitrate (aq), 15 wt% methanol) at a flow rate of 1 
mL/min.  The system was calibrated with Polyethylene Oxide (PEO) standards (24, 40 
and 79 kDa) prepared analogous to polymer samples.  OmniSEC software (Malvern 
Instruments Ltd, Worcestershire, UK) was used for GPC data analysis. 
2.3.4 Sodium Dodecyl Sulphate Polyacrylamide Gel Electrophoresis 
(SDS-PAGE) 
Typically, polymer/protein samples (1-10 μg) were prepared to a standard 
volume (7.5 μL) in 1x PBS.  NuPAGE® LDS sample loading buffer 4x (2.5 μL) was 
added and samples heated at 95 °C for 10 min.  A NuPAGE® Novex® 4 - 12% Bis-
Tris Gel (1.0 mm, 12 well) was placed into a Novex Mini-Cell gel tank (Invitrogen, Life 
Technologies, Paisley, UK) and filled with NuPAGE® MES SDS Running Buffer (1x 
diluted in 1x PBS).  Samples (10 μL) were loaded onto the gel, plus loading buffer (1x, 
outer wells) and Novex® Sharp Pre-stained Protein Standard or SeeBlue® Plus2 Pre-
stained Protein Standard molecular weight markers.  The samples were run at 200 V 
for 20 min using a Pharmacia Biotech Electrophoresis Power Supply (Amersham, GE 
Healthcare, Buckinghamshire, UK).  The gel was removed from the tank and stained 
with InstantBlue™ Coomassie gel stain for 1 h whilst rocking on an Infors HT plate 
shaker (Infors AG, Basel, Switzerland).  The gel was de-stained overnight in dH2O 
(whilst rocking) and imaged using an Epson Perfection V700 Photo Scanner (Epson, 
Hertfordshire, UK) for polymer/protein visualisation, or using a VersaDoc™ MP 4000 
(Bio-Rad, Hertfordshire, UK) for fluorescent staining. 
2.3.5 Mass Spectrometry (MS) 
Samples were prepared in 1x PBS as appropriate.  EMCH-DARPin samples 
were run and analysed by Dr Alan Sandercock (MedImmune, Cambridge, UK) using 
an AB4800 MALDI-TOF/TOF mass spectrometer (AB Sciex, Concord, Ontario, 
Canada).  Samples were diluted into MALDI matrix solution (α-cyano-4-
hydroxycinnamic acid, dissolved at 10 mg/ml in 70% acetonitrile 0.1% TFA), applied 
to a MALDI target and allowed to dry.  Spectra were acquired in positive linear mode, 
and analysed using the Data Explorer software supplied with the mass spectrometer. 
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2.3.6 PP-75 AFC Thin Layer Chromatography (TLC) 
PP-75 AFC sodium salt derivatives, unconjugated fluorescein derivatives and 
PP-75 sodium salt were dissolved in acetonitrile and spotted along the baseline of a 
TLC sheet.  The sheet was developed under a 2.5% acetic acid, 2.5% tert-Butanol, 
5% methanol, 90% DCM solvent system and visualised under UV light (shortwave 254 
nm; long-wave 365 nm). 
2.3.7 Pyridine-2-Thione Absorption Assay 
PP-75 PDPH cross-linked derivatives (1-10 mg) were dissolved in appropriate 
solvents (1 mL).  Polymer samples (20 μM, 100 μL) were added to a 96-well, clear, 
round bottom, polypropylene assay plate (Greiner) and DTT (500 μM, 2 μL) was added 
and mixed.  After 15 min the absorbance (340 nm) was measured.  Plates were read 
using an EnVision® Multilabel Reader (PerkinElmer, Massachusetts, USA). 
The absorbance (340 nm) of a known quantity of 2-mercaptopyridine (pyridine-
2-thione) in the appropriate solvent (1 mg/mL stock) was used as a calibration curve. 
2.3.8 Absorbance and Fluorescence Assays 
Stock solutions of PP-75 AFC and PP-75 sodium salt polymers (1 mg) were 
prepared in DMF: PBS (1:9 v/v, 1 mL).  Polymer samples (20 μM, 100 μL) were added 
to a 96-well, clear, flat bottom assay plate to measure absorbance (490 nm) and to a 
96-well, white, flat bottom assay plate to measure fluorescence (excitation/emission 
485/520 nm).  Plates were read using an EnVision® Multilabel Reader (PerkinElmer, 
Massachusetts, USA). 
The absorbance (490 nm) and fluorescence (485/520 nm) of a known quantity 
of unconjugated 6-aminofluorescein (100 μg/mL stock) in DMF: PBS (1:9 v/v, 1 mL) 
were used as calibration curves. 
The absorbance (550 nm) and fluorescence (550/570 nm) of Cy3 labelled 
siRNA was also similarly measured against a PBS blank. 
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2.3.9 Agarose Gel Electrophoresis 
A 1% gel was made by dissolving agarose (0.75 g) in TAE (75 mL) and heating 
in a microwave for 2 min until clear.  SYBR® Safe DNA gel stain (7.5 μL) was added 
to the agarose solution and mixed (by swirling).  The agarose solution was poured into 
a gel tray and a gel comb was inserted before leaving the gel to set at room 
temperature for 1 h.  Once set, the gel was placed into a gel electrophoresis tank (Mini-
Sub® Cell GT System, Bio-Rad, Hertfordshire, UK) and filled with TAE buffer.  Loading 
dye (1 μL) was added to PP-75 PDPH siRNA conjugates, PP-75 PDPH and siRNA (5 
μL) and 1 kb Plus DNA Ladder (5 μL).  Samples (5 μL) were loaded onto the gel and 
run at 100 V for 20 min using a PowerPac™ Basic Power Supply (Bio-Rad, 
Hertfordshire, UK).  The gel was removed from the tank and visualised following 
exposure under UV light using a Trans-Illuminator Dark Reader (Clare Chemical 
Research, Colorado, USA). 
2.3.10 DARPin Enzyme-Linked Immunosorbent Assay (ELISA) 
96-well, clear, flat bottom assay plates were treated with serially diluted 
concentrations of PP-75 linked DARPin conjugates, PP-75 and DARPin only.  The 
coated plate was incubated (4 °C) overnight.  The plate was washed three times with 
1x PBS (200 μL) and blocked with skimmed milk powder (300 μL, 3% w/v 1x PBS) 
and left to incubate at room temperature for 1 h.  The plate was washed three times 
with 1x PBS/0.1% Tween before addition of anti-DARPin or anti-polyhistidine detection 
antibodies (50 μL, as per manufacturer’s guidelines) and left to incubate at room 
temperature for 1 h.  The plate was washed three times with 1x PBS/0.1% Tween and 
plates treated with secondary antibodies conjugated to HRP (50 μL, as per 
manufacturer’s guidelines) and left to incubate at room temperature for 1 h.  The plate 
was washed three times with 1x PBS/0.1% Tween and three times with 1x PBS.  TMB 
substrate (50 μL) was added to the plate and left to incubate at room temperature for 
15 min before addition of sulphuric acid (50 μL, 0.5 M).  Absorbance (450 nm) was 
measured using an EnVision® Multilabel Reader (PerkinElmer, Massachusetts, USA).   
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2.3.11 Dynamic Light Scattering (DLS) 
Stock solutions of sodium salt polymers (1 mg) were prepared in 1x PBS (1 mL, 
pH 5.5, 6.5, 7.4 and 8.4; adjusted with 0.2 M NaOH and 0.2 M HCl) and diluted 10- 
and 100-fold.  Samples were passed through Millex® syringe filter units (0.45 μm) and 
allowed to equilibrate for 24 h before use.  DLS traces were obtained measuring 
polymer samples (50 µL) in 1 mL quartz glass cuvettes (Malvern Instruments, 
Worcestershire, UK), using a Zetasizer Nano Z system, and analysed with the 
Zetasizer software (Malvern Instruments, Worcestershire, UK). 
2.4 Cell Culture 
All cell culture was performed in aseptic conditions in a Holten LaminAir Safe 
2010 Class II Biological Safety Cabinet (Thermo Fisher Scientific, Leicestershire, UK) 
in a designated tissue culture suite.  Working surfaces were sterilised with Distel and 
washed with 70% ethanol before and after use.  To prevent cell line contamination, 
where possible, sterile, disposable plasticware was routinely used.  Designated hand-
held cell culture pipettes were kept in the safety cabinet to pipette solutions < 1 mL.  
All solutions > 1 mL were pipetted using serological plastic pipettes and a hand-held 
Hirschmann® Pipetus® rechargeable pipette (Hirschmann Laborgeräte GmbH & Co, 
Eberstadt, Germany).  Waste liquids were aspirated into 2% Virkon using a SAM 12 
suction unit and trap aspirator (MG Electric, Colchester, UK). 
2.4.1 Parental and Dual Luciferase Reporter Cell Lines 
SK-BR-3 (Her2+) (parental) and SK-BR-3 (Her2+) fluc/Rluc reporter cell lines 
were maintained in Modified McCoy’s 5A Medium and cultured on Corning® 175 cm² 
cell culture flasks.  MDA-MB-231 (Her2-) (parental) and MDA-MB-231 (Her2-) 
fluc/Rluc reporter cell lines were maintained in RPMI 1640 + GlutaMAX™ and cultured 
on Nunc™ 175 cm² cell culture flasks.  All cell media was supplemented with 10% 
(v/v) heat-inactivated foetal bovine serum (FBS).  Cultures were visualised under an 
Olympus CKX41 inverted microscope (KeyMed (Medical & Industrial Equipment) Ltd, 
Essex, UK) and maintained in 5% CO2, 95% air, at 37 °C in a Heracell™ 240i CO2 
Incubator (Thermo Fisher Scientific, Leicestershire, UK). 
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2.4.2 Maintaining Adherent Cell Lines 
Spent culture media was aspirated from the cell culture flask and adherent cells 
were washed with 1x PBS (5 mL).  Accutase® cell detachment solution (5 mL) was 
added onto the cells and the flask was placed in the incubator (5 min).  Adherent cells 
were detached from the flask surface by gentle agitation.  Complete (FBS 
supplemented) media (5 mL) was added to the flask and the cell suspension (10 mL) 
transferred to a Falcon™ tube (15 mL).  Cells were isolated via centrifugation (400 x 
g, 5 min) using an IEC CL40 Centrifuge (Thermo Scientific, Leicestershire, UK) and 
cell pellets were re-suspended in fresh complete culture media providing a single cell 
suspension.  Cells were seeded into a 175 cm² cell culture flask containing complete 
media (35 mL) and incubated (5% CO2, 95% air, 37 °C).  Cells were passaged to 
maintain healthy cell growth; an adherent monolayer, ideally not exceeding 80-90% 
confluent cells maintains a viable cell population within the exponential growth phase. 
2.4.3 Determination of Cell Concentration 
Trypan Blue Solution 0.4% (10 μL) was added to a single cell suspension (10 
μL).  Cell concentration was determined by manual cell count using a C-Chip 
disposable haemocytometer (Digital Bio, Hopkinton, USA).  The average of four 
counts was taken from the grid located at the centre of the C-Chip haemocytometer.  
Cell number was expressed as a concentration (x104 viable cells/mL).  Non-viable 
cells (dead/apoptotic) appeared dark-blue and were excluded from the count unless 
total cell number was required. 
2.4.4 Cryopreservation of Cells for Long-Term Storage 
Cell suspensions were prepared as described previously (Section 2.4.2).  Cells 
(1 - 2 x106 cells/mL) were re-suspended in freezing media (90% FBS, 10% DMSO) 
and transferred to cryogenic vials (1 mL aliquots).  Cells were frozen (-80 °C) at a 
controlled rate (1 °C/min) within a Mr Frosty™ (Nalgene, Thermo Scientific, 
Leicestershire, UK) containing 100% isopropanol.  After 24 h, cryovials were 
transferred to a liquid nitrogen (boiling point -196 °C) cell bank for long-term storage. 
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2.4.5 Reviving Cells 
A cryovial was removed from the liquid nitrogen cell bank and snap-thawed (1 
min, 37 °C water-bath).  Cells (1 mL) were transferred to a Falcon™ tube (15 mL) 
containing pre-warmed (37 °C) complete culture media (9 mL) and centrifuged (400 x 
g, 5 min) using an IEC CL40 Centrifuge (Thermo Scientific, Leicestershire, UK).  The 
supernatant was removed and replaced with fresh complete media (10 mL) and 
seeded into a 75 cm² cell culture flask containing complete media (10 mL).  After 24 h 
incubation (5% CO2, 95% air, 37 °C) spent media was aspirated and replaced with 
fresh complete media (15 mL).  Once confluent, cells were passaged and cultured as 
described previously (Section 2.4.2). 
2.4.6 Viable Growth Curves 
Cells were harvested from a 175 cm² cell culture flask as described previously 
(Section 2.4.2) and a single cell suspension (1 mL, 2 x105 cells/mL) seeded into a 6-
well, clear, flat bottom, tissue culture plate containing fresh complete culture media (1 
mL/well).  After 24 h incubation (5% CO2, 95% air, 37 °C) an adherent cell monolayer 
formed (Note: 24 h after seeding is designated time (t) = 0 h).  Cells were harvested 
from the 6-well tissue culture plate and viable cell number was counted as described 
previously (Sections 2.4.2 and 2.4.3) at 24 h intervals over a 5 day period (t = 0, 24, 
48, 72, 96 h). 
Parallel counts on multiple cell lines were performed using a TC10™ 
Automated Cell Counter (Bio-Rad, Hertfordshire, UK) to reduce the time viable cells 
were out of culture.  Viable cell number was calculated and expressed as a 
concentration of 106 cells/mL. 
2.4.7 Calculating Cell Line Generation Time 
Following cell growth counts, an X-Y scatter plot of time vs. viable cell number 
could be constructed.  Cell generation time (or doubling time) was calculated based 
on the exponential growth phase of the growth curve, excluding the lag phase.  Viable 
cell number was transformed using log10 to produce a linear graph.  The number of 
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generations and the generation times were calculated as in Equation 2.1 and Equation 
2.2. 
2.1  Number of generations(c) =
b - a
log10(2)
 
 
2.2    Generation time   = 
c
t2 - t1
 
 
Equation 2.1 and Equation 2.2: Determining Cell Generation Number and Time. 
Where: c     is the number of generations 
 a     is the viable cell number at the start of exponential growth 
 b     is the viable cell number at the end of exponential growth 
 t1     is the time at the start of exponential growth 
t2     is the time at the end of exponential growth 
The generation time for each cell line was expressed closest to the nearest hour. 
 
2.5 Biological Characterisation of PP-75 Delivery Systems 
A range of in vitro cell assays were performed to determine the biocompatibility, 
pH-responsive membrane destabilisation, intracellular localisation and siRNA 
mediated gene knockdown capabilities of PP-75 and its derivatives.  Prior to all 
assays, polymer solutions were filtered through Millex® syringe filter units (0.45 μm) 
and allowed to equilibrate for 24 h before use. 
2.5.1 PP-75 Cytotoxicity Testing 
2.5.1.1 Viable Cell Count  
fluc/Rluc reporter cell lines were seeded as optimised (Section 2.4.6).  Sodium 
salt polymers (PP-75: 0.5, 1.0 mg/mL; PLP: 1 mg/mL) were dissolved in complete 
culture media.  After 24 h incubation (5% CO2, 95% air, 37 °C) spent culture media 
was aspirated and adherent cells were treated with polymer (2 mL) at t = 0 h.  Cells 
were harvested from the 6-well tissue culture plate and viable cell number was 
determined as described previously (Sections 2.4.2 and 2.4.3) at 24 h intervals over a 
5 day period (t = 0, 24, 48, 72, 96 h). 
70 
2.5.1.2 AlamarBlue® Cytotoxicity Assay 
Optimisation 
fluc/Rluc reporter cell lines were harvested from a 175 cm² cell culture flask as 
described previously (Section 2.4.2).  Cells were seeded (200 μL) into a 96-well black, 
clear flat bottom, tissue culture plate across a 2-fold dilution range (1.25 x104 to 8.0 
x105 cells/mL).  After 24 h incubation (5% CO2, 95% air, 37 °C) alamarBlue® (20 µL) 
was added to all wells and the assay plate returned to incubator.  Assay plate 
fluorescence (excitation/emission 560/590 nm) was measured using a Varioskan™ 
Flash Multimode Reader (Thermo Scientific, Leicestershire, UK) at t = 1 h.  
Measurements were repeated, with continued plate incubation (5% CO2, 95% air, 37 
°C), every hour following addition of alamarBlue® until t = 8 h.  Media only wells (no 
cells) were measured establishing background absorbance.  Plates were also seeded 
to measure t = 24 h and 48 h time-points.  Fluorescence was measured within the 
linear assay range (2 – 6 h) as established in the first 24 h. 
Polymer Cytotoxicity 
Sodium salt polymers (PP-75: 0.01 - 5.0 mg/mL; PLP: 1 mg/mL) were dissolved 
in complete culture media.  Assay set-up was as optimised.  After 24 h incubation (5% 
CO2, 95% air, 37 °C) spent culture media was aspirated and adherent cells were 
treated with polymers (200 μL) at t = 0 h.  Media only wells (no cells), untreated cells 
and Triton™ X-100 (0.1%) treated cells were included to establish background 
absorbance and as control wells.  At t = 21 h alamarBlue® (20 µL) was added to the 
assay plate and returned to the incubator as optimised (3 h).  Fluorescence was 
measured as previously described at t = 24 h.  Plates were also seeded to measure t 
= 48 h and 72 h time-points. 
2.5.1.3 Cell Titre-Glo® Luminescent Cell Viability Assay 
Assay reagents were prepared as outlined in the Cell Titre-Glo® Luminescent 
Cell Viability Assay Technical Bulletin (Promega) and the protocol followed with 
modifications. 
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fluc/Rluc reporter cell lines were harvested from a 175 cm² cell culture flask as 
described previously (Section 2.4.2) and a single cell suspension (200 μL) was seeded 
as optimised (7.5 x104 cells/mL and 5.0 x104 cells/mL for SK-BR-3 (Her2+) fluc/Rluc 
and MDA-MB-231 (Her2-) fluc/Rluc cells respectively) into a 96-well, white, flat bottom 
tissue culture plate.  Sodium salt polymers (PP-75: 0.01 – 2.5 mg/mL; PLP: 1 mg/mL) 
were dissolved in complete culture media.  After 24 h incubation (5% CO2, 95% air, 
37 °C) spent culture media was aspirated and adherent cells were treated with 
polymers (200 μL) at t = 0 h.  Media only wells (no cells), untreated cells and Triton™ 
X-100 (0.1%) treated cells were included to establish background luminescence and 
as control wells.  At t = 24 h cells plates were removed from the incubator and left to 
equilibrate at room temperature for 30 min.  Spent culture media was aspirated and 
fresh complete media (100 μL) was added to wells followed by CellTiter-Glo® Reagent 
(100 µL).  Plate contents was mixed using a DPC MicroMix® 5 Shaker (Promega, 
Southampton, UK) for 2 min and then left to incubate for a further 10 min at room 
temperature.  Luminescence was measured using an EnVision® Multilabel Reader 
(PerkinElmer, Massachusetts, USA).  Plates were also seeded to measure t = 48 h 
and 72 h time-points. 
2.5.2 Lactate Dehydrogenase (LDH) Assay 
Assay reagents were prepared as outlined in the CytoTox-ONE™ 
Homogeneous Membrane Integrity Assay Technical Bulletin (Promega) and the 
protocol followed with modifications. 
fluc/Rluc reporter cell lines were harvested from a 175 cm² cell culture flask as 
described previously (Section 2.4.2) and a single cell suspension (200 μL) was seeded 
as optimised (1.0 x105 cells/mL) into a 96-well, white, flat bottom tissue culture plate.  
Stock solutions of sodium salt polymers and polymer conjugates (20 mg) were 
prepared in 1x PBS (1 mL, pH 5.5, 6.5 and 7.4) and diluted 10-, 100- and 1000-fold in 
cell culture media.  After 24 h incubation (5% CO2, 95% air, 37 °C) spent culture media 
was aspirated and adherent cells were treated with polymers (100 μL) at t = 0 h.  Media 
only wells (no cells), untreated cells and lysed cells were included to establish 
background luminescence and as control wells.  At t = 10 min cell plates were removed 
from the incubator and left to equilibrate at room temperature for 10 min.  Lysis 
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Solution (2 μL) was added to control wells (lysed) and the plate was incubated for a 
further 10 min at room temperature.  CytoTox-ONE™ Reagent (50 µL) was added to 
the assay plate and the contents mixed before a further 10 min incubation at room 
temperature.  Stop Solution (25 µL) was added to the assay plate and shaken for 10 
sec using a DPC MicroMix® 5 Shaker (Promega, Southampton, UK).  Fluorescence 
(excitation/emission 550/600 nm) was measured (t = 0.5 h) using an EnVision® 
Multilabel Reader (PerkinElmer, Massachusetts, USA).  Plates were also seeded to 
measure t = 1 h, 2 h, 3 h, 6 h and 24 h time-points. 
2.5.3 Intracellular Localisation of PP-75 AFC 
2.5.3.1 Laser Scanning Confocal Microscopy (LSCM) 
PP-75 AFC sodium salt polymer (0.5 mg/mL) was dissolved in complete culture 
media.  MDA-MB-231 (Her2-) fluc/Rluc cells were harvested from a 175 cm² cell 
culture flask as described previously (Section 2.4.2) and a single cell suspension (500 
µL) was seeded as optimised (1.0 x105 cells/mL) into a pre-equilibrated 35 mm glass 
bottom culture dish (MatTek, USA).  Additional media (1500 µL) was added once the 
cells were settled (after 30 min).  After 24 h incubation (5 % CO2, 95% air, 37 °C) spent 
culture media was aspirated and adherent cells were treated with PP-75 AFC (500 μL) 
at t = 0 h.  Untreated cells and 6-aminofluorescein treated cells were included as 
control wells.  Cells were left to incubate (5% CO2, 95% air, 37 °C) for 1 h before spent 
culture media was aspirated and cells were washed with 1x PBS (500 μL).  Cells were 
stained with Hoechst 33342 (30 min at room temperature), Lysotracker Red (40 min 
at room temperature) and CellMask™ Deep Red Plasma membrane Stain (5 min at 
room temperature) and washed with 1x PBS/ 0.1% Tween (200 μL).  Cells were 
imaged using an Olympus FluoView™ FV300 inverted laser scanning confocal 
microscope with a 60× oil immersion objective to obtain high resolution images. 
2.5.3.2 Flow Cytometry 
PP-75 AFC sodium salt polymer (0.5 mg/mL) was dissolved in complete culture 
media.  MDA-MB-231 (Her2-) fluc/Rluc cells were harvested from a 175 cm² cell 
culture flask as described previously (Section 2.4.2).  A single cell suspension (1 mL, 
4 x105 cells/mL) was seeded into a 6-well, clear, flat bottom, tissue culture plate 
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containing fresh complete culture media (1 mL/well) and left to incubate (5% CO2, 95% 
air, 37 °C) for 24 h.  Spent culture media was aspirated and adherent cells were treated 
with polymer (2 mL) at t = 0 h.  Cells were held on ice (4 °C) or left to incubate (5% 
CO2, 95% air, 37 °C) for 1 h before spent culture media was aspirated.  Cells were 
washed with Trypan Blue Solution 0.4% (1 mL) and 1x PBS (1 mL).  Cells were 
harvested from the 6-well tissue culture plate and cell number was determined as 
described previously (Sections 2.4.2 and 2.4.3).  Cells (2 x106) were re-suspended in 
pre-cooled (on ice) FACS buffer (1x PBS, 2% v/v FBS, 0.1% w/v sodium azide) (2 mL) 
and centrifuged (400 x g, 5 min) before fixation (20 min at room temperature) in 
paraformaldehyde (3.7% v/v in FACS buffer, 2 mL).  Cells were re-suspended in FACS 
buffer (1 mL) and aliquots (100 μL; 2 x105 cells) were transferred to a 96-well, clear, 
conically tapered, assay plate (Greiner).  Untreated cells were included as control 
wells.  FACS analysis was run using a FACSCanto™ II (BD Biosciences, Ontario, 
Canada) and analysed using FlowJo 7.6.5 Software (FlowJo, LLC, Oregon, USA). 
2.5.3.3 Opera® High Content Cell Screening 
PP-75 AFC sodium salt polymer (0.5 mg/mL) and PP-75 siRNA Cy 3 
conjugates (500 nM) were dissolved in complete culture media.  Fluc/Rluc reporter 
cell lines were harvested from a 175 cm² cell culture flask as described previously 
(Section 2.4.2) and a single cell suspension (200 μL) was seeded as optimised (1.0 
x105 cells/mL) into a 96-well, black, clear flat bottom, collagen treated, tissue culture 
plate (Greiner).  After 24 h incubation (5 % CO2, 95% air, 37 °C) spent culture media 
was aspirated and adherent cells were treated with polymers (200 μL) at t = 0 h.  
Untreated cells, 6-aminofluorescein treated cells, siRNA Cy 3 treated cells and siRNA 
Cy 3 plus Lipofectamine® 2000 treated cells were included as control wells.  Cells 
were left to incubate (5% CO2, 95% air, 37 °C) for 1 h before spent culture media was 
aspirated and cells were washed with 1x PBS/ 0.1% Tween (200 μL).  Cells were fixed 
(20 min at room temperature) in paraformaldehyde (3.7% v/v 1x PBS, 100 μL) and 
washed with 1x PBS/ 0.1% Tween (200 μL).  Cells were stained with Hoechst 33342 
(30 min at room temperature) and CellMask™ Deep Red Plasma membrane Stain (5 
min at room temperature) and washed with 1x PBS/ 0.1% Tween (200 μL).  Cells were 
also stained with Rab5, Rab7 and LAMP1 monoclonal antibodies (1 h at room 
temperature) plus anti-rabbit IgG Alexa Fluor® 610 conjugate secondary antibody, (1 
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h at room temperature) following permeablisation (5 min at room temperature) with 
Triton™ X-100 (0.2%, 100 μL) and washing with 1x PBS/ 0.1% Tween (200 μL).  Cells 
were imaged using an Opera® High Content Screening System (PerkinElmer, 
Massachusetts, USA).  Plates were also seeded to measure t = 6 h and 24 h time-
points. 
2.5.4 PP-75 Mediated Intracellular siRNA Delivery 
siRNA duplexes were designed, based on a fluc mRNA target sequence in a 
similar region to that identified by Lewis (Lewis et al. 2002).  Duplexes were 
synthesised by Integrated DNA Technologies (Leuven, Belgium) with 5’ thiol 
modification to allow conjugation with PP-75 PDPH polymers.  Scrambled (non-
specific) siRNA and Cy 3 labelled siRNA were also purchased as control and traceable 
payloads respectively. 
2.5.4.1 Protein Knockdown 
2.5.4.1.1 Dual Luciferase® Reporter (DLR) Assay 
Assay reagents were prepared as outlined in the Dual-Luciferase® Reporter 
Assay Technical Manual (Promega) and the protocol followed with modifications. 
Optimisation - fluc/Rluc Expression 
fluc/Rluc reporter cell lines were harvested from a 175 cm² cell culture flask as 
described previously (Section 2.4.2) and a single cell suspension (200 μL) was seeded 
as optimised (2.5 x104 cells/mL and 5.0 x104 cells/mL for SK-BR-3 (Her2+) fluc/Rluc 
and MDA-MB-231 (Her2-) fluc/Rluc cells respectively) into a 96-well, clear flat bottom, 
tissue culture plate.  After 24 h incubation (5% CO2, 95% air, 37 °C) spent culture 
media was aspirated and cells were washed with 1x PBS (200 μL) and aspirated.  
Passive lysis buffer (30 μL) was added to adherent cells and incubated at room 
temperature for 15 min, rocking gently.  Cell lysates (20 μL) were transferred into a 
96-well, white, flat bottom assay plate.  LAR II (50 μL) was added to the assay plate 
and fluc luminescence was measured using an EnVision® Multilabel Reader 
(PerkinElmer, Massachusetts, USA).  Stop & Glo® Reagent (50 μL) was then added 
75 
to the assay plate and Rluc luminescence was measured.  Reagent only wells (minus 
cells) were measured, establishing background luminescence. 
PP-75 siRNA Conjugate fluc/Rluc Knockdown 
Assay set-up was as optimised.  PP-75 siRNA conjugates (fluc target specific 
and scrambled (non-specific)) at defined concentrations were dissolved in complete 
culture media.  After 24 h incubation (5% CO2, 95% air, 37 °C) spent culture media 
was aspirated and adherent cells were treated with polymer conjugates (100 μL) at t 
= 0 h.  Media only wells (no cells), untreated cells, siRNA plus Lipofectamine® 2000 
treated cells, siRNA treated cells, PP-75 treated cells and Lipofectamine® 2000 
treated cells were included to establish background luminescence and as control 
wells.  At t = 6 h complete culture media (100 μL) was added to the cells.  After 24 h 
incubation (5% CO2, 95% air, 37 °C) spent culture media was aspirated and cells were 
washed with 1x PBS (200 μL) and aspirated.  Cells were lysed from the 96-well tissue 
culture plate and fluc/Rluc luminescence measured as described previously.  Plates 
were also seeded to measure t = 48, 72 and 96 h time-points where appropriate. 
2.5.4.2 mRNA Knockdown 
2.5.4.2.1 RNA Extraction 
Assay reagents were prepared as outlined in the RNeasy Plus Mini Kit 
Handbook (Qiagen) and the RNase-Free DNase Set (Qiagen).  The protocols were 
followed without modification. 
Cell pellets were re-suspended in Buffer RLT (600 μL) and transferred to a 
QIAshredder column placed in a collection tube (2 mL).  Columns were centrifuged 
(maximum speed, 3 min) using a Heraeus™ Fresco™ 21 Microcentrifuge (Thermo 
Scientific, Leicestershire, UK).  Ethanol (70%; 600 μL) was added to the cell lysate 
and thoroughly mixed by pipetting before being transferred to an RNeasy Mini spin 
column placed in a collection tube (2 mL).  Columns were centrifuged (10,000 x g, 15 
sec) and the flow through discarded.  Buffer RW1 (350 μL) was added to the column 
and centrifuged (10,000 x g, 15 sec).  DNase I stock solution (10 μL) was added to 
Buffer RDD (70 μL) and mixed gently before adding directly onto the RNeasy column 
membrane.  After 15 min incubation at room temperature Buffer RW1 (350 μL) was 
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added onto the column and centrifuged (10,000 x g, 15 sec).  Flow-through was 
discarded and Buffer RPE (500 μL) was added to the column and centrifuged (10,000 
x g, 15 sec).  Flow-through was again discarded and Buffer RPE (500 μL) was added 
to the column and centrifuged (10,000 x g, 2 min).  The spin column was placed into 
a fresh collection tube (2 mL) and RNase-free water (50 μL) was added directly onto 
the spin column membrane.  The column was centrifuged (10,000 x g, 1 min) to elute 
the RNA.  RNA concentration was measured (260 nm) using a NanoDrop 1000 
Spectrophotometer (Thermo Fisher Scientific, Leicestershire, UK) and was stored (-
80 °C) until use. 
2.5.4.2.2 Reverse Transcription: cDNA Synthesis 
Assay reagents were prepared as outlined in the Precision nanoscript™ 
Reverse Transcription Kit Manual (Primerdesign Ltd) and the protocol followed without 
modification. 
Oligo-dT and random nonamer primers were mixed with RNA (1 μg) extracted 
as described previously (Section 2.5.4.2.1) and heated (65 °C) for 5 min using a 
Techne Dri-block® DB 2A heater (Bibby Scientific Limited, Staffordshire, UK), before 
immediately cooling on ice.  Primed RNA templates were mixed with the RT (reverse 
transcription) reaction mix and held at room temperature for 5 min.  Samples were left 
to incubate (55 °C) for 20 min followed by heat inactivation (75 °C) for 15 min.  Positive 
control cDNA was synthesised from synthetic sequence-specific template (fluc/Rluc 
primer amplicon) and a dH2O (RNA negative) control was also included.  cDNA 
concentration was measured (260 nm) using a NanoDrop 1000 Spectrophotometer 
(Thermo Fisher Scientific, Leicestershire, UK) and was stored (-20 °C) until use. 
2.5.4.2.3 GeNorm™ Reference Gene Selection 
Assay reagents were prepared as outlined in the geNorm™ Reference Gene 
Selection Kit Manual (Primerdesign Ltd) and the protocol followed without 
modification. 
Lyophilised primer and probe mixes for GAPDH, CYC1, B2M, ACTB, SDHA 
and 18S reference genes were re-suspended in RNAse/DNAse free water and 
combined with 2x Precision™ Mastermix.  Primer/probe mixes were added to 96-well 
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BrightWhite Real-time PCR plates.  cDNA (5 ng/μL) synthesised as described 
previously (Sections 2.5.4.2.2) was added to the plate.  cDNA was PCR amplified for 
40 cycles (Table 2.1) using an ABI PRlSM® 7900 HT Sequence Detection System 
(Applied Biosystems, Life Technologies, Paisley, UK).  RT-qPCR analysis was 
performed using geNorm software: qBasePLUS.  Positive control cDNA and a dH2O 
(cDNA negative) control was also included. 
Table 2.1: PCR Amplification Protocol. 
Step Temperature (ºC) and Time Process 
Activation 95, 10 min enzyme activation 
Denaturation 95, 15 sec dsDNA → ssDNA 
Extension 60, 60 sec primer binding and DNA amplification 
Cooling 40, held constant end of cycle 
 
cDNA was PCR amplified for 40 cycles consisting of enzyme activation (95 °C, 10 min) denaturation 
(95 °C, 15 sec) and extension (60 °C, 60 sec).  Protocol run on an ABI PRlSM® 7900 HT Sequence 
Detection System (Applied Biosystems, Life Technologies, Paisley, UK). 
2.5.4.2.4 Real Time–quantitative PCR 
Assay reagents were prepared as outlined in the Custom Designed Real-Time 
PCR Assay Kit Manual (Primerdesign Ltd) and the protocol followed without 
modification. 
Validation - fluc/Rluc and Reference Gene Expression 
Lyophilised primer and probe mixes for fluc and Rluc genes were re-suspended 
in RNAse/DNAse free water and the PCR reaction was carried out as previously 
described (Section 2.5.4.2.3). 
Standard Curves – Quantitative PCR Validation 
Template DNA was serially diluted and the PCR reaction was carried out as 
previously described (Section 2.5.4.2.3). 
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PP-75 siRNA Conjugate fluc/Rluc Knockdown 
Fluc/Rluc reporter cell lines were harvested from a 175 cm² cell culture flask as 
described previously (Section 2.4.2) and a single cell suspension (1 mL, 2.5 x105 
cells/mL and 2.5 x105 cells/mL for SK-BR-3 (Her2+) fluc/Rluc and MDA-MB-231 (Her2-
) fluc/Rluc cells respectively) seeded into a 6-well, clear, flat bottom, tissue culture 
plate containing fresh complete culture media (1 mL/well).  PP-75 siRNA conjugates 
(fluc target specific and scrambled (non-specific)) at specific concentrations were 
dissolved in complete culture media.  After 24 h incubation (5% CO2, 95% air, 37 °C) 
spent culture media was aspirated and adherent cells were treated with polymers (1 
mL) at t = 0 h.  Untreated cells, siRNA treated cells and siRNA plus Lipofectamine® 
2000 treated cells were included as control wells.  At t = 6 h complete culture media 
(1 mL) was added to the cells.  After 24 h incubation (5% CO2, 95% air, 37 °C) spent 
culture media was aspirated and cells were washed with 1x PBS (200 μL) and 
aspirated.  Cells were lysed from the 6-well tissue culture plate as described previously 
(Section 2.4.2).  Cell lysates were centrifuged using a Heraeus™ Fresco™ 21 
Microcentrifuge (Thermo Scientific, Leicestershire, UK) and the supernatant aspirated 
and the cell pellets frozen (-80 °C) prior to RNA extraction and cDNA synthesis, as 
described previously (Sections 2.5.4.2.1 and 2.5.4.2.2).  Lyophilised primer and probe 
mixes for fluc and Rluc genes were re-suspended in RNAse/DNAse free water and 
the PCR reaction was carried out as previously described (Section 2.5.4.2.3), 
measuring fluc/Rluc gene knockdown.  Plates were also seeded to measure t = 48, 72 
and 96 h time-points where appropriate. 
2.5.5 DARPin Targeted PP-75 Delivery 
To provide an accurate comparison for PP-75 Her2 targeted delivery, a 
negative control, two-repeat DARPin demonstrating no affinity towards Her2 was 
isolated. 
2.5.5.1 Isolating Negative Control DARPin from Library 
A DARPin library containing 1012 phage with 109 diversity was established in 
house by MedImmune according to Zahnd (Zahnd et al. 2007a). 
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Transformation of TG1 E.coli Cells to express Phage 
A single TG1 E.coli colony grown on a 2x TYAG agar plate (2x TY media plus 
glucose (30 mg/mL) and ampicillin (0.1 mg/mL)) was picked with a disposable plastic 
loop and inoculated into 2x TY media (50 mL) in a plastic Erlenmeyer cell culture flask 
(250 mL).  The culture was incubated (37 °C, 200 rpm) for 4 h until exponential growth 
(~0.5 OD600) was recorded using a BioPhotometer® plus (Eppendorf, Hamburg, 
Germany) in 1 mL disposable plastic cuvettes (Eppendorf, Hamburg, Germany).  The 
phage DARPin library was diluted (1: 106) in 2x TY media and diluted 100-fold into 
TG1 E.coli culture (10 mL) in a plastic Falcon™ tube (50 mL).  The culture was 
incubated (37 °C, 150 rpm) using an Infors HTEcotron Shaking Incubator (Infors AG, 
Basel, Switzerland) for 1 h.  The DARPin library (500 μL) was then spread onto 2x 
TYAG agar bioassay plates in 2-, 10- and 20- fold dilutions and left to incubate (30 °C) 
overnight.  TYAG media (150 μL/well) was added to 96-well, clear round bottom, assay 
plates and single colonies picked from the bioassay plates and inoculated using 
disposable plastic pipette tips.  Following overnight incubation (37 °C, 200 rpm) in a 
G24 Scientific Environmental Incubator Shaker (New Brunswick Scientific, Eppendorf, 
Hamburg, Germany) plates were checked for growth and colony cultures (40 μL) were 
transferred to fresh 96-well plates for DNA sequencing (stored at -20 °C). 
Glycerol stocks were made following addition of glycerol (50 μL, 50%) into the 
remaining culture (100 μL) in the 96-well source plate and stored (-80 °C).  Following 
sequence confirmation, DARPin glycerol stocks were streaked onto 2x TYAG petri 
dishes using disposable plastic loops and left to incubate (30 °C) overnight.  An 
individual colony was picked from each petri dish and inoculated into 2x TYAG media 
(2 mL) in a universal tube (25 mL) and left to incubate (37 °C, 200 rpm) overnight.  
Glycerol stocks were made following addition of overnight cultures (1 mL) into 
cryovials containing glycerol (500 μL, 50%) and stored (-80 °C).  Cultures were 
sequenced as previously described. 
Her2 DARPin and Controls 
Single colonies from Her2 DARPin and CEA6 (negative scFv) were inoculated 
in 2x TYAG media (2 mL) in universal tubes (25 mL) and incubated (25 °C, 280 rpm) 
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overnight using a Kuhner shaker (Kuhner Shaker Ltd, Derbyshire, UK).  Glycerol (500 
μL) was added to each culture (1 mL) and stored (-80 °C). 
2.5.5.2 Phage Enzyme-Linked Immunosorbent Assay (ELISA) on Cells 
Day 0 
fluc/Rluc reporter cell lines were harvested from a 175 cm² cell culture flask as 
described previously (Section 2.4.2) and a single cell suspension (200 μL) was seeded 
as optimised (7.5 x104 cells/mL and 5.0 x104 cells/mL for SK-BR-3 (Her2+) fluc/Rluc 
and MDA-MB-231 (Her2-) fluc/Rluc cells respectively) into a 96-well, clear flat bottom, 
tissue culture plate.  After 48 h incubation (5% CO2, 95% air, 37 °C) spent culture 
media was aspirated. 
Day 1 
TG1 E.coli colonies infected with phage displaying DARPins were added to 2x 
TYAG media (500 μL/well) in a 96-well, deep-well assay plate (Greiner) and incubated 
(37 °C, 280 rpm) for 5 h.  Helper phage (25 μL) was added to 2x TYAG media and 
added (100 μL) to the assay plates followed by further incubation (37 °C, 150 rpm) for 
1 h.  The phage plate was centrifuged (1700 x g, 10 min) using an IEC CL40 Centrifuge 
(Thermo Scientific, Leicestershire, UK) and the supernatant removed before re-
suspension of phage in 2x TY media plus ampicillin (0.1 mg/mL) and kanamycin (0.05 
mg/mL) (2x TYAK media, 500 μL/well).  The phage plate was incubated (25 °C, 280 
rpm) overnight. 
Day 2 
The cell plate was washed three times with 1x PBS (200 μL) and blocked with 
skimmed milk powder (300 μL, 3% w/v 1x PBS).  The phage plate was blocked with 
skimmed milk powder (500 μL, 6% w/v 1x PBS).  Cell and phage plates were left to 
incubate at room temperature for 1 h.  The cell plate was washed three times with 1x 
PBS whilst the phage plate was centrifuged (1700 x g, 5 min).  Phage plate 
supernatant (50 μL) was transferred to the cell plate and left to incubate at room 
temperature for 1 h.  The plate was washed three times with 1x PBS/ 0.1% Tween 
before addition of M13-HRP (50 μL, 3% w/v skimmed milk powder in 1x PBS) and left 
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to incubate at room temperature for 1 h.  The plate was washed three times with 1x 
PBS/0.1% Tween and three times with 1x PBS.  TMB substrate (50 μL) was added to 
the plate and left to incubate at room temperature for 15 min before addition of 
sulphuric acid (50 μL, 0.5 M).  Absorbance (450 nm) was measured using an 
EnVision® Multilabel Reader (PerkinElmer, Massachusetts, USA).  Untreated wells, 
Her2-binding DARPin wells, CEA6 scFv wells, and M13-HRP only wells were included 
as control wells. 
2.5.5.3 Sub-cloning DARPin Clones into pET-16b Expression Vector 
Individual colonies from the DARPin library were PCR amplified with primers 
designed to introduce NdeI and BamHI restriction sites into the N and C termini 
respectively.  Two glycines and a cysteine residue were also introduced into the 
reverse primer to allow DARPin conjugation with PP-75 EMCH polymers. 
Colony PCR 
A bacterial clone containing the plasmid encoding DARPin DNA was inoculated 
into 2x ReddyMix™ PCR Master Mix (50 μL) containing pET16bDP_Fwd (2 μL, 10 
μM) and pET16bDP_Rev (2 μL, 10 μM) PCR primers in nuclease-free water (46 μL) 
in disposable thin walled, plastic PCR tubes (0.2 mL).  PCR amplification was carried 
out using a Tetrad 2 thermal cycler (Bio-Rad, Hertfordshire, UK), heating (94 °C, 3 
min) samples prior to 25x PCR cycles consisting of denaturing (94 °C, 30 sec), 
annealing (55 °C, 30 sec) and extension (72 °C, 105 sec) steps.  A final extension (72 
°C, 5 min) was performed and PCR products were cooled (10 °C) before storage (-20 
°C). 
Primer sets were used in combination to achieve optimal DARPin sequence 
amplification. 
Agarose Gel Electrophoresis 
A 1% gel was made by dissolving agarose (0.75 g) in TAE (75 mL) in a glass 
beaker and heating in a microwave for 2 min until clear.  SYBR® Safe DNA gel stain 
(7.5 μL) was added to the agarose solution and mixed (by swirling).  The agarose 
solution was poured into a gel tray and a gel comb was inserted before leaving the gel 
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to set at room temperature for 1 h.  Once set, the gel was placed into a gel 
electrophoresis tank (Mini-Sub® Cell GT System, Bio-Rad, Hertfordshire, UK) and 
filled with TAE buffer.  Loading dye (1 μL) was added to PCR amplified DARPin DNA 
(5 μL) and 1 kb Plus DNA Ladder (5 μL).  Samples (5 μL) were loaded onto the gel 
and run at 100 V for 20 min using a PowerPac™ Basic Power Supply (Bio-Rad, 
Hertfordshire, UK).  The gel was removed from the tank and visualised following 
exposure under UV light using a Trans-Illuminator Dark Reader (Clare Chemical 
Research, Colorado, USA). 
PCR Purification 
Excluding those that did not run at the correct molecular weight on the agarose 
gel PCR amplified DARPin DNA from the PCR reaction mix was purified.  Assay 
reagents were prepared as outlined in the GenElute™ PCR Clean-Up Kit Technical 
Bulletin (Sigma-Aldrich) and the procedure followed without modification.  The 
concentration of purified dsDNA was measured (260 nm) using a NanoDrop 1000 
Spectrophotometer (Thermo Fisher Scientific, Leicestershire, UK). 
PCR Restriction Endonuclease Digestion 
PCR amplified DARPin product (500 ng) was added to 10x NEBuffer 4 digest 
buffer (5 μL) containing restriction endonucleases NdeI (1 μL) and BamHI-HF (1 μL).  
Nuclease-free water was added to a final volume of 50 μL.  The digest was left to 
incubate (37 °C) overnight.  NdeI (5 μL) and BamHI-HF (5 μL) were added to the digest 
and left to incubate (37 °C) for 2 h.  Digests were run on a 1% agarose gel (200 mL) 
containing SYBR® Safe DNA gel stain (20 μL).  Loading dye (10 μL) was added to the 
DARPin digest (50 μL) and 1 kb Plus DNA Ladder (5 μL) and samples (50 μL) were 
loaded onto the gel.  pET16b vector (300 μg) was added to 10x NEBuffer 4 digest 
buffer (50 μL) containing restriction endonucleases NdeI (25 μL) and BamHI-HF (25 
μL).  Nuclease-free water was added to give a final volume (500 μL).  Linearised pET-
16b vector (5 μL) was run alongside DARPin digests for confirmation.  The gel was 
run and visualised as previously described. 
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DNA Gel Extraction 
Bands were excised from the gel using a sterile disposable scalpel and purified 
using a QIAquick® Gel Extraction Kit.  Assay reagents were prepared as outlined in 
the QIAquick Spin Handbook (Qiagen).  The protocols were followed without 
modification. 
Excised gel was weighed in a disposable plastic Eppendorf (0.5 mL).  Buffer 
QG (3 volumes; 100 mg gel approx. equiv. 100 μL buffer) was added to the gel and 
left to incubate (55 °C) using a Techne Dri-block® DB 2A heater (Bibby Scientific 
Limited, Staffordshire, UK) for 10 min until dissolved.  Isopropanol (1 volume) was 
added to the sample and mixed before addition onto a QIAquick spin column placed 
into a Vac-Man® Laboratory vacuum manifold (Promega, Southampton, UK) until all 
sample had passed through.  Buffer QG (500 μL) was added to the column and 
centrifuged (17,900 x g, 1 min) using a Heraeus™ Fresco™ 21 Microcentrifuge 
(Thermo Scientific, Leicestershire, UK) and flow-through discarded.  Buffer PE (750 
μL) was added to the column and centrifuged (17,900 x g, 1 min) discarding flow-
through.  The column was placed into a fresh collection tube (2 mL) and dsDNA was 
eluted following addition of Buffer EB (50 μL) onto the QIAquick column membrane 
and centrifugation (17,900 x g, 1 min).  dsDNA concentration was measured (260 nm) 
using a NanoDrop 1000 Spectrophotometer (Thermo Fisher Scientific, Leicestershire, 
UK). 
Ligation 
DARPin product (50 ng, NdeI/BamHI cut) was ligated into pET-16b vector (100 
ng, NdeI/BamHI cut) in 10x T4 DNA Ligase Reaction Buffer (3 μL) and T4 DNA Ligase 
(1 μL).  Nuclease-free water was added to give a final volume (30 μL).  The ligation 
mix was incubated at room temperature for 1 h and held on ice. 
Transformation of pET-16b plus DARPin into XL-1 Blue Cells for DNA Amplification 
Ligation mix (3 μL) was added to XL-1 Blue competent cells (50 μL) and 
incubated on ice for 15 min, before heat-shocking (42 °C water bath) the cells for 45 
sec.  Cells were then held on ice for a further 3 min.  Transformed XL-1 Blue cells 
were inoculated into 2x TY media (500 μL) and incubated (37 °C, 200 rpm) for 1 h.  
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The inoculated culture (50 μL) was streaked onto a 2x TYAG petri dish containing 
tetracycline (25 μL, 1:1000 DF in EtOH).  The remaining culture was centrifuged (1500 
x g, 2 min) and the supernatant discarded.  The cell pellet was re-suspended in dH2O 
(50 μL) and streaked onto another 2x TYAG petri dish containing tetracycline.  Petri-
dishes were left to incubate (37 °C) overnight. 
Colonies were picked and inoculated into 2x TYAG media (150 μL/well) plus 
tetracycline (400 μL, 12.5 mg/mL) in a 96-well, clear round bottom, assay plate and 
incubated (37 °C, 200 rpm) overnight.  Glycerol stocks were made following addition 
of overnight cultures (1 mL) into cryovials containing glycerol (500 μL, 50%) and stored 
(-80 °C). 
Mini-Prep to Isolate pET-16b plus DARPin DNA from XL-1 Blue Cells 
Assay reagents were prepared as outlined in the QIAprep® Miniprep Handbook 
(Qiagen) and the protocol followed without modification. 
Clones were harvested by centrifugation (6800 x g for 3 min) following overnight 
culture of glycerol stocks in 5 mL 2x TYAG, incubated (37 °C, 200 rpm).  Pelleted 
bacteria was re-suspended in Buffer P1 (250 μL).  Buffer P2 (250 μL) was added and 
mixed by inverting 5 times, followed by addition of Buffer N3 (350 μL) and immediate 
inversion 5 times.  The sample was centrifuged (17,900 x g, 10 min) using a Heraeus™ 
Fresco™ 21 Microcentrifuge (Thermo Scientific, Leicestershire, UK).  The supernatant 
was added to a QIAprep spin column placed in a collection tube (2 mL) and centrifuged 
(17,900 x g, 1 min).  Flow-through was discarded and Buffer PE (750 μL) was added 
to the column and centrifuged (17,900 x g, 1 min).  Flow-through was discarded and 
the column was centrifuged (17,900 x g, 1 min) once more.  The QIAprep column was 
placed in a fresh collection tube (2 mL) and DNA eluted following the addition of Buffer 
EB (50 μL) onto the spin column membrane.  The column was left to incubate at room 
temperature for 1 min before centrifugation (10,000 x g, 1 min).  dsDNA concentration 
was measured (260 nm) using a NanoDrop 1000 Spectrophotometer (Thermo Fisher 
Scientific, Leicestershire, UK).  DNA was sequenced as previously described (Section 
2.5.5.1). 
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Midi-Prep to Isolate pET-16b Vector from XL-1-Blue Cells 
Assay reagents were prepared as outlined in the Plasmid Plus Purification 
Handbook (Qiagen) and the protocol followed with modifications. 
Clones were harvested by centrifugation (6800 x g for 3 min) following overnight 
culture of glycerol stocks in 5 mL 2x TYAG, incubated (37 °C, 200 rpm).  Pelleted 
bacteria containing vector and DARPin were-suspended in Buffer P1 (4 mL) in a 
Falcon™ tube (15 mL) and mixed using a Vortex Genie 2 Shaker (Scientific Industries 
Inc, New York, USA). Buffer P2 (4 mL) was added to the lysate and inverted to mix 
before being left to incubate at room temperature for 3 min.  Buffer S3 (pre-cooled on 
ice) was added to the lysate and mixed immediately by inverting 5 times.  The lysate 
was transferred to a QIAfilter cartridge and left to incubate at room temperature for 10 
min.  Filtered cell lysate from the QIAfilter cartridge was eluted into a fresh Falcon™ 
tube (15 mL) and Buffer BB (2 mL) added before inverting 5 times to mix.  The lysate 
was transferred to a QIAGEN Plasmid Plus Midi spin column plus tube extender and 
placed into a Vac-Man® Laboratory vacuum manifold (Promega, Southampton, UK).  
Once the sample was drawn through Buffer ETR (700 μL) was added followed by 
Buffer PE (700 μL).  The column was placed into a fresh collection tube (2 mL) and 
dsDNA eluted following addition of Buffer EB (50 μL) onto the spin column membrane.  
The column was left to incubate at room temperature for 1 min before centrifugation 
(10,000 x g, 1 min) using a using a Heraeus™ Fresco™ 21 Microcentrifuge (Thermo 
Scientific, Leicestershire, UK).  dsDNA concentration was measured (260 nm) using 
a NanoDrop 1000 Spectrophotometer (Thermo Fisher Scientific, Leicestershire, UK). 
Transformation into BL21 (DE3) E.coli to Express DARPin 
Mini-prep plasmid DNA (2 μL) was transformed into BL21 (DE3) E.coli (50 μL) 
by holding the cells on ice for 15 min before heat-shocking (42 °C water bath) the cells 
for 45 sec and then holding on ice for a further 3 min. 
Transformed BL21 (DE3) E.coli was inoculated into 2x TYAG media (500 μL) 
and left to incubate (37 °C, 200 rpm) for 1 h.  The inoculated cultures (50 μL) were 
streaked onto 2x TYAG petri dishes using disposable plastic loops.  The remaining 
culture was centrifuged (12,000 x g, 2 min) and the supernatant discarded.  The cell 
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pellet was re-suspended in dH2O (50 μL) and streaked onto a 2x TYAG petri dish.  
Petri dishes were left to incubate (37 °C) overnight.  Colonies were inoculated into 2x 
TYAG media in a 96-well, clear round bottom, assay plate, and incubated (37 °C, 200 
rpm) overnight.  Glycerol stocks were made and cultures were sequenced as 
previously described (Section 2.5.5.1). 
His-Prep to Express DARPins 
Single colonies were streaked onto 2x TYAG petri dishes and left to incubate 
(37 °C) overnight.  Plates were provided to the His-prep team at MedImmune 
(Cambridge, UK) for DARPin expression as follows. 
DARPin constructs in pET-16b vector transformed BL-21 cells were cultured in 
2xTY (25ml) plus Ampicillin overnight (37°C).  The culture (24 mL) was inoculated into 
400 mL 2xTY (+ Amp), and incubated for 2 hours (37°C, 280 rpm) prior to addition of 
IPTG to a final concentration of 0.6 mM. Cultures were incubated for 3.5 hours (37°C, 
280 rpm) prior to collection by centrifugation (8,000 rpm, 10 min).  Cell pellets were 
lysed in 25 mL BugBuster (25 µL Benzonase nuclease) for 25 min and lysates cleared 
by centrifugation (16,000 x g, 20 min, 4 °C).  Samples were purified with ASPEC 
standard buffers, according to the manufacturer instructions.  Buffer exchange into 
PBS was performed with NAP-10 columns.  
DARPin concentration was calculated measuring absorbance (280 nm) using a 
NanoDrop 1000 Spectrophotometer (Thermo Fisher Scientific, Leicestershire, UK). 
2.5.5.4 DARPin Enzyme-Linked Immunosorbent Assay (ELISA) on cells 
Optimisation 
Cells were harvested from 175 cm² cell culture flask as described previously 
(Section 2.4.2) and a single cell suspension (200 μL) was seeded (1.25 x105 cells/mL 
and 1.0 x105 cells/mL for SK-BR-3 (Her2+) fluc/Rluc and MDA-MB-231 (Her2-) 
fluc/Rluc cells respectively) into a 96-well, clear flat bottom, tissue culture plate.  After 
24 h incubation (5% CO2, 95% air, 37 °C) spent culture media was aspirated and the 
cells were washed three times with 1x PBS.  Skimmed milk powder (300 μL, 3% w/v 
1x PBS) was added to the cells and left to incubate at room temperature for 1 h.  The 
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plate was washed three times with 1x PBS and cells were treated with unconjugated 
DARPin (50 μL, 0.025 – 40 μg/mL) and left to incubate at room temperature for 1 h.  
BSA treated cells, untreated cells and secondary only antibody treated cells were 
included as control wells.  The plate was washed three times with 1x PBS/0.1% Tween 
and cells were treated with mouse anti-polyhistidine or anti-DARPin detection 
antibodies (50 μL, 1 μg/mL) and left to incubate at room temperature for 1 h.  The plate 
was washed three times with 1x PBS/0.1% Tween and cells were treated with an anti-
mouse IgG (Fc specific) HRP secondary antibody (50 μL, 1.7 μg/mL) and left to 
incubate at room temperature for 1 h.  The plate was washed three times with 1x 
PBS/0.1% Tween and three times with 1x PBS.  TMB substrate (50 μL) was added to 
the plate and left to incubate at room temperature for 15 min before addition of 
sulphuric acid (50 μL, 0.5 M).  Absorbance (450 nm) was measured using an 
EnVision® Multilabel Reader (PerkinElmer, Massachusetts, USA). 
PP-75 DARPin Conjugate Binding 
Assay set-up was as optimised.  The plate was washed three times with 1x PBS 
and cells were treated with PP-75 DARPin conjugates at specific concentrations (50 
μL) and left to incubate at room temperature for 1 h.  BSA treated cells, untreated cells, 
unconjugated DARPin treated cells and secondary only antibody treated cells were 
included to as control wells.  The plate was washed three times with 1x PBS/0.1% 
Tween and the ELISA run as previously described. 
2.5.5.5 DARPin Sandwich Enzyme-Linked Immunosorbent Assay (ELISA) 
The ELISA was run as previously described (Section 2.3.10) with modification.  
A sandwich ELISA was set up whereby plates were coated with a standard 
concentration of recombinant Her2 protein rather than PP-75 DARPin conjugates.  
Following overnight incubation the protocol was followed as described with the 
addition of PP-75 linked DARPin conjugate, PP-75 and DARPin only treatment step.  
Treated plates were incubated at room temperature for 1 h and washed three times 
with 1x PBS (200 μL) prior to addition of detection antibodies.  The remainder of the 
protocol was followed without modification.  
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Chapter 3 
3 Polymer Synthesis, siRNA and DARPin Conjugation and 
Characterisation 
This chapter describes the novel modifications made to PP-75, in order to 
demonstrate its potential application as a targetable, intracellular delivery agent, 
capable of controlled payload release.  The synthesis and characterisation of PP-75 
and its derivatives with siRNA payloads and DARPin constructs are discussed, with 
pH-responsive function also explored.  Conclusions are drawn with a view to validate 
PP-75 intracellular functionality. 
3.1 Introduction 
PP-75 was designed as a biomimetic polymer, mimicking the function and 
conformational activity of viral fusogenic peptides, capable of entering the cell interior 
(Chen et al. 2009c, Chen et al. 2009b).  The poly(L-lysine iso-phthalamide) (PLP) 
backbone provides the peptide-like, pH-responsive, and amphiphilic polymer 
properties.  Grafting with the hydrophobic amino acid L-phenylalanine alters the 
amphiphilicity of the polymer, controlling the pH-dependent conformational transition 
(Chen et al. 2009c).  PP-75 is thought to be most active across pH 6.0 – 7.0, typical 
of early endosomes.  The conformational transition of PP-75 occurs with the 
increasingly acidic maturation of the endo-lysosomal pathway, as described 
previously.  Characteristic to PP-75, the L-phenylalanine aromatic ring further 
enhances hydrophobic interactions with the membrane, inducing membrane-
disruptive polymer activity (Plank et al. 1994, Zhang et al. 2011). 
PP-75 is therefore proposed as a DDS, capable of delivering novel, disulphide-
linked siRNA payloads into the cell interior.  siRNA unloading is achieved following 
disulphide bond reduction once within the reducing environment of the cytoplasm.  
Khormaee (Khormaee et al. 2012) demonstrated PP-75 siRNA conjugate delivery into 
glioma cells.  The work presented here will explore PP-75 AFC and PP-75 siRNA 
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delivery into two breast cancer cell lines, therefore extending the application of the PP-
75 delivery platform.  
Grafting of L-phenylalanine onto PLP is achieved using DCC/DMAP mediated 
amide-coupling (Figure 3.1).  DCC is a commonly used coupling agent, for the 
formation of peptide bonds.  The addition of DMAP, a nucleophilic catalyst, is known 
to aid this reaction.  Building on this synthetic route, the same reaction mechanism 
was proposed to graft thiol reactive cross-linkers, as well as 6-aminofluorescein, onto 
PP-75, to allow functionalization with payloads, and intracellular imaging, respectively.  
PP-75 grafted with PDPH and EMCH linkers, and 6-aminofluorescein has not been 
demonstrated previously.  siRNA conjugation was proposed via the PDPH cross-
linker; conjugated onto the PP-75 backbone, prior to siRNA conjugation.  This is in 
contrast to the Khormaee protocol (Khormaee et al. 2012) whereby siRNA is cross-
linked prior to PP-75 conjugation.  This newly proposed method facilitates more 
efficient payload conjugation owing to the efficiency of disulphide exchange over 
peptide coupling.  siRNA payloads are therefore not unnecessarily lost during 
conjugation onto PP-75.  The application of PP-75 for use in targeted delivery has also 
not been previously explored, successful conjugation of DARPins onto PP-75 via both 
EMCH and PDPH is achieved.  
PP-75 cell membrane destabilisation is further examined in this work using the 
novel breast cancer reporter cells as whole cell models of the endosomal membrane, 
indicating pH-responsive function. 
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Figure 3.1: Mechanism of DCC/DMAP Mediated Peptide Bond Formation. 
To enhance the electrophilicity of the carboxylate group, the negatively charged oxygen must first be 
‘activated’ into a better leaving group.  DCC is used for this purpose.  The negatively charged oxygen 
acts as a nucleophile, attacking the central carbon in DCC.  DCC is temporarily attached to the former 
carboxylate group as a highly reactive O-acylisourea, making nucleophilic attack by an amino group 
(on the attaching amino acid) to the former C-terminus (carbonyl group) more efficient.  DMAP acts as 
a nucleophile, reacting with the activated ester to form an even more highly electrophilic 
acetylpyridinium intermediate.  This intermediate then reacts with the amine group of the incoming 
amino acid or cross-linker, forming the peptide bond.  The DMAP leaving group is displaced, therefore 
regenerating the catalyst, whilst DCC is consumed, forming DCU as a by-product. 
Peptide bonds are created, coupling the carboxyl group, of L-lysine, with the incoming amino group of 
L-phenylalanine.  The carboxyl group of L-phenylalanine is protected as a methyl ester, preventing 
peptide elongation which would result in branching along the polymer backbone.  The amine group of 
L-Phenylalanine is therefore unable to react with protected carboxyl groups of other phenylalanine 
groups, and only along the PLP backbone.  Without terminal protection, polymerisation of unprotected 
phenylalanine groups could occur.  Post reaction the protecting groups are removed in a de-protection 
step. 
+
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3.2 Results and Discussion 
3.2.1 PLP and PP-75 
PLP and PP-75 were synthesised and characterised following published 
protocols (Eccleston et al. 1999, Chen et al. 2009a, Chen et al. 2009b).  PLP provided 
the platform onto which phenylalanine was grafted at stoichiometrically defined ratios; 
adjusting the hydrophobic properties of the polymer for optimal intracellular drug 
delivery. 
FT-IR and NMR techniques were used in all cases, providing characteristic 
spectra, enabling structural identification of bonds and functional groups present within 
the synthesised compounds; therefore confirming polymer and polymer derivative 
identities in line with published work.  Characterisation data has been individually 
described for PLP and PP-75, with conclusions drawn collectively for both polymers 
following the results (Section 3.2.1.3). 
3.2.1.1 Poly(L-lysine iso-phthalamide) (PLP) 
Single phase polymerisation was used to synthesise PLP from L-lysine methyl 
ester and iso-phthaloyl chloride (Figure 2.1).  To ensure correct polymer synthesis, the 
PLP methyl ester intermediate was fully characterised.  Hydrolysis and purification 
steps were subsequently completed to obtain the PLP backbone, which was further 
characterised. 
3.2.1.1.1 Poly(L-lysine iso-phthalamide) (PLP) methyl ester 
Characteristic absorption peaks in the PLP methyl ester FT-IR spectrum (Figure 
3.2) of the C=O bond 1635 cm-1 and the N-H bond at 1521 cm-1 indicate secondary 
amide bond formation following poly-condensation.  The presence of the C=O bond 
peak at 1730 cm-1 and C-O bond peak at 1242 cm-1 indicates the presence of the 
carboxylic acid ester. 
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Figure 3.2: FT-IR Structural Characterisation of PLP Methyl Ester. 
Characteristic peaks indicate amide bond formation as a result of polycondensation between L-lysine 
methyl ester dihydrochloride and iso-phthaloyl chloride. 
1H-NMR and 13C-NMR spectrometry (in d6-DMSO at 500 and 300 MHz, 
respectively, at room temperature) were used to further verify the structure of the PLP 
methyl ester (Figure 3.3).  
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Figure 3.3: NMR Structural Characterisation of PLP Methyl Ester. 
1H-NMR spectrum (top) and 13C-NMR spectrum (bottom) of PLP methyl ester in DMSO-d6 at room 
temperature. Peaks were assigned according to chemical shifts and 2D NMR.  
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PLP methyl ester structure was characterised, assigning spectral peaks using 
a combination of 1D and 2D NMR spectrometry techniques (Table 3.1). 
Table 3.1: Structural Composition of PLP Methyl Ester characterised by NMR. 
 
Spectral peaks were assigned using a combination of 1D and 2D NMR spectrometry techniques.  
Correlation Spectroscopy (COSY) coupling indicates coupling between proton environments in NMR 
spectra.  Hetronuclear multiple quantum correlation (HMQC) coupling spectra indicate direct proton to 
carbon coupling. 
1H-NMR (500 MHz, DMSO-d6): δ (ppm) 1.45 (Hd-CH2) 1.61 and (Hc-CH2), 1.87 
(He-CH2), 3.34 (Hb-CH2), 3.66 (Hh-CH3), 4.47 (Hf-CH), 7.53 (complex multiplet 
aromatic H5-CH), 7.87 - 8.08 (complex multiplet aromatic H4-CH and H6-CH), 8.35 (H2-
CH), 8.63 (Ha-NH), 8.92 (Hg-NH). 
13C-NMR (300 MHz; DMSO-d6): δ (ppm) 23.2 (Ce-CH2), 28.5 (Cd-CH2), 29.8 
(Cf-CH2), 38.6 - 40.2 (Cc-CH2 and d6-DMSO), 51.6 (Ci-CH2), 52.8 (Cg-CH2), 126.3 
(aromatic C2-CH), 128.4 (aromatic C5-CH), 130.5 (aromatic C4-CH and C6-CH), 133.8 
(quaternary aromatic C1 or C3), 134.6 (quaternary aromatic C1 or C3), 165.6  (Ca or Cb 
Ar-CO-NH), 166.2 (Ca or Cb Ar-CO-NH), 172.8 (Ch-COOH). 
3.2.1.1.2 Poly(L-lysine iso-phthalamide) (PLP) 
The PLP backbone was obtained following hydrolysis and purification of the 
PLP methyl ester intermediate, the resulting product was further characterised. 
1H-NMR (ppm) Integral COSY coupling HMQC coupling 1H Assignment 
1.45 2H 1.61, 1.87 23.2 Hd 
1.61 2H 1.45, 3.34 28.5 Hc 
1.87 2H 1.45, 4.47 29.8 He 
3.34 2H 1.61, 8.63 38.6 – 40.2 Hb 
3.66 3H - 51.6 Hh 
4.47 1H 1.87, 8.92 52.8 Hf 
7.53 1H 7.97 – 8.08 128.4 H5 
7.87 – 8.08 2H 7.53, 8.35 130.5 H4, H6 
8.35 1H 7.97 – 8.08 126.3 H2 
8.63 1H 3.34 (amide) Ha 
8.92 1H 4.47 (amide) Hg 
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The characteristic C=O absorption peak in the PLP FT-IR spectrum (Figure 3.4) 
at 1719 cm-1 indicates carboxylic acid group presence, indicating the change from a 
saturated ester to a saturated acid and therefore complete ester hydrolysis.  The broad 
O-H absorption peak at 2566 cm-1 further supports this. 
 
Figure 3.4: FT-IR Structural Characterisation of PLP. 
Carboxylic acid group OH and carbonyl group peaks indicate ester hydrolysis. 
1H-NMR and 13C-NMR spectrometry (in d6-DMSO at room temperature) were 
used to further verify the structure of the PLP (Figure 3.5).  The characteristic 1H and 
13C peaks of PLP methyl ester (labelled Hh and Ci seen in Figure 3.3) were not present 
in the PLP 1H-NMR and 13C-NMR spectra, also confirming complete ester hydrolysis.  
Following purification, the acetone in the 1H-NMR PLP methyl ester spectra was not 
present in the 1H-NMR PLP spectra.  
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Figure 3.5: NMR Structural Characterisation of PLP. 
1H-NMR spectrum (top) and 13C-NMR spectrum (bottom) of PLP in DMSO-d6at room temperature. 
Peaks were assigned according to according to chemical shifts and 2D NMR.  
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1H-NMR (500 MHz; DMSO-d6): δ (ppm) 1.45 (Hd-CH2), 1.62  (Hc-CH2), 1.87 
(He-CH2), 3.34 (Hb-CH2), 4.40 (Hf-CH), 7.55 (complex multiplet aromatic H5-CH), 7.90-
8.12 (complex multiplet aromatic H4-CH and H6-CH), 8.36 (complex multiplet aromatic 
H2-CH), 8.62 (Ha-NH), 8.84 (Hg-NH). 
13C-NMR (300 MHz; DMSO-d6): δ (ppm) 23.5 (Ce-CH2-), 28.8 (Cd-CH2-), 30.2 
(Cf-CH2), 38.6 – 40.1 (Cc-CH2- and d6-DMSO), 52.6 (Cg-CH2), 126.1 (aromatic C2-CH), 
128.2 (aromatic C5-CH), 130.3 (aromatic C4-CH and C6-CH), 134.1 (quaternary 
aromatic C1 or C3), 134.6 (quaternary aromatic C1 or C3),165.8 (Ca or Cb Ar-CO-NH), 
166.2 (Ca or Cb Ar-CO-NH), 173.7 (Ch-COOH). 
GPC analysis was performed to provide further characterisation data for the 
polymers; indicating the molecular weight (weight average (Mw) and number average 
(Mn)) and molecular size distribution (polydispersity (PDI)) within a given sample 
(where PDI = Mw/Mn). 
PLP molecular weight was characterised via aqueous phase GPC, calibrated 
with PEO standards.  GPC trace data and PLP molecular weight were provided by Dr 
Xiaohua Sun (Department of Chemical Engineering and Biotechnology, University of 
Cambridge, Cambridge, UK) (Table 3.2). 
Table 3.2: GPC Molecular Weight Characterisation of PLP. 
Polymer Mw (Da) Polymer Mn (Da) PDI Repeat unit Mw (Da) Polymer units* 
42075 21721 1.94 276 152 
 
*The average number of PLP repeat units per PLP polymer chain was calculated from the GPC 
determined Mw and PLP repeat unit Mw. 
GPC revealed the molecular weight and polydispersity of PLP differed 
marginally to those previously published (Chen et al. 2009b, Chen et al. 2009c).  Due 
to the random polymerisation technique used for PLP synthesis, moderately 
polydisperse polymer samples were expected.  PLP synthesis was therefore 
considered consistent with published data (Eccleston et al. 1999, Eccleston et al. 
2000). 
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3.2.1.2 PLP Grafted with L-Phenylalanine 
Phenylalanine was grafted onto PLP to increase the hydrophobicity of the 
backbone, raising the pH of membrane disruptive activity in line with the pH profile of 
early endosomes as previously reported (Chen et al. 2009a, Chen et al. 2009b, Chen 
et al. 2009c).  The degree of grafting was controlled by the stoichiometric molar ratio 
of L-phenylalanine [NH2] to PLP [COOH]. 
3.2.1.2.1 PP-75 
PP-75 was synthesised by grafting PLP with L-phenylalanine methyl ester 
followed by ester hydrolysis.  FT-IR analysis of PP-75 was not essential as the bonds 
present in PP-75 are the same as those in the PLP backbone.  No distinguishable 
structural information would have been provided by a PP-75 FT-IR spectrum. 
1H-NMR and 13C-NMR spectra of PP-75 (Figure 3.6) confirmed L-phenylalanine 
grafting onto the PLP backbone.  Additional peaks not seen in the un-grafted parent 
polymer spectra are seen in both PP-75 spectra corresponding to the presence of the 
L-phenylalanine hydrocarbon chain (2.84 - 3.36 and 4.38 - 4.56 ppm) and aromatic 
groups (7.12 - 7.32 ppm).  L-phenylalanine methyl ester hydrolysis is also confirmed 
by the absence of a peak corresponding to any methyl (-CH3) (as seen in Figure 3.3). 
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Figure 3.6: NMR Structural Characterisation of PP-75. 
1H-NMR spectrum (top) and 13C-NMR spectrum (bottom) of PP-75 in DMSO-d6 at room temperature. 
Peaks were assigned according to chemical shifts and 2D NMR.  
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1H-NMR (500 MHz; DMSO-d6): δ (ppm) 1.03 - 1.89 (Hd-CH2, Hc-CH2,He-CH2), 
2.84 - 3.36 (Hb-CH2, Hj-CH2), 4.38 - 4.56 (Hf-CH, Hi-CH), 7.12 - 7.32 (complex multiplet 
aromatic HAr2-CH), 7.46 - 8.75 (complex multiplet aromatic H5-CH, H4-CH and H6-CH, 
H2-CH, complex series of peaks amide Ha-NH, Hg-NH, Hh-NH).  
13C-NMR (300 MHz; DMSO-d6): δ (ppm) 25.3 - 36.5 (Ck-CH2, Ce-CH2, Cd-CH2, 
Cf-CH2), 39.1 - 40.3 (Cc-CH2 and d6-DMSO), 47.5 - 53.4 (Cg-CH2 and Ci-CH2), 126.1 - 
130.3 (all aromatic C1-CH to C12-CH), 165.7 - 172.9 (Ca and Cb Ar-CO-NH, Ch and Ci 
COOH). 
The actual degree of grafting (i.e. the number of L-phenylalanine grafts per 100 
carboxylic acid groups along the polymer backbone) was determined by comparing 
the ratio of the integral of L-phenylalanine aromatic side chain protons (HAr2-CH) in the 
range , 7.12 - 7.32 to the integral of polymer backbone protons (H5-CH, H4-CH, H6-
CH, H2-CH, Ha-NH, Hg-NH, Hh-NH) in the range of 7.46 - 8.75 as determined by 1H-
NMR (Figure 3.6).  PP-75 grafting efficiency was calculated as described in Equation 
3.1. 
            
1H Phe aromatic sidechain
1H polymer backbone
 = 
integral 7.12 - 7.32
integral 7.46 - 8.75
 
  5x
[6(100 - x)+7x]
 = 
1
2
 
                                                                             x = 67 
Equation 3.1: PLP L-phenylalanine Grafting Efficiency. 
Where: x is the degree of grafting (i.e. the number of grafts per 100 backbone monomer units) 
 5 is the number of 1H from HAr2-CH 
 6 is the number of 1H from H5-CH, H4-CH, H6-CH, H2-CH, Ha-NH, Hg-NH 
 7  is the number of 1H from H5-CH, H4-CH, H6-CH, H2-CH, Ha-NH, Hg-NH, Hh-NH 
Therefore PP-75 (75% stoichiometric molar concentration) demonstrated 67% 
(actual) degree of grafting.  That is 67 mol% of the carboxyl groups along the polymer 
backbone substituted with L-phenylalanine. 
Actual PP-75 percentage grafting was within the degree of expected grafting 
based on the stoichiometric, 75% molar ratio.  This was comparable to the results 
published by Chen et al. (Chen et al. 2009b), describing 63.2 mol% L-phenylalanine 
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grafting.  Due to the nature of the random polymerisation technique employed for PP-
75 synthesis, this was not considered to negatively impact upon the application of PP-
75 as a drug delivery platform. 
GPC analysis could not be accurately carried out for PP-75 due to the 
hydrophobic, branched nature of the grafted polymer meaning elution times did not 
reflect the increased molecular weight of the samples, also reported previously 
(Eccleston et al. 2004, Yue et al. 2005a, Yue et al. 2005b, Dai et al. 2006).  As GPC 
could not be reliably used to characterise PP-75 molecular weight, the weight was 
calculated from the NMR determined degrees of grafting and the PDI of the PLP parent 
polymer (Yue et al. 2005b, Yue et al. 2005a).  In line with the increased PLP molecular 
weight and the increased actual graft of L-phenylalanine onto PLP, compared to that 
published, PP-75 molecular weight (Table 3.3) was calculated as higher than the 
previously reported value of 24.9 kDa (Chen et al. 2009a, Chen et al. 2009b). 
Table 3.3: Grafting Efficiency and Molecular Weight Characterisation of PP-75. 
Actual graft  
(mol%) 
Repeat unit Mw 
(Da)* 
Polymer  
units 
Polymer Mw 
(Da)** 
Polymer Mn 
(Da)** 
PDI 
67 373 152 56696 29270 1.94 
 
*PP-75 average repeat unit Mw was calculated using the mol% actual graft and the calculated PLP and 
PP-75 repeat unit Mw. 
**PP-75 Mw and Mn were calculated from the average repeat unit Mw, average number of PP-75 repeat 
units per polymer chain and the PDI (assumed consistent with PLP). 
3.2.1.3 PLP and PP-75 
PLP and PP-75 were run on a denaturing, non-reducing SDS polyacrylamide 
gel (Figure 3.7).  Polymer migration prior to payload conjugation was indicated. 
Separation of the polymers based on molecular weight was not clear due to the 
smear of polymer samples down the gel.  This smeared appearance was not 
unexpected due to the diverse range of polymer molecular weights present within 
polymer sample populations, as indicated by their PDI.  Liechty (Liechty et al. 2009) 
previously reported that broad staining by polymer samples may also be due to the 
formation of variable-sized hydrophobic aggregates within the polymer population. 
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Figure 3.7: Polymer Migration Characterised by SDS PAGE. 
PLP and PP-75 (1 µg) were run against a protein standard Mw marker in SDS running buffer (pH 7.4) 
and imaged following staining.  Smearing of the polymer samples was observed due to the polydisperse 
nature of the polymers.  The L-phenylalanine grafted PP-75 polymers run through the gel whilst the 
ungrafted PLP backbone shows a more smeared staining pattern. 
Molecular weight could not be accurately judged, as polymer sample 
comparison was made against a protein standardised molecular weight marker.  It is 
likely that due to the hydrophobic and negatively charged nature of the PLP and PP-
75 polymers, they ran through the gel at an increased rate (relative to a protein of the 
same molecular weight) giving rise to their apparent low molecular weights.  As 
indicated by GPC, grafting with phenylalanine influenced polymer structure and 
conformation, not just molecular weight.  PP-75 polymer samples migrated through 
the gel at a faster rate, compared to PLP.  The increased hydrophobicity of PP-75 may 
therefore have resulted in an increased association with the SDS detergent and so 
increased the negative charge of PP-75, above that of PLP. 
Despite offering inconclusive molecular weight data, the gel provided a useful 
indication of polymer migration prior to payload conjugation. 
160
110
80
kDa
260
60
50
40
30
20
15
10
3.5
103 
3.2.2 PP-75 plus Cross-linkers 
PP-75 was grafted with thiol reactive cross-linkers at defined stoichiometric 
ratios to produce novel PP-75 cross-linked derivatives.  The degree of grafting was 
controlled by the stoichiometric molar ratio of the cross-linker to PP-75.  Two 
commercially available cross-linkers were used; 
1. PDPH: a cleavable (reducing) pyridyldithiol-and-hydrazide cross-linker, similar in 
functionality to SPDP-cad (Khormaee et al. 2012) (Section 2.2.3.1) 
2. EMCH: a non-cleavable (non-reducing) maleimide-and-hydrazide cross-linker 
(Section 2.2.3.2). 
Derivatisation of PP-75 with these cross-linkers has not been previously 
investigated and therefore offers insight into the use of alternative linkers for 
conjugation of payloads and DARPin targeting ligands onto the PP-75 backbone. 
The cleavable nature of the PDPH cross-linkers provided a quantitative 
characterisation method to determine linker grafting efficiency.  The 2-pyridyldithio 
group within PDPH is readily reduced and results in the displacement of pyridine-2-
thione (P-2-T).  The concentration of P-2-T, and therefore cross-linker grafting, was 
determined by measuring the absorbance of P-2-T at 343 nm.  Release of P-2-T in the 
presence of a reducing environment also acted to confirm the functionality of the 
cleavable linker, which would later facilitate controlled payload release. 
Characterisation data has been individually described for PP-75 PDPH (Section 
3.2.2.1) and PP-75 EMCH (Section 3.2.2.2) linker grafts, with conclusions drawn 
collectively following the results (Section 3.2.2.3). 
3.2.2.1 PP-75 (3-[2-Pyridyldithio]propionyl hydrazide) (PP-75 PDPH) 
The degree of grafting was controlled by the stoichiometric molar ratio of PDPH 
[NH2] to PP-75 [COOH] (Figure 2.3).  Stoichiometric molar ratios of 5 and 20% PDPH 
to PP-75 were synthesised to ensure linker availability for siRNA payload and DARPin 
conjugations. 
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The pyridine-2-thione (P-2-T) absorption assay confirmed PP-75 PDPH grafting 
in accordance with the Pierce Biotechnology Protocol.  Modifications were made to 
calculate the extinction coefficient (ε) of P-2-T in DMF, as PP-75 PDPH samples were 
insoluble in the standard PBS assay buffer at the concentrations required for 
measurement (data not shown). 
P-2-T ε in DMF at 340 nm was determined from the calibration curve and 
calculated using the Beer-Lambert Law (Appendix Section 8.1 and 8.2).  Using the 
calibration curve PDPH concentration (μg/mL) was calculated (Equation 3.2).  
Following conversion to molar concentrations (M) the average number of PP-75 units 
per polymer chain was used to calculate the molar ratio of PDPH to PP-75 repeat units 
(equivalent to PDPH percentage graft).  Molecular weights were determined from the 
degrees of grafting (Table 3.4). 
μg/mL pyridine-2-thione = 
A
0.0078
 
Equation 3.2: Linear Section of the P-2-T Absorbance Curve. 
Where A = absorbance, 0.0078 = gradient of the P-2-T calibration curve (m or ε) and μg/mL P-2-T 
released is equivalent to μg/mL PDPH grafted onto PP-75. 
 
Table 3.4: PP-75 PDPH Grafting Efficiency and Molecular Weight. 
Abs  
340 nm 
C 
(μg/mL) 
μM 
mol PDPH per 
mol PP-75 
mol PDPH per 
mol PP-75 unit* 
Repeat unit Mw 
(Da) 
Polymer Mw 
(Da) 
0.148 18.97 170.69 9.68 0.064 386 58623 
0.387 49.62 446.34 25.31 0.167 409 62151 
 
Determined by P-2-T absorbance in DMF.  Where mol PDPH calculated per 1 mg/mL PP-75, * 
equivalent to a 6 % and 17% PDPH graft. 
3.2.2.2 PP-75 3,3´-N-[ε-Maleimidocaproic acid] hydrazide, trifluoroacetic acid 
salt (EMCH) 
The degree of grafting was controlled by the stoichiometric molar ratio of EMCH 
[NH2] to PP-75 [COOH (Figure 2.4)]. 
The actual degree of EMCH grafting onto PP-75 was not confirmed using the 
P-2-T DMF absorption assay as EMCH forms a thiol-maleimide linkage, with no 
cleavable P-2-T leaving group.  Grafting efficiency was therefore assumed comparable 
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to that of PDPH due to the analogous grafting reaction mechanism.  PP-75 EMCH 
molecular weight was therefore calculated based upon this assumption (Table 3.5). 
Table 3.5: PP-75 EMCH Grafting Efficiency and Molecular Weight. 
Graft (mol%) Repeat unit Mw (Da)* Polymer Mw (Da)* 
6* 383 58272 
 
*assumed analogous with PP-75 PDPH grafting efficiencies. 
3.2.2.3 PP-75 PDPH and PP-75 EMCH 
Successful conjugation of the cross-linkers onto PP-75 was demonstrated, as 
controlled by the stoichiometric molar ratio of linker [NH2] to PP-75 [COOH]. 
Limited solubility of the polymers in PBS meant that the P-2-T assay was 
performed in DMF.  One potential reason for enhanced polymer solubility in organic 
solvents compared with aqueous solvents, is the polar, aprotic nature of DMF and 
DMSO.  These organic solvents are able to interact with the charged groups and 
electronegative atoms present along the peptide bonded polymer backbone, in a 
similar way to PBS.  However, polar aprotic organic solvents act as potent hydrogen 
bond acceptors, but cannot act as hydrogen-bond donors due to their lack of free 
protons.  Energy is not required to break existing hydrogen bond networks, present 
within aqueous solutions, and therefore less energy is needed to achieve polymer and 
P-2-T solvation in DMF and DMSO. 
The concentration dependent effect of PP-75 PDPH ability to release P-2-T was 
also investigated in DMF (Table 3.6).  When assayed at 1.0 mg/mL, all polymers tested 
demonstrated P-2-T release close to the stoichiometric grafting values.  As polymer 
concentration increased, apparent P-2-T release decreased. 
Table 3.6: Concentration Dependent Release of P-2-T. 
Polymer (stoich. graft) PP-75 PDPH (20%) PP-75 PDPH (5%) 
Concentration (mg/mL) 1.0 5.0 10.0 1.0 5.0 10.0 
P-2-T Abs (340 nm) 0.387 0.194 0.125 0.148 0.067 0.048 
% Graft 17 8 5 6 3 2 
 
Values were calculated using the P-2-T assay DMF characterisation data. In all cases at higher polymer 
concentrations, less P-2-T was released. 
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This could be explained by the concentration dependent intermolecular 
interaction of PP-75 molecules.  At higher concentrations the polymers are able to 
aggregate into more compact structures, due to enhanced intermolecular hydrophobic 
interactions (Vidal et al. 2008).  Linker grafts might therefore be hidden within the 
globular polymer conformation, and unable to release P-2-T as a result of polymer 
reduction.  This must therefore be considered with subsequent synthesis steps, to 
ensure most efficient payload linking. 
PP-75 EMCH could not be characterised in the same way as PP-75 PDPH due 
to the lack of cleavable leaving group.  PP-75 EMCH grafting was therefore assumed 
analogous with PDPH grafting as reactions had undergone the same DCC/DMAP 
coupling chemistry (Figure 3.1).  A cross-linker graft at 5% was equivalent to an 
average of 7.6 polymer units grafted with functional linker (average chain length 152 
monomer units as determined by GPC (Table 3.2)); therefore a 1% graft was 
equivalent to 1.5 units per polymer available for DARPin conjugation.  Characterisation 
of PP-75 EMCH grafting could be confirmed following successful DARPin conjugation 
in subsequent synthesis reactions. 
3.2.3 PP-75 plus Payloads 
Novel PP-75 payload conjugates were synthesised following attachment of 
payload directly onto PP-75 or by conjugation to cross-linked PP-75 at defined 
stoichiometric ratios. 
3.2.3.1 PP-75 plus 6-aminofluorescein (PP-75 AFC) 
PP-75 was directly grafted with 6-aminofluorescein (AFC), an amine containing 
fluorescein dye derivative (Figure 2.5) to facilitate the study of PP-75 intracellular 
localisation and trafficking, through confocal imaging.  In parallel with demonstrating 
intracellular localisation, the small molecule fluorescein dye acted as a novel model 
payload, demonstrating PP-75 intracellular delivery subsequent to endosomal uptake. 
PP-75 AFC grafting was controlled by the stoichiometric molar ratio of 
aminofluorescein [NH2] to PP-75 [COOH].  TLC analysis revealed that PP-75 AFC 
demonstrated fluorescence and contained no free AFC post conjugation.  This was 
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confirmed by a lack of migration of PP-75 AFC off the baseline, compared to AFC 
alone.  Un-grafted PP-75 did not fluoresce. 
Using AFC calibration curves (Appendix Section 8.3 and 8.4) to measure 
absorbance (490 nm) and fluorescence (520 nm) respectively, PP-75 AFC grafting 
was confirmed (Table 3.7 and Table 3.8).  The moles of AFC per mole of PP-75 was 
calculated and the average number of PP-75 units per PP-75 polymer chain was used 
to convert to moles of AFC per mole of PP-75 unit (equivalent to AFC percentage 
graft). 
Table 3.7: PP-75 AFC Grafting Efficiency (Absorption Calibration Curve). 
 Abs 490 nm* C (μg/mL) Mw C (μM) 
mol AFC per 
 mol PP-75 
mol AFC per  
mol PP-75 unit 
AFC in  
PP-75 AFC 
0.017 0.29 347 0.84 
0.05 0.0003** 
PP-75 0.000 1000 56696 17.64 
 
*relative absorbance (background subtracted; PP-75 standardised). 
**equivalent to 0.03% AFC graft. 
 
Table 3.8: PP-75 AFC Grafting Efficiency (Fluorescence Calibration Curve). 
 Fluoro* C (μg/mL) Mw C (μM) 
mol AFC per  
mol PP-75 
mol AFC per  
mol PP-75 unit 
AFC in 
PP-75 AFC 
271313 7.36 347 21.22 
1.20 0.008 
PP-75 0 1000 56696 17.64 
 
*relative fluorescence emission at 520 nm (background subtracted; PP-75 standardised). 
**equivalent to 0.8% AFC graft. 
Despite the high degree of stoichiometric grafting (20 mol%) to ensure AFC 
labelling onto PP-75 (5 and 10 mol% stoichiometric grafts were unsuccessful), less 
than 1 mol% grafting was detected when assayed by both absorbance (490 nm) and 
fluorescence (ex/em 485/520 nm) of the grafted polymers.  AFC is less nucleophilic 
(and therefore less reactive) than L-phenylalanine and PDPH due to the close 
proximity of the amide group to the fluorescein aromatic ring system.  The lower 
electronegativity of the nitrogen within the reacting amide has therefore resulted in a 
less effecient grafting reaction.  Chen (Chen et al. 2008) previously reported a 1 mol% 
degree of FITC labelling onto PP-75; grafting was kept deliberately low to avoid 
significant modulation of the polymer properties and fluorescence quenching. 
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Fluorescence characterisation data indicated a slightly higher degree of PP-75 
AFC grafting relative to absorbance characterisation; the molecular weight of PP-75 
AFC was calculated from this data (Table 3.9).  An explanation for the differing degrees 
of grafting calculated by absorbance and fluorescence was likely due to the more 
sensitive nature of fluorescence measurements over absorbance measurements.  
Fluorescence measures light emitted from the sample, rather than the light transmitted 
through the sample, and therefore results in a stronger signal to background ratio. 
Table 3.9: PP-75 AFC Degree of Grafting and Molecular Weight. 
 AFC Graft (mol%) Repeat unit Mw (Da) Polymer Mw (Da) 
PP-75 AFC 0.8% 376 57199 
 
Determined via AFC Fluorescence Calibration Curve in 10% DMF: 90% PBS. 
An additional factor to consider may by the pH-responsive properties of 
fluorescein (Xu et al. 2011).  Fluorescein is highly sensitive to changes in pH, therefore 
in solutions close to its pKa of 6.4, fluorescein will absorb at different wavelengths (Xu 
et al. 2011).  This was observed in the conversion between neutral polymer (soluble 
in organic solvent) and salt form polymer (soluble in aqueous solvents) when PP-75 
AFC was titred against 2 M sodium hydroxide.  A noticeable change in polymer 
appearance from yellow to pale blue was observed.  This PP-75 AFC material was 
characterised and demonstrated no detectable absorbance at 490 nm, however 
fluorescence of the polymer was still observed at 520 nm (although to a lesser extent).  
In exposing fluorescein derivatives to high or low pH their absorbance/fluoresce 
properties are therefore altered (Xu et al. 2011).  This observation highlighted the 
difference in absorption and fluorescence measurements.  Future conversion to salt 
form polymers were therefore titred against less concentrated sodium hydroxide (0.2 
M) and no significant colour change was observed; PP-75 AFC remained pale yellow. 
Intracellular delivery of the PP-75 polymers was to be visualised using 
fluorescence based confocal microscopy, therefore fluorescence characterisation was 
also deemed most appropriate. 
A caveat to this rationale was the observation that the AFC fluorescence 
standard curve became saturated at a concentration of AFC between 6.25 – 12.5 
μg/ml, with maximum fluorescence measured between 45,000 – 50,000 (Figure 3.8).  
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The signal becomes quenched above the saturation concentration, demonstrated by 
the negative slope at higher concentrations; the relationship between fluorescence 
and concentration no longer following the linear equation of the Beer-Lambert Law. 
 
Figure 3.8: Extended AFC Fluorescence Calibration Curve (10% DMF:90% PBS). 
The fluorescence (520 nm) of known quantities of AFC in DMF:PBS (1 mg/mL stock concentration; 2-
fold serial dilution) were measured to provide a standard florescence calibration curve.  The linear 
section of the curve was used to determine AFC concentration in PP-75 AFC.  Extension beyond the 
concentration range corresponding to the linear region of the graph demonstrates fluorescence 
saturation at high concentrations of AFC. 
PP-75 AFC fluorescence was measured nearly six times above the saturation 
limit of un-grafted AFC (Table 3.8).  It could be inferred that when grafted to PP-75, 
the AFC molecules are held apart in the polymer with a more extended conformation.  
The fluorescent signal remains unquenched and fluorescence is enhanced.  
Determining an accurate degree of grafting would be useful for future studies and 
aiding batch-to-batch comparisons.  PP-75 alone shows no fluorescence. 
The primary purpose of the PP-75 AFC derivative was to visually confirm 
intracellular uptake of the PP-75 polymer.  AFC grafting and PP-75 AFC functional 
activity was qualitatively confirmed following treatment of the model breast cancer 
reporter cell lines.  PP-75 AFC intracellular delivery was imaged by confocal 
microscopy, as described in Chapter 5. 
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3.2.3.2 PP-75 AFC EMCH 
The successfully synthesised and characterised PP-75 AFC was chosen to 
graft with EMCH (Figure 2.6).  This would facilitate DARPin conjugation, and enable 
the study of PP-75 AFC EMCH DARPin uptake compared to PP-75 AFC alone. 
AFC and EMCH grafting was assumed analogous with previously characterised 
reactions (Table 3.5 and Table 3.9), repeat unit molecular weight (387 Da) and 
polymer molecular weight (58772) were calculated as such.  Characterisation of PP-
75 AFC EMCH would be confirmed by successful DARPin conjugation; as 
demonstrated by target ligand binding (Section 3.2.3.4 and Section 3.2.3.5). 
3.2.3.3 PP-75 PDPH linked siRNA 
Khormaee (Khormaee et al. 2012 supplementary supporting information figure 
S5E: HPLC characterisation) covalently linked 5’ sulfhydryl modified siRNA to an 
SPDP-cad cross-linker, prior to grafting onto PP-75.  This approach was not repeated 
as the DCC/DMAP coupling reaction between polymer and payload was considered 
to be less efficient than disulphide exchange between siRNA and PP-75 plus cross-
linker. 
Novel siRNA payloads were instead conjugated onto PP-75 PDPH (Figure 2.7).  
siRNA loading onto PP-75 could be more easily controlled and the loss of valuable 
siRNA payloads during synthesis was avoided.  The delivery of PP-75 PDPH siRNA 
conjugates could further demonstrate the application of PP-75 for intracellular siRNA 
delivery. 
Thiol modified siRNA duplexes (purchased from IDT) were designed to target 
the fluc reporter gene expressed in the model breast cancer reporter cell lines.  These 
siRNAs were conjugated onto PP-75 PDPH via disulphide bond formation.  Once 
within the cell siRNA release would be facilitated following disulphide reduction.  
Target-specific firefly luciferase (fluc), and scrambled, non-specific siRNAs were 
conjugated at a 1:1 stoichiometric molar ratio of payload to polymer.  A Cy3 containing 
siRNA duplex was also conjugated to PP-75 PDPH to study the cellular uptake and 
the intracellular trafficking of the PP-75 delivered siRNA payload. 
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PP-75 PDPH siRNA conjugation was characterised measuring the absorption 
of the P-2-T leaving group; indicating siRNA conjugation as a result of thiol group 
displacement (Table 3.10).  Conjugation efficiencies were high and avoided the loss 
of siRNA payloads; disulphide exchange provided a more efficient means of siRNA 
loading, rather than the published method of siRNA coupling. 
Table 3.10: PP-75 PDPH siRNA Conjugation Efficiency Determined by P-2-T Assay. 
 
Abs 340 
nm 
µM P-2-T 
released 
µM siRNA 
added 
Conjugation 
Efficiency 
Conjugate Mw 
(Da) 
PP-75 PDPH siRNA 0.086 99.2 85.3 >100% 72931 
PP-75 PDPH siRNA Cy 3 0.070 80.7 85.3 95% 73576 
PP-75 PDPH siRNA Scr 0.046 53.1 85.3 62% 72175 
 
Values were calculated using P-2-T characterisation data and were representative of typical siRNA 
conjugation reactions. 
Both target specific PP-75 PDPH siRNA conjugates (+/- Cy3) demonstrated 
efficient disulphide exchange, with over 95% of siRNA displacing P-2-T to facilitate 
loading onto PP-75 at a 1:1 ratio.  The scrambled control siRNA did not appear to 
conjugate at such high efficiency.  An increase in P-2-T absorption was observed, 
indicating disulphide exchange, equivalent to a 60% conjugation; therefore, over half 
the polymer population was grafted with siRNA.  Polymer molecular weights were 
calculated according to the 1:1 siRNA conjugation ratio.  The differences in effective 
siRNA loading would be accounted for in cell studies. 
PP-75 siRNA conjugates were run on agarose gel (Figure 3.9) and samples 
were imaged.  All samples containing siRNA were visible, whilst the lane containing 
PP-75 PDPH only, appeared blank (due to a lack of nucleic acid material).  The three 
siRNA duplexes, 23 bp’s long, ran as expected below the 500 bp marker.  siRNA 
(+Cy3) ran slightly higher than siRNA (-Cy3), and in turn Scr siRNA, corresponding 
with their molecular weights of 14953, 14308 and 13552 respectively. Despite loading 
at comparable concentrations the scrambled conjugate bands still appeared less 
intense.  This could be explained by the less efficient loading, as observed via P-2-T 
assay.  To investigate this result further the absorbance of the reconstituted siRNA 
concentrated stocks (in accordance to manufacturer’s guidelines) were measured at 
260 nm (Table 3.11).  The absorbance of the scrambled stock was just under half that 
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of the target-specific siRNA, indicating the scrambled stock was much less 
concentrated; again accounting for the lower conjugation yields. 
 
Figure 3.9: PP-75 siRNA Conjugation Characterised by Agarose Gel Electrophoresis. 
PP-75 PDPH siRNA (+/- Cy 3) and Scr siRNA conjugates, PP-75 PDPH and siRNA (+/- Cy 3) and Scr 
alone, were run against a DNA standard Mw marker and imaged under UV light.  siRNA presence was 
detected in all conjugate samples, indicating successful PP-75 siRNA loading.  Conjugated siRNA 
samples ran equivalent to their unconjugated siRNA counterparts, whilst ungrafted PP-75 PDPH was 
not visible on the gel (containing no nucleic acid, as expected). 
 
Table 3.11: siRNA Stock Concentration 
 Reconstituted Stock Concentration (mg/mL) Relative Abs 260 nm 
siRNA 1 1.00 
siRNA Cy3 1 1.00 
siRNA Scr 1 0.47 
 
siRNA stocks were reconstituted as per manufacturers guidelines to 1 mg/mL. Absorbance was 
measured to confirm stock concentration. 
The PP-75 PDPH conjugated siRNA, in all cases, did not appear to alter siRNA 
migration through the gel.  It was expected that siRNA conjugated onto PP-75 would 
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migrate at a slower rate, the addition of polymer molecular weight retarding siRNA 
movement through the gel.  However, as PP-75 itself was negatively charged, the 
polymer may aid migration through the gel, toward the positively charged cathode thus 
counterbalancing the increase in molecular weight. 
PP-75 PDPH siRNA conjugates were highly water soluble, whereas PP-75 
PDPH alone was not.  The P-2-T assay results and altered PP-75 properties therefore 
suggested successful siRNA loading onto PP-75 PDPH.  These PP-75 PDPH siRNA 
conjugates were therefore taken forward into the cell assays. 
3.2.3.4 PP-75 AFC EMCH linked DARPin 
PP-75 AFC EMCH was conjugated with DARPin constructs (Figure 2.8) to 
determine if PP-75 could be modified to improve cell targeting capabilities.  Following 
exposure to cells, PP-75 AFC EMCH Her2-binding DARPin conjugate uptake could 
be compared to that of PP-75 AFC EMCH negative control DARPin conjugate and PP-
75 AFC alone.  Before exposure to cells the conjugates required full characterisation 
to enable comparative studies. 
Cysteine modified DARPin sequences were conjugated to PP-75 AFC EMCH 
via formation of thioether bonds.  Target-specific Her2-binding (positive) and non-
specific (negative) DARPin sequences were conjugated at a 1:1 stoichiometric ratio of 
DARPin per polymer. 
PP-75 AFC EMCH DARPin conjugates were characterised by confirming the 
presence of PP-75 AFC EMCH via fluorescence detection, and DARPin via protein 
stain and binding capacity.  By establishing the functional properties of both polymer 
and targeting ligands, successful conjugation could be confirmed. 
PP-75 AFC EMCH DARPin conjugates were run on a denaturing, reducing SDS 
polyacrylamide gel to aid characterisation.  Samples were loaded at comparable 
concentrations and imaged, detecting protein presence and fluorescence respectively 
(Figure 3.10). 
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Figure 3.10: PP-75 AFC EMCH DARPin Conjugations Characterised by SDS PAGE. 
PP-75 AFC EMCH DARPin conjugates, PP-75 AFC EMCH, PP-75, AFC and DARPin constructs were 
run against a protein standard Mw marker and imaged visualising polymer, protein and AFC presence 
following staining.  Polymer smears and DARPin bands were detected in conjugate samples, running 
equivalent to their unconjugated counterparts.  Fluorescence bands were detected as highlighted (black 
box). 
As previously described SDS PAGE identifies the presence of protein within a 
sample, owing to separation based on molecular weight.  Unconjugated DARPins ran 
at approximately 15 kDa corresponding to the correct molecular weight for the Her2-
binding DARPin and negative control DARPin modified sequences (15.95 and 16.14 
kDa respectively).  The presence of DARPin dimers, seen at approximately 30 kDa 
was not expected due to the addition of TCEP, in molar excess, to DARPin samples.  
Following TCEP removal it was likely that some dimerization occurred between 
monomers, preventing total DARPin conjugation.  Monomer concentration still 
exceeded that of the dimers, therefore the majority of DARPin was available for 
conjugation.  Unconjugated PP-75 and PP-75 AFC EMCH smears were observed 
down the gel as seen previously for polymer migration.  PP-75 AFC EMCH DARPin 
conjugates demonstrated the presence of both DARPin and polymer, although the 
Her2-binding conjugate appears less concentrated for both DARPin and polymer.  A 
loss of DARPin concentration between conjugates and unconjugated DARPin, was 
98
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also apparent indicated by the presence of smaller bands, despite attempts to load the 
gel at comparable concentrations.  The difference in concentration might be explained 
following weight quantification of mg sample masses. 
Visualised under fluorescence detection the SDS gel revealed the presence of 
AFC in PP-75 AFC EMCH and in the negative control DARPin conjugate.  This was 
indicated by the light band staining on the fluorescence detection gel (highlighted 
within the black box).  Fluorescence was less apparent in the Her2-binding DARPin 
conjugate, again, likely due to a lower concentration loaded onto the gel.  As expected, 
free AFC was not detected, as the small molecule migrated through the gel at a much 
faster rate.  AFC is a similar size to Coomassie and would run comparably with the 
stain.  The fluorescence detected at close to 6 kDa was therefore indicative of AFC 
conjugation onto PP-75.  The darker stained bands observed in the DARPin only lanes 
can be attributed to the strong stain as a result of high protein concentration, not due 
to fluorescence. 
DARPin presence within the PP-75 AFC EMCH DARPin conjugates was 
measured across a concentration range, and detected by ELISA.  Conjugate coated 
plates were assayed using an anti-DARPin detection antibody (Figure 3.11). 
 
Figure 3.11: ELISA to Determine DARPin Presence in PP-75 AFC EMCH DARPin Conjugates. 
PP-75 AFC EMCH DARPin conjugates demonstrated comparable affinities to the unconjugated 
DARPin constructs, as determined by anti-DARPin antibody detection.  PP-75 AFC EMCH, PP-75, AFC 
and the untreated control (UTC) were not detected.  Sample concentrations were adjusted to give 
comparable molar ratios of conjugate components. 
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DARPin presence within the conjugates was indicated by an increase in signal 
detection (absorbance) when probed with an anti-DARPin detection antibody.  Both 
Her2-binding and negative control DARPin conjugates demonstrated DARPin 
presence, equivalent to DARPin only coated wells.  Polymers alone did not 
demonstrate detection indicating no DARPin presence. 
Fluorescence measurements were also recorded for PP-75 AFC EMCH 
DARPin conjugates to further confirm polymer presence within the conjugate samples 
(Figure 3.12).  Unconjugated DARPin sequences demonstrated no detectable 
fluorescence when compared with the blank control.  An increase in fluorescence was 
detected in the PP-75 AFC EMCH DARPin conjugates, indicating the presence of the 
polymer.  The relative fluorescence was less than PP-75 AFC at the same 
concentration.  The decrease in fluorescence observed in the conjugates could be as 
a result of a more compact conjugate structure, quenching fluorescence.  However, 
these results were consistent with the SDS gel; the negative control DARPin conjugate 
appeared more fluorescent than the Her2-binding conjugate. 
 
Figure 3.12: Relative Fluorescence of PP-75 AFC DARPin Conjugates. 
Fluorescence (520 nm) was measured and plotted relative to PP-75 AFC following background 
subtraction of the blank untreated control.  Fluorescence was detected in DARPin conjugated samples, 
and not in unconjugated DARPin constructs. 
The presence of polymer and DARPin within the conjugate samples was 
demonstrated indicating the successful synthesis of novel PP-75 DARPin conjugates. 
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3.2.3.5 PP-75 PDPH EMCH linked DARPin 
An alternative approach to PP-75 DARPin conjugation was explored, 
conjugating the DARPin sequences to the EMCH linker prior to conjugation onto PP-
75 PDPH (Figure 2.9).  PP-75 PDPH EMCH DARPin conjugates were synthesised to 
enable subsequent PP-75 siRNA conjugation with the cleavable PDPH linker. 
The reaction between the EMCH linker and DARPin sequences was confirmed 
by mass spectrometry (MS) (Figure 3.13), indicating the potential for successful 
DARPin conjugation onto PP-75 via EMCH. 
 
Figure 3.13: MALDI-TOF/TOF MS EMCH DARPin Linkage. 
DARPin constructs (Her2 binding DARPin (top) and Negative-binding DARPin (bottom)) were coupled 
with the EMCH cross-linkers prior to conjugation onto PP-75 PDPH.  EMCH linked DARPin mass was 
confirmed at the expected molecular weight following BOC de-protection. 
Her2-binding target-specific (positive) and non-specific (negative control) 
DARPin constructs (red traces) demonstrated single peaks about their expected 
masses of 15.95 kDa and 16.14 kDa respectively.  An increase in the mass to charge 
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ratio was observed on reaction with EMCH; the addition of the 339 Da linker 
corresponded to the peak shift (green traces).  The MS traces demonstrated both 
Her2-binding and the negative-binding DARPins were linked with EMCH.  The 
negative control DARPin reacted more completely with the EMCH linker.  Unreacted 
DARPin remained present post reaction; however this was removed during dialysis 
following PP-75 PDPH conjugation. 
Following PP-75 PDPH EMCH DARPin conjugation, at a 1:1 stoichiometric ratio 
of DARPin to polymer, samples were run on a denaturing, non-reducing SDS 
polyacrylamide gel to characterise conjugation.  Samples were loaded at comparable 
concentrations and Coomassie stained to detect protein presence (Figure 3.14). 
 
Figure 3.14: PP-75 PDPH EMCH DARPin Conjugations Characterised by SDS PAGE. 
PP-75 PDPH EMCH DARPin conjugates, PP-75 PDPH, and EMCH-DARPin constructs, were run 
against a protein standard Mw marker and imaged following staining.  Polymer smears and DARPin 
bands were detected in conjugate samples, running equivalent to their unconjugated counterparts. 
SDS-PAGE characterisation of the PP-75 PDPH EMCH-DARPin conjugates, 
demonstrated a slight increase in molecular weight between conjugated and 
unconjugated DARPin migration.  PP-75 PDPH runs at less than 3.5 kDa, therefore 
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the mass shift expected would be similarly small (less than 3.5 kDa).  Minimal DARPin 
dimers were observed owing to DARPin EMCH conjugation.  Conjugated samples 
demonstrated the presence of both PP-75 PDPH, as a low molecular weight (3.5 kDa) 
smear observed previously, and DARPin sequences, corresponding to correct 
molecular weights, when compared to the unconjugated controls. 
3.2.3.6 PP-75 PDPH linked DARPin 
PP-75 PDPH Her2-binding DARPin conjugates (Figure 2.10) were also 
synthesised.  Following enhanced uptake via DARPin internalisation, DARPin function 
would no longer be required, therefore cleavage within the reducing environment of 
the cytoplasm would act to enhance the biodegradable nature of the targeted PP-75 
delivery system. 
DARPin conjugation onto PP-75 PDPH was monitored via the P-2-T release 
assay.  PP-75 PDPH DARPin conjugations were monitored in parallel with PP-75 
PDPH plus DTT, PP-75 PDPH plus siRNA and PP-75 PDPH alone for comparison.  
To monitor the reaction more closely and enhance PP-75 PDPH DARPin conjugation 
conditions a kinetic read-out that measured the change in absorbance of P-2-T (at 340 
nm) with time was performed.  The effect of DARPin concentration relative to PP-75 
PDPH was also explored, conjugating at 1:1, 2:1 and 5:1 molar ratios. 
The P-2-T assay demonstrated much higher signal to background in organic 
solvents when compared to the same reactions in PBS (Figure 3.15) as observed 
previously.  At high DARPin concentrations, there was evidence of DARPin 
aggregation when run in DMF.  This was indicated in the 5:1 conjugation ratio showing 
decreased P-2-T release, assosciated with DARPin precipitation from solution owing 
to the formation of trimer and tetramer DARPin forms, as observed in SDS-PAGE 
(Figure 3.16).  The limited tolerance of DARPin structure in organic solvents was 
investigated via ELISA binding assays and the DARPins showed preference for 
aqueous environments (data not shown).  The P-2-T release assay in PBS revealed 
that DARPin conjugation at a 5:1 ratio was most efficient, displacing P-2-T at a similar 
efficiency as DTT.  Signal strength for DARPin conjugation at 2:1 and 1:1 ratios was 
not distinguishable from PP-75 PDPH alone (demonstrating no increase in 
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absorbance).  PP-75 siRNA conjugation (at a 1:1 ratio) was the most efficient reaction, 
resulting in the strongest increase in absorbance. 
 
Figure 3.15: P-2-T Release Assay 
PP-75 PDPH DARPin and siRNA conjugation efficiencies as determined via P-2-T release in DMF (top) 
and PBS (bottom). 
PP-75 PDPH DARPin conjugates were run on denaturing, non-reducing SDS 
polyacrylamide gels to further aid characterisation.  Samples were loaded at 
comparable concentrations and imaged, detecting protein presence and fluorescence 
respectively (Figure 3.16).  Polymer smears were present as previously observed, and 
successful conjugation with PP-75 does not appear to alter how siRNA and DARPin 
samples run also similar to previous findings.  The same behaviour is observed for 
PP-75 interacting with Apoptin protein in native PAGE, where polymer smears are 
observed and interaction with Apoptin does not alter the migration of the protein 
through the gel (Leichty et al. 2009).  The presence of a higher concentration of 
monomeric samples observed is also indicative of conjugated samples (unconjugated 
monomers with exposed thiol groups would react to form more stable dimers for both 
siRNA and DARPin samples).  This is indicated by the increasing concentration of 
DARPin monomers with conjugation ratio (observed in PBS) and also the siRNA 
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conjugated samples (in PBS and to some extent in DMF).  Despite the low signal from 
the P-2-T assay, conjugation within PBS appeared successful for both siRNA and 
DARPin samples. 
 
Figure 3.16: PP-75 PDPH EMCH DARPin Conjugations Characterised by SDS PAGE. 
PP-75 PDPH conjugates, PP-75 PDPH, siRNA and DARPin constructs, were run against a protein 
standard Mw marker and imaged following staining (top gels; pre-stain, middle gels; Coomassie blue 
stain, bottom gels; Cy3 imaged).  Polymer smears, siRNA and DARPin bands were detected in 
conjugate samples, running equivalent to their unconjugated counterparts. 
The successful synthesis of novel PP-75 PDPH DARPin conjugates was 
confirmed.  A PP-75 DARPin conjugation ratio greater than 1:1 was recommended to 
maximise DARPin conjugation efficiency and compensate for the formation of DARPin 
dimers that may occur post reduction. 
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3.2.4 pH-Responsive Polymer Function 
The Dynamic Light Scattering (DLS) capabilities and the cellular release of 
lactate dehydrogenase (LDH) by PLP and PP-75 was explored to confirm polymer 
ability to respond to changes in pH, undergo conformational transition and facilitate 
membrane destabilization. 
3.2.4.1  pH-Responsive Conformational Properties 
The aggregation and conformation of PLP and PP-75 in aqueous solutions of 
differing pH was measured by DLS as an indication of pH-responsive polymer activity. 
PLP did not demonstrate significant alteration in polymer hydrodynamic size in 
response to decreasing pH at the highest concentrations tested (1 mg/mL and 0.1 
mg/mL, data not shown).  A relatively uniform peak ranging between 2 – 20 nm, with 
a mean diameter 10 nm, was observed for samples across all pH’s tested.  At those 
higher concentrations PLP aggregated more readily, the non-polar nature of the 
polymer backbone resulted in hydrophobic attraction between polymer chains, 
causing aggregation independent of pH.  At 0.01 mg/mL (Figure 3.17), the lowest 
concentration tested, a clear separation between PLP peaks was observed with 
changing pH. 
 
Figure 3.17: DLS Traces to Indicate PLP pH-Responsive Function. 
The aggregation and conformation of PLP at 0.01 mg/mL in aqueous solutions of differing pH was 
measured to indicate pH-responsive polymer function.  The average of 5 DLS traces has been plotted. 
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At pH 8.4, PLP was most likely in its extended linear conformation, able to form 
loose polymer associates with particle diameter greater than 100 nm.  With decreasing 
pH, polymer conformation became more compact; globular particles with a reduced 
diameter formed as a result of the neutralised charge on carboxylate groups.  At lower 
pH, electrostatic repulsion between polymer chains decreased and the hydrophobic 
characteristics of the polymer predominated resulting in aggregation.  The average 
particle size at pH 7.4 was 4 nm, decreasing to less than 1 nm at pH 6.5 and 5.5.  PLP 
therefore clearly demonstrated pH-dependent size distribution, at low polymer 
concentration.  Similar trends describing PLP concentration-dependent aggregation 
and changes in polymer hydrodynamic size as a result of decreasing pH have been 
reported by Chen et al. (Chen et al. 2008). 
PP-75 demonstrated similar trends to PLP, although less uniform.  At high 
concentration the polymers associated more rapidly and the size distribution peaks 
overlapped across the pH range tested (data not shown).  A mean diameter of 10 - 15 
nm was observed; polymer aggregation was again independent of pH.  At low 
concentration, 0.01 mg/mL size distribution was more varied (Figure 3.18) and no 
visible phase separation was observed. 
 
Figure 3.18: DLS Traces to Indicate PP-75 pH-Responsive Function. 
The aggregation and conformation of PP-75 at 0.01 mg/mL in aqueous solutions of differing pH was 
measured to indicate pH-responsive polymer function.  The average of 5 DLS traces has been plotted. 
This was demonstrated by the large hydrodynamic size distribution observed 
for PP-75 across the pH ranges tested.  At higher pH, 7.4 and 8.4, PP-75 particle size 
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ranged up to 300 nm, with mean diameter close to 50 nm.  At pH 6.5 particle size was 
most reduced, in line with PLP pH-responsive properties (Chen et al. 2009b), 
displaying particle size of around 10 nm average.  Ho (Ho et al. 2011) report a PP-75 
mean hydrodynamic size of 17 nm at pH 6, again close to the 10 nm average 
observed.  Size was reported to increase with increasing pH. 
These results are more closely linked to those published by Chen et al. (Chen 
et al. 2009b) who found that at sufficiently high PP-75 concentrations, > 0.5 mg/mL, 
the grafted polymers form compact hydrophobic domains over the pH range examined 
(pH 4.0 – 8.0).  An increase in polymer concentration enhances aggregation due to 
intermolecular interactions.  At low concentrations < 0.1 mg/mL, pH-dependent 
conformation is displayed.  Chen et al. (Chen et al. 2009b) demonstrate 0.025 mg/mL 
PP-75 begins to undergo hydrophobic association and therefore conformational 
transition from a linear to a globular conformation at pH 7.2. 
The onset of hydrophobic association occurs at a higher pH than the pH of 
precipitation (Ho et al. 2011), indicating that hydrophobic domains are formed prior to 
polymer precipitation.  Grafting with hydrophobic L-phenylalanine has been shown to 
widen the pH range of hydrophobic association (Chen et al. 2009a). 
As previously discussed (Section 1.5), decreasing pH causes protonation of the 
polymer backbone.  This facilitates the adoption of a more globular conformation, held 
together by enhanced intra- and inter-molecular forces within and between polymer 
strands.  The polymer chains are able to associate more closely, and this tighter 
interaction decreases polymeric diameter.  Mean hydrodynamic size of PP-75 
decreased with lower pH, until pH 5.5, where PP-75 particle size appears to slightly 
increase, in comparison to at pH 6.5.  This may be explained by the precipitation of 
PP-75 due to the increasingly acidic environment.  PP-75 may no longer remain in 
solution, therefore hydrodynamic volume cannot be accurately measured.  It is the 
intermolecular interactions that influence precipitation pH; once precipitated polymers 
display no membrane disruptive properties (Chen et al. 2008). 
PP-75 demonstrated a greater variation in size distribution than PLP, which 
may be attributed to the more branched nature of PP-75.  DLS is considered most 
reliable for measuring spherical particles, and not linear or branched polymers.  The 
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grafted nature of PP-75, although able to enhance intramolecular aggregation from 
linear to globular conformations, the polymer aggregates may demonstrate a less-
uniform cross section due to inconsistent intermolecular aggregations.  The particles 
in suspension would therefore scatter light in a less consistent manner, revealing a 
variable size distribution profile. 
It is also reported that increasingly dilute polymer concentrations may be unable 
to generate sufficient hydrophobic domains (Chen 2009b).  Therefore a critical 
polymer concentration, above which hydrophobic association can overcome 
electrostatic repulsion may be required.  Khormaee (Khormaee et al. 2010) could 
detect no hydrophilic micro-domains in PP-75 concentrations < 0.02 mg/mL, when 
using pyrene as a probe for hydrophobic environments.  The results presented here 
indicated hydrophobic influence at a 0.01 mg/mL polymer concentration.  Detection 
using pyrene may have been limited by the inability of pyrene to respond to changes 
in hydrophobicity at low concentrations.  However, DLS measurement sensitivity is 
also limited, and thus considered less reliable below sample concentrations of 0.1 
mg/mL.  These results therefore require further confirmation; complementary particle 
sizing techniques such as transmission electron microscopy (TEM), atomic force 
microscopy (AFM) (Han et al. 2012, Han et al. 2011, Xu et al. 2008), or small-angle 
neutron scattering (SANS) (Mu et al. 2008) could be used. 
3.2.4.2 pH-Responsive Membrane Activity 
The pH-responsive membrane activity of PLP and PP-75 at differing pH was 
measured by LDH release as an indication of pH-responsive polymer activity (Figure 
3.19 and Figure 3.20 respectively).  The LDH assay was adapted; using whole-cell 
membranes to mimic the endosomal membrane, culture media pH was altered to 
mimic changes in endosomal pH.  The effect of polymer concentration and exposure 
time at differing pH on cell membranes was investigated
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Figure 3.19: Cell Lysis as an Indicator of pH-Responsive PLP Membrane Activity. 
PLP membrane disruptive activity was studied using the LDH release assay.  SK-BR-3 (Her2+) fluc/Rluc (top) and MDA-MB-231 (Her2-) fluc/Rluc reporter cell 
(bottom) lysis as a result of polymer activity was recorded, comparing the effects of polymer concentration, pH and time.  Concentration dependent pH-
responsive activity was not significant across the concentration range tested.  Time dependent effects were also limited.  A trend toward increased membrane 
activity was observed at lower pH; PLP was essentially non-lytic at pH 7.4 (n=3; error bars represent the standard deviation). 
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Figure 3.20: Cell Lysis as an Indicator of pH-Responsive PP-75 Membrane Activity. 
PP-75 membrane disruptive activity was studied using the LDH release assay.  SK-BR-3 (Her2+) fluc/Rluc (top) and MDA-MB-231 (Her2-) fluc/Rluc reporter 
cell (bottom) lysis as a result of polymer activity was recorded, comparing the effects of polymer concentration, pH and time.  Limited concentration dependent 
pH-responsive activity was observed within the concentration range tested.  At extended time points SK-BR-3 (Her2+) fluc/Rluc cells revealed more membrane 
lysis at higher concentrations.  MDA-MB-231 (Her2-) fluc/Rluc cells were less susceptible to polymer treatment.  A trend toward increased membrane activity 
was observed at pH 6.0; PP-75 demonstrated limited membrane lytic activity at pH 7.4 (n=3; error bars represent the standard deviation)
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Limited membrane lysis was observed in both cell lines for PLP or PP-75 at pH 
7.4 as expected.  This is a desirable characteristic for a pH-responsive drug delivery 
system, avoiding premature membrane destabilisation and off target cytotoxicity.  In 
general, cell membrane lysis was shown to increase with decreasing pH, as dictated 
by the pH-responsive nature of the PLP and PP-75 polymers.  Across the majority of 
time-points tested activity was most prominent at pH 6 for both polymers and cell lines. 
Polymer treatment of SK-BR-3 (Her2+) fluc/Rluc cells resulted in increased 
membrane lysis at more acidic pH values, demonstrating more effective LDH release.  
PLP resulted in 40 - 50% cell lysis between 1 – 6 h, whilst at 24 h PP-75 resulted in 
almost 70% cell lysis.  Following polymer treatment of MDA-MB-231 (Her2-) fluc/Rluc 
cells, less than 20% lysis was observed across almost all time points (6 h only shown 
for comparison), in some cases LDH release was similar to the untreated control cells, 
showing no or marginal release above baseline. 
Neither PLP or PP-75 demonstrated significant concentration dependent effect 
over the 0.02 – 2.00 mg/mL concentration ranges tested in the SK-BR-3 (Her2+) 
fluc/Rluc and MDA-MB-231(Her2-) fluc/Rluc reporter cell lines. 
Complete cell lysis by PLP and PP-75 was not expected at the concentrations 
tested, nor is this required for payload release from the endosomes into the cytoplasm.  
These results were therefore in line with previously published data regarding polymer 
mode of action; the formation of pores within the membrane facilitated payload release 
without membrane lysis (Khormaee et al. 2012). 
PLP facilitated LDH release at pH 5.5 has been previously investigated 
following exposure of different cell lines to 1.0 mg/mL polymers for 60 min (Eccleston 
et al. 2000, Chen et al. 2005).  The published data reports that at 60 min, COS1 cell 
viability was decreased to 40%, indicating approximately 60% of cells lysed by PLP.  
CHO cell viability was 60%, whilst HeLa cell viability decreased to approximately 50% 
after PLP treatment.  At concentrations of 0.02, 0.20 and 2.00 mg/mL, relative viability 
remained between 60 - 80% for both CHO and HeLa lines (Chen et al. 2005, Chen et 
al. 2008), therefore membrane lysis was between 20 - 40% efficient. 
129 
PP-75 facilitated LDH release has not been previously reported in the literature.  
A complementary assay, measuring red blood cell haemolysis following polymer 
treatment, is instead employed as a model of membrane lytic activity.  Following 60 
min red blood cell exposure 0.025 mg/mL PP-75 demonstrates limited haemolysis at 
pH 7.4 (< 20%), but demonstrates over 80% haemolysis at pH 6.5.  1.0 mg/mL PP-75 
however demonstrates haemolysis at pH 7.4 (Chen et al. 2009c). 
The differences observed in apparent membrane lytic capacity of PP-75 can be 
explained by the different endosomal models.  Endosomes are formed from the inward 
budding of the external cell membrane and are therefore made of the same cell 
membrane components.  Despite red blood cell membranes also being composed of 
a lipid bilayer, the whole cell model used in the LDH assay is likely to provide a more 
accurate endosomal model.  Red blood cells may also be considered as a less robust 
cell model; their lack of intracellular structure facilitates their less rigid nature, allowing 
passage through blood stream capillaries.  The membrane lytic capacity of PP-75 may 
be overestimated using the haemolysis model in comparison to the LDH assay. 
PP-75 demonstrates enhanced membrane disruptive capacity over PLP, in SK-
BR-3 (Her2+) fluc/Rluc cells at 24 h treatment and in MDA-MB-231 (Her2-) fluc/Rluc 
cells at 6 h treatment, across the concentration range tested.  This was due to the 
increased hydrophobicity of PP-75 as a result of amino acid grafting with hydrophobic 
phenylalanine.  Chen (Chen et al. 2005) reports that the onset of the haemolytic activity 
by grafted polymers is within the desired pH range, typical of the early endosomal 
compartment (7.4 > pH > 5.5).  This was apparent when comparing PLP and PP-75 
membrane lytic capacity by the LDH assay. 
Complete membrane lysis is not necessarily required to facilitate endosomal 
payload release.  Two possible PP-75 membrane disruptive mechanisms are 
proposed; endosomal rupture, or, endosomal pore formation.  Khormaee (Khormaee 
et al. 2012) observed that fluorescently labelled PP-75 resulted in a circular staining 
pattern about the endosomes, and that rupturing had not occurred.  Co-localised 
staining of endosomally released calcein, in association with PP-75, indicates the 
partial release of calcein is from intact but leaky endosomes.  In addition, PP-75 is 
shown to release TMR-dextran, a branched 70 kDa polysaccharide, into the 
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cytoplasm.  These findings support the idea of endosomal pore formation, rather than 
endosomal membrane rupture.  Delivery of dextran was indicative that 13 - 15 kDa 
siRNA payloads are capable of traversing the endosomal pores, into the cytoplasm, 
without significant membrane lysis. 
3.3 Conclusions 
The proposal of PP-75 as a delivery platform, capable of delivering novel target-
specific siRNA payloads into the cell interior, was the driving force behind the research 
presented in this chapter.  The novel addition of an active targeting moiety, in the form 
of a DARPin, aimed to further enhance the novel nature and specific uptake of the 
delivery system, therefore minimising off-target effects. 
PLP and PP-75 synthesis was consistent with previously published data, 
demonstrating the reproducibility of PP-75 for future work.  PP-75 cross-linker 
conjugates, PP-75 AFC, PP-75 siRNA conjugate and PP-75 DARPin conjugate 
polymer stocks were all successfully synthesised as novel PP-75 derivatives.  Their 
structures and molecular weights were characterised by a variety of techniques as 
described, including NMR and FT-IR, MS, GPC and gel analysis. 
The pH-responsive physiochemical properties and membrane disruptive 
activity of PP-75 were investigated via DLS, drawing comparisons with previously 
published data and cellular LDH release respectively.  PP-75 membrane activity was 
demonstrated within two novel breast cancer cell lines.  PP-75 size distribution and 
structural hydrodynamic aggregation showed concentration, as well as pH-dependent 
effects.  Increasing PP-75 concentration, demonstrated a reduction in hydrodynamic 
size due to increased intermolecular interactions and chain aggregation as result of 
the hydrophobic nature of the polymer.  Polymer membrane disruptive activity was 
shown to be limited at physiological pH 7.4, with enhanced lytic effects associated with 
decreasing pH, typical of early endosomes.  Polymer facilitated LDH release was more 
effective from the SK-BR-3 (Her2+) fluc/Rluc reporter cell line, in comparison to the 
MDA-MB-231 (Her2-) fluc/Rluc reporter line.  These differences highlight the potential 
variability in PP-75 uptake by independent cell types, or disease models and confirms 
the need to investigate the application of PP-75 across disease types. 
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The degree of cross-linker grafting, siRNA, and DARPin conjugation was determined, 
where possible, by measuring the change in absorption of the leaving group P-2-T.  
An average of one siRNA molecule to one polymer chain was conjugated onto PP-75 
for delivery into cells.  Initial results indicated PP-75 DARPin conjugation was most 
successful at a ratio of 5:1 DARPin to PP-75 concentrations in PBS.  PP-75 EMCH 
DARPin conjugates were also synthesised, demonstrated by the detection of both 
DARPin constructs and polymers detected within the conjugated samples.  Successful 
conjugation with PP-75 did not appear to significantly alter how siRNA and DARPin 
payloads samples migrate through SDS-PAGE or agarose gel. 
In order to demonstrate the potential of the PP-75 polymers to facilitate efficient 
intracellular delivery and controlled payload release, PP-75, the novel PP-75 
derivatives, and PP-75 siRNA and DARPin conjugate functions were assessed in vitro.  
The results are outlined in the subsequent results chapters.  
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Chapter 4 
4 Cell Line Characterisation and PP-75 Cytotoxicity 
This chapter describes the characterisation of the novel SK-BR-3 (Her2+) and 
MDA-MD-231 (Her2-) fluc/Rluc model cell lines used for the biological testing of PP-
75 and the PP-75 siRNA and DARPin conjugates.  PP-75 and siRNA cytotoxicity is 
investigated, with assay design and optimisation explored.  The results are discussed 
within the context of providing background information to the findings highlighted in 
subsequent chapters.  Conclusions are drawn with a view to establishing the set up 
and optimisation of all assays using the novel reporter cell lines.  These assays will be 
subsequently used to demonstrate PP-75 as a non-toxic, intracellular delivery agent. 
4.1 Introduction 
Key to any drug delivery platform is the need to confirm that drug treatment 
results in target-specific modulation of the cell of interest.  Off-target activity, causing 
damage or death to healthy cells is to be avoided. 
To investigate the effect of intracellular siRNA knockdown, dual luciferase 
reporter technology (Promega 2015) was employed to discriminate between target 
specific and off-target cellular effects.  The stable cell transfection of lentiviral particles 
containing firefly (fluc) and Renilla luciferase (Rluc) gene constructs, was carried out 
by Tim Avis at MedImmune (Cambridge, UK).  Two human epithelial, breast 
adenocarcinoma, cancer cell lines, SK-BR-3 (Her2+) and MDA-MD-231 (Her2-) were 
chosen for transfection due to their differential expression of the extracellular Her2 
receptor (Yao et al. 2012).  Breast cancer is the most diagnosed cancer in the UK, 
accounting for a third of all cancer diagnoses in women, but with less than a 30% 
prevention rate (CRUK 2015).  Her2 is reportedly over-expressed in at least 20 - 35% 
of invasive breast carcinomas; expression correlating with aggressive tumour 
presentation, metastasis and poor prognosis.  The ability to target Her2 expressing 
cells therefore provides an important determinant for diagnosis and therapeutic 
direction.  PP-75 intracellular delivery has not previously been examined in breast 
cancer cell lines; the reporter cells provided a novel disease type and reporter assay 
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to investigate the application of PP-75.  The attachment of Her2 binding ligands to 
confer PP-75 cell specificity could be investigated with the cell types chosen.  
Transfected cells were grown under antibiotic selection to ensure gene construct 
inclusion.  Single cells were cultured from the mixed parental populations to select for 
low, mid, and high fluc/Rluc protein expressing clones.  Cells were screened using the 
Promega Dual Luciferase® Reporter (DLR) Assay (Section 2.5.4.1.1).  Clones 
demonstrating similar levels of firefly and Renilla luciferase protein expression were 
chosen as clones of interest. 
The successful integration of both firefly and Renilla luciferase constructs into 
cells, generated the novel SK-BR-3 (Her2+) fluc/Rluc and MDA-MB-231 (Her2-) 
fluc/Rluc dual reporter lines.  Reporter cell read-out to determine firefly luciferase 
target-specific knockdown, following siRNA delivery, whilst measuring Renilla 
luciferase gene expression in parallel indicates non-specific, off-target toxicity.  
Luciferase-specific gene knockdown was chosen, providing a sensitive and visible 
assay readout.  Following confirmation of fluc target-knockdown, facilitated by PP-75 
siRNA delivery, disease-relevant siRNA targets, with more complex disease 
phenotypes could be investigated. 
The variation in Her2 expression between the SK-BR-3 (Her2+) and MDA-MD-
231 (Her2-) fluc/Rluc reporter lines provides a comparable cellular platform, allowing 
investigation into extracellular Her2 targeted drug delivery.  Once validated for the 
Her2 receptor, alternative binding ligands for additional disease-relevant targets could 
be studied. 
SK-BR-3 (Her2+) and MDA-MD-231 (Her2-) parental and fluc/Rluc dual 
reporter cell lines were characterised to determine baseline properties, indicating 
differences between parental and modified cell lines.  This was required as lentiviral 
particle transfection can result in random insertion of transfected genes within gene 
loci that are essential to the growth and viability of the parental cell lines (Goyvaerts 
et al. 2013).  Similarly, the over expression of transfected genes (very high levels) 
induced by the cytomegalovirus (CMV) promoter, can be inhibitory to the function of 
the cell (Sopko et al. 2006).  Understanding the differences between the two 
adenocarcinoma lines and the behavioural characteristics of the two model-cell 
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platforms will enhance data analysis and interpretation of results, accurately 
determining the effects of PP-75 delivered siRNA treatment. 
Interaction between the PP-75 delivery system and the model cell lines was 
investigated to rule out potential cytotoxicity or unexpected adverse effects caused by 
the PP-75 delivery system itself.  Further development of a robust and reliable PP-75 
drug delivery platform could be pursued once baseline characterisations were 
determined. 
The SK-BR-3 (Her2+) fluc/Rluc and MDA-MD-231 (Her2-) fluc/Rluc reporter cell 
assays were designed to allow rapid measurement of targeted siRNA delivery and 
toxicity in parallel.  The key questions regarding PP-75 effectiveness as a siRNA 
delivery agent and the ability to avoid off-target cytotoxicity can be explored. 
4.2 Results and Discussion 
Cell line characterisation was required prior to testing the effects of the novel 
compounds, to ensure that cell culture maintains a healthy and representative cell 
population.  Key characteristics were determined to ensure subsequent cell assays 
could provide accurate and reliable results as a consequence of experimental 
variables, rather than inherent inconsistencies between uncharacterised cell types.  
Differences between parental and fluc/Rluc reporter cell lines have been considered, 
to ensure model reliability, as close to the parental lines as possible. 
4.2.1 Characterisation of Model Cell Lines 
Following stable transfection of the parental cell lines, two fluc/Rluc expressing 
SK-BR-3 (Her2+) and MDA-MD-231 (Her2-) clones were selected for in vitro assays. 
The dual reporter cell lines allowed for the simultaneous expression and 
measurement of two luciferase reporter genes, within a single cell sample.  The 
experimental reporter gene, firefly luciferase, was used to detect target gene 
knockdown following siRNA treatment.  The co-transfected, control reporter gene, 
Renilla luciferase, provided an internal control by means of measuring a cellular 
baseline response, determining overall cytotoxicity, i.e. non-targeted cell death.  Gene 
construct expression was confirmed as part of cell line characterisation. 
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The SK-BR-3 (Her2+) and MDA-MD-231 (Her2-) parental and fluc/Rluc reporter 
cell source, type and culture conditions are outlined in Table 4.1. 
Table 4.1: Cell Line Characteristics of Parental and fluc/Rluc Reporter Cell Lines. 
Cell Line 
Source and Cell 
Type 
Parental 
Reporter 
Construct 
Culture 
Conditions 
SK-BR-3 
(Her2+) 
43 year-old female 
Breast 
Adenocarcinoma 
ATCC-HTB-
30 
Amsbio #LVP283 
lentiviral construct 
transfected by 
MedImmune, 
Cambridge, UK 
McCoy’s 5A 
medium 
(Invitrogen) 
10% FBS 
MDA-MB-231 
(Her2-) 
51 year-old female 
Breast 
Adenocarcinoma 
ATCC-HTB-
26 
Amsbio #LVP371 
lentiviral construct 
transfected by 
MedImmune, 
Cambridge, UK 
RPMI-1640 
(Invitrogen) 
10% FBS  
 
The original source and cell type is listed along with cell line-specific media.  All cell lines are of human 
origin.  Abbreviations: ATCC = American Type Culture Collection, RPMI = Roswell Park Memorial 
Institute. 
4.2.1.1 Growth Characterisation of Model Cell Lines 
Assessing the viable growth of cell lines provided a qualitative and quantitative 
comparison of cell numbers between different cell populations (strains and/or 
treatments).  Characterising the growth of the parental cell lines from which the 
fluc/Rluc reporter cell strains were derived, was key to ensuring the expression of the 
fluc and Rluc constructs did not affect cell growth.  Viable growth of all cultured cell 
lines was established as a baseline for healthy cell growth. 
The SK-BR-3 (Her2+) and MDA-MB-231 (Her2-) parental and fluc/Rluc reporter 
constructs revealed slight variation in their growth characteristics, although not 
considered significant.  The SK-BR-3 (Her2+) and MDA-MB-231 (Her2-) cell lines, as 
expected, demonstrated differences in their viable growth characteristics across the 
96 h time period.  This was evident from cell line proliferation and viability, assayed 
via trypan blue cell staining (Figure 4.1), and calculation of cell line generation times 
(Table 4.2).  Trypan blue is a cell membrane impermeable dye.  Exclusion of the dye 
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is indicative of viable cells with intact cell membranes, whereas uptake of the 
impermeable cell stain results from cell membrane damage, symptomatic of non-
viable, apoptotic cells (Strober 2001). 
 
Figure 4.1: Growth of Parental and fluc/Rluc Reporter Cell Lines. 
Cell lines were seeded at 2 x105 cells per well in six-well plates and cell growth monitored over 96 h.  
Total cell count (top left), viable cell count (as a percentage of total cells) (top right) and estimated 
percentage cell confluency (bottom left) were recorded (n=3; error bars represent the standard 
deviation). 
 
Table 4.2: Cell Line Generation Time 
Cell Line Generation Time (h) 
SK-BR-3 (Her2+) (parental) 47 ± 3 
SK-BR-3 (Her2+) fluc/Rluc reporter construct 54 ± 6 
MDA-MB-231 (Her2-) (parental) 28± 2 
MDA-MB-231 (Her2-) fluc/Rluc reporter construct 34± 2 
 
Generation times were calculated based on exponential cell growth of viable cells ±SEM (n=3). 
MDA-MB-231 (Her2-) parental cells displayed the fastest growth, with a 
generation time of 28 h, reaching confluency at 72 h when seeded at 2 x105 cells per 
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well (6-well plate).  The MDA-MB-231 (Her2-) fluc/Rluc reporter line demonstrated 
similar growth characteristics to its parental strain, but with a slightly slower generation 
time of 34 h, indicating slower proliferation.  Confluency of both strains was above 
80% at 72 h suggesting entry into the cell lag phase; the cells no longer demonstrated 
exponential growth.  Cell viability also tailed off at 96 h, indicating this phase shift.  
Despite this, cell viability remained high for both MDA-MB-231 (Her2-) strains.  SK-
BR-3 (Her2+) parental cells and fluc/Rluc reporter cells also showed similar growth 
characteristics.  The generation times, again indicated the fluc/Rluc reporter strain 
proliferated at a slightly inhibited rate of 54 h compared to 47 h for the parental cells.  
Despite the slower generation times, SK-BR-3 (Her2+) confluency was comparable to 
MDA-MB-231 (Her2-) cells; SK-BR-3 (Her2+) viability was most reduced at the latter 
time point, more significantly so for the SK-BR-3 (Her2+) fluc/Rluc reporter strain. 
SK-BR-3 (Her2+) and MDA-MB-231 (Her2-) parental cell line generation times 
were reported very similar to those described in the literature.  The MDA-MB-231 
(Her2-) cells are cited with the same generation time of 28 h (Hilchie et al. 2001) and 
SK-BR-3 (Her2+) confirm a similar proliferation rate revealing generation times of 48 
h ± 7 h (Myc et al. 2010).  The SK-BR-3 (Her2+) viable growth curves did not 
demonstrate significant exponential proliferation in the first 72 h, the gradient of the 
curve remaining shallow.  It was observed that following cell passage SK-BR-3 (Her2+) 
cells demonstrated an initial lag in growth; their cell sufficiency dependent on cell 
density.  Routine culture of the SK-BR-3 (Her2+) cells revealed this was the case, and 
the SK-BR-3 (Her2+) cells were split less frequently and at a lower ratio than the MDA-
MB-231 (Her2-) cell strains.  SK-BR-3 (Her2+) cells were also observed to remain 
more adherent to their growth surface than the MDA-MB-231 (Her2-) cells, requiring 
extended incubation with accutase when passaging cells. 
The similarity between parental and fluc/Rluc reporter strain generation times 
suggested the inclusion of the fluc/Rluc reporter constructs did not cause significant 
differences to cell growth and viability in either SK-BR-3 (Her2+) or the MDA-MB-231 
(Her2-) cell lines.  These findings verified that luciferase reporter gene expression did 
not significantly impact upon cell growth and the fluc/Rluc reporter strains could be 
effectively used to study target gene knockdown, in comparison to their parental cell 
types. 
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Phase contrast microscopy confirmed cell proliferation with time in all strains.  
The SK-BR-3 (Her2+) cells appeared slightly larger and tended to be rounded, whilst 
the MDA-MB-231 (Her2-) cells appeared smaller, spindle-shaped, and more compact; 
hence the differences observed regarding confluency and cell number (ATCC (SK-
BR-3) & (MDA-MB-231)).  It was observed that SK-BR-3 (Her2+) cells grew 
preferentially as a result of colony formation; cell proliferation was supported by 
extended colony growth.  This further demonstrated the need for higher seeding 
densities to counteract SK-BR-3 (Her2+) initial lag in cell growth.  MDA-MB-231 (Her2-
) cells tended to stretch-out, making use of the available space, but became 
compacted with further proliferation.  Despite SK-BR-3 (Her2+) and MDA-MB-231 
(Her2-) cell strains being described as adherent lines, they both appeared to stack and 
not sit as a cell monolayer within the culture flasks.  Stacking was observed at early 
time points, and was not as a result of overcrowding within the culture flask. 
4.2.1.2 Luciferase Construct Expression in Model Cell Lines 
fluc/Rluc protein expression by the dual reporter cell lines was confirmed by 
Tim Avis at MedImmune, differentiating between low, mid, and high expressing clones.  
The high expressing SK-BR-3 (Her2+) and MDA-MD-231 (Her2-) fluc/Rluc reporter 
strains were selected for in vitro assays to maximise the assay window when 
measuring siRNA knockdown.  A potential limitation to this, being that saturation of 
fluorescence expression would be more likely in highly expressing clones.  Had this 
been the case a mid-expressing clone would be chosen to avoid signal saturation, 
whilst still providing an adequate window for gene knockdown.  Expression levels of 
the fluc and Rluc proteins within the reporter lines were characterised and provided 
quantitative baseline data.  Luciferase mRNA expression (fluc and Rluc respectively) 
was confirmed within the reporter lines.  The parental lines were found not to express 
either the fluc or Rluc protein or mRNA. 
4.2.1.2.1 fluc/Rluc Protein Expression 
The Dual Luciferase® Reporter (DLR) Assay was employed to provide 
sequential measurement of firefly (Photinus pyralis) and Renilla (Renilla reniformis, 
known as sea pansy) luciferase proteins (fluc and Rluc respectively), expressed within 
the reporter cell lines.  Due to their divergent evolution, fluc and Rluc enzymes 
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acquired independent structures, with different substrate and cofactor requirements.  
These differences in enzyme/substrate specificity facilitated the selective 
discrimination between respective bioluminescent reactions.  Expression of the 
luciferase reporter genes could be measured via fluorescence or luminescence 
detection, fluc fluoresces green/yellow between 550 – 570 nm, and Rluc fluoresces 
blue at 480 nm.  Luminescence measurement did not require detection at specific 
wavelengths.  Luminescence was the preferred method of detection in the DLR™ 
assay, as less background noise was associated with measurement and provided a 
more sensitive assay.  fluc activity was measured following addition of LAR II, 
generating a stable luminescence signal.  Once quantified, the fluc signal was 
quenched, and Rluc was measured following addition of Stop & Glo® reagent.  
Normalising the activity of the experimental fluc reporter gene, to the activity of the 
Rluc internal control, minimised experimental variation, accounting for differences in 
cell viability and treatment/transfection efficiency. 
Due to their developmental lineages, the differences in fluc and Rluc gene 
sequences allowed for selective siRNA knockdown.  The successful intracellular 
delivery of a specific fluc siRNA resulting in fluc gene specific knockdown.  Rluc gene 
expression levels are expected to remain constant in the absence of off-target 
treatment effects. 
To ensure stable transfection and expression of the dual reporter genes, the 
DLR assay was used to confirm levels of fluc and Rluc expression prior to siRNA 
treatment (Figure 4.2).  SK-BR-3 (Her2+) fluc/Rluc and MDA-MB-231 (Her2-) fluc/Rluc 
dual reporter lines were compared to the parental lines, validating fluc/Rluc reporter 
construct expression.  Expression of fluc and Rluc resulted in luciferase activity, 
measurable in the reporter lines only.  As expected, the SK-BR-3 (Her2+) fluc/Rluc 
and MDA-MB-231 (Her2-) fluc/Rluc lines expressed high levels of the luciferase 
proteins; exceeding 4 x107 LU (relative unit of measurement), at least seven orders of 
magnitude above the parental strains.  fluc expression was similar, within error, 
between the two reporter strains, with maximal expression measured in the region of 
1 x108 LU.  Rluc expression was slightly lower in both strains, expressing around 5 
x107 LU.  The SK-BR-3 (Her2+) reporter strain expressed relatively similar levels of 
both fluc and Rluc (with similar levels of variability), the MDA-MB-231 (Her2-) reporter 
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strain expressed half an order of magnitude less Rluc than fluc.  Normalising luciferase 
expression post siRNA treatment will minimise these differences caused by 
experimental variation. 
 
Figure 4.2: Luciferase Protein Expression Determined via DLR™ Assay. 
fluc and Rluc protein expression in SK-BR-3 (Her2+) and MDA-MB-231 (Her2-) parental and fluc/Rluc 
reporter cell lines (n=4; error bars represent the standard deviation). 
4.2.1.2.2 fluc/Rluc mRNA Expression 
mRNA expression and knockdown was measured via Real Time quantitative 
Polymerase Chain Reaction (RT-qPCR).  Polymerase, a thermostable enzyme, 
synthesised single stranded complementary DNA sequences, from double-stranded 
DNA templates.  Amplification of target gene specific DNA within a sample required 
use of complimentary DNA primers, priming the template for polymerase recognition.  
The PCR was temperature dependent, regulating polymerase activity and enabling 
primers to bind and be released from the template.  Exponential DNA amplification 
occurred with each repeated reaction.  After each proceeding cycle, DNA content was 
recorded, quantifying amplification in real time.  DNA was visualised following 
incorporation of a fluorescent probe into the reaction.  The probe bound specifically to 
the amplified DNA; amplification of DNA was therefore proportional to fluorescence of 
the sample. 
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RT-qPCR investigated fluc siRNA knockdown, quantifying levels of luciferase 
RNA within the cells.  Baseline mRNA expression levels were established prior to 
siRNA treatment in the SK-BR-3 (Her2+) fluc/Rluc and MDA-MB-231 (Her2-) fluc/Rluc 
dual reporter lines, again comparing to the parental lines, further validating reporter 
construct expression. 
4.2.1.2.2.1 RNA Extraction 
Successful extraction of pure, high quality RNA was essential to achieve 
reliable experimental data.  Following RNA extraction, RNA concentration was 
assessed by measuring absorbance at 260 nm, within a linear range between 0.2 - 
1.2.  A 260/280 absorbance ratio close to 2.0 indicates RNA purity.  An RNA 
concentration of 2 ng – 2 μg was required for cDNA synthesis.  cDNA has a linear 
relationship with the template RNA across this range.  An excess of siRNA, was 
extracted from all cell lines.  RNA concentration and purity was within the required 
specifications for cDNA synthesis. 
4.2.1.2.2.2 cDNA Synthesis 
Reverse transcription (RT) converted the extracted RNA into the cDNA 
template as required for PCR.  The RNA was primed, following addition of single-
stranded DNA (ssDNA) primers that bound the RNA.  Reverse transcriptase, a 
thermostable enzyme capable of efficient catalysis at higher temperatures (approx. 55 
ºC) can bind the primed RNA.  Complimentary DNA was synthesised, at high yield, 
following addition of deoxy-nucleotide triphosphates (dNTP’s), the DNA bases. 
cDNA concentration was assessed, measuring absorbance at 260 nm, within a 
linear range between 0.2 - 1.2.  A 260/280 absorbance ratio close to 1.8 indicated 
DNA purity. 
4.2.1.2.2.3 Primer Design 
Use of high quality primers was essential to obtaining good RT-qPCR data.  
Primers were required to be specific to their target and efficient at initiating PCR.  PCR 
amplification required forward and reverse primers (FP and RP respectively).  
Complimentary sequences within and between forward and reverse primers were 
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avoided, preventing amplification of primer dimers.  To avoid amplification of genomic 
DNA, PCR primers were designed to span exon-exon boundaries.  However as fluc 
and Rluc target genes were not present within cell line genomic DNA (due to stable 
transfection), primers could anneal anywhere along the target gene sequence.  The 
fluorescent probe was designed to bind within the amplicon sequence.  Primer/Probe 
design guidelines (Table 4.3) facilitated efficient PCR, with optimal efficiency for 
amplicons between 50 - 150 bp. 
Table 4.3: Primer and Probe Design Guidelines 
Primers Probes 
Length 9 – 40 bp  (20 bp ideal) 9 – 40 bp in length 
GC content 20 – 80% GC content 20 – 80% with G ≤ C 
Maxm 2/5 G or C @ 3’ end No G @ 5’ end 
Tm 50 – 60 ºC < 4 contiguous G 
< 2 ºC Tm difference FP:RP Tm 10 ºC higher than FP/RP Tm 
 
Similar guidelines (with explanation) can be found at: https://www.idtdna.com/pages/decoded/decoded-
articles/pipet-tips/decoded/2013/10/21/designing-pcr-primers-and-probes 
Primer and probe sequences were designed to detect fluc and Rluc genes 
(Table 4.4) within the firefly Luciferase-II-orf (1656bp) and Renilla Luciferase-orf 
(936bp) (Appendix Section 8.1).  The primers and probe for fluc gene detection were 
designed to avoid the siRNA targeting region (Section 5.2.1) to prevent any inhibitory 
siRNA interaction.  The fluc amplicon was a total of 84 bp’s, and the Rluc amplicon 
was 81 bp in length. 
Table 4.4: Primer and Probe Sequences 
 fluc Rluc 
FP ATCATACAAAAGATCATCATCATGGATA CTGGACTCCTTCATCAACTACTAT 
RP CAAATGGGAAGTCACGAAGGT GGAGGCAGCGTTACCATG 
probe CAAGACCGACTACCAGGGCTTCCAAAG CCGAGAAGCACGCCGAGAACGC 
 
fluc and Rluc sequence detection was confirmed following RT-qPCR with primer and probe sequences. 
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4.2.1.2.2.4 RT-qPCR 
RT-qPCR provides a sensitive method to validate reporter construct expression 
in the SK-BR-3 (Her2+) fluc/Rluc and MDA-MB-231 (Her2-) fluc/Rluc dual reporter 
lines.  Measuring mRNA expression provides upstream information regarding 
fluc/Rluc reporter gene expression. 
In its most basic form, RT-qPCR results are expressed in Ct.  Ct is equivalent 
to the cycle number it takes to amplify the cDNA above the threshold (background).  A 
one Ct increase is equivalent to the cDNA concentration exponentially doubling.   
There is therefore an inverse relationship between Ct and mRNA expression.  The 
lower the Ct, the fewer number of cycles to reach threshold, and therefore the more 
mRNA present within the sample.  Less amplification cycles are required to increase 
the level of cDNA above residual background expression.  During the PCR set up, the 
number of amplification cycles was programmed to 40.  Therefore a Ct value of 40 
indicated no detectable mRNA expression, and the reaction was gone to completion 
before amplification of the template reaches the threshold.  Approximation of Ct value 
was therefore enough to confirm fluc/Rluc gene expression, with Ct values less than 
29 indicating an abundance of target RNA within the sample, resulting in a strong 
positive PCR result (Mylvaganam et al. 2010). 
RT-qPCR analysis of the SK-BR-3 (Her2+) fluc/Rluc and MDA-MB-231 (Her2-
) fluc/Rluc dual reporter lines (Figure 4.3) demonstrated clear and sensitive detection 
of fluc and Rluc mRNA from the 5 ng/µL cDNA tested.  Both reporter cells lines highly 
expressed fluc and Rluc mRNA with Ct values less than 20.  The Ct values were at 
comparable levels for both genes, across both cell lines.  As expected, the SK-BR-3 
and MDA-MB-231 (Her2-) parental cells did not demonstrate fluc and Rluc expression; 
no detectable luciferase mRNA was present within the cell samples, indicated by Ct 
values of 40 (or recorded as undetermined).  Comparison of target gene expression 
to an endogenously expressed reference gene allowed for relative comparison; the 
reference gene was subject to the same level of error as the target gene.  Detection 
of the endogenous housekeeping gene GAPDH was measured across all cell lines; 
fluc/Rluc reporter and parental lines at comparable levels, again displaying Ct values 
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of less than 20.  The stability of the extracted RNA was therefore confirmed across all 
samples. 
 
Figure 4.3: Luciferase Gene Expression Determined via RT-qPCR 
Fluc and Rluc gene expression in SK-BR-3 (Her2+) and MDA-MB-231 (Her2-) Parental and Reporter 
cell lines, including RT-PCR controls (n=4; error bars represent the standard deviation). 
To provide a stable positive control, a synthetic, copy number template of fluc 
and Rluc amplicons were cloned into an expression vector.  As a reliable template, 
these positive controls allowed for consistent comparison between PCR samples.  The 
positive controls were analysed in parallel with the cell lines, also providing 
assessment of inter-assay variability and standardisation of the threshold to be used 
for relative quantification.  fluc and Rluc positive controls demonstrated high levels of 
detection, with Ct values relative to those seen within the reporter cells.  Ct values of 
around 20 were recorded.  No GAPDH detection was observed for the positive control 
due to the synthetic nature of the controls (i.e. not from cell origin). 
A PCR negative control was included, containing RNase/DNase free water in 
the place of cDNA, to confirm no cross-contamination between sample wells occurred.  
To ensure genomic DNA was not a contaminating factor during RT-qPCR reactions, 
a DNase treatment was routinely included during RNA extraction.  A reverse 
transcriptase (RT) negative control was also included to further confirm no sample 
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contamination.  From the data it can be seen both negative controls resulted in a lack 
of fluc, Rluc or GAPDH detection, with undetermined Ct values obtained. 
Following the detection of fluc and Rluc gene constructs, the reporter cell lines 
were again confirmed as SK-BR-3 (Her2+) fluc/Rluc and MDA-MB-231 (Her2-) 
fluc/Rluc expressing. 
4.2.1.2.3 Quantification of Protein and mRNA Expression 
Quantitative mRNA and protein knockdown analysis was performed in parallel 
for each cell study; measuring the degree of silencing at the mRNA and protein level. 
Protein knockdown is often considered most relevant to phenotypic change; 
however, changes at the protein level do not always correlate with changes at the RNA 
level.  It has been well reported in the literature that protein and mRNA levels do not 
necessarily correlate (Vogel et al 2010, Lundberg et al 2010, Schwanhäusser et al. 
2011).  Many processes occur between mRNA transcription and protein translation, 
that impact upon gene expression control.  RNA and protein stability, as well as RNA 
processing, and post-translational modification, influence regulatory control.  The half-
life of proteins can vary from minutes to days whereas the degradation rate of mRNA 
lies approximately between 2 - 7 hours (Vogel & Marcotte 2012).  Therefore the long 
half lives of many proteins often mask the effect of RNAi at the protein level, 
particularly in the case of transient transfections (analogous to drug dosing) (Wang et 
al. 2006).  Other factors include the lower rate of mRNA transcription compared to 
protein translation in mammalian cells; on average two mRNA’s are transcribed per 
hour in contrast with multiple proteins per mRNA per hour (Vogel & Marcotte 2012).  
Changes in gene expression level are therefore frequently not reflected in protein 
level.  Measurement at mRNA level provides a more direct validation of RNA 
interference, underscoring the importance of assessing siRNA-mediated effects by 
measuring both mRNA and protein levels (Aleman et al. 2007). 
4.2.2 PP-75 Cytotoxicity Testing 
Testing the cytotoxic potential of PP-75 on cell viability in vitro, was an essential 
step in predicting any potential toxic effects, prior to in vivo studies.  Successful drug 
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delivery platforms are required to be non-toxic, ensuring the delivery of payloads to 
diseased cells, without any off-target cytotoxicity. 
4.2.2.1 AlamarBlue® Cytotoxicity Assay 
The alamarBlue® Assay was used to quantitatively measure cell-line 
proliferation following treatment with PP-75 across a range of concentrations; 
establishing any potential PP-75 cytotoxicity (relative to untreated cells). 
Cell growth, requires respiration, the intracellular conversion of nutrients into 
energy.  This is achieved under oxidative processing, so generating electrons.  By 
accepting electrons cellular species e.g. NAD, FAD and cytochromes become 
reduced; therefore contributing to and maintaining the reduced intracellular 
environment.  The alamarBlue® reagent, containing a redox indicator dye, assays for 
cellular metabolic activity, measuring levels of respiration, and therefore cell viability 
and growth rate (Abd-Serotech 2015).  Cell proliferation results in greater reduction of 
the alamarBlue® reagent, corresponding to a measurable increase in fluorescence 
signal, whereas inhibition of growth (and/or cell death) results in much less observed 
cellular respiration and therefore less fluorescence, corresponding to a more oxidised 
environment. 
Optimisation 
The two main variables affecting cellular response within the alamarBlue® 
assay were the reagent incubation time and the seeding density of cells to be assayed.  
For any given incubation time, the range in cell density (therefore, cell number) was 
relative to alamarBlue® reduction (equivalent to cell fluorescence) as determined by 
a linear response.  These were therefore optimised prior to establishing relative PP-
75 cytotoxicity (Figure 4.4 and Figure 4.5).
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Figure 4.4: alamarBlue® Assay Optimisation for SK-BR-3 (Her2+) fluc/Rluc Cells. 
Cell seeding density and alamarBlue® reagent incubation time were optimised following 24 h adherence, t =0.  The range in cell density (therefore, cell number) 
for any given incubation time, is relative to alamarBlue® reduction (equivalent to cell fluorescence) as determined by a linear response. Results were plotted 
demonstrating optimal seeding densities compared to assay incubation time (n=3; error bars represent the standard deviation). 
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Figure 4.5: alamarBlue® Assay Optimisation for MDA-MB-231 (Her2-) fluc/Rluc Cells. 
Cell seeding density and alamarBlue® reagent incubation time were optimised following 24 h adherence, t =0.  The range in cell density (therefore, cell number) 
for any given incubation time, is relative to alamarBlue® reduction (equivalent to cell fluorescence) as determined by a linear response. Results were plotted 
demonstrating optimal seeding densities compared to assay incubation time (n=3; error bars represent the standard deviation).
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In the 96-well plate format, a seeding density of 1.5 x104 cells/well, and 1 x104 
cells/well, was determined for SK-BR-3 (Her2+) fluc/Rluc and MDA-MB-231 (Her2-) 
fluc/Rluc cells.  Both cell lines demonstrated a linear response with reference to 
incubation time at 1 x104 cells/well, however, due to the slower growth rate (1.5-fold 
slower) and preference for cell contact SK-BR-3 (Her2+) cells were seeded at the 
higher density.  The optimal alamarBlue® incubation time was determined as 3 h, 
again corresponding to the linear gradients shown for both SK-BR-3 (Her2+) fluc/Rluc 
and MDA-MB-231 (Her2-) fluc/Rluc cells.  A linear gradient was observed for all 
incubation times between 2 - 5 h, at the determined seeding densities.  As the assay 
format was likely to extend beyond 48 h following polymer treatments, a shorter 
incubation time was chosen to pre-empt increased cell numbers.  Interestingly the 
maximum fluorescence detected following alamarBlue® incubation in the SK-BR-3 
(Her2+) fluc/Rluc cells was approximately 2-fold greater than that recorded for MDA-
MB-231 (Her2-) fluc/Rluc cells.  This was likely due to the increased seeding density; 
the increased cell population able to proliferate at a higher relative rate, which resulted 
in a greater reduction of the alamarBlue® reagent, corresponding to increased 
fluorescence.  The lower fluorescence detection of the MDA-MB-231 (Her2-) fluc/Rluc 
cells was therefore not due to a less healthy cell population; cells at 48 h were still 
viable with no tail off in fluorescence levels detected. 
PP-75 Cell Toxicity 
Cell line proliferation, following PP-75 treatment up to 2.5 mg/mL (equivalent to 
~45 µM) was investigated following incubation with alamarBlue® (Figure 4.6 and 
Figure 4.7; SK-BR-3 (Her2+) fluc/Rluc and MDA-MB-231 (Her2-) fluc/Rluc cells 
respectively).  Results were plotted relative to untreated control cells (UTC) at the 
equivalent time-point, indicating healthy cell growth as standard. 
Triton™ X-100, a non-ionic detergent commonly used as an active cell lysis 
reagent was used as a positive control; indicating cytotoxicity.  Cells exposed to 
relatively low concentrations of Triton™ X-100, over time, were no longer viable due 
to the surfactant toxicity resulting in cell membrane disruption (Koley & Bard 2010, 
Dayeh et al. 2004).
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Figure 4.6: PP-75 Treatment of SK-BR-3 (Her2+) fluc/Rluc Cells (alamarBlue®). 
SK-BR-3 (Her2+) fluc/Rluc reporter cells were seeded at 1.5 x10
4
 cells per well (96 well plate) following 
24 h adherence, equivalent to time (t) = 0 h.  PP-75 cytotoxicity was assayed via alamarBlue® over 72 
hours (at t = 0, 24, 48 and 72 h).  Results plotted as % growth of untreated cells (UTC as negative 
control); compared to the PLP parent polymer, 0.1% Triton™ X-100 treated cells (positive control) (n=3; 
error bars represent the standard deviation). 
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Figure 4.7: PP-75 Treatment of MDA-MB-231 (Her2-) fluc/Rluc Cells (alamarBlue®). 
MDA-MB-231 (Her2-) fluc/Rluc reporter cells were seeded at 1.0 x10
4
 cells per well (96 well plate) 
following 24 h adherence, equivalent to time (t) = 0 h.  PP-75 cytotoxicity was assayed via alamarBlue® 
over 72 hours (at t = 0, 24, 48 and 72 h).  Results plotted as % growth of untreated cells (UTC as 
negative control); compared to the PLP parent polymer, 0.1% Triton™ X-100 treated cells (positive 
control) (n=3; error bars represent the standard deviation).
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For both SK-BR-3 (Her2+) fluc/Rluc and MDA-MB-231 (Her2-) fluc/Rluc 
reporter cells, incubation with alamarBlue® demonstrated that treatment with PP-75 
initially enhances cell proliferation between 1.25- and 1.5-fold, relative to untreated 
control cells (at t = 24).  This was a somewhat concentration dependent effect, 
between 0.25 – 2.5 mg/mL PP-75 treatment.  Triton™ X-100 treated cells, as 
expected, displayed no cell proliferation, resulting in almost complete death of the cell 
population.  After 48 h, trends in both cell types remained similar; SK-BR-3 (Her2+) 
fluc/Rluc cells demonstrated up to 1.5-fold viability again, between 0.25 – 2.5 mg/mL.  
MDA-MB-231 (Her2-) fluc/Rluc cell viability was enhanced also up to 1.5-fold between 
the slightly reduced range of 0.25 – 1 mg/mL.  Viability was 0.5-fold reduced for MDA-
MB-231 (Her2-) fluc/Rluc cells treated at 2.5 mg/mL PP-75.  Noticeably, 1 mg/mL PLP 
treatment also resulted in a significant loss in cell viability, similar to treatment with 
Triton™ X-100.  A sight trend for lower viability in the MDA-MB-231 (Her2-) fluc/Rluc 
cells treated at 0.01 – 0.05 mg/mL concentrations was also observed, however viability 
remained relatively high.  At 72 h, SK-BR-3 (Her2+) fluc/Rluc cells again displayed the 
same trend.  No reduction in cell viability was observed across the full PP-75 
concentration range and at the highest concentrations close to a 1.5-fold increase in 
viability was still observed.  Exposure to Triton™ X-100 was the only treatment shown 
to effect SK-BR-3 (Her2+) fluc/Rluc viability, resulting in complete growth inhibition.  At 
72 h MDA-MB-231 (Her2-) fluc/Rluc cells appeared to show recovered viability across 
all but the top PP-75 concentration.  Again, at several concentrations a 1.25-fold 
excess in viability was recorded, relative to the untreated control cells.  PP-75 
treatment of the MDA-MB-231 (Her2-) fluc/Rluc cell line therefore appeared to 
demonstrate a time and concentration dependent cytotoxic effect at 2.5 mg/mL only.  
Similar increases in cell proliferation, relative to untreated control cells following PP-
75 treatment have been reported by Chen et al. (Chen et al. 2005).  HeLa cells treated 
with PA, a poly(ethylene glycol) (PEG) grafted PLP polymer, demonstrated increased 
viability, more pronounced than reported here.  Viability was assessed via the MTT 
assay, another commonly used cytotoxicity assay.  MTT provides an alternative 
measure of cellular metabolic activity, assessing redox activity by measuring 
mitochondrial reductase.  MTT cell viability at 48 h varied up to 1.8-fold of the untreated 
cells.  PP-75 treatment of HeLa cells, assayed via alamarBlue® (data not shown) also 
demonstrated enhanced cell proliferation in a time and concentration dependent 
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manner up to 0.5 mg/mL.  At increased concentrations viability began to decrease, but 
remained close to 90% with PP-75 concentrations < 2.5 mg/mL.  Following 24 h 
treatment, 1- to 2.5-fold proliferation was recorded, relative to cells at t = 0.  At 48 h 
proliferation increased up to 3-fold, for the polymer treated cells, compared to that of 
the untreated control.  HeLa cells treated with 5 mg/mL PP-75 for 48 h revealed 
cytotoxicity similar to the Triton™ X-100 treated control cells.  A 1 mg/mL PLP 
treatment of HeLa cells also resulted in similar cell proliferation enhancement. 
4.2.2.2 CellTitre-Glo® Cell Viability Assay 
The discrepancies in determining the effect of PP-75 treatment on cells 
indicated by routine toxicity assays highlighted the need for several complementary 
techniques, in order to understand the potential effects of PP-75.  The CellTiter-Glo® 
Assay was therefore chosen to again, quantitatively determine cell viability, following 
PP-75 treatment across the same concentration range of 0.01 – 2.5 mg/mL as 
investigated via alamarBlue®. 
The CellTiter-Glo® Assay was chosen as it is considered a faster and more 
sensitive method than some other commonly viable cell assays (e.g. MTT or Calcein-
AM).  It does not require prolonged incubation steps, needed to facilitate metabolic 
conversion of indicator molecules into a detectable signal.  Instead the CellTiter-Glo® 
reagent assays for cellular ATP, immediately following cell lysis.  Metabolically active 
cells release their intracellular ATP, generating a luminescent signal proportional to 
cell number.  The glow-type signal is created by the conversion of beetle luciferin to 
oxyluciferin, catalysed by a luciferase.  Endogenous intracellular enzymes e.g. 
ATPases are simultaneously inhibited on addition of the reagent, allowing for a more 
accurate ATP measurement (CellTitre-Glo Manual Promega 2015). 
CellTiter-Glo® assessment of SK-BR-3 (Her2+) fluc/Rluc and MDA-MB-231 
(Her2-) fluc/Rluc reporter cell viability demonstrated PP-75 treatments were well 
tolerated across the concentration range tested, to a maximum of 2.5 mg/mL (Figure 
4.8 and Figure 4.9; SK-BR-3 (Her2+) fluc/Rluc and MDA-MB-231 (Her2-) fluc/Rluc 
cells respectively).
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Figure 4.8: PP-75 Treatment of SK-BR-3 (Her2+) fluc/Rluc Cells (CellTitre-Glo®). 
SK-BR-3 (Her2+) fluc/Rluc reporter cells were seeded at 1.5 x10
4
 cells per well (96 well plate) following 
24 h adherence, t =0 equivalent to time (t) = 0 h.  PP-75 cytotoxicity was assayed via CellTitre-Glo® 
cytotoxicity assay over 72 hours (at t = 0, 24, 48 and 72 h).  Results plotted as % growth of untreated 
cells (negative control); compared to the PLP parent polymer, 0.1% Triton™ X-100 treated cells 
(positive control) (n=3; error bars represent the standard deviation). 
 
 
 
 
The effect of PP-75 treatment on SK BR3 Reporter cell line toxicity, measured via CellTitre-Glo® assay. 
Cells seeded at 1.5 x104 cells per well (96 well plate).  Results plotted as % growth of untreated cells (n=3 in triplicate; error bars 
represent standard deviation).
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The effect of PP-75 treatment on SK BR3 Repor er cell lin toxicity, measured via CellTitre-Glo® assay. 
Cells seeded at 1.5 x104 cells per well (96 well plate).  Results plotted as % growth of untreated cells (n=3 in triplicate; error bars 
represent standard deviation).
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Figure 4.9: PP-75 Treatment of MDA-MB-231 (Her2-) fluc/Rluc Cells (CellTitre-Glo®). 
MDA-MB-231 (Her2-) fluc/Rluc reporter cells were seeded at 1.0 x10
4
 cells per well (96 well plate) 
following 24 h adherence, equivalent to time (t) = 0 h.  PP-75 cytotoxicity was assayed via CellTitre-
Glo® cytotoxicity assay over 72 hours (at t = 0, 24, 48 and 72 h).  Results plotted as % growth of 
untreated cells (negative control); compared to the PLP parent polymer, 0.1% Triton™ X-100 treated 
cells (positive control) (n=3; error bars represent the standard deviation).
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The effect of PP-75 treatment on MDA-MB-231 Reporter cell line toxicity, measured via CellTitre-
Glo® assay.
Cells seeded at 1x104 cells per well (96 well plate).  Results plotted as % growth of untreated cells (n=3 in triplicate; error bars represent 
standard deviation).
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The effect of PP-75 treatme t on MDA-MB-231 Reporter cell line toxicity, measured via CellTitre-
Glo® assay.
Cells seeded at 1x104 cells per well (96 well plate).  Results plotted as % growth of untreated cells (n=3 in triplicate; error bars represent 
standard deviation).
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CellTiter-Glo® assay results further confirmed the lack of PP-75 induced 
cytotoxicity upon the SK-BR-3 (Her2+) fluc/Rluc and MDA-MB-231 (Her2-) fluc/Rluc 
reporter cells.  PP-75 enhanced cell proliferation was not observed to the same degree 
as in the alamarBlue® assay (with the exception of SK-BR-3 (Her2+) fluc/Rluc cells at 
48 h), mean values appeared parallel to those of the untreated control cells. 
Negligible variation was detected in treatment of the SK-BR-3 (Her2+) fluc/Rluc 
cells across the 72 h time period.  Viability remained comparable to the untreated 
control cells.  PLP treatment (1 mg/mL) revealed a mean 25% decrease in viability at 
72h, however the standard deviation (represented by the error bars) extended to 100% 
viability, and the results were unlikely to be significant.  Equally, MDA-MB-231 (Her2-
) fluc/Rluc cells responded in the same way, with limited variability demonstrating a 
lack of concentration and time dependence in response to PP-75 exposure.  An almost 
negligible decrease was visible at 2.5 mg/mL across 48 – 72 h, but viability remains 
close to 100%.  As with the alamarBlue® assay, the positive control of Triton™ X-100 
treated cells, resulted in extensive cell population death in all cases. 
Chen (Chen et al. 2005) similarly reported differences between cytotoxicity 
assay formats.  The MTT viability assay, like alamarBlue® demonstrated HeLa cell 
proliferation following PLP-PEG treatment, whilst the addition of polymer followed by 
trypan blue staining did not increase cell viability.  Chen (Chen et al. 2005) described 
the possibility of these discrepancies arising due to polymer enhancement of enzyme 
activity, as measured by MTT.  It is unlikely that PP-75 reacts with the alamarBlue 
reagent, however the addition of PP-75 to the cell population may alter the redox 
environment of the cells, therefore artificially altering alamarBlue® readout.  
Alternatively PP-75 may affect the metabolic activity of the cell resulting in increased 
mitochondrial function, thus providing increased signal in the alamarBlue® assay and 
falsely indicating cell proliferation. 
CellTitre-Glo® measured ATP levels, which were unaffected by PP-75 
presence within the cells and therefore represented a more accurate measure of cell 
viability.  CellTitre-Glo® is reported to show reproducible and enhanced sensitivity 
over redox based readouts when grown in microtitre plates over several days (Petty 
et al. 1995).  It was possible that metabolism of the amide bonds within PP-75 may 
157 
release lysine and phenylalanine, providing essential amino acids to the cells, and 
could promote cell proliferation.  However, were this to be the case, both viability 
assays would show increased cell proliferation.  It is therefore unlikely that PP-75 
promotes cell growth and more likely has no effect on cell viability at the concentrations 
tested. 
4.3 Conclusions 
Characterisation of the model cell lines used for the biological testing of PP-75 
was essential prior to treatment with the delivery system.  Cell growth characteristics 
and seeding densities were determined in both 96- and 6-well formats for cytotoxicity 
and functional assays.  SK-BR-3 (Her2+) and MDA-MB-231 (Her2-) parental cell line 
generation times were found to be similar to those previously reported (Watanabe et 
al. 2001, Myc et al. 2010) providing a benchmark for subsequent cell studies. 
Successful transfection of both firefly and Renilla luciferases to provide the SK-
BR-3 (Her2+) and MDA-MB-231 (Her2-) reporter cell lines was confirmed at both the 
protein and mRNA level, by the Dual Luciferase® Reporter Assay and RT-qPCR 
respectively.  Differences between the expression levels of fluc and Rluc proteins were 
observed in the MDA-MB-231 (Her2-) fluc/Rluc cell line; fluc protein levels were 2-fold 
above those recorded for Rluc.  The SK-BR-3 (Her2+) fluc/Rluc cell line showed similar 
expression levels for both luciferase proteins.  Levels of fluc and Rluc mRNA detected 
in the cell lines did not directly correlate with protein expression; and instead indicated 
equivalent expression of both fluc and Rluc in both SK-BR-3 (Her2+) fluc/Rluc and 
MDA-MB-231 (Her2-) fluc/Rluc reporter cell lines.  Differences in mRNA and protein 
expression, as discussed, have been well reported in the literature, and this was 
therefore not considered a disadvantage to the model system.  However, this did 
highlight the requirement to measure changes in luciferase gene expression at both 
the mRNA and protein levels; fundamental when studying siRNA mediated 
knockdown. 
Both RT-qPCR and DLR™ assays were optimised and confirmed as robust and 
reliable assays, providing sensitive readouts of the reporter genes.  Any differences in 
expression between samples and strains could therefore be accounted for during 
relative analysis between the endogenous internal control genes and fluc gene 
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knockdown.  Comparing results relative to untreated control cells, allowed response 
above baseline to be determined. 
Insertion of the fluc/Rluc constructs was considered to not significantly affect 
cell growth characteristics of the reporter lines compared to the parental SK-BR-3 
(Her2+) and MDA-MB-231 (Her2-) cell lines.  The two reporter strains were therefore 
considered as reliable cell models permitting the investigation of PP-75 facilitated, 
siRNA mediated, intracellular knockdown. 
Employment of two reporter systems allowed a more detailed study of PP-75 
delivery capacity.  Characteristic differences between SK-BR-3 (Her2+) fluc/Rluc and 
MDA-MB-231 (Her2-) fluc/Rluc cells were observed in terms of growth and luciferase 
protein expression.  The effects of PP-75 have not been previously studied in breast 
cancer cells.  PP-75 cytotoxicity was studied, determining cell proliferation and viable 
growth in a time and concentration dependent manner.  Complementary cell-based 
assays were undertaken to better validate toxicity results.  PP-75 was confirmed to 
show limited cytotoxicity to SK-BR-3 (Her2+) fluc/Rluc and MDA-MB-231 (Her2-) 
fluc/Rluc cell lines and was tolerated across a wide range of concentrations up to 2.5 
mg/mL (~45 µM) over a 72 h time period.  As a result PP-75 was validated as non-
toxic, essential to PP-75 application as an intracellular delivery agent. 
Treatment of healthy ‘non-diseased’ cell populations with PP-75 would further 
confirm the polymers suitability as a platform for intracellular drug delivery; endorsing 
low PP-75 cytotoxicty and the ability to achieve targeted delivery. 
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Chapter 5 
5 PP-75 Mediated Intracellular Delivery and siRNA 
Knockdown 
This chapter describes the intracellular uptake of PP-75, its location within the 
cell interior and the delivery capacity of PP-75 to mediate target-specific siRNA 
knockdown.  The results are discussed within the context of PP-75 mediated 
intracellular delivery, with comparison to Lipofectamine® 2000 transfection agent (Life 
Technologies), considered the gold-standard in efficient cell transfection (Sandbichler 
et al. 2013).  PP-75 intracellular localisation was observed by confocal microscopy 
and flow cytometry techniques, following treatment with fluorescently labelled PP-75 
(PP-75 AFC).  Intracellular siRNA knockdown was examined following optimisation of 
the DLR™ and RT-qPCR assays, as described in Chapter 4.  Conclusions are drawn 
discussing PP-75 efficiency as an intracellular delivery agent, with application to 
targeted delivery and enhanced cell uptake. 
5.1 Introduction 
The ability of PP-75 to enter cells is key to its function as an intracellular delivery 
platform.  PP-75 has been shown to achieve intracellular delivery across a range of 
cell types including human cervical cancer (HeLa) cells (Chen et al. 2009), human 
osteogenic sarcoma (Saos-2) cells (Liechty et al. 2010) and human malignant glioma 
(U251) cells (Khormaee et al. 2012), but not yet breast cancer cell lines.  Therefore 
PP-75 intracellular uptake and intracellular location could be examined in an 
alternative disease target, extending the application of PP-75 as a drug delivery agent. 
For efficient intracellular delivery, payloads must pass through the cell 
membrane.  PP-75 uptake is facilitated through the process of endocytosis, the most 
common route of entry for macro-drugs.  The process of endocytosis, mediated by the 
acidification of the endo-lysosomal pathway, results in the maturation of endosomes 
to lysosomes (Mukherjee et al. 1997).  Lack of endosomal escape is a common 
limitation to many existing drug delivery platforms.  The proposed pH-responsive 
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activity of PP-75 therefore directly addresses this barrier, permitting PP-75 to disrupt 
the endosomal membrane. 
Visualising PP-75 intracellular location was key to understanding the process 
of uptake, and delivery capabilities of PP-75.  For PP-75 to be functional as an agent 
of siRNA delivery, it must escape from the endosomal pathway, facilitating siRNA 
payload release into the cytoplasm.  Once within the cytoplasm siRNA must be shown 
to facilitate target-specific knockdown.  Off target effects due to non-specific siRNA 
knockdown or toxicity of the delivery vehicle were undesirable.  To best study this, it 
was determined that siRNA mediated knockdown of the firefly luciferase (fluc) reporter 
gene would provide an easily interpretable and visual read-out.  Once siRNA mediated 
knockdown via PP-75 delivery was confirmed in the model-system, more disease-
relevant targets could be investigated.  Initial use of the model-system was intended 
to investigate specific reporter gene knockdown that would be more challenging to 
confirm by studying disease targets; siRNA therapeutics often act to illicit cancer cell 
death.  The non-selective, off-target delivery of certain therapeutics, to healthy cells 
can result in unwanted cell death, resulting in the common-place side-effects often 
associated with chemotherapies.  To ensure directed gene-knockdown was target-
specific, knockdown lending to a visible readout rather than cell death was more 
amenable to demonstrating gene-targeting effects. 
siRNA mediated knockdown was investigated at both the mRNA and protein 
level to further understand the potential delivery capacity of PP-75. 
Lipofectamine® 2000 is a cationic liposome based transfection reagent, often 
considered the gold-standard for the efficient transfection of nucleic acids into cells 
(Sandbichler et al. 2013).  Lipofectamine® is the most cited and recognized reagent 
available for transfection, but is not without its drawbacks (ThermoFisher 2015).  As 
with all transfection agents and delivery systems, once inside the cell, escape from the 
endosomal pathway must be achieved, prior to transport through the cytoplasm and 
delivery to the payload site of action.  The high transfection efficiency of 
Lipofectamine® 2000 is paralleled by its high cytoxicity; seeding densities greater than 
90% are required to achieve recovery of the cell population (ThermoFisher 2015).  
Lipofectamine® transfection requires serum-free cell media to avoid the uptake of 
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excess protein within the cell at a higher ratio than the nucleic acid.  Lack of serum 
acts to starve the cells, they are therefore more likely to scavenge for nutrients, 
increasing the rate of endocytosis and facilitating enhanced intracellular uptake.  The 
pay-off for enhanced transfection is a loss in cell viability due to non-optimal growth 
conditions.  Depletion of serum within cell growth media also triggers biological 
responses such as autophagy, therefore influencing experimental outcome.  However, 
due to its high transfection efficiency Lipofectamine® was chosen as the positive 
control.  Lipofectamine® is able to effectively deliver siRNA to the cell interior and 
provides a relative comparison for PP-75 delivery, shown to be non-toxic to cells 
(Section 4.2.2).  Another key advantage to PP-75 delivery is its anionic polymer 
properties.  Application of PP-75 was less likely to result in non-specific interactions 
with components in systemic circulation than cationic agents such as Lipofectamine®.  
Unfavourable biodistribution of cationic agents can also occur due to interaction with 
the negatively charged cell surface, hindering cell specific delivery. 
To validate the use of the SK-BR-3 (Her2+) fluc/Rluc and MDA-MB-231 (Her2-
) fluc/Rluc reporter cells as an effective model to determine intracellular siRNA 
knockdown using PP-75, the DLR™ assay and RT-qPCR protocols were initially 
performed using Lipofectamine®, acting as a positive control.  Lipofectamine® 
delivered fluorescently labelled (Cy3) siRNA was used to further confirm siRNA uptake 
and intracellular localisation via confocal microscopy.  Lipofectamine® delivery 
therefore confirmed fluc siRNA functionality, having measured fluc specific mRNA and 
protein knockdown within the cells. 
Following validation of the model system PP-75 cellular uptake and 
internalisation was investigated to give a more comprehensive overview of the PP-75 
delivery mechanism. 
Confocal microscopy was used to demonstrate PP-75 cell uptake by MDA-MB-
231 (Her2-) fluc/Rluc reporter cells.  Fluorescently labelled PP-75 (PP-75 AFC) 
qualitatively demonstrated the presence of PP-75 and its intracellular distribution.  
Cellular counterstains were applied to establish co-localisation of PP-75 within the cell 
compartments.  Flow cytometry was used, to further confirm PP-75 AFC cell uptake 
within MDA-MB-231 (Her2-) fluc/Rluc cells.  Subsequent studies imaging PP-75 AFC, 
162 
and PP-75 Cy3 siRNA, pre and post conjugation were investigated in SK-BR-3 (Her2+) 
fluc/Rluc and MDA-MB-231 (Her2-) fluc/Rluc cells, carried out using the high content 
OPERA® imaging system. 
The DLR™ assay and RT-qPCR were used to provide quantitative siRNA 
knockdown data. 
5.2 Results and Discussion 
5.2.1 siRNA Payload Design 
The fluc siRNA payload was designed to target the fluc gene at a similar region 
to that published by Lewis (Lewis et al. 2002) (Table 5.1).  Firefly luciferase expression 
was inhibited by 80 - 90% following injection in vivo when compared to control mice 
not injected with fluc siRNA.  Rluc expression was unaffected by fluc siRNA treatment, 
indicating specific target gene response (Lewis et al. 2002).  Based upon this 
sequence, a novel siRNA payload was designed for use in the SK-BR-3 (Her2+) 
fluc/Rluc and MDA-MB-231 (Her2-) fluc/Rluc reporter cell lines.  The siRNA targeted 
the fluc gene expressed in the pGL4 luciferase reporter vector (Promega, 
Southampton, UK) within the reporter cell lines; Lewis et al. transfected via pGL3 
vector with subtle sequences differences. 
Table 5.1: fluc siRNA Targeting Sequence. 
siRNA targeted fluc DNA sequence (5’-3’) 
R                     
rCrCrTrArCrGrCrCrGi.A GrTrArCrTr.TrCrGrArTr T 
 
fluc mRNA coding sequence (5’- 3’) 
 
rCrCrUrArCrGrCrCrGrArGrUrArCrUrUrCrGrArUrU 
 
 
fluc targeting siRNA duplex  
5’ thiol modified  
 
. 
rUrUrGrGrArUrGrCrGrGrCrUrCrArUrGrArArGrCrU 
/5ThiolMC3-D/rCrCrUrArCrGrCrCrGrArGrUrArCrUrUrCrGrAdGdA 
 
fluc targeting siRNA duplex + Cy3 
5’thiol modified 3’ Cy3 labelled 
. 
rUrUrGrGrArUrGrCrGrGrCrUrCrArUrGrArArGrCrU 
/5ThiolMC3-D/rCrCrUrArCrGrCrCrGrArGrUrArCrUrUrCrGrAdGdA/3Cy3/ 
 
Scr siRNA duplex 
3’ thiol modified 
.               
               .rUrUrGrArArUrGrCrGrArCrUrCrArUrGrArArGrCrU 
..rCrUrUrArCrGrCrUrGrArGrUrArCrUrUrCrGrAdGdA/3ThiolMC3-D/ 
 
 
fluc siRNA duplexes were designed to specifically bind the pGL4 expressed fluc coding sequence nt 
157-176.  The duplex consisted of the anti-sense strand (red) that binds the mRNA sequence and the 
corresponding complimentary sense strand (black).  The siRNA duplex enabled association with the 
RISC complex prior to siRNA gene silencing.  A scrambled (Scr) siRNA sequence that was non-specific 
to the fluc gene was also designed as a negative control; the altered nucleotides have been underlined. 
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During siRNA targeting the antisense (complementary) strand binds the target 
mRNA sequence.  The fluc targeting siRNA was therefore designed such that the 
sense (coding) strand was the modified sequence, incorporating the 5’ thiol to facilitate 
conjugation onto PP-75.  The addition of the 3’ Cy3 fluorescent label was also on the 
sense strand (conversely the non-targeting scrambled (Scr) siRNA sequence was thiol 
modified on the 3’ antisense strand). 
Replacement of the two terminal RNA bases with DNA bases at the 3’-end of 
the sense strand increases processing by Dicer.  The anti-sense strand incorporates 
a UU RNA overhang to mimic the product of Dicer processing of RNA for incorporation 
into the RISC complex (IDT 2005). 
5.2.2 Lipofectamine® Mediated siRNA Delivery 
5.2.2.1 OPERA Imaging 
Cells treated with Lipofectamine® complexed Cy3 labelled siRNA were imaged 
to demonstrate intracellular siRNA delivery and localisation.  The OPERA® platform 
provided a high content image screening system with confocal capacity.  High 
throughput imaging on a 96-well scale, analogous to the quantitative assays was 
therefore achieved.  Variability between assays was minimised in terms of cell seeding 
densities and assay format. 
SK-BR-3 (Her2+) fluc/Rluc and MDA-MB-231 (Her2-) fluc/Rluc reporter cells 
were treated with Lipofectamine® plus Cy3 labelled siRNA and compared to cells 
treated with siRNA alone and untreated control cells.  The effective delivery of siRNA 
was observed with siRNA Cy3 located intracellulary (Figure 5.1 and Figure 5.2). 
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Figure 5.1: Intracellular Localisation of Lipofectamine® Delivered siRNA Cy3 at 1, 6 and 24 h Post Treatment to SK-BR-3 (Her2+) fluc/Rluc Cells. 
SK-BR-3 (Her2+) fluc/Rluc reporter cells were treated with Lipofectamine® plus Cy3 labelled siRNA (yellow) and compared to siRNA Cy3 alone and untreated 
control (UTC) cells.  Cell nuclei were stained with Hoechst (blue) to demonstrate intracellular localisation.  Cells were imaged at time (t) = 1, 6 and 24 h.  Images 
are representative of multiple fields of view across replicate wells; scale bar represents 50 µm. 
50 μm
Lipofectamine® + siRNA Cy3
50 μm
50 μm
50 μm
50 μm
50 μm
50 μm
50 μm
50 μm
50 μm
siRNA Cy3 UTC
T = 1
T = 6
T = 24
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Figure 5.2: Intracellular Localisation of Lipofectamine® Delivered siRNA Cy3 at 1, 6 and 24 h Post Treatment to MDA-MB-231 (Her2-) fluc/Rluc Cells. 
MDA-MB-231 (Her2-) fluc/Rluc reporter cells were treated with Lipofectamine® plus Cy3 labelled siRNA (yellow) and compared to siRNA Cy3 alone and 
untreated control (UTC) cells.  Cell nuclei were stained with Hoechst (blue) to demonstrate intracellular localisation.  Cells were imaged at time (t) = 1, 6 and 
24 h.  Images are representative of multiple fields of view across replicate wells; scale bar represents 50 µm. 
50 μm
Lipofectamine® siRNA Cy3 complexes
50 μm
50 μm
50 μm
50 μm
50 μm
50 μm
50 μm
50 μm
50 μm
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T = 24
166 
The, untreated control (UTC) cells provided a comparison to the siRNA treated 
cells, the Hoechst (blue) stained cell nuclei indicates a healthy cell population.  No 
siRNA Cy3 was observable within the cells treated with siRNA Cy3 alone (minus 
Lipofectamine®) indicating that the siRNA did not enter the cells.  Cells treated with 
Lipofectamine® siRNA complexes demonstrated strong uptake of siRNA Cy3 (yellow) 
observable within the cells at all time points imaged.  A time dependent effect was 
seen, cells incubated with siRNA Cy3 for 6 and 24 h show increased uptake relative 
to 1 h treatment, demonstrated by increased staining present within the cells.  At 6 h 
the Lipofectamine® siRNA Cy3 complex treated MDA-MB-231 (Her2-) fluc/Rluc cell 
population looked to be less dense when compared to siRNA only and UTC cells, this 
may be indicative of Lipofectamine® cytotoxicity, however this was not observed in 
the SK-BR-3 (Her2+) fluc/Rluc cells to the same extent. 
Intracellular siRNA Cy3 localisation was further demonstrated within the cells 
with the addition of a CellMask™ stain (pink) to confirm siRNA location within the cell 
interior.  Rab5, Rab7 and LAMP 1 staining was also investigated to indicate if siRNA 
was located within the early or late endosomes, or within the lysosome respectively 
(Figure 5.3 and Figure 5.4).  The overlaid images demonstrated the co-localisation of 
siRNA within the cells, demonstrated by the CellMask™ staining.  Endosomal and 
lysosomal stains also demonstrated some co-localisation with the siRNA indicating 
entrapment within these vesicles in some cases.  
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Figure 5.3: Intracellular Localisation of Lipofectamine® Delivered siRNA Cy3 in SK-BR-3 (Her2+) 
fluc/Rluc Cells. 
SK-BR-3 (Her2+) fluc/Rluc reporter cells were treated with Lipofectamine® siRNA Cy3 (yellow).  Cells 
were stained with Hoechst (blue) and CellMask™ (pink) to demonstrate nuclei and whole cell 
respectively, therefore indicative of siRNA intracellular localisation.  Endosomal and lysosomal stains 
were also used, Rab5 for early endosomes, Rab7 late endosomes and LAMP1 for lysosomes (red).  
Cells were imaged at t = 6 h.  Images are representative of multiple fields of view across replicate wells; 
scale bar represents 50 µm 
Lipofectamine® siRNA Cy3 complex 
With LAMP1 
Lysosomal Stain 
 
Panels are Top Left: Hoechst and siRNA 
Cy3, Top Right: Hoechst and LAMP1, 
Bottom Left: Hoechst, siRNA Cy3 and 
LAMP1 overlay, Bottom Right: Hoechst, 
siRNA Cy3, LAMP1 and CellMask™ 
overlay. 
Lipofectamine® siRNA Cy3 complex 
With Rab5 
Early Endosomal Stain 
 
Panels are Top Left: Hoechst and siRNA 
Cy3, Top Right: Hoechst and Rab5, Bottom 
Left: Hoechst, siRNA Cy3 and Rab5 
overlay, Bottom Right: Hoechst, siRNA 
Cy3, Rab5 and CellMask™ overlay. 
Lipofectamine® siRNA Cy3 complex 
With Rab7 
Late Endosomal Stain 
 
Panels are Top Left: Hoechst and siRNA Cy3, 
Top Right: Hoechst and Rab7, Bottom Left: 
Hoechst, siRNA Cy3 and Rab7 overlay, Bottom 
Right: Hoechst, siRNA Cy3, Rab7 and 
CellMask™ overlay. 
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Figure 5.4: Intracellular Localisation of Lipofectamine® Delivered siRNA Cy3 in MDA-MB-231 
fluc/Rluc Cells. 
MDA-MB-231 (Her2-) fluc/Rluc reporter cells were treated with Lipofectamine® plus Cy3 labelled siRNA 
(yellow).  Cells were stained with Hoechst (blue) and CellMask™ (pink) to demonstrate nuclei and whole 
cell respectively, therefore indicative of siRNA intracellular localisation.  Endosomal and lysosomal 
stains were also used (red).  Cells were imaged at t = 6 h.  Images are representative of multiple fields 
of view across replicate wells; scale bar represents 50 µm 
 
Lipofectamine® siRNA Cy3 complex 
With Rab5 
Early Endosomal Stain 
 
Panels are Top Left: Hoechst and siRNA 
Cy3, Top Right: Hoechst and Rab5, Bottom 
Left: Hoechst, siRNA Cy3 and Rab5 
overlay, Bottom Right: Hoechst, siRNA 
Cy3, Rab5 and CellMask™ overlay. 
Lipofectamine® siRNA Cy3 complex 
With Rab7 
Late Endosomal Stain 
 
Panels are Top Left: Hoechst and siRNA 
Cy3, Top Right: Hoechst and Rab7, Bottom 
Left: Hoechst, siRNA Cy3 and Rab7 
overlay, Bottom Right: Hoechst, siRNA 
Cy3, Rab7 and CellMask™ overlay. 
Lipofectamine® siRNA Cy3 complex 
With LAMP1 
Lysosomal Stain 
 
Panels are Top Left: Hoechst and siRNA 
Cy3, Top Right: Hoechst and LAMP1, 
Bottom Left: Hoechst, siRNA Cy3 and 
LAMP1 overlay, Bottom Right: Hoechst, 
siRNA Cy3, LAMP1 and CellMask™ 
overlay. 
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5.2.2.2 Dual Luciferase® Reporter Assay 
As described previously (Section 4.2.1.2.1) the DLR™ assay allows for 
sequential measurement of firefly and Renilla luciferases (fluc and Rluc respectively), 
expressed within the reporter cell lines.  The successful intracellular delivery of fluc 
targeting siRNA, results in fluc, gene specific, knockdown.  Rluc gene expression 
levels were expected to remain constant in the absence of off-target toxicity, therefore 
demonstrating the absence of non-specific treatment effects and confirming PP-75 
facilitated specific siRNA delivery.  siRNA delivery via Lipofectamine® was first tested 
and demonstrated siRNA functionality and knockdown capacity whilst also optimising 
cell seeding density (Figure 5.5 and Figure 5.6).  siRNA concentration and the siRNA 
incubation time to achieve efficient protein knockdown was explored (Figure 5.7 and 
Figure 5.8).
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Figure 5.5: Relative fluc Protein Expression in SK-BR-3 (Her2+) fluc/Rluc Reporter Cells via 
Lipofectamine® Delivered fluc Targeting siRNA as Measured via DLR™ Assay. 
fluc targeting siRNA functionality was confirmed at a 50 nM concentrations across a 96 – 168 h time 
period.  Seeding density of the cells was also varied to ensure cells would not become over confluent 
during extended incubation.  SK-BR-3 (Her2+) fluc/Rluc reporter cells were incubated with 
Lipofectamine® siRNA complexes following 24 h adherence, t = 0.  Results were plotted relative to 
Rluc, acting as an internal control, before fold change in expression was plotted relative to the delivery 
control.  Time and concentration knockdown effects are observed across both cell lines (n=1). 
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Figure 5.6: Relative fluc Protein Expression in MDA-MB-231 (Her2-) fluc/Rluc Reporter Cells via 
Lipofectamine® Delivered fluc Targeting siRNA as Measured via DLR™ Assay. 
fluc targeting siRNA functionality was confirmed at a 50 nM concentrations across a 96 – 168 h time 
period.  Seeding density of the cells was also varied to ensure cells would not become over confluent 
during extended incubation.  MDA-MB-231 (Her2-) fluc/Rluc reporter cells were incubated with 
Lipofectamine® siRNA complexes following 24 h adherence, t = 0.  Results were plotted relative to 
Rluc, acting as an internal control, before fold change in expression was plotted relative to the delivery 
control.  Time and concentration knockdown effects are observed across both cell lines (n=1).
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50 nM siRNA and siRNA Cy3 were delivered in complexation with 
Lipofectamine® to both fluc/Rluc reporter cell lines across a 96 – 168 h period to 
estimate the optimal window to observe fluc protein knockdown.  SK-BR-3 (Her2+) 
fluc/Rluc cells seeded at 5 x104 (seeding density (SD) 1), 2.5 x104 (SD2), and 1 x104 
(SD3) cells per well (6-well plates), whilst MDA-MB-231 (Her2-) fluc/Rluc cells with 
shorter doubling times were seeded lower at 2.5 x104 (SD1), 1 x104 (SD2), and 0.75 
x104 (SD3) cells per well (6-well plates).  No significant differences were observed 
between treatment with Lipofectamine® delivered siRNA or siRNA Cy3 (except Figure 
5.6; t = 96, SD1, likely an anomalous error and not seen in subsequent DLR™ assay 
runs), therefore validating the use of either siRNA for knockdown and intracellular 
localisation studies.  The two cell lines did however respond slightly differently to 
siRNA treatment.  The SK-BR-3 (Her2+) fluc/Rluc cells demonstrated an observable 
time and seeding density effect in relation to Lipofectamine® delivered siRNA 
treatment and relative fluc protein knockdown.  Knockdown was observed across all 
time points and all seeding densities.  The least densely seeded cells (SD3) received 
a higher dose of siRNA relative to the cells at SD1, as all wells are subject to 50 nM 
siRNA treatment, and therefore increased fluc protein knockdown is observed.  At 96 
h the effect of knockdown was between 75 – 90 %, comparable to levels reported by 
Lewis (Lewis et al. 2002).  Knockdown effects appeared to reduce with time as the 
effect of siRNA treatment was lost; fluc protein levels within the cells were recovering 
and inhibition was no longer observed.  Full recovery to the levels of untreated control 
cells was still not seen at 168 h and approximately 30% knockdown was still observed 
at SD1, and 90% at SD3.  The MDA-MB-231 (Her2-) fluc/Rluc cells demonstrated 
sustained fluc protein knockdown as a result of Lipofectamine® delivered siRNA, 
across all seeding densities and all time points at > 90%.  It was therefore decided 
knockdown could be observed at lower siRNA concentrations and at shorter time 
points.  A single seeding density, SD1 was chosen for both SK-BR-3 (Her2+) fluc/Rluc 
and MDA-MB-231 (Her2-) fluc/Rluc cells, seeding at 5 x104 and 2.5 x104 cells per well 
in a 6-well plate, respectively.  The highest seeding density was chosen so that 
increasing knockdown may be observed in subsequent experiments. 
173 
Cells were subject to treatment with Lipofectamine® delivered siRNA, siRNA 
Cy3 and Scr siRNA, as well as siRNA alone at reduced concentrations between 5 - 25 
nM.  fluc protein knockdown was measured between 24 – 72 h.  Across the low and 
narrow concentration range of siRNA treatments no observable concentration 
dependent effect was seen; fluc protein knockdown was strong at close to 90% 
between 48 - 72 h time points in both cell lines.  Comparable knockdown between 
Lipofectamine® delivered siRNA and siRNA Cy3 was again observed confirming the 
Cy3 modification did not alter siRNA functionality.  No observable knockdown was 
seen with the Scr siRNA control, as expected owing to the lack of fluc gene specificity.  
Increased fluc protein expression observed in the untreated control cells across both 
reporter cell lines across 24 – 72 h indicated the level of toxicity Lipofectamine® exerts 
on the cells as the data is plotted relative to the delivery vehicle.  Increased expression 
was also observed in siRNA only treated cells (minus Lipofectamine®, excepting for 
Figure 5.8; t =72, unlikely to be a real result, or as a result of unhealthy cells), further 
confirming Lipofectamine® cytoxicity. 
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Figure 5.7: Relative fluc Protein Expression in SK-BR-3 (Her2+) fluc/Rluc Reporter Cells via Lipofectamine® Delivered fluc Targeting siRNA as 
Measured via DLR™ Assay. 
fluc targeting siRNA functionality was further confirmed at lower concentrations (5 – 25 nM) across a shorter 72 h time period.  SK-BR-3 (Her2+) fluc/Rluc 
reporter cells were incubated with Lipofectamine® siRNA complexes following 24 h adherence, t = 0.  Results were plotted relative to Rluc, acting as an internal 
control, before fold change in expression was plotted relative to the delivery control.  Time and concentration knockdown effects are observed across both cell 
lines (n=5 in triplicate; error bars represent the standard deviation). 
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Figure 5.8: Relative fluc Protein Expression in MDA-MB-231 (Her2-) fluc/Rluc Reporter Cells via Lipofectamine® Delivered fluc Targeting siRNA as 
Measured via DLR™ Assay. 
fluc targeting siRNA functionality was further confirmed at lower concentrations (5 – 25 nM) across a shorter 72 h time period.  MDA-MB-231(Her2-) fluc/Rluc 
(bottom) reporter cells were incubated with Lipofectamine® siRNA complexes following 24 h adherence, t = 0.  Results were plotted relative to Rluc, acting as 
an internal control, before fold change in expression was plotted relative to the delivery control.  Time and concentration knockdown effects are observed across 
both cell lines (n=5 in triplicate; error bars represent the standard deviation). 
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Optimisation of the DLR™ Assay confirmed the SK-BR-3 (Her2+) fluc/Rluc and 
MDA-MB-231 (Her2-) fluc/Rluc reporter cells lines as a robust model cell system.  The 
reporter lines were shown to be amenable to siRNA target knockdown with functional 
fluc targeting siRNA at concentrations as low as 5 nM.  Protein knockdown was 
observed as early as 24 h and was sustained with continued siRNA incubation to at 
least 72 h in both cell lines.  At higher concentrations (tested at 50 nM) fluc protein 
knockdown was observed until 168 h.  Lipofectamine® delivery although effective, 
demonstrated at least 50% cytotoxicity when compared to cells minus Lipofectamine® 
exposure in some cases. 
5.2.2.3 RT-qPCR 
mRNA expression was measured via RT-qPCR as described previously 
(Section 4.2.1.2.2).  To investigate intracellular siRNA knockdown cells were treated 
with Lipofectamine® complexed siRNA and knockdown was measured up to 72 hours 
post treatment, analogous to protein knockdown measured via the DLR™ assay. 
5.2.2.3.1 Normalisation: GeNorm™ Reference Gene Analysis 
Following RNA extraction, through to cDNA synthesis, errors can arise due to 
differences in extraction and reaction efficiencies.  To accurately compare relative 
gene expression, sample variability needs to minimised, establishing how much cDNA 
is present within the sample.  Normalisation to an endogenously expressed reference 
gene allows for relative comparison.  Reference genes are subject to the same level 
of error as the target gene and therefore provide a relative control.  mRNA integrity of 
the samples is also indicated. 
Reference genes are those found commonly within cells, expressed as part of 
internal pathways, essential to cell metabolism and function (Kozera & Rapacz 2013).  
These genes are not always stably expressed across experimental models.  It was 
therefore essential to establish reference genes that would provide accurate scientific 
comparison.  This had not been essential when confirming the presence of fluc/Rluc 
gene expression previously (Section 4.2.1.2.2). 
A panel of six commonly used internal reference genes, GAPDH, CYC1, B2M, 
ACTB, SDHA and 18S, were tested across both SK-BR-3 (Her2+) and MDA-MB-231 
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(Her2-) cell lines.  Their relative expression was quantified via geNorm™ analysis 
(Figure 5.9) a commercial algorithm used to determine the stability of gene expression 
following RT-qPCR analysis (qBasePLUS 2015).  Reference gene stability measure 
(referred to here as geNORM Score, or M in the literature) is the average pairwise 
variation of a specific reference gene in relation to other reference genes across a 
sample cell population.  Genes with the lowest score (M) are the most stably 
expressed within the tested cell sets (Vandesompele et al. 2002). 
 
Figure 5.9: GeNorm™ Analysis; Average Expression Levels of Endogenous Genes. 
GeNorm™ analysis was initiated on four samples; SK-BR-3 (Her2+) and MDA-MB-231 (Her2-) parental 
and fluc/Rluc reporter cell lines.  Six reference gene targets were assessed; GAPDH, CYC1, B2M, 
ACTB, SDHA and 18S. 
Experimental design was confirmed by the analysis software, and all samples 
were measured in the same run for a given reference target (according to Helleman’s 
sample maximisation strategy (Hellemans et al. 2007).  Candidate reference genes 
were ranked in order of expression level following software analysis of the relative 
expression of each gene, to give the following; ACTB (expressed most consistently 
across cell lines) > GAPDH > B2M > CYC1 >18S > SDHA (expressed least 
consistently between cell lines).  To further improve experimental control it was 
determined that two reference genes would be used, enhancing relative expression 
comparisons.  Therefore ACTB and GAPDH were chosen as the reference gene 
controls for RT-qPCR normalisation. 
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5.2.2.3.2 Relative Quantification; the Delta (Δ) Ct Method 
To gain the most from gene expression data, analysis via relative quantification 
is most useful; assessing the change (delta Δ) in gene level expression, between one 
subject group relative to another.  If PCR reactions work efficiently, for every Ct a 
doubling in cDNA is measured; that is one Ct value is equivalent to a 2-fold change in 
target expression.  Δ Ct is the difference between mean triplicate target Ct values and 
the endogenous control gene Ct values.  To avoid false positives, a difference of at 
least two Ct between specific and non-specific amplification is desired.  For Δ Ct to be 
valid, the amplification efficiencies of the target genes and the endogenous control 
must be approximately equal.  This is determined, measuring the efficiency of cDNA 
amplification via serial dilutions to produce standard curves. 
Delta delta Ct (Δ Δ Ct) is the expression of target mRNA normalised to the 
expression of the endogenous control, reported relative to a positive or untreated 
control.  This method limits inter-assay variability making for more reliable results. 
5.2.2.3.3 Standard Curves 
The efficiency of primers to measure amplification of the target genes (the 
amplicon) was determined by the standard curves for each primer set.  An efficiency 
of 100% would mean that with every PCR cycle, the presence of each amplicon is 
doubled.  The efficiency of the PCR reaction is key to determining reaction sensitivity. 
Reaction efficiency was determined by the gradient of the standard curve 
(Figure 5.10).  A gradient between -3.1 to -3.6 is equivalent to 90 - 110% reaction 
efficiency.  For all genes across both cell lines, efficiency was within close range, 
indicating successful amplification by the designed primers of near to 100%.  Genes 
with a correlation coefficient (R2) close to 1 demonstrate quantitative PCR, 
independent of the amount of RNA template.  Likewise, all genes, across both cell 
lines, all measured R2 values within 0.05 of 1, with a standard deviation between the 
genes and cell lines < 0.01.  Similar Y intercepts between the genes suggested 
analogous sensitivity between gene assays, again apparent in all cases.  fluc and Rluc 
genes demonstrated parallel amplification, with ACTB and GAPDH also equivalent, 
within a range of 0.3.  All four genes demonstrated similar sensitivity across both cell 
179 
lines indicating a robust assay set-up, allowing for relative comparisons between target 
and endogenous control genes. 
 
Figure 5.10: Primer Efficiency Indicative of Quantitative Gene Expression. 
Fluc, Rluc, ACTB, GAPDH gene expression in SK-BR-3 (Her2+) and MDA-MB-231 (Her2-) Reporter 
cell lines was measured to ensure primer efficiency (n=2; error bars represent the standard deviation). 
 
Figure 5.11: Relative Expression Indicative of Quantitative Gene Expression. 
Fluc and Rluc target gene expression relative to ACTB and GAPDH endogenous control genes in SK-
BR-3 (Her2+) fluc/Rluc and MDA-MB-231 (Her2-) fluc/Rluc Reporter cell lines (n=2; error bars represent 
the standard deviation). 
This is also confirmed by the expression of target genes relative to endogenous 
control genes, delta (Δ) Ct (Figure 5.11).  Where the gradient is close to zero, target 
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and reference genes demonstrate comparable efficiencies regarding gene 
amplification. 
Once RT-qPCR primer validation was completed the RT-qPCR assay could be 
used to more quantitatively measure siRNA-mediated fluc mRNA knockdown. 
5.2.2.3.4 Fluc mRNA Knockdown 
Run in parallel with the initial optimisation for protein knockdown, 
Lipofectamine® siRNA complexes were incubated with cells and determined the 
measurable window for fluc mRNA knockdown, preceding that of the fluc protein.  
Quantitative Δ Δ Ct analysis was calculated; the expression of target fluc mRNA 
normalised to the expression of the Rluc endogenous control, and reported relative to 
the Lipofectamine® control.  Therefore true siRNA target knockdown was observed, 
and not that as a result of cell toxicity.  The higher the Δ Ct or Δ Δ Ct the bigger the 
knockdown.  Taking into account that a one Ct value change is equivalent to 2-fold 
change in target expression, 2- Δ Δ Ct indicates the amount of mRNA that remains after 
knockdown.  A lower value demonstrates more efficient siRNA knockdown (Figure 
5.12 and Figure 5.13).  Parallel expression of the endogenous ACTB and GAPDH 
genes (data not shown) indicated mRNA integrity within the samples, ensuring 
comparable concentrations.  Plotting 2- Δ Δ Ct relative to these genes also confirmed 
fluc targeted knockdown, whilst Rluc expression remained comparable). 
Strong fluc mRNA knockdown was observed across all concentrations as a 
result of fluc targeting siRNA treatment.  mRNA knockdown in the SK-BR-3 (Her2+) 
fluc/Rluc cells appeared less at the later time point ~60%, potentially indicating 
recovery of mRNA levels, which was matched by the recovery of the fluc protein seen 
at later time points also.  Again knockdown in the MDA-MB-231 (Her2-) fluc/Rluc cells 
appeared slightly more sustained, with knockdown between 80 – 90%.  The effect of 
siRNA treatment across the 25 - 200 nM range did not appear to be concentration 
dependent. 
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Figure 5.12: Relative fluc mRNA Knockdown in SK-BR-3 (Her2+) fluc/Rluc Reporter Cells via 
Lipofectamine® Delivered fluc Targeting siRNA as Measured via RT-qPCR. 
fluc targeting siRNA was confirmed to demonstrate mRNA knockdown less than 200 nM concentrations 
across a 48 – 72 h incubation.  SK-BR-3 (Her2+) fluc/Rluc reporter cells were incubated with 
Lipofectamine® siRNA complexes following 24 h adherence, t = 0.  Results were plotted relative to 
Rluc, acting as an internal control, before fold change in expression was plotted relative to the delivery 
control (n=2 in triplicate ; error bars represent the standard deviation). 
 
Figure 5.13: Relative fluc mRNA Knockdown in MDA-MB-231 (Her2-) fluc/Rluc Reporter Cells via 
Lipofectamine® Delivered fluc Targeting siRNA as Measured via RT-qPCR. 
fluc targeting siRNA was confirmed to demonstrate mRNA knockdown less than 200 nM concentrations 
across a 48 – 72 h incubation.  MDA-MB-231 (Her2-) fluc/Rluc reporter cells were incubated with 
Lipofectamine® siRNA complexes following 24 h adherence, t = 0.  Results were plotted relative to 
Rluc, acting as an internal control, before fold change in expression was plotted relative to the delivery 
control (n=2 in triplicate; error bars represent the standard deviation). 
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5.2.3 PP-75 Intracellular Delivery 
5.2.3.1 PP-75 AFC Intracellular Localisation 
Breast cancer cells were treated with PP-75 AFC to visualise PP-75 uptake, 
internalisation and subcellular fate.  AFC therefore acted as a novel model payload 
being delivered into the breast cancer cells via conjugation onto PP-75. 
5.2.3.1.1 Laser Scanning Confocal Microscopy (LSCM) 
Confocal microscopy was used to preliminary confirm PP-75 uptake and 
functional activity (Figure 5.14).  Diffuse staining of PP-75 AFC (green) was observed 
within the MDA-MB-231 (Her2-) fluc/Rluc cells after only 1 h incubation.  This was 
indicative of efficient PP-75 AFC intracellular delivery.  PP-75 AFC was not restricted 
to within the endo/lysosomal trafficking pathway but had undergone endosomal 
escape due to PP-75 pH-responsive activity.  A lack of co-localisation with the 
Lysotracker® (red) also demonstrated release from the endosome and delivery into 
the cytoplasm, within the intact cell membrane (shown by the phase contrast image).  
Uptake by the majority of the cell population was also apparent.  PP-75 AFC was still 
present within the cells after 24 h incubation (Figure 5.15).  Chen (Chen et al. 2009c, 
Liechty et al. 2009, Ho et al. 2011) published similar results demonstrating delivery of 
PP-75 FITC, as well as PP-75 delivery of the membrane impermeable dye calcein into 
HeLa cells (Chen et al. 2009c).  The successful delivery of PP-75 AFC into MDA-MB-
231 cells demonstrates the wider application of PP-75 a drug delivery system able to 
enhance delivery in a variety of cell types.  
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Figure 5.14: PP-75 AFC Intracellular Uptake and Localisation following 1 h Treatment plus 1 h 
incubation with MDA-MB-231 (Her2-) fluc/Rluc cells. 
P-75 AFC was delivered to MDA-MB-231 (Her2-) fluc/Rluc reporter cells to investigate intracellular 
uptake and intracellular localisation.  Cells were treated with 0.5 mg/mL (8.74 µM) PP-75 AFC (green) 
for 1 h and imaged after a further 1 h incubation.  Lysotracker® Red (red) was also incubated with the 
cells as an endosomal and lysosomal marker.  Diffuse staining of PP-75 AFC was observed 
demonstrating release from the endo-lysosomal pathway and delivery into the cytoplasm of the MDA-
MB-231 (Her2-) fluc/Rluc cells.  A phase contrast image (grey) and an overlay panel of PP-75 AFC and 
Lysotracker® Red have been included to demonstrate co-localisation.  Images are representative of 
multiple fields of view across replicate wells; scale bar represents 25 µm. 
 
Figure 5.15: PP-75 AFC Intracellular Uptake and Localisation following 1 h Treatment plus 24 h 
incubation with MDA-MB-231(Her2-) fluc/Rluc cells. 
PP-75 AFC was delivered to MDA-MB-231 (Her2-) fluc/Rluc reporter cells to investigate intracellular 
uptake and intracellular localisation.  Cells were treated with 0.5 mg/mL (8.74 µM) PP-75 AFC (green) 
for 1 h and imaged after a further 24 h incubation.  Lysotracker® Red (red) and Hoechst (blue) were 
also incubated with the cells as markers of endosomes/lysosomes and the nucleus respectively.  Diffuse 
staining of PP-75 AFC was observed demonstrating release from the endo-lysosomal pathway and 
delivery into the cytoplasm of the MDA-MB-231 fluc/Rluc cells.  A phase contrast image (grey) and an 
overlay panel of PP-75 AFC and Lysotracker® Red and Hoechst have been included to demonstrate 
co-localisation.  Images are representative of multiple fields of view across replicate wells; scale bar 
represents 50 µm. 
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5.2.3.1.2 Flow Cytometry 
Flow cytometry is a technique that measures and analyses the characteristics 
of cells as they flow through a beam of light.  Fluorescently labelled compounds absorb 
light energy at characteristic wavelengths, the transition of light energy results in 
fluorescence. 
PP-75 AFC treated MDA-MB-231 (Her2-) fluc/Rluc cells demonstrated a shift 
in population due to increased fluorescence, when compared to untreated cells.  This 
indicatied PP-75 AFC uptake and internalisation by the cells (Figure 5.16). 
 
Figure 5.16: PP-75 AFC Intracellular Uptake Measured via Flow Cytometry. 
MDA-MB-231 (Her2-) fluc/Rluc cells were treated with PP-75 AFC to investigate uptake and 
internalisation of PP-75.  Cells were treated with 0.5 mg/mL (8.74 µM) PP-75 AFC (green) for 1 h and 
imaged after a further 1 h incubation.  Treated cells were also held at 4 ºC to prevent endocytosis, to 
investigate the route of PP-75 uptake in MDA-MB-231 cells.  PP-75 AFC treated cells were compared 
to untreated control (UTC) cells at both 4 and 37 ºC.  The overlaid histograms show the shift in 
population; cells treated with PP-75 AFC at 37 ºC demonstrating a shift due to the increase in 
fluorescence, also indicated by the shift in geometric mean. 
Cells were also held at 4 °C to prevent internalisation via endocytosis to confirm 
the route of uptake.  These cells demonstrated no shift in fluorescence, indicating PP-
75 AFC was not internalised at 4 ºC, Khormaee (Khormaee et al. 2012) previously 
reported a similar result in glioma cells; indicating PP-75 uptake may be similar across 
cell types.  Any external fluorescence present within the samples was quenched via 
trypan blue washing.  This ensured detected fluorescence was due to the internal 
uptake of PP-75 AFC and not that which was within the cell media that had not been 
internalised.  The geometric mean indicates the central tendency of the cell population, 
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therefore the shift in geometric mean indicates the differences between the cell 
populations; those that fluoresce due to PP-75 AFC uptake compared to those that 
have not been treated with polymer. 
Fluorescent activated cell sorting further confirms uptake of PP-75 AFC 
compared to untreated control cells.  PP-75 internalisation was confirmed to be via 
endocytosis, indicated by the temperature dependent uptake observed. 
5.2.3.1.3 OPERA Imaging 
Further imaging of PP-75 AFC internalisation was carried out via the OPERA® 
set up, offering improved image resolution in comparison to the preliminary LSCM 
imaging.  Imaging of PP-75 uptake was carried out in both SK-BR-3 (Her2+) fluc/Rluc 
and MDA-MD-231 (Her2-) fluc/Rluc cells (Figure 5.17, Figure 5.18, Figure 5.19 and 
Figure 5.20). 
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Figure 5.17: PP-75 AFC Intracellular Uptake and Localisation following 1, 6 and 24 h Treatments to SK-BR-3 (Her2+) fluc/Rluc Cells. 
PP-75 AFC was delivered to SK-BR-3 (Her2+) fluc/Rluc reporter cells to investigate intracellular uptake and intracellular localisation.  Cells were treated with 
0.5 mg/mL (8.74 µM) PP-75 AFC (green), free AFC at equivalent concentration and compared to untreated control cells (UTC) and imaged after incubation.  
Cells were fixed with 3.7% PFA post-treatment. Hoechst (blue) was also incubated with the cells as a nuclear marker.  Scale bar represents 50 µm. 
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Figure 5.18: PP-75 AFC Intracellular Uptake and Localisation following 1, 6 and 24 h Treatments to MDA-MB-231 (Her2-) fluc/Rluc Cells. 
PP-75 AFC was delivered to MDA-MB-231 (Her2-) fluc/Rluc reporter cells to investigate intracellular uptake and intracellular localisation.  Cells were treated 
with 0.5 mg/mL (8.74 µM) PP-75 AFC (green), free AFC at equivalent concentration and compared to untreated control cells (UTC) and imaged after incubation.  
Cells were fixed with 3.7% PFA post-treatment. Hoechst (blue) was also incubated with the cells as a nuclear marker. Scale bar represents 50 µm. 
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Diffuse staining of PP-75 AFC (green) was observed demonstrating PP-75 AFC 
release from the endo-lysosomal pathway and delivery into the cytoplasm of the SK-
BR-3 (Her2+) fluc/Rluc and MDA-MB-231 (Her2-) fluc/Rluc cells.  PP-75 AFC delivery 
increased with time between 1 – 6 h, demonstrated by more diffuse and intense AFC 
distribution.  At 24 h PP-75 AFC appeared less diffuse, with more intense punctate 
staining, this suggested PP-75 AFC was being recycled back out of the cells.  Delivery 
of free AFC (without PP-75) did not result in uptake and internalisation as 
demonstrated by no fluorescence within the cells.  This was comparable to the 
untreated control (UTC) cells, also demonstrating no intracellular fluorescence. 
The addition of CellMask™ (Figure 5.19 and Figure 5.20) further confirms 
where PP-75 AFC is located intracellulary. 
The effect of washing the cells post PP-75 AFC treatment was investigated 
(Figure 5.21).  Washed cells demonstrated less diffuse staining, most apparent at 6 h.  
This was expected as continual PP-75 AFC uptake could not occur.  PP-75 AFC 
concentrations at 24 h appear similar in both washed and unwashed cells indicating 
this may be the maximum the cells could internalise.  Enhanced staining at 6 h as 
seen in all previous studies may have been due to saturated uptake. 
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Figure 5.19: PP-75 AFC Intracellular Uptake and Localisation following 1, 6 and 24 h Treatments to SK-BR-3 (Her2+) fluc/Rluc Cells. 
PP-75 AFC was delivered to SK-BR-3 (Her2+) fluc/Rluc reporter cells to investigate intracellular uptake and intracellular localisation.  Cells were treated with 
0.5 mg/mL (8.74 µM) PP-75 AFC (green), free AFC at equivalent concentration and compared to untreated control cells (UTC) and imaged after incubation.  
Cells were fixed with 3.7% PFA post-treatment. Hoechst (blue) and CellMask™ Deep Red (pink) were also incubated with the cells as a marker of the nucleus 
and the cell respectively.  Scale bar represents 50 µm. 
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Figure 5.20: PP-75 AFC Intracellular Uptake and Localisation following 1, 6 and 24 h Treatments to MDA-MB-231 (Her2-) fluc/Rluc Cells. 
PP-75 AFC was delivered to MDA-MB-231 (Her2-) fluc/Rluc reporter cells to investigate intracellular uptake and intracellular localisation.  Cells were treated 
with 0.5 mg/mL (8.74 µM) PP-75 AFC (green), free AFC at equivalent concentration and compared to untreated control cells (UTC) and imaged after incubation.  
Cells were fixed with 3.7% PFA post-treatment. Hoechst (Blue) and CellMask™ Deep Red (Pink) were also incubated with the cells as a marker of the nucleus 
and the cell respectively.  Scale bar represents 50 µm. 
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Figure 5.21: PP-75 AFC Intracellular Uptake and Localisation following 1, 6 and 24 h Treatments 
to SK-BR-3 (Her2+) fluc/Rluc Cells. 
PP-75 AFC was delivered to SK-BR-3 (Her2+) fluc/Rluc reporter cells to investigate intracellular uptake 
and intracellular localisation.  Cells were treated with 0.5 mg/mL (8.74 µM) PP-75 AFC (green) and 
imaged after incubation.  Cells were fixed with 3.7% PFA post-treatment. Hoechst (blue) was also 
incubated with the cells as a nuclear marker.  Cells were washed post incubation to investigate the 
effects of uptake.  Scale bar represents 50 µm. 
5.2.3.2 PP-75 siRNA Conjugate Intracellular Localisation 
Following confirmation of PP-75 induced cell uptake, cells were treated with 
PP-75 siRNA Cy3 conjugates in order to visualise uptake, internalisation and 
subcellular fate of the polymer plus payload (Figure 5.22). 
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Figure 5.22: Intracellular Localisation of PP-75 siRNA Cy3 Conjugates at 1, 6 and 24 h Post 
Treatment to SK-BR-3 fluc/Rluc and MDA-MB-231 fluc/Rluc Cells. 
PP-75 siRNA Cy3 (yellow) was delivered to SK-BR-3 (Her2+) fluc/Rluc and MDA-MB-231 (Her2-) 
fluc/Rluc reporter cells to investigate intracellular uptake and intracellular localisation.  Cells were fixed 
with 3.7% PFA post-treatment.  Hoechst (blue) was also incubated with the cells as a nuclear marker.  
Scale bar represents 50 µm. 
PP-75 siRNA Cy3 conjugates were observed in the SK-BR-3 (Her2+) fluc/Rluc 
cell wells, conjugate presence appeared to decrease with time.  No PP-75 siRNA Cy3 
was observed in the MDA-MB-231 (Her2-) fluc/Rluc cells.  Further work would be 
required to confirm more robustly if the PP-75 siRNA conjugates had been taken up 
by either reporter cell line.  PP-75 siRNA Cy3 treated cells were incubated with the 
endosomal and lysosomal markers (Rab5, Rab7 and LAMP1), however, polymer 
treatment appeared to hinder the uptake of these stains and they were not visible 
T = 1
T = 6
T = 24
PP-75 siRNA Cy3 Conjugate 
SK-BR-3 (Her2+)  fluc/Rluc cells
PP-75 siRNA Cy3 Conjugate 
MDA-MB-231 (Her2-) fluc/Rluc cells
50 μm
50 μm
50 μm
50 μm
50 μm
50 μm
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within the cells (data not shown).  PP-75 siRNA localisation within the cells could 
therefore not be confirmed visually. 
5.2.3.3 PP-75 mediated Intracellular siRNA Knockdown 
5.2.3.3.1 Dual Luciferase® Reporter Assay 
To investigate PP-75 enhanced siRNA knockdown, cells were treated with PP-
75 mixed with siRNA (Figure 5.23).  Protein knockdown was measured via the DLR™ 
assay, fluc knockdown was plotted relative to Rluc to indicate siRNA targeted 
knockdown. 
 
Figure 5.23: Relative fluc Protein Knockdown in fluc/Rluc Reporter Cells via PP-75 plus fluc 
targeting siRNA (mixed components). 
fluc targeting siRNA mixed with PP-75 was delivered to cells at 5 – 25 nM across a 72 h time period.  
SK-BR-3 (Her2+) fluc/Rluc (top) and MDA-MB-231 (Her2-) fluc/Rluc (bottom) reporter cells were 
incubated with PP-75 siRNA mixture and Lipofectamine® siRNA complexes following 24 h adherence, 
t = 0.  Results were plotted relative to Rluc, acting as an internal control, before fold change in 
expression was plotted relative to the delivery control.  Time dependent knockdown effects are 
observed across both cell lines with Lipofectamine® siRNA complexes, however no knockdown is 
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observed via PP-75 when mixed with the siRNA (n=3 in triplicate; error bars represent the standard 
deviation). 
As previously observed Lipofectamine® delivered siRNA resulted in time 
dependent knockdown of the fluc protein, confirming use of the SK-BR-3 (Her2+) 
fluc/Rluc and MDA-MB-231 (Her2-) fluc/Rluc reporter cells within the DLR™ assay.  
Treatment of cells with siRNA alone and PP-75 mixed with siRNA did not result in 
siRNA knockdown of the fluc protein, and was comparable to that of the untreated 
control cells (UTC).  This was not unexpected and had been previously reported in 
glioma cells (Khormaee et al. 2012).  PP-75 plus payloads must be co-localised within 
the same endosome in order to facilitate PP-75 induced pH-responsive endosomal 
escape of the siRNA.  At neutral pH both PP-75 and siRNA were negatively charged 
and mixing of the PP-75 plus siRNA payload did not result in complexation as with 
Lipofectamine® plus siRNA.  It is therefore likely that PP-75 and siRNA did not 
associate when mixed and underwent electrostatic repulsion.  If not in close proximity 
it was unlikely the pH-responsive properties of PP-75 can be utilised in siRNA delivery. 
Conjugation of siRNA onto PP-75 was therefore proposed to enhance 
association of polymer plus siRNA payload ensuring co-uptake via endocytosis (Figure 
5.24).  Lipofectamine® delivered siRNA again resulted in the successful time 
dependent knockdown of fluc protein confirming the DLR™ assay as robust.  
Treatment of cells with siRNA alone was comparable to that of the untreated control 
cells, again confirming siRNA could not enter the cells without an efficient delivery 
vehicle, PP-75 conjugated to scrambled siRNA (non-targeting) also did not result in 
targeted fluc protein knockdown as expected. 
 
PP-75 conjugated to fluc targeting siRNA at the same concentration as 
Lipofectamine® plus siRNA did not result in fluc protein knockdown.  The addition of 
supplementary PP-75 to the PP-75 fluc siRNA conjugates also did not result in fluc 
protein knockdown. 
195 
 
Figure 5.24: Relative fluc Protein Knockdown in SK-BR-3 (Her2+) fluc/Rluc and MDA-MB-231 (Her2-) fluc/Rluc Reporter Cells via PP-75 Conjugated 
fluc Targeting siRNA. 
PP-75 fluc siRNA conjugates were delivered at 5 – 25 nM across 72 h time period.  SK-BR-3 (Her2+) fluc/Rluc (top) and MDA-MB-231 (Her2-) fluc/Rluc (bottom) 
reporter cells were incubated with PP-75 siRNA conjugates and Lipofectamine® siRNA complexes following 24 h adherence, t = 0.  Results were plotted relative 
to Rluc, acting as an internal control, before fold change in expression was plotted relative to the delivery control.  siRNA delivery was not observed via PP-75 
conjugates, or with the supplemented treatment, top-up with additional PP-75 (n=5 in triplicate; error bars represent the standard deviation). 
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To further investigate why PP-75 siRNA conjugates did not result in fluc siRNA 
knockdown SK-BR-3 (Her2+) fluc/Rluc and MDA-MD-231 (Her2-) fluc/Rluc cells were 
treated with PP-75 siRNA conjugates delivered via Lipofectamine® to determine if fluc 
targeting siRNA was still functional post conjugation with PP-75 (Figure 5.25). 
 
Figure 5.25: Relative fluc Protein Knockdown in SK-BR-3 (Her2+) fluc/Rluc and MDA-MB-231 
(Her2-) fluc/Rluc Reporter Cells via PP-75 fluc Targeting siRNA Conjugates. 
fluc targeting siRNA conjugated with PP-75 was delivered to cells at 500 nM and at 25 nM across a 72 
h time period.  SK-BR-3 (Her2+) fluc/Rluc (left) and MDA-MB-231 (Her2-) fluc/Rluc (right) reporter cells 
were incubated with PP-75 siRNA conjugates and compared to Lipofectamine® siRNA complexes 
following 24 h adherence, t = 0.  Results were plotted relative to Rluc, acting as an internal control, 
before fold change in expression was plotted relative to the delivery control.  Minimal knockdown was 
observed via PP-75 siRNA conjugates at high concentration 500 nM, whilst knockdown was observed 
at the lower concentration 25 nM with the addition of Lipofectamine® (n=3; error bars represent the 
standard deviation). 
PP-75 conjugated to fluc targeting siRNA, when delivered in combination with 
Lipofectamine® demonstrated comparable knockdown to siRNA delivery when 
complexed with Lipofectamine®.  This confirmed the fluc targeting siRNA was 
functional post conjugation with PP-75.  PP-75 siRNA conjugates were also delivered 
to the cells at higher concentration to establish if PP-75 delivery concentration required 
further optimisation.  Neither treatment with PP-75 siRNA conjugates at higher 
concentration (500 nM) or with additional PP-75 top-up treatment (10 uM) resulted in 
fluc protein knockdown, these results were comparable to siRNA alone at low and high 
concentrations tested. 
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From these results it was unclear as to why PP-75 siRNA conjugates did not 
result in fluc protein knockdown.  Discrepancies in intracellular uptake between PP-75 
AFC and PP-75 siRNA conjugates due to the differing molecular weights and charge 
of the effective payloads may provide an explanation.  AFC is a small molecule with 
low molecular weight and no charge, when grafted onto PP-75 at low percentage it is 
unlikely to affect the polymer properties.  By comparison siRNA is a much larger 
payload with a molecular weight approximately a quarter that of PP-75; siRNA also 
carries a negative charge.  It was therefore likely that the finely tuned hydrophobicity-
hydrophilicity balance of PP-75 became altered when larger and negatively charged 
siRNA payloads were conjugated.  Charged hydrophilic payloads are likely to shift the 
hydrophobicity-hydrophilicity balance in favour of becoming more hydrophilic, and 
therefore altering the critical pH at which endosomal release occurs; shifting it back in 
line with PLP, to the more acidic pH of the lysosomes.  Studies have also shown that 
cellular internalisation is size-dependent; polymers with higher molecular weights are 
taken up by cells more slowly than those with lower molecular weight (Pratten et al. 
1982, Lloyd et al. 1984).  It was possible that the knockdown window optimised for 
delivery of siRNA complexed to Lipofectamine®, and the delivery of PP-75 AFC was 
too short for delivery of the much larger molecular weight PP-75 siRNA conjugates. 
Owing to the effective knockdown in combination with Lipofectamine® it was 
possible that PP-75 siRNA conjugates were not able to effectively enter the SK-BR-3 
(Her2+) fluc/Rluc or MDA-MB-231 (Her2-) fluc/Rluc reporter cells.  To improve cell 
uptake the attachment of a soluble, high affinity targeting ligand onto PP-75 was 
proposed. 
5.3 Conclusions 
Laser scanning and high content confocal microscopy were used to confirm cell 
uptake and PP-75 functionality, visualising the intracellular delivery and diffuse 
staining of AFC conjugated to PP-75 within SK-BR-3 (Her2+) fluc/Rluc and MDA-MB-
231 (Her2-) fluc/Rluc reporter cells.  Co-localisation with intracellular organelle stains 
demonstrated release from the endosomal membrane and delivery into the cytoplasm, 
within the intact cell membrane.  Flow cytometry was also used to further confirm 
internalisation of PP-75 AFC compared to untreated control cells.  Uptake was 
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confirmed to be via endocytosis, as no PP-75 AFC internalisation occurred at 4 ºC.  
AFC acted as a model payload and successfully demonstrated application of the PP-
75 delivery mechanism to deliver AFC into breast cancer cells.  As a novel compound, 
PP-75 AFC underwent cell uptake and internalisation prior to demonstrating 
endosomal escape and delivery to the cell interior. 
siRNA target-gene knockdown, and therefore siRNA functionality, was 
confirmed following Lipofectamine® delivery of fluc targeting siRNA.  RT-qPCR was 
used to measure cellular mRNA concentrations of fluc and Rluc; relative to 
endogenously expressed reference genes ACTB and GAPDH, which were validated 
as consistently expressed within the two reporter cell lines.  fluc protein knockdown 
was demonstrated in the Dual-Luciferase® Reporter assay, providing a visually 
quantitative read-out, expressed relative to the Rluc protein that provided an internal 
control.  Both assays reported targeted knockdown of firefly luciferase, relative to non-
specific cytotoxicity (change in Renilla luciferase expression).  The results 
demonstrated time dependent intracellular knockdown following treatments using 5 – 
50 nM siRNA concentrations over 24 - 168 h.  Fluorescently labelled Cy3 siRNA was 
observed within the cells following treatment when complexed with Lipofectamine®. 
Despite effective delivery of PP-75 AFC, the PP-75 fluc targeting siRNA 
conjugates did not appear to enter the cells unaided.  PP-75 siRNA conjugates were 
confirmed to have retained payload functionality when delivered alongside 
Lipofectamine® demonstrating comparable levels of knockdown when delivered at 
equivalent siRNA concentrations.  However PP-75 siRNA conjugates alone, and with 
additional PP-75 top-up, attempting to aid endosomal escape, did not result in fluc 
protein knockdown as measured by the DLR™ assay.  The pharmacokinetics and 
pharmacodynamics of drugs are known to be altered following conjugation with 
polymers, also altering drug biodistribution (Kopeček et al. 2000).  It is therefore likely 
the conjugation of payloads onto PP-75 altered polymer properties.  The OPERA® 
images of the cells treated with PP-75 siRNA Cy3 conjugates suggested a lack of 
uptake by MDA-MB-231 fluc/Rluc (Her2-) cells and although some Cy3 is visible in the 
SK-BR-3 fluc/Rluc (Her2+) cells the conjugate presence appeared to decrease with 
time.  Gilleron (Gilleron et al. 2013) has described that therapeutic doses of siRNA are 
not effectively released from endosomes despite endosomal bursting or membrane 
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permiabilisation.  Release is calculated at approximately 1 - 2% and is described to be 
restricted to a limited number of siRNAs escaping from multiple endosomes.  siRNA 
release is described as not detectable within the cytoplasm by fluorescence 
microscopy. 
PP-75 siRNA conjugate delivery therefore remained to be confirmed within the 
breast cancer cell lines studied.  The attachment of a soluble, high affinity targeting 
ligand onto PP-75 was investigated with the hope of improving cell uptake.  
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Chapter 6 
6 PP-75 Targeted Delivery 
This chapter describes the selection and validation of target-specific DARPin 
moieties for conjugation onto the PP-75 polymer.  Enhancing the affinity of PP-75 
toward the extracellular membrane was proposed to facilitate targeted delivery of PP-
75 conjugated siRNA payloads whilst also promoting intracellular uptake.  A Her2 
targeting DARPin sequence, demonstrating picomolar binding affinity for the Her2 
receptor (Zahnd et al. 2007b), was chosen for conjugation with PP-75 to target Her2 
expressing cells.  A non-specific negative control DARPin sequence was also isolated 
for comparison.  Introduction of a free cysteine to the carboxy termini of both Her2-
positive and negative-binding DARPin sequences facilitated conjugation onto PP-75.  
DARPin binding specificity was demonstrated by ELISA detection, and the ability to 
reliably detect DARPin presence was investigated using an anti-His tag antibody.  
DARPin binding functionality post conjugation to PP-75 was demonstrated as well as 
the affinity of the Her2-binding DARPin for the Her2 receptor.  The work in this chapter 
offers preliminary findings and requires further investigation and clarification.  
Conclusions have been drawn by discussing the potential for PP-75 DARPin conjugate 
targeted delivery of payloads with application to targeted delivery and enhanced cell 
uptake. 
6.1 Introduction 
Membrane-bound receptor proteins displayed on the surface of disease 
specific target cells can be exploited to enhance endocytotic cell uptake.  The inclusion 
or attachment of high affinity ligands as part of intracellular delivery systems may 
therefore regulate cellular recognition and encourage intracellular localisation 
(Bareford & Swaan 2007).  Active targeting of delivery systems, plus their payloads, 
can overcome passive diffusion effects, whilst also circumventing delivery to non-
target tissues.  Targeted delivery can avoid major hurdles in non-specific toxicity, poor 
distribution and low dosage of therapeutic payloads. 
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The addition of human epidermal growth factor (Her2) targeting ligands onto 
PP-75 was proposed to facilitate the targeted delivery of PP-75 fluc targeting siRNA 
conjugates towards the SK-BR-3 (Her2+) fluc/Rluc reporter cell line, relative to MDA-
MD-231(Her2-) cells.  The addition of a targeting ligand may improve cell uptake, 
therefore offering a potential solution to the lack of PP-75 siRNA conjugate 
functionality observed previously (Chapter 5).  PP-75 delivery functionality is 
dependent on its entry into the endosomal trafficking pathway; acidification of 
endosomal vesicles effectively activates the membrane activity of the polymeric carrier 
(Rozema et al. 2007, Sonawane et al. 2003).  When delivered via Lipofectamine® PP-
75 siRNA conjugates were able to facilitate fluc protein knockdown.  This hypothesis 
was developed using the high affinity designed ankyrin repeat protein (DARPin) G3, 
published by Zahnd, which has picomolar affinity for the Her2 receptor (Zahnd et al. 
2007b, Zahnd et al. 2010). 
DARPin scaffolds provide viable and alternative targeting ligands, due to their 
small size, high stability and ease of expression.  The potential for cell targeting is 
reported as proportional to ligand binding affinity; therefore the addition of high affinity 
DARPins onto PP-75 was proposed to enhance tumour targeting (Zahnd et al. 2010).  
As a result of their low molecular weight, DARPins are able to readily penetrate 
tumours, and demonstrate increased tumour accumulation in contrast to non-target 
tissues (a high tumour-to-tissue ratio) when in vivo.  However, these tumour targeting 
properties may be altered when conjugated to the high molecular weight PP-75. 
The G3 Her2-binding DARPin consists of two randomised repeat modules, in 
contrast to the more commonly expressed three repeat DARPin structures (Zahnd et 
al. 2007b).  Each ankyrin repeat module consists of two alpha-helices, flanked by 
amino and carboxy terminal, capping ankyrin repeats (also with alpha helical 
secondary structures).  The complete G3 Her2-binding DARPin structure therefore 
comprises a total of eight alpha helices made of 136 residues.  The central, designed 
(and therefore variable) ankyrin repeats provide the sequence diversity that facilitates 
DARPin binding specificity (Zahnd et al. 2007b, Zahnd et al. 2010). 
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6.2 Results and Discussion 
DARPin expression and functionality was investigated prior to attachment onto 
PP-75 to ensure Her2-specific binding was observed in SK-BR-3 (Her2+) fluc/Rluc 
cells, and not in MDA-MB-231(Her2-) fluc/Rluc cells.  To confirm DARPin binding was 
not as a result of a non-specific interaction with the extracellular membrane, a 
negative-binding DARPin was screened and provided a control ligand.  The non-
specific negative control DARPin was also and tested prior to conjugation; and 
confirmed a lack of binding with SK-BR-3 (Her2+) fluc/Rluc and MDA-MB-231 (Her2-) 
fluc/Rluc reporter cells. 
DARPin sequences were expressed from a DARPin phage library and sub-
cloned into alternative expression vectors to facilitate incorporation of linker residues 
and His-tag purification.  Gel electrophoresis confirmed the DARPin sequences were 
accurately expressed at their correct molecular weights.  ELISA binding screens 
determined DARPin affinity and specificity following conjugation with PP-75.  DARPin 
detection was assessed to establish no loss of function; therefore facilitating further 
investigation into Her2-receptor mediated uptake. 
6.2.1 DARPin Expression 
The screened DARPin library comprises 1012 phage, with 109 DARPin diversity.  
440 unselected DARPins were sequenced from the library and 7 were identified to 
contain two-repeats rather than three (Table 6.1).  The two-repeat DARPin sequences 
were selected as potential negative control DARPins, and provided a more accurate 
comparison to the selected two-repeat Her2 binding DARPin (Zahnd et al. 2007b). 
A primary phage ELISA screen was performed on SK-BR-3 (Her2+) fluc/Rluc 
and MDA-MB-231 (Her2-) fluc/Rluc cells (Figure 6.1), comparing the two-repeat 
DARPin sequences to CEA6, a human carcinoembryonic antigen (CEA)-specific scFv 
acting as a baseline negative-binding control.  This better indicated the negative-
binding and potential non-specific interactions of the negative-binding control 
DARPins. 
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Table 6.1: Negative-Binding Control DARPin Sequences from DARPin Library Screen. 
 
Seven two-repeat DARPin sequences were isolated from 440 picked colonies and compared to the 
Her2 binding DARPin sequence. Highlighted base pairs reveal sequence diversity. 
DARPin Sequence
Her2-binding - - - D L G K K L L E A A R A G Q D D E V R I L M A N G A D V N A
5G G3 Neg - - - D L G K K L L E A A R A G Q D D E V R I L M A N G A D V N A
5H C3 Neg - - - D L G K K L L E A A R A G Q D D E V R I L M A N G A D V N A
5I A6 Neg - - - D L G K K L L E A A R A G Q D D E V R I L M A N G A D V N A
5I G8 Neg - - - D L G K K L L E A A R A G Q D D E V R I L M A N G A D V N A
5I H1 Neg - - - D L G K K L L E A A R A G Q D D E V R I L M A N G A D V N A
5J G4 Neg - - - D L G K K L L E A A R A G Q D D E V R I L M A N G A D V N A
5K D1 Neg - - - D L G K K L L E A A R A G Q D D E V R I L M A N G A D V N A
DARPin Sequence
Her2-binding K D E Y G L T P L Y L A T A H G H L E I V E V L L K N G A D V N A
5G G3 Neg H D Y L G F T P L H L A A L Y G H L E I V E V L L K Y G A D V N A
5H C3 Neg L D S M G L T P L H L A A Y H G H L E I V E V L L K Y G A D V N A
5I A6 Neg M D H A G A T P L H L A A H D G H L E I V E V L L K H G A D V N A
5I G8 Neg N D S D G Y T P L H L A A W M G H L E I V E V L L K Y G A D V N A
5I H1 Neg R D S M G Y T P L H L A A L M G H L E I V E V L L K Y G A D V N A
5J G4 Neg H D H W G S T P L H L A A R L G H L E I V E V L L K Y G A D V N A
5K D1 Neg T D Q F G L T P L H L A A L F G H L E I V E V L L K Y G A D V N A
DARPin Sequence
Her2-binding V D A I G F T P L H L A A F I G H L E I A E V L L K H G A D V N A
5G G3 Neg R D H H G S T P L H L A A T R G H L E I V E V L L K N G A D V N A
5H C3 Neg H D T W G K T P L H L A A M W G H L E I V E V L L K Y G A D V N A
5I A6 Neg Y D S A G I T P L H L A A H H G H L E I V E V L L K Y G A D V N A
5I G8 Neg H D L A G S T P L H L A A W W G H L E I V E V L L K H G A D V N A
5I H1 Neg L D L T G S T P L H L A A I N G H L E I V E V L L K H G A D V N A
5J G4 Neg V D N R G H T P L H L A A Q T G H L E I V E V L L K H G A D V N A
5K D1 Neg H D A M G Q T P L H L A A Y H G H L E I V E V L L K Y G A D V N A
DARPin Sequence
Her2-binding Q D K F G K T A F D I S I G N G N E D L A E I L Q K L - - - - - -
5G G3 Neg Q D K F G K T A F D I S I D N G N E D L A E I L Q K L - - - - - -
5H C3 Neg Q D K F G K T A F D I S I D N G N E D L A E I L Q K L - - - - - -
5I A6 Neg Q D K F G K T A F D I S I D N G N E D L A E I L Q K L - - - - - -
5I G8 Neg Q D K F G K T A F D I S I D N G N E D L A E I L Q K L - - - - - -
5I H1 Neg Q D K F G K T A F D I S I D N G N E D L A E I L Q K L - - - - - -
5J G4 Neg Q D K F G K T A F D I S I D N G N E D L A E I L Q K L - - - - - -
5K D1 Neg Q D K F G K T A F D I S I D N G N E D L A E I L Q K L - - - - - -
N-Cap
Repeat 1
Repeat 2
C-Cap
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Figure 6.1: Phage ELISA Screen of Negative-Binding DARPin Sequences. 
DARPin sequences were screened in a phage ELISA format to test for non-specific binding by negative-
binding control DARPin clones, whilst confirming Her2 binding by the positive DARPin.  Binding signal 
was calculated relative to the CEA6 negative-binding scFv control, a 3-fold increase in signal is routinely 
recognised as a hit; therefore anything below 3-fold indicated a lack of DARPin affinity, therefore 
negative binding.  Potential non-specific binding was observed where fold increases were close to or 
greater than 3-fold (highlighted dark green). 
The DARPins displayed on the surface of the phage were incubated with SK-
BR-3 fluc/Rluc (Her2+) and MDA-MB-231 (Her2-) cells, DARPin binding affinity for the 
Her2 antigen was measured.  A 3-fold increase in binding, relative to the CEA6 
negative-binding scFv control indicated a target hit; therefore values less than a 3-fold 
increase were indicative of low affinity or negative-binding against the SK-BR-3 
(Her2+) fluc/Rluc and MDA-MD-231 (Her2-) fluc/Rluc cell lines.  The majority of clones 
demonstrated very little affinity for the fluc/Rluc reporter cells, with less than a 1.5-fold 
increase relative to the standard CEA6 negative-binding control (highlighted red).  
Limited and inconsistent, non-specific binding was observed.  The positive Her2-
binding DARPin demonstrated at least a 3-fold increase in binding to the SK-BR-3 
(Her2+) fluc/Rluc reporter cell line. Specific binding to the Her2 receptor was 
confirmed.  As anticipated, the Her2-binding DARPin did not demonstrate affinity for 
the MDA-MB-231 (Her2-) fluc/Rluc cells (Rust et al. 2013); this confirmed the Her2-
binding DARPin was selective between the established SK-BR-3 (Her2+) and MDA-
MD-231 (Her2-) fluc/Rluc reporter cell models.  As a preliminary screen the phage 
ELISA did not conclusively rule out any of the negative-binding control DARPins; the 
unfixed fixed unfixed fixed
HER2-binding 3.0 5.1 1.6 1.1
5G G3 Neg 0.5 1.2 1.0 2.1
5H C3 Neg 1.0 1.1 1.1 1.1
5I A6 Neg 0.7 1.9 4.1 1.0
5I G8 Neg 1.5 1.5 2.4 1.5
5I H1 Neg 0.9 1.2 2.0 3.2
5J G4 Neg 0.8 3.5 1.3 1.0
5K D1 Neg 0.8 2.9 2.3 0.9
CEA6 Neg scFv 1.0 1.0 1.0 1.0
DARPin Sequence
MDA-MB-231 (HER2-) fluc/Rluc cellsSK-BR-3 (HER2+) fluc/Rluc cellsSK-BR-3 fluc/Rluc cells
unfixed fixed unfixed fixed
HER2-binding 3.0 5.1 1.6 1.1
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CEA6 Neg scFv 1.0 1.0 1.0 1.0
DARPin Sequence
MDA-MB-231 fluc/Rluc cells
> 3.0 > 2.5 > 2.0 >1.5 <1.5
3 fold increase = HIT
HER2-binding
5G G3 Neg
5H C3 Neg
5I A6 Neg
5I G8 Neg
5I H1 Neg
5J G4 Neg
5K D1 Neg
CEA6 Neg scFv
0.8
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assay was not normalised for phage concentration, therefore more robust controlled 
screens were required. 
DARPin DNA sequences were sub cloned into the bacterial, pET-16b protein 
expression vector, designed specifically to allow high-level expression of His-tagged 
proteins.  Following PCR amplification of the two-repeat DARPin colonies, insertion of 
DARPin DNA into the pET-16b vector.  This was achieved following the introduction 
of NdeI and BamHI restriction sites into the amino and carboxy termini of the DARPin 
sequences.  Specific PCR primers were designed to incorporate these restriction sites, 
as well as three additional amino acid residues onto the C termini of the DARPin 
sequences (Table 6.2).  Two glycine (GG) residues were added to provide a short 
spacer, downstream of the functional DARPin sequence, whilst the addition of cysteine 
(C) facilitated conjugation onto the PP-75 polymer following disulphide exchange. 
Table 6.2: PCR Forward and Reverse Primer Design. 
 
Despite similarities in the DARPin protein sequences between the Her2-binding and negative-binding 
control DARPins, specific primers were required to ensure optimal, sequence specific amplification.  
The variation between protein sequences were further amplified when comparing DARPin DNA 
sequences, as required for PCR.  A combination of 4 primer sets was used.  Inclusion of the NdeI 
(CATATG) and BamHI (GGATCC) restriction sites (underlined) were also built into the forward and 
reverse primer designs respectively.  The C terminal cysteine (highlighted red) was also incorporated 
through amplification of the reverse primer. Full protein and DNA sequences are included in the 
Appendix (Section 8.6). 
Following PCR, the amplified DARPin DNA was analysed by agarose gel 
electrophoresis (Figure 6.2).  DARPin DNA PCR reactions were run in triplicate, 
DARPin sequence Forward Primer 5’-3’ (plus NdeI) Reverse Primer 5’-3’ (plus BamHI)
DR pET16bHER2DP_Fwd (FP1) DR pET16bHER2DP_Rev (RP1)
CGATCATATGGATCTAGGCAAGAAACTACTTGAGGC ATCGGGATCCTTATTAGCAGCCGCCTAACTTTTGGAG
5G-G3 Neg
5H-C3 Neg
5I-G8 Neg DR pET16bNegDPA_Fwd (FP2) DR pET16bNegDPA_Rev (RP2)
5I-H1 Neg CGATCATATGGATCTGGGAAAAAAACTGCTGGAAGC ATCGGGATCCTTATTAGCAGCCGCCCAGTTTCTGCAG
5J-G4 Neg
5K-D1 Neg
DR pET16bNegDPB_Fwd (FP3) DR pET16bNegDPA_Rev (RP2)
CGATCATATGATCTGGGAAAAAAACTGCTGGAAGCC ATCGGGATCCTTATTAGCAGCCGCCCAGTTTCTGCAG
DR pET16bNegDPA_Fwd (FP2) DR pET16bNegDPB_Rev (RP3)
CGATCATATGGATCTGGGAAAAAAACTGCTGGAAGC ATCGGGATCCTTATTAGCAGCCGCCCAGTTTTTGCAG
Her2-binding 
5I-A6 Neg
5J-G4 Neg
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picking TG1 clones from a single colony to ensure a stably expressed representative 
clone would be taken forward as the negative-binding DARPin control.  DARPin DNA 
bands were visualised corresponding to the 400 bp marker of the DNA ladder; both 
the Her2 binding DARPin and the negative-binding DARPins were 378 bp sequences.  
A single reaction from the 5J G4 and 5I A6 negative-binding DARPins resulted in a 
500 bp PCR product (raised bands); these bands were discarded and not taken 
forward for ligation and transformation into the pET-16b expression vector.  The PCR 
negative control lanes confirmed no DNA contamination and no non-specific primer 
amplification. 
 
Figure 6.2: Agarose Gel Analysis of PCR Amplified DARPin Clones. 
Triplicate clone samples plus loading dye were run across a 1% agarose gel and compared to a 1 kb 
DNA ladder.  Bands were observed at the correct size, approximately 400 bp.  PCR negative controls 
were also included for each primer set, demonstrating no contamination due to the lack of visible bands. 
DNA was visible under UV light following the use of SYBR® Safe DNA gel stain. 
Pooled DARPin DNA and the pET-16b expression vector were digested with 
NdeI and BamHI restriction enzymes and analysed by agarose gel electrophoresis 
(Figure 6.3).  Bands corresponding to the 400 bp marker of the DNA ladder were 
observed as previous.  Digestion of the pET-16b expression vector removed a 500 bp 
insert (lower band) to provide the 5711 bp vector (bright upper band).  Bands were cut 
from the gel and DARPin and vector DNA were extracted and sequenced in 
preparation for ligation. 
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Figure 6.3: Agarose Gel Analysis of DARPin Clone Restriction Digest. 
DARPin samples plus loading dye were run across a 1% agarose gel and compared to a 1 kb DNA 
ladder.  DARPin bands were observed at the correct size, approximately 400 bp, whilst the pET-16b 
vector ran at close to 6000 bp.  DNA was visible under UV light following the use of SYBR® Safe DNA 
gel stain and bands were cut from the gel to allow DNA extraction. 
DARPin DNA sequences were therefore sub cloned into the pET-16b 
expression vector following ligation of the digested DARPin and vector PCR products 
(Figure 6.4). 
 
Figure 6.4: Schematic of Vector plus DARPin Ligation. 
The pET-16b vector was digested using NdeI and BamHI restriction enzymes to allow ligation of 
DARPin DNA, containing the same restriction sites, into pET-16b. 
Transformation into XL-1 Blue competent E. coli cells, facilitated amplification 
and isolation of the pET-16b vector encoding the Her2 binding and negative-binding 
control DARPin sequences.  Colonies were picked and the DARPin sequences within 
the pET-16b vector were PCR amplified.  Agarose gel electrophoresis confirmed which 
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clones contained the correct DARPin sequences.  Bands ran above 400 bp due to 
primer amplification of DARPin sequences plus His-tag and flanking sequences 
(confirmed ligation within the pET-16b vector).  Clones were sequenced and only 
those of correct sequence were combined.  Clones 5I A6 and 5J G4 were dropped 
from the screen due to poor expression and inconsistent sequencing. 
Ligation of DARPin DNA into pET-16b vectors was selected for growth on LB 
agar containing Kanamycin (as pET-16b encodes Kanamycin resistance). 
Following mini-prep to isolate pET-16b plus DARPin DNA, transformation into 
BL21 (DE3) competent E.coli cells facilitated the expression of DARPin sequences 
within the pET-16b vector.  BL21 (DE3) cells which had expressed DARPin proteins 
were lysed and the DARPin was purified by immobilised metal affinity chromatography 
on a Nickel-NTA resin column to bind the decahistadine tag (carried out in-house by 
MedImmune His-prep team). 
To isolate a negative-binding DARPin for PP-75 conjugation, a concentration 
dependent DARPin ELISA under anti-His detection was run on the remaining 
negative-binding clones (Figure 6.5).  Variable binding signals were observed across 
the panel of negative-binding DARPins.  Concentration dependent binding was not 
observed over the narrow DARPin concentration range of 1 – 20 µg (representative 
data from 1µg shown).  From the DARPin ELISA screen the 5K D1 negative-binding 
clone was chosen as the lead negative-binding DARPin.  Relative to the CEA6 
negative-binding scFv control, 5K D1 demonstrated low affinity with low fold-increase 
in binding to SK-BR-3 (Her2+) fluc/Rluc cells at all concentrations.  MDA-(Her2-) MB-
231 fluc/Rluc cells also demonstrated comparatively low affinity across the DARPin 
concentration range.  Selective Her2 binding by the positive control DARPin was again 
verified, observed only in SK-BR-3 (Her2+) fluc/Rluc cells and not MDA-MB-231 
(Her2-) fluc/Rluc cells. 
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Figure 6.5: Primary DARPin ELISA Screen of Negative-Binding DARPin Sequences. 
DARPin sequences were primarily screened under an ELISA format to indicate non-specific binding by 
negative-binding DARPin clones, whilst confirming Her2-binding by the positive DARPin.  Binding 
affinity was calculated relative to the CEA6 negative-binding scFv control, a 3-fold increase in affinity is 
routinely recognised as a target hit; therefore anything below 3-fold indicated a lack of binding affinity, 
therefore negative binding.  Non-specific binding was observed where fold increases were close to or 
greater than 3-fold (highlighted green) (n=2 in triplicate). 
Validation of specific, Her2-binding DARPin affinity against the SK-BR-3 
(Her2+) fluc/Rluc reporter cell lines, and, lack of non-specific binding of the negative-
control DARPin to both SK-BR-3 (Her2+) fluc/Rluc and MDA-MB-231 (Her2-) fluc/Rluc 
reporter cell lines was confirmed.  Large scale expression of positive and negative 
DARPins were carried out and sequences were again verified (Table 6.3) following 
His-prep purification (as run by the in-house facility at MedImmune).  The ability of 
DARPins to act as targeting ligands and promote cell-specific intracellular delivery was 
further investigated. 
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Table 6.3: Her2 Binding and 5K D1 Negative-Binding DARPin Sequences. 
 
Positive and negative two-repeat DARPin sequences were expressed following His-prep purification.  
DARPin sequence diversity was demonstrated with variable amino acids highlighted yellow. 
6.2.2 DARPin Binding Affinity for fluc/Rluc Reporter Cell Lines 
Following the preliminary ELISA screens antibody capture/detection of the 
Her2-binding and negative-binding DARPins was further optimised, with the aim to 
demonstrate Her2-specific binding above that of the negative control.  This was 
essential to facilitate investigation into target specific delivery of PP-75 siRNA 
conjugates.  Detection of free (unconjugated) DARPin was first assessed via a 
combination of direct, indirect and sandwich ELISA formats.  
Further investigation into the binding affinity of the Her2-binding and negative-
binding DARPins for SK-BR-3 (Her2+) fluc/Rluc and MDA-MB-231 (Her2-) fluc/Rluc 
cells was investigated.  Cells were probed with increased concentrations of Her2-
binding and negative-binding control DARPins to maximise chance of signal detection 
when using cells compared to purified Her2 coated plates.  The previously probed top 
concentration of DARPin (1000 ng/mL) lay in the middle of the extended concentration 
range. 
DARPin Sequence
Her2-binding M G H H H H H H H H H H S S G H I E G R H M
5K D1 negative-binding M G H H H H H H H H H H S S G H I E G R H M
DARPin Sequence
Her2-binding D L G K K L L E A A R A G Q D D E V R I L M A N G A D V N A
5K D1 negative-binding D L G K K L L E A A R A G Q D D E V R I L M A N G A D V N A
DARPin Sequence
Her2-binding K D E Y G L T P L Y L A T A H G H L E I V E V L L K N G A D V N A
5K D1 negative-binding T D Q F G L T P L H L A A L F G H L E I V E V L L K Y G A D V N A
DARPin Sequence
Her2-binding V D A I G F T P L H L A A F I G H L E I A E V L L K H G A D V N A
5K D1 negative-binding H D A M G Q T P L H L A A Y H G H L E I V E V L L K Y G A D V N A
DARPin Sequence
Her2-binding D K F G K T A F D I S I G N G N E D L A E I L Q K L
5K D1 negative-binding D K F G K T A F D I S I D N G N E D L A E I L Q K L
DARPin Sequence
Her2-binding G G C
5K D1 negative-binding G G CC
Double Glycine Spacer plus Cysteine
Repeat 1
N-Cap
His-Tag
Repeat 2
C-Cap
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As observed previously the Her2-binding DARPin demonstrated target specific 
binding at high affinity towards SK-BR-3 (Her2+) fluc/Rluc expressing cells (Figure 6.6 
and Figure 6.7) and no binding affinity toward the MDA-MB-231 (Her2-) fluc/Rluc cells 
following detection with and anti-His antibody.  Similarly the negative-binding control 
DARPin demonstrated no affinity for either cell line. 
 
Figure 6.6: DARPin Cell ELISA Binding Affinity via Anti-His Antibody Detection. 
DARPin affinity for SK-BR-3 (Her2+) fluc/Rluc and MDA-MB-231 (Her2-) fluc/Rluc cell lines was 
assessed following detection via anti-His antibody. 
 
Figure 6.7: ELISA Fold Change in Binding Affinity on fluc/Rluc Reporter Cells via Anti-His 
Antibody Detection (Relative to Secondary Only Control). 
Signal intensity above background absorbance indicates the fold-change in affinity of anti-His detection 
of DARPin-binding when compared to non-specific (BSA treatment; data not shown) and untreated 
controls. 
Signal above background was detected at 50 ng/mL (3.2 nM) with a 3-fold 
increase in signal above the untreated control detected at 250 ng/mL (16 nM).  As 
discussed previously a 3-fold increase over negative control is the threshold at which 
a positive hit can be confirmed; demonstrating Her2-specific binding relative to the 
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0.00 ng/mL 25  ng/mL 50  ng/mL 100  ng/mL 250  ng/mL 500  ng/mL 1000  ng/mL 5000  ng/mL 10000  ng/mL 20000  ng/mL 40000 ng/mL
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DARPin Sequence
SK-BR-3 (Her2+) fluc/Rluc cells 
DARPin Sequence
MDA-MB-231 (Her2-) fluc/Rluc cells
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negative-binding control.  This was also confirmed at a concentration of 16 nM (Figure 
6.8). 
 
Figure 6.8: ELISA Fold Change in Binding Affinity on fluc/Rluc Reporter Cells with Anti-His 
Antibody Detection, Relative to Negative-Binding DARPin. 
Signal intensity above background absorbance indicates the fold-change in affinity of anti-His detection 
of the Her2 binding DARPin relative to the negative-binding DARPin. 
Background signal remained low across the cell ELISA data sets, non-specific 
secondary antibody interactions were not observed as with the recombinant Her2 
coated plates. 
Anti-His detection was therefore considered an appropriate method to 
distinguish between Her2-target specific binding affinities across the model reporter 
cell lines.  Enhanced signal over background was demonstrated across a range of 
DARPin concentrations and provided a considerable assay window for future 
investigation into the effect of DARPin targeting on the PP-75 polymer conjugates. 
6.3 Conclusions 
Successful screening and expression of the novel DARPin 5K D1 as a negative-
binding control DARPin was achieved.  The negative DARPin demonstrated no affinity 
for either SK-BR-3 (Her2+) fluc/Rluc or MDA-MD-231 (Her2-) fluc/Rluc cell lines.  The 
Her2-binding DARPin demonstrated specificity for the SK-BR-3 (Her2+) fluc/Rluc 
cells, and did not bind the MDA-MD-231 (Her2-) fluc/Rluc cells as expected. 
Owing to time constraints, the work in this chapter provides novel and 
preliminary findings on which to base further investigations supporting future studies 
of targeted PP-75 delivery following attachment of targeting ligands. 
PEGylated DARPins demonstrate strong accumulation to tumour cells, but via 
much slower uptake (Stumpp et al. 2008), therefore PP-75 DARPin conjugates may 
0.00 ng/mL 25  ng/mL 50  ng/mL 100  ng/mL 250  ng/mL 500  ng/mL 1000  ng/mL 5000  ng/mL 10000  ng/mL 20000  ng/mL 40000 ng/mL
Her2 : Neg 1.20 1.24 1.44 1.67 4.00 4.93 4.89 4.01 3.60 3.76 3.71
0.00 ng/mL 25  ng/mL 50  ng/mL 100  ng/mL 250  ng/mL 500  ng/mL 1000  ng/mL 5000  ng/mL 10000  ng/mL 20000  ng/mL 40000 ng/mL
Her2 : Neg 1.02 0.98 0.98 1.02 0.98 1.05 1.02 0.95 0.87 0.94 1.32
DARPin Sequence
MDA-MB-231 (Her2-) fluc/Rluc cells
DARPin Sequence
SK-BR-3 (Her2+) fluc/Rluc cells 
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require longer incubation and treatment times for optimal uptake.  This may be 
explained by the fact that molecules of small molecular weight must bind their cell 
receptors very tightly to prevent rapid clearance (as a result of their smaller size).  With 
larger molecules or conjugates, the affinity requirement is not as strong as they remain 
in circulation.  PEGylated molecules can reside in the serum for much longer (Stumpp 
et al. 2008). 
The coupling of DARPins to PP-75 may need to be site specific, or requiring a 
remote attachment point.  Large polymeric moieties (eg. PEG) may interfere with 
DARPin binding to epitopes, if the point of conjugation is close to the DARPin paratope 
(binding region of the DARPin with affinity for the epitope) (Stumpp et al. 2008).  
Determining a remote binding site may also be advantageous in terms of PP-75 
function.  A longer cross-linker between PP-75 and the DARPin may decrease steric 
encumbrance on the DARPin and may also minimise a shift in PP-75 pH-responsive 
function. 
Following the treatment of SK-BR-3 (Her2+) fluc/Rluc and MDA-MD-231 (Her2-
) fluc/Rluc with PP-75 AFC DARPin conjugates, cell imaging to visualise association 
of Her2-targeting PP-75 with the Her2 receptor could be carried out.  Enhanced cell 
uptake may be observed.  Flow cytometry and fluorescently activated cell sorting 
(FACS) could aid quantification of PP-75 AFC DARPin uptake.  Confirmation of PP-
75 Her2-binding DARPin conjugate affinity for SK-BR-3 (Her2-) fluc/Rluc cells, and not 
MDA-MD-231 (Her2-) fluc/Rluc cells would be investigated.  No change in uptake by 
the PP-75 negative-binding DARPin conjugates, in either cell line is also desirable.  
Conjugation of PP-75 DARPin and siRNA could be better considered once these 
outcomes were achieved. 
Using PP-75 AFC DARPin conjugates and Cy3 labelled siRNA, both polymer 
and payloads could be visualised within the cells therefore demonstrating the 
intracellular location of each key component of the delivery complex.  Insight into 
polymer-payload release could also be gained.  siRNA target knockdown assays 
would be repeated to confirm payload specificity for the target via the DLR™ assay 
and RT-qPCR.  
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Chapter 7 
7 Conclusions 
The delivery of therapeutic agents to the cell interior presents a significant 
challenge in the effective treatment of disease.  PP-75 a pH-responsive polymer, 
capable of transitioning from a coil-to-globule conformation, following endosomal 
acidification, demonstrates potential for application to enhance intracellular drug 
delivery.  The aims of this project were to develop a more detailed understanding of 
intracellular drug delivery.  Understanding PP-75 activity as an intracellular delivery 
agent would provide the foundations for future work, specifically, developing a strategy 
for the targeted, intracellular delivery of antagonistic siRNA to specific cell populations. 
The successful synthesis of novel PP-75 cross-linker conjugates, PP-75 AFC, 
PP-75 siRNA conjugate and PP-75 DARPin conjugate polymer stocks was achieved.  
Chemical structures and molecular weights were characterised and calculated.  PP-
75 cross-linker grafting, AFC, siRNA, and DARPin conjugations were confirmed.  An 
average of one siRNA molecule to one polymer chain was conjugated onto PP-75 for 
delivery into cells.  Results indicated PP-75 DARPin conjugation was at a sub-
stoichiometric ratio (5:1) therefore increased DARPin concentration was required to 
yield a 1:1 DARPin to polymer conjugation. 
PP-75 physiochemical properties demonstrated concentration dependent, as 
well as pH-dependent effects on polymer size.  PP-75 membrane disruptive activity in 
breast cancer cells has been described for the first time; shown to be limited at 
physiological pH 7.4, with PP-75 lytic effects associated with decreasing pH, typical of 
early endosomes. 
Successful transfection of firefly and Renilla luciferase genes into SK-BR-3 
(Her2+) and MDA-MB-231 (Her2-) was confirmed at the protein and mRNA level 
providing a novel assay read-out to confirm target gene knockdown.  Characterisation 
of the two model reporter cell lines SK-BR-3 (Her2+) fluc/Rluc and MDA-MB-231 
(Her2-) fluc/Rluc confirmed the novel reporter lines as fit-for-purpose prior to treatment 
with PP-75 plus payloads. 
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PP-75 treatment was tolerated across a wide range of concentrations, up to 2.5 
mg/mL (~45 µM) over 72 h following delivery to SK-BR-3 (Her2+) fluc/Rluc and MDA-
MB-231 (Her2-) fluc/Rluc cell lines.  PP-75 was therefore considered non-toxic to the 
reporter cell lines over the range tested. 
Laser scanning and high content confocal microscopy confirmed reporter cell 
uptake of PP-75, also demonstrating PP-75 function with visualisation of diffuse AFC 
staining when conjugated to PP-75.  Co-localisation with intracellular organelle stains 
indicated release from the endosomal membrane and delivery into the cytoplasm, 
within the intact cell membrane.  Flow cytometry confirmed cellular internalisation of 
PP-75 AFC was via endocytosis in the novel cell lines tested.  AFC acted as a model 
payload, demonstrating the PP-75 delivery mechanism. 
siRNA functionality was confirmed following siRNA knockdown of the fluc 
target-gene.  This was facilitated by complexation with Lipofectamine®, used as a 
positive-control delivery vehicle.  fluc mRNA and protein knockdown was time 
dependent within the 5 – 50 nM treatment range tested over 24 - 168 h.  The delivery 
of fluorescently labelled siRNA was also observed within the cells following treatment 
when complexed with Lipofectamine®. 
Despite effective delivery of the novel compound PP-75 AFC, novel PP-75 fluc 
targeting siRNA conjugates did not appear to enter the cells unaided.  PP-75 siRNA 
conjugates were confirmed to have retained payload functionality when delivered 
alongside Lipofectamine®; demonstrating comparable levels of knockdown when 
delivered at equivalent siRNA concentrations.  PP-75 siRNA conjugates alone, and 
with additional PP-75 top-up, to aid endosomal escape, did not result in fluc protein 
knockdown as measured by the DLR™ assay.  OPERA® imaging of cells treated with 
PP-75 siRNA Cy3 conjugates confirmed a lack of uptake and internalisation by the by 
MDA-MB-231 fluc/Rluc (Her2-) and SK-BR-3 fluc/Rluc (Her2+) reporter cells. 
Further discrepancies in uptake between PP-75 AFC and PP-75 siRNA 
conjugates could be explained by the difference in payload molecular weight.  AFC, a 
small, low molecular weight molecule without charge, when grafted onto PP-75 at low 
percentage did not affect PP-75 pH-responsive properties.  By comparison siRNA was 
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a much larger, and negatively charged payload with a molecular weight approximately 
a quarter that of the PP-75 polymer.  The increased molecular weight of the PP-75 
siRNA conjugates and the potential for aggregation were thought to have prevented 
effective cell uptake. 
The attachment of a soluble, high affinity Her2-targeting DARPin onto PP-75 
was subsequently investigated.  Effective extracellular targeting by the Her2 DARPin, 
prior to conjugation, was confirmed, demonstrated by specificity for the SK-BR-3 
(Her2+) fluc/Rluc cells, and did not MDA-MD-231 (Her2-) fluc/Rluc cells.  Expression 
of a novel but structurally similar negative control DARPin (5K D1) that demonstrated 
no affinity for either SK-BR-3 (Her2+) fluc/Rluc or MDA-MD-231 (Her2-) fluc/Rluc 
reporter cell line was isolated for relative comparison.  The successful conjugation of 
DARPins onto PP-75 was confirmed however owing to time constraints the PP-75 
DARPin conjugates were not synthesised on a large scale to enable further analysis. 
7.1 Future Scope of the Project 
Further investigation to support future studies of targeted PP-75 delivery 
following DARPin and siRNA conjugation (Figure 7.1) would therefore be required. 
Following conformation of PP-75 Her2 specific binding via DARPin ELISA, cell 
imaging to visualise the association of Her2-targeting PP-75 conjugates with the Her2 
receptor is recommended to demonstrate the potential for targeted cell uptake.  Flow 
cytometry and fluorescently activated cell sorting (FACS) could be used to aid 
quantification of PP-75 AFC Her2 binding DARPin uptake, relative to the non-targeted 
conjugates. 
Using PP-75 AFC DARPin conjugates and Cy3 labelled siRNA, both polymer 
and payloads could be visualised within the cells to demonstrate intracellular 
localisation of each key component of the delivery complex.  Insight into polymer-
payload release may also be gained.  siRNA target knockdown assays could then be 
repeated to confirm payload specificity for the target via the DLR™ assay and RT-
qPCR. 
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Figure 7.1: PP-75 PDPH siRNA and DARPin Conjugation Schematic. 
PP-75 PDPH can be conjugated at a 1:1 ratio with thiol modified fluc Cy3 labelled siRNA and at a 1:5 
ratio with cysteine modified Her2 targeting DARPin sequences as indicated by preliminary work.  PP-
75 PDPH siRNA and DARPin conjugates could be synthesised following the procedures outlined 
previously (Sections 2.2.4.3 with modification and 2.2.4.6) (remaining R groups could also be hydroxyl 
OH). 
7.1.1 Characterisation of PP-75 and Derivatives 
NMR may in future provide useful confirmation of PP-75 PDPH siRNA 
conjugation, further enhancing confidence in polymer-siRNA loading.  Access to 
further mass spectrometry capabilities would be of benefit to polymer characterisation 
and soft-ionisation techniques may be more informative.  Matrix-assisted laser 
desorption/ionisation (MALDI) mass spectrometry is considered the most reliable 
method for synthetic polymer characterisation as MALDI mass spectrometry has a 
mass resolution discreet enough to distinguishing the repeating unit mass also.  
Conjugation of siRNA and DARPin sequences could be more accurately determined 
by measuring absorbance, therefore establishing molar concentration ratios and 
allowing for more comparable characterisations. 
Site specific coupling onto PP-75 may be necessary, requiring a remote 
attachment point.  Facilitating greater control of payload attachment may be valuable 
in terms of maintaining PP-75 function.  Investigation into the length of cleavable 
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linkers for payload conjugation was intended, this would provide more insight into 
polymer properties post payload conjugation.  A longer cross-linker between PP-75 
and the DARPin may also decrease steric hindrance on the DARPin and may minimise 
shifts in PP-75 pH-responsive function.  These findings would indicate whether further 
fine-tuning of PP-75 properties are required dependent on payload mass and charge.  
Adjusting the balance between hydrophilic and hydrophobic components in 
combination with the PP-75 platform will therefore facilitate membrane disruptive 
effects within the endosomal pH range.  Investigation into polymer-payload conjugate 
size would also be advantageous to indicate the level of membrane disruption or pore 
formation.  Techniques such as TEM, AFM and SANS can be employed as previously 
mentioned; with PP-75 pH-responsive activity studied more closely via pH titration. 
Investigating PP-75 activity across different cell membrane compositions 
(differnet cell types) would also further enhance understanding of the PP-75 drug 
delivery platform; differeing membranes may require different polymer compositions 
to illicit memebrane destabilisation. 
7.1.2 PP-75 Payload Release 
PP-75 siRNA conjugates were designed to facilitate siRNA release when 
delivered to the reducing environment of the cytoplasm.  The disulphide bond between 
the polymer and payload would be cleaved, allowing the siRNA payload to specifically 
interact with the target sequence.  Glutathione (GSH) is a tri-peptide of L-glutamine, 
L-cysteine and glycine amino acids, synthesised in the cytosol of cells.  GSH provides 
the overall reducing power within the cell interior, with concentrations up to 10 mM, 
preventing formation of protein disulphide bonds (Chakravarthi et al. 2006).  Cysteine 
also present within the cytoplasm has reducing capabilities.  In order to test the 
capability of the PP-75 conjugates to release their payloads, release experiments to 
mimic the intracellular environment were attempted, but required further exploration.  
PP-75 conjugates demonstrated a 15% siRNA release rate (data not shown).  This 
experimental set up would require further optimisation to demonstrate the effective 
payload release as shown by siRNA knockdown ability within the cell studies. 
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Slow or sustained release of the siRNA from PP-75 may be advantageous 
when in vivo, allowing for less frequent dosing regimes. 
7.1.3 Therapeutic Potential 
Developing the cellular applications of PP-75 as a drug delivery platform will be 
achieved through conjugation of therapeutic siRNA payloads that target different 
diseases, for example mutated or over expressed oncogenes presnet within the breast 
cancer reporter cells.  Delivery of protein therapeutic payloads can be investigated, 
owing to successful conjugation of DARPins onto PP-75.  DARPins themselves can 
also be applied as therapeutic payloads (Plückthun 2015). 
Conjugation of DARPins with affinity for alternative extracellular targets could 
be explored to extend the delivery platform to alternative disease targets.  
7.1.4 Subcellular Fate of Polymers and Biodegradability 
Isolation of cellular compartments, in particular the early and late endosomes 
and lysosomes will be useful to determine PP-75 delivery efficiency and subcellular 
localisation.  Methods of density gradient centrifugation have been described in the 
literature (Schroter et al. 1999, Araujo et al. 2008). 
Cleavage of the amino acid backbone and the thioether bonds of the polymer 
may be investigated to ensure post-delivery the polymer can be excreted from the 
body.  This will be important to prevent accumulation of the delivery system within 
circulation. 
7.2 Closing Remarks 
The research presented within this thesis offers to further develop the current 
understanding of intracellular drug delivery.  Insight into PP-75 cellular uptake and 
endosomal escape has been gained providing foundation work for the further 
development of the PP-75 delivery platform with respect to delivery to breast cancer 
cells.  Successful siRNA and DARPin conjugation methods onto PP-75 have paved 
the way for further intracellular studies.  Application and function of siRNA and DARPin 
components have been effectively demonstrated.  The model reporter cell system has 
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been fully optimised and demonstrates a robust platform to demonstrate targeted cell 
knockdown. 
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Appendix 
8 Appendix 
8.1 P-2-T Calibration Curve (DMF) 
 
The absorbance (340 nm) of known quantities of P-2-T in DMF (1 mg/mL stock concentration; 2-fold 
serial dilution) were measured to provide a standard calibration curve (n=3, error bars represent the 
standard deviation).  The linear section of the curve was used to determine P-2-T concentration within 
PP-75 PDPH grafted samples. 
8.2 Beer-Lambert Law 
A= εcl 
Where A = absorbance, ε = extinction coefficient (µg/mL-1 path length-1), c = concentration (µg/mL), l = 
path length (path length was not known and so was arbitrarily assigned as 1, ensuring that sample 
volume was kept constant at 100 μL per well).  Absorbance was measured using the Envision Reader. 
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8.3 AFC Absorption Calibration Curve (10% DMF: 90% PBS) 
 
The absorbance (490 nm) of known quantities of AFC in DMF:PBS (1 mg/mL stock concentration; 2-
fold serial dilutions) were measured to provide a standard absorbance calibration curve.  The linear 
equation was used to determine AFC concentration in PP-75 AFC.  Calibration curves were set up with 
each characterisation therefore the curve shown is representative (n=1, in duplicate). 
8.4 AFC Fluorescence Calibration Curve (10% DMF: 90% PBS) 
 
The fluorescence (520 nm) of known quantities of AFC in DMF: PBS (1 mg/mL stock concentration; 2-
fold serial dilution) were measured to provide a standard fluorescence calibration curve.  The linear 
equation was used to determine AFC concentration in PP-75 AFC.  Calibration curves were set up with 
each characterisation therefore the curve shown is representative (n=1, in duplicate). 
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8.5 Luciferase Gene Sequences with PCR Primers and Probes 
> firefly Luciferase-II-orf (1656bp) 
ATGATGGAAGATGCCAAAAACATTAAGAAGGGCCCAGCGCCATTCTACCCACTCGAAGACGGGACCGCCGGCGAG
CAGCTGCACAAAGCCATGAAGCGCTACGCCCTGGTGCCCGGCACCATCGCCTTTACCGACGCACATATCGAGGTG
GACATTACCTACGCCGAGTACTTCGAGATGAGCGTTCGGCTGGCAGAAGCTATGAAGCGCTATGGGCTGAATACA
AACCATCGGATCGTGGTGTGCAGCGAGAATAGCTTGCAGTTCTTCATGCCCGTGTTGGGTGCCCTGTTCATCGGT
GTGGCTGTGGCCCCAGCTAACGACATCTACAACGAGCGCGAGCTGCTGAACAGCATGGGCATCAGCCAGCCCACC
GTCGTATTCGTGAGCAAGAAAGGGCTGCAAAAGATCCTCAACGTGCAAAAGAAGCTACCGATCATACAAAAGATC
ATCATCATGGATAGCAAGACCGACTACCAGGGCTTCCAAAGCATGTACACCTTCGTGACTTCCCATTTGCCACCC
GGCTTCAACGAGTACGACTTCGTGCCCGAGAGCTTCGACCGGGACAAAACCATCGCCCTGATCATGAACAGTAGT
GGCAGTACCGGATTGCCCAAGGGCGTAGCCCTACCGCACCGCACCGCTTGTGTCCGATTCAGTCATGCCCGCGAC
CCCATCTTCGGCAACCAGATCATCCCCGACACCGCTATCCTCAGCGTGGTGCCATTTCACCACGGCTTCGGCATG
TTCACCACGCTGGGCTACTTGATCTGCGGCTTTCGGGTCGTGCTCATGTACCGCTTCGAGGAGGAGCTATTCTTG
CGCAGCTTGCAAGACTATAAGATTCAATCTGCCCTGCTGGTGCCCACACTATTTAGCTTCTTCGCTAAGAGCACT
CTCATCGACAAGTACGACCTAAGCAACTTGCACGAGATCGCCAGCGGCGGGGCGCCGCTCAGCAAGGAGGTAGGT
GAGGCCGTGGCCAAACGCTTCCACCTACCAGGCATCCGCCAGGGCTACGGCCTGACAGAAACAACCAGCGCCATT
CTGATCACCCCCGAAGGGGACGACAAGCCTGGCGCAGTAGGCAAGGTGGTGCCCTTCTTCGAGGCTAAGGTGGTG
GACTTGGACACCGGTAAGACACTGGGTGTGAACCAGCGCGGCGAGCTGTGCGTCCGTGGCCCCATGATCATGAGC
GGCTACGTTAACAACCCCGAGGCTACAAACGCTCTCATCGACAAGGACGGCTGGCTGCACAGCGGCGACATCGCC
TACTGGGACGAGGACGAGCACTTCTTCATCGTGGACCGGCTGAAGAGCCTGATCAAATACAAGGGCTACCAGGTA
GCCCCAGCCGAACTGGAGAGCATCCTGCTGCAACACCCCAACATCTTCGACGCCGGGGTCGCCGGCCTGCCCGAC
GACGATGCCGGCGAGCTGCCCGCCGCAGTCGTCGTGCTGGAACACGGTAAAACCATGACCGAGAAGGAGATCGTG
GACTATGTGGCCAGCCAGGTTACAACCGCCAAGAAGCTGCGCGGTGGTGTTGTGTTCGTGGACGAGGTGCCTAAA
GGACTGACCGGCAAGTTGGACGCCCGCAAGATCCGCGAGATTCTCATTAAGGCCAAGAAGGGCGGCAAGATCGCC
GTGTAA 
FP: ATCATACAAAAGATCATCATCATGGATA 
RP: CAAATGGGAAGTCACGAAGGT (REVERSE COMPLIMENT:ACCTTCGTGACTTCCCATTTG) 
Amplicon Length 84bp 
PROBE: CAAGACCGACTACCAGGGCTTCCAAAG 
mRNA amplification sequence TACCTACGCCGAGTACTTCGAGA (to avoid in Primer/Probe design) 
 
> Renilla Luciferase-orf (936bp) 
ATGGCTTCCAAGGTGTACGACCCCGAGCAACGCAAACGCATGATCACTGGGCCTCAGTGGTGGGCTCGCTGCAAG
CAAATGAACGTGCTGGACTCCTTCATCAACTACTATGATTCCGAGAAGCACGCCGAGAACGCCGTGATTTTTCTG
CATGGTAACGCTGCCTCCAGCTACCTGTGGAGGCACGTCGTGCCTCACATCGAGCCCGTGGCTAGATGCATCATC
CCTGATCTGATCGGAATGGGTAAGTCCGGCAAGAGCGGGAATGGCTCATATCGCCTCCTGGATCACTACAAGTAC
CTCACCGCTTGGTTCGAGCTGCTGAACCTTCCAAAGAAAATCATCTTTGTGGGCCACGACTGGGGGGCTTGTCTG
GCCTTTCACTACTCCTACGAGCACCAAGACAAGATCAAGGCCATCGTCCATGCTGAGAGTGTCGTGGACGTGATC
GAGTCCTGGGACGAGTGGCCTGACATCGAGGAGGATATCGCCCTGATCAAGAGCGAAGAGGGCGAGAAAATGGTG
CTTGAGAATAACTTCTTCGTCGAGACCATGCTCCCAAGCAAGATCATGCGGAAACTGGAGCCTGAGGAGTTCGCT
GCCTACCTGGAGCCATTCAAGGAGAAGGGCGAGGTTAGACGGCCTACCCTCTCCTGGCCTCGCGAGATCCCTCTC
GTTAAGGGAGGCAAGCCCGACGTCGTCCAGATTGTCCGCAACTACAACGCCTACCTTCGGGCCAGCGACGATCTG
CCTAAGATGTTCATCGAGTCCGACCCTGGGTTCTTTTCCAACGCTATTGTCGAGGGAGCTAAGAAGTTCCCTAAC
ACCGAGTTCGTGAAGGTGAAGGGCCTCCACTTCAGCCAGGAGGACGCTCCAGATGAAATGGGTAAGTACATCAAG
AGCTTCGTGGAGCGCGTGCTGAAGAACGAGCAGTAA 
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FP: CTGGACTCCTTCATCAACTACTAT 
RP: GGAGGCAGCGTTACCATG(REVERSE COMPLIMENT:CATGGTAACGCTGCCTCC) 
Amplicon Length 81bp 
PROBE: CCGAGAAGCACGCCGAGAACGC 
8.6 Negative Binding DARPin Sequences with PCR Primers 
>Her2 DO1 
Protein 
DLGKKLLEAARAGQDDEVRILMANGADVNAKDEYGLTPLYLATAHGHLEIVEVLLKNGADVNAVDAIGFTPLHLA
AFIGHLEIAEVLLKHGADVNAQDKFGKTAFDISIGNGNEDLAEILQKL 
DNA (378 bp) 
GATCTAGGCAAGAAACTACTTGAGGCAGCGAGAGCCGGACAGGACGATGAGGTTAGGATATTGATGGCTAATGGT
GCAGACGTCAACGCTAAGGATGAATATGGCCTAACCCCTCTTTACTTAGCGACGGCTCATGGTCATTTGGAGATA
GTCGAAGTGCTGTTGAAGAACGGTGCCGATGTAAACGCCGTGGACGCAATTGGGTTTACTCCACTTCACCTGGCG
GCATTCATTGGGCATCTCGAAATCGCGGAGGTATTACTCAAACACGGCGCTGACGTTAATGCACAAGACAAATTC
GGAAAAACAGCCTTTGATATCAGTATAGGAAATGGGAATGAAGATCTGGCTGAAATTCTCCAAAAGTTAGGCGGC
TGC 
FP:  5’ – CGATCATATGGATCTAGGCAAGAAACTACTTGAGGC – 3’ 
RP:  5’ – ATCGGGATCCTTATTAGCAGCCGCCTAACTTTTGGAG – 3’ 
 
>ZZ1I5G-G03 
Protein 
DLGKKLLEAARAGQDDEVRILMANGADVNAHDYLGFTPLHLAALYGHLEIVEVLLKYGADVNARDHHGSTPLHLA
ATRGHLEIVEVLLKNGADVNAQDKFGKTAFDISIGNGNEDLAEILQKL 
DNA (378 bp) 
GATCTGGGAAAAAAACTGCTGGAAGCCGCGCGTGCCGGGCAGGACGATGAGGTCCGTATTCTTATGGCGAACGGT
GCAGATGTTAACGCGCACGATTACCTGGGTTTCACGCCGCTGCATCTGGCAGCGCTGTACGGTCACCTCGAAATT
GTGGAAGTGCTGTTGAAGTATGGTGCAGATGTTAACGCGCGCGATCACCACGGTAGCACGCCGCTGCATCTGGCA
GCGACGCGCGGTCACCTCGAAATTGTGGAAGTGCTGTTGAAGAATGGTGCAGATGTGAATGCTCAGGATAAGTTT
GGCAAAACCGCGTTTGATATCTCCATTGATAATGGCAACGAAGATTTAGCGGAAATCCTGCAGAAACTGGGCGGC
TGC 
FP: 5’ – CGATCATATGGATCTGGGAAAAAAACTGCTGGAAGC – 3’ 
RP: 5’ – ATCGGGATCCTTATTAGCAGCCGCCCAGTTTCTGCAG – 3’ 
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>ZZ1I5H-C03 
Protein 
DLGKKLLEAARAGQDDEVRILMANGADVNALDSMGLTPLHLAAYHGHLEIVEVLLKYGADVNAHDTWGKTPLHLA
AMWGHLEIVEVLLKYGADVNAQDKFGKTAFDISIGNGNEDLAEILQKL 
DNA (378 bp) 
GATCTGGGAAAAAAACTGCTGGAAGCCGCGCGTGCCGGGCAGGACGATGAGGTCCGTATTCTTATGGCGAACGGT
GCAGATGTTAACGCGCTGGATAGCATGGGTCTGACGCCGCTGCATCTGGCAGCGTACCACGGTCACCTCGAAATT
GTGGAAGTGCTGTTGAAGTACGGTGCAGATGTTAACGCGCACGATACGTGGGGTAAAACGCCGCTGCATCTGGCA
GCGATGTGGGGTCACCTCGAAATTGTGGAAGTGCTGTTGAAGTATGGTGCAGATGTGAATGCTCAGGATAAGTTT
GGCAAAACCGCGTTTGATATCTCCATTGATAATGGCAACGAAGATTTAGCGGAAATCCTGCAGAAACTGGGCGGC
TGC 
FP: 5’ – CGATCATATGGATCTGGGAAAAAAACTGCTGGAAGC – 3’ 
RP: 5’ – ATCGGGATCCTTATTAGCAGCCGCCCAGTTTCTGCAG – 3’ 
 
ZZ1I5I-A06 
Protein 
DLGKKLLEAARAGQDDEVRILMANGADVNAMDHAGATPLHLAAHDGHLEIVEVLLKHGADVNAYDSAGITPLHLA
AHHGHLEIVEVLLKYGADVNAQDKFGKTAFDISIGNGNEDLAEILQKL 
DNA (377 bp) 
ATCTGGGAAAAAAACTGCTGGAAGCCGCGCGTGCCGGGCAGGACGATGAGGTCCGTATTCTTATGGCGAACGGTG
CAGATGTTAACGCGATGGATCACGCAGGTGCAACGCCGCTGCATCTGGCAGCGCACGATGGTCACCTCGAAATTG
TGGAAGTGCTGTTGAAGCATGGTGCAGATGTTAACGCGTACGATAGCGCAGGTATTACGCCGCTGCATCTGGCAG
CGCACCACGGTCACCTCGAAATTGTGGAAGTGCTGTTGAAGTACGGTGCAGATGTGAATGCTCAGGATAAGTTTG
GCAAAACCGCGTTTGATATCTCCATTGATAATGGCAACGAAGATTTAGCGGAAATCCTGCAGAAACTGGGCGGCT
GC 
FP: 5’ – CGATCATATGATCTGGGAAAAAAACTGCTGGAAGCC– 3’ 
RP: 5’ – ATCGGGATCCTTATTAGCAGCCGCCCAGTTTCTGCAG – 3’ 
 
>ZZ1I5I-G08 
Protein 
DLGKKLLEAARAGQDDEVRILMANGADVNANDSDGYTPLHLAAWMGHLEIVEVLLKYGADVNAHDLAGSTPLHLA
AWWGHLEIVEVLLKHGADVNAQDKFGKTAFDISIGNGNEDLAEILQKL 
DNA (378 bp) 
GATCTGGGAAAAAAACTGCTGGAAGCCGCGCGTGCCGGGCAGGACGATGAGGTCCGTATTCTTATGGCGAACGGT
GCAGATGTTAACGCGAACGATAGCGATGGTTACACGCCGCTGCATCTGGCAGCGTGGATGGGTCACCTCGAAATT
GTGGAAGTGCTGTTGAAGTACGGTGCAGATGTTAACGCGCACGATCTGGCAGGTAGCACGCCGCTGCATCTGGCA
GCGTGGTGGGGTCACCTCGAAATTGTGGAAGTGCTGTTGAAGCATGGTGCAGATGTGAATGCTCAGGATAAGTTT
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GGCAAAACCGCGTTTGATATCTCCATTGATAATGGCAACGAAGATTTAGCGGAAATCCTGCAGAAACTGGGCGGC
TGC 
FP: 5’ – CGATCATATGGATCTGGGAAAAAAACTGCTGGAAGC – 3’ 
RP: 5’ – ATCGGGATCCTTATTAGCAGCCGCCCAGTTTCTGCAG – 3’ 
>ZZ1I5I-H01 
Protein 
DLGKKLLEAARAGQDDEVRILMANGADVNARDSMGYTPLHLAALMGHLEIVEVLLKYGADVNALDLTGSTPLHLA
AINGHLEIVEVLLKHGADVNAQDKFGKTAFDISIGNGNEDLAEILQKL 
DNA (378 bp) 
GATCTGGGAAAAAAACTGCTGGAAGCCGCGCGTGCCGGGCAGGACGATGAGGTCCGTATTCTTATGGCGAACGGT
GCAGATGTTAACGCGCGCGATAGCATGGGTTACACGCCGCTGCATCTGGCAGCGCTGATGGGTCACCTCGAAATT
GTGGAAGTGCTGTTGAAGTACGGTGCAGATGTTAACGCGCTGGATCTGACGGGTAGCACGCCGCTGCATCTGGCA
GCGATTAACGGTCACCTCGAAATTGTGGAAGTGCTGTTGAAGCACGGTGCAGATGTGAATGCTCAGGATAAGTTT
GGCAAAACCGCGTTTGATATCTCCATTGATAATGGCAACGAAGATTTAGCGGAAATCCTGCAGAAACTGGGCGGC
TGC 
FP: 5’ – CGATCATATGGATCTGGGAAAAAAACTGCTGGAAGC – 3’ 
RP: 5’ – ATCGGGATCCTTATTAGCAGCCGCCCAGTTTCTGCAG – 3’ 
 
>ZZ1I5J-G04 
Protein 
DLGKKLLEAARAGQDDEVRILMANGADVNAHDHWGSTPLHLAARLGHLEIVEVLLKYGADVNAVDNRGHTPLHLA
AQTGHLEIVEVLLKHGADVNAQDKFGKTAFDISIGNGNEDLAEILQKL 
DLGKKLLEAARAGQDDEVRILMANGADVNAHDHWGSTPLHLAAWVGHLEIVEVLLKYGADVNAVDSRGNTPLHLA
AQIGHLEIVEVLLKYGADVNAQDKFGKTAFDISIDNGNEDLAEILQKL 
DNA (378 bp) 
GATCTGGGAAAAAAACTGCTGGAAGCCGCGCGTGCCGGGCAGGACGATGAGGTCCGTATTCTTATGGCGAACGGT
GCAGATGTTAACGCGCACGATCACTGGGGTAGCACGCCGCTGCATCTGGCACCGTGGGTCGGCCACCTCAAATTT
GTGAAATGGTTGTTGAATTACGGGGCAAAGGTTAACGCGTGCAATACCCGCGGCAGCACCCCGCTGCTTCGGGCA
CCGCACATTGGCCACCTCAAATTTGTGAAATTGCTGTTAAATTACGGGGCAAAGGTGAATGCTCAGGATAAGTTT
GGCAAACCCCCGTTTGATATCTCCCTTGATAATGGCACCTAAAATTTATCGAAAATCCTGCAAAAACTGGGCGGC
TGC 
GATCTGGGAAAAAAACTGCTGGAAGCCGCGCGTGCCGGGCAGGACGATGAGGTCCGTATTCTTATGGCGAACGGT
GCAGATGTTAACGCGCACGATCACTGGGGTAGCACGCCGCTGCATCTGGCAGCGTGGGTCGGTCACCTCGAAATT
GTGGAAGTGCTGTTGAAGTACGGTGCAGATGTTAACGCGGTCGATAGCCGCGGTAACACGCCGCTGCATCTGGCA
GCGCAAATTGGTCACCTCGAAATTGTGGAAGTGCTGTTGAAGTACGGTGCAGATGTGAATGCTCAGGATAAGTTT
GGCAAAACCGCGTTTGATATCTCCATTGATAATGGCAACGAAGATTTAGCGGAAATCCTGCAGAAACTGGGCGGC
TGC 
FP: 5’ – CGATCATATGGATCTGGGAAAAAAACTGCTGGAAGC– 3’ 
RP: 5’ – ATCGGGATCCTTATTAGCAGCCGCCCAGTTTTTGCAG– 3’ 
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FP: 5’ – CGATCATATGGATCTGGGAAAAAAACTGCTGGAAGC– 3’ 
RP: 5’ – ATCGGGATCCTTATTAGCAGCCGCCCAGTTTCTGCAG– 3’ 
 
>ZZ1I5K-D01 
Protein 
DLGKKLLEAARAGQDDEVRILMANGADVNATDQFGLTPLHLAALFGHLEIVEVLLKYGADVNAHDAMGQTPLHLA
AYHGHLEIVEVLLKYGADVNAQDKFGKTAFDISIGNGNEDLAEILQKL 
DNA (378 bp) 
GATCTGGGAAAAAAACTGCTGGAAGCCGCGCGTGCCGGGCAGGACGATGAGGTCCGTATTCTTATGGCGAACGGT
GCAGATGTTAACGCGACGGATCAATTCGGTCTGACGCCGCTGCATCTGGCAGCGCTGTTCGGTCACCTCGAAATT
GTGGAAGTGCTGTTGAAGTATGGTGCAGATGTTAACGCGCACGATGCAATGGGTCAAACGCCGCTGCATCTGGCA
GCGTACCACGGTCACCTCGAAATTGTGGAAGTGCTGTTGAAGTATGGTGCAGATGTGAATGCTCAGGATAAGTTT
GGCAAAACCGCGTTTGATATCTCCATTGATAATGGCAACGAAGATTTAGCGGAAATCCTGCAGAAACTGGGCGGC
TGC 
FP: 5’ – CGATCATATGGATCTGGGAAAAAAACTGCTGGAAGC – 3’ 
RP: 5’ – ATCGGGATCCTTATTAGCAGCCGCCCAGTTTCTGCAG– 3’ 
 
